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Introduction: The human menstrual cycle is regulated by sex-steroid hormones, 
including oestrogen (E), progesterone (P4) and androgens which act by ligand binding 
to their cognate receptors. Perturbation of the complex series of events governing the 
menstrual cycle may lead to heavy menstrual bleeding (HMB). This is a common 
debilitating condition and often associated with uterine fibroids. There remains an 
unmet need for effective, long-term medical treatment so women avoid surgery and 
preserve their fertility.  
Selective progesterone receptor modulators (SPRMs, e.g. ulipristal acetate, UPA) are 
synthetic ligands that bind the progesterone receptor (PR). Many SPRMs have been 
developed but only mifepristone (for the management of unwanted pregnancy) and UPA 
are in current clinical use. UPA is licensed for the intermittent treatment of symptomatic 
fibroids. SPRMs have potential utility for treatment of HMB as administration rapidly 
induces amenorrhoea but the mechanisms by which this is achieved are unknown. 
 
SPRM administration results in unique endometrial morphological changes 
(progesterone receptor modulator-associated endometrial changes; PAEC). Despite 
endometrial unopposed estradiol exposure these morphological changes do not appear 
to be associated with malignancy or pre-malignancy risk. Indeed endometrial cell 
proliferation appears reduced despite relative progesterone-antagonism.  
 
Based upon findings with other SPRMs it was hypothesised that: (i) administration of 
UPA would have an endometrial specific effect upon the reproductive tract, with regard 
to alteration in morphology, localisation of sex steroid receptors (SSR) and cell 
proliferation.; (ii) administration of UPA would impact upon progesterone-regulated (P-
regulated) genes in the endometrium. 
 
Methods: The data presented within this thesis are derived from biopsies obtained at 
hysterectomy from the endometrium, fallopian tubes and cervices of women with 
symptomatic fibroids administered UPA for 8-15 weeks.  Samples were obtained for 
histological assessment, immunohistochemistry and RNA extraction for subsequent 
quantitative RT-qPCR of sex-steroid receptors (SSR) and proliferation markers. In 
addition key P-regulated genes within the endometrium were investigated by RT-qPCR 
and selected protein expression. To further interrogate the anti-proliferative effect, RNA 
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was extracted from “paired” endometrial biopsies from the same woman in the 
proliferative phase of the menstrual cycle and following subsequent treatment with UPA 
for at least eight weeks and microarray gene analyses undertaken.  
 
Results: Morphological alteration of the endometrium with UPA administration was 
consistent with previously published data, but with a higher prevalence than previously 
described. There was a striking alteration in expression and localization of SSRs, 
particularly PR and androgen receptor (AR), and alteration of many P-regulated genes, 
consistent with UPA acting with low progesteroneagonism within the endometrium. 
There was no alteration of SSR expression within the cervix and proliferation was 
unchanged. Fallopian tube morphology and SSR expression was consistent with 
proliferative phase but cell proliferation was reduced following UPA administration, 
consistent with secretory phase levels.  
 
Microarray analyses identified multiple transcripts altered relative to proliferative 
phase, with GREM2 the most significantly down-regulated gene and MUC1 one of the 
most significantly upregulated genes. Consistent with low levels of mitotic figures and 
cell proliferation, the most down regulated KEGG pathway was the cell cycle. Multiple 
elements within this were subsequently validated (RT-qPCR) and included key 
regulators of all elements of the mitotic cell cycle, many of which were novel to those 
previously described following administration of another SPRM, mifepristone. 
 
In summary the novel data presented in this thesis considerably extend the data 
available to date concerning the actions of the SPRM, UPA, on the female reproductive 
tract, and increases knowledge regarding a compound with promising utility for the 











Heavy periods are a common problem for women of child-bearing age and impact 
significantly on quality of life. A common cause of heavy periods is fibroids (non-
cancerous tumours of the muscle layer of the womb). Current medical treatments often 
fail and many women eventually undergo surgical removal of the uterus (hysterectomy). 
Ulipristal acetate (UPA) is a new tablet treatment for fibroids which reduces bleeding but 
how it works is unknown. 
 
The menstrual cycle of women is regulated by two key hormones oestrogen and 
progesterone. These are known as sex-steroids and act by binding to receptors. These 
receptors frequently occur in the endometrium (lining of the womb) but can also be 
found elsewhere in the body, including in the fallopian and tube and cervix. UPA acts by 
binding with the receptor for progesterone. 
 
Our early work suggested that UPA reduces the replication of cells in the endometrium 
but we don’t know exactly how this happens, nor which cell type in the endometrium is 
most significantly affected. The endometrial cells look different when seen under a 
microscope compared to untreated women but so far there has been no evidence that 
women taking UPA have an increased risk of cancer of the endometrium. We also do not 
know what the effect of treatment with UPA has upon the fallopian tube and cervix. 
 
The work presented in this thesis has examined the effect of UPA on the appearance of 
cells in the endometrium, fallopian tube and cervix, and whether there was an alteration 
in the appearance of cells and a change in the number and location of the receptors for 
key sex-steroid hormones. This was done using samples taken from the womb of women 
with heavy periods and fibroids after hysterectomy. Some of these had had treatment 
with UPA before their operation. Other samples of endometrium were obtained in the 
gynaecology clinic from women before and after treatment with UPA. The effect of 
treatment with UPA on levels of genes regulated by progesterone in the endometrium 
was also investigated. Finally in order to try and further understand how UPA treatment 
reduces cell replication in the lining of the womb endometrial samples from women 
before and after UPA treatment were compared. 
 
I found that treatment with UPA changes the appearance of the endometrium. This is in 
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keeping with other people’s findings. New data presented here describes how the 
patterns of sex-steroid receptors were altered and genes controlled by progesterone 
were also altered. I found that cervix samples from women treated with UPA were 
unaltered, and that the fallopian tubes from these women looked similar to those of 
women in the first half of their menstrual cycle, but had a lower level of cell replication. 
 
In keeping with our earlier findings I found samples from women taking UPA had a lower 
level of cell replication in the lining of the womb than before they started treatment. New 
data generated during my studies revealed that genes involved in cell replication were 
also altered. Many of these have not been demonstrated before with other medications 
similar to UPA. 
 
In summary, the findings presented in this thesis extend the knowledge base about the 
effects of UPA on the lining of the womb, fallopian tubes and cervix. This is important as 
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In humans the female reproductive system comprises the hypothalamic, pituitary and 
ovarian axis (HPO axis) and the reproductive tract (fallopian tubes, uterus, cervix and 
vagina). The principle functions of this system are to produce an ovum, enable its 
fertilisation and implantation, and allow growth and safe delivery of the foetus into the 
external world. In the absence of pregnancy, the functional layer of the endometrium is 
shed. This is followed by subsequent rapid proliferation and remodelling in anticipation 
of implantation of another potential blastocyst. This process of cyclical development, 
differentiation and shedding of the endometrium is termed the menstrual cycle. The 
average length of the cycle in the female human is 28 days. Hence the shedding of the 
endometrium is termed menses, the plural of the Latin word for month, mensis. 
 
1.1 Why women menstruate 
Menstruation is not a ubiquitous process to all female animals. Whilst all female 
placental mammals have a uterine lining that is receptive at fertile time-points, 
menstruation is predominantly limited to primates, elephant shrews and several species 
of bat (Martin 2007). In all other species, where there is no outward menstruation, 
oestrus cycles are followed by ‘covert menstruation’ in which the receptive 
endometrium is completely reabsorbed (Strassmann 1996). The benefits of one system 
over another remain incompletely understood. Previous hypotheses included that the 
energy expenditure of maintaining the endometrium outweighed shedding and 
rebuilding (Strassmann 1996) or that it was an evolutionary defence against sperm 
carried pathogens (Finn 1996). Current thinking is that menstruation is a consequence 
of decidualisation. This is the process of conversion of endometrial stromal cells into 
specialised decidual cells that have the capacity to sustain an embryo.  In menstruating 
species decidualisation occurs prior to fertilisation, in contrast, non-menstruating 
mammals decidualise only at the point of implantation. Decidualisation is thought to 
confer evolutionary benefits through facilitating placental invasion of healthy embryos, 
enabling an element of embryo selection by the uterus in menstruating species (Finn 
1998).  
 
1.2 Physiology of the menstrual cycle 
Menstrual cycle physiology may be considered at different levels; hypothalamic, 










Figure 1.1 The menstrual cycle 
Schematic representation of pituitary and ovarian hormones and response of the ovary and 
endometrium across the menstrual cycle  
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Communication between the hypothalamus, pituitary and target organs of the 
reproductive tract is determined by a combination of peptide and steroid hormones to 
regulate menstruation. The predominant hormones of the menstrual cycle are 
gonadotrophin-releasing hormone (GnRH), follicle stimulating hormone (FSH), 
luteinising hormone (LH), oestrogen (predominantly oestradiol, (E2)) and progesterone 
(P4).  Function of this endocrine system is affected by the stage of reproductive life.  
 
1.2.1 Hypothalamic-pituitary regulation of ovarian function 
Regulation of the menstrual cycle begins with the hypothalamus and GnRH (Figure 1.2). 
GnRH is produced and released by axonal transport from the hypothalamus into the 
capillaries of the hypophyseal portal system for delivery to the anterior pituitary gland, 
where it stimulates the synthesis and secretion of LH and FSH from the gonadotrophs.  
 
GnRH is secreted in a pulsatile manner. In the normal cycling woman GnRH pulses are of 
low amplitude, but increase in their frequency during the follicular phase, to a frequency 
of every 60 minutes during late follicular phase. High GnRH pulse frequency favours LH 
release, thus LH release is predominant over FSH in the late follicular phase. In contrast 
the luteal phase is characterised by high amplitude and low frequency (approximately 
every 216 minutes) of pulsatile GnRH secretion. Low GnRH pulsatility stimulates FSH 
secretion, which is dominant over LH in the luteal and early follicular phase necessary 
for follicular development (Figure 1.1-2). LH stimulates androgen production, the 
hormonal precursor for E2, by binding to theca cells in the ovary; FSH promotes follicular 
growth, activates aromatase and induces expression of LH receptors on the granulosa 
cell in preparation to respond to the pre-ovulatory LH surge (Messinis, Messini et al. 
2014). Kisspeptin, a hypothalamic neuropeptide, is now recognised as key regulator of 
pulsatile GnRH secretion (Figure 1.2) (Skorupskaite, George et al. 2014). 
 
During the menstrual cycle GnRH and gonadotropin activity is highly regulated by 
ovarian feedback loops. In the follicular phase, oestrogen exerts negative feedback at the 
level of hypothalamus to suppress LH and FSH secretion. However in the late follicular 
phase, by yet unclear mechanisms negative oestrogen feedback switches to positive 
oestrogen feedback, culminating in the pre-ovulatory LH surge (and to a lesser extent a 




Figure 1.2 Regulation of the menstrual cycle 
Release of gonadotrophin-releasing hormone (GnRH) from the hypothalamus signals to the 
anterior pituitary. This in turn results in follicle stimulating hormone (FSH) and luteinising 
hormone (LH) secretion from the gonadotrophs. These stimulate the ovary to produce 
oestradiol and progesterone which regulate endometrial function.  
 
GnRH and gonadotropin signalling is tightly regulated by negative and positive gonadal-
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Following ovulation progesterone from the corpus luteum mediates negative feedback 
to slow down GnRH pulse frequency and subsequently LH secretion. With demise of the 
corpus luteum in the absence of pregnancy, gonadal steroid secretion declines, and 
progesterone withdrawal results in menstruation and stimulation of FSH secretion in 
response to a loss of negative sex-steroid feedback (Critchley, Kelly et al. 2001). 
 
1.2.2 Ovarian function 
Ovarian function within the menstrual cycle can be broadly divided into the follicular 
phase, ovulation, luteal phase and finally the luteal-follicular transition. 
 
Follicular phase 
Throughout ovarian life the oocytes reside within follicles. At any time point in the 
reproductive years there are follicles at different developmental stages within the ovary 
(Binelli and Murphy 2010, Rimon-Dahari, Yerushalmi-Heinemann et al. 2016). 
 
Initially, primary oocytes develop in primordial follicles, consisting of a primary oocyte 
surrounded by a single flattened layer of granulosa cells. At the beginning of each 
menstrual cycle, a cohort of primordial follicles transition into primary follicles, before 
developing into larger pre-antral follicles. At this stage, the zona pellucida develops 
between the oocyte and granulosa cells and surrounding stromal cells differentiate to 
form the theca. Subsequently, the follicles enlarge, developing a fluid-filled cavity termed 
the antrum. As well as producing E2, pre-antral and early antral follicles produce anti-
Mullerian hormone (AMH), which appears to have an inhibitory action on the growth of 
nearby primordial follicles, thus preventing their activation (Eppig 2001, Binelli and 
Murphy 2010, Rimon-Dahari, Yerushalmi-Heinemann et al. 2016).  
 
As the follicles grow they acquire FSH and LH receptors and become increasingly 
gonadotrophin dependent, with antral follicles completely dependent on FSH for 
granulosa cell proliferation and LH for theca cell sex steroidogenesis. The largest follicle 
in the cohort is termed the dominant follicle, with all other growing follicles undergoing 
atresia. The dominant follicle produces E2, resulting in a rapid rise in serum E2 
concentration and consequent reduction in FSH and LH levels by negative feedback at 
the hypothalamus. This dominant follicle matures into a pre-ovulatory follicle and 
expresses LH receptors on both granulosa and theca cells. There is a short period of 
positive feedback in the late follicular phase whereby increasing E2 levels result in a 
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surge of LH.  The pre-ovulatory follicle responds to this surge by undergoing ovulation 
(Eppig 2001, Rimon-Dahari, Yerushalmi-Heinemann et al. 2016). 
 
Ovulation 
Following the LH surge, and just prior to ovulation the oocyte responds to its hormonal 
environment and re-enters meiosis. The granulosa cells decrease E2 secretion as a result 
of decreased sensitivity to FSH and progesterone production is initiated. The rise in LH 
and FSH causes an increase in antral blood flow and the increased vascularity and local 
secretion of prostaglandins causes an increase in size of the follicle, distending the 
surface of the ovary. Proteolytic enzymes are synthesised in the theca and activated by 
prostaglandins, causing degradation of the distended follicular wall followed by rupture 
of the follicle capsule and ejection of the oocyte. This occurs on around day 14 of the 
menstrual cycle (Rimon-Dahari, Yerushalmi-Heinemann et al. 2016). Under the influence 
oestrogens prior to ovulation, increased tubal motility and elevated activity of the 
densely ciliated fimbriae allows approximation of the aperture of the distal fallopian tube 
to the ovary (Pauerstein and Eddy 1979). This promotes passage of the expelled oocyte 
into the tube to be met by the ascending spermatozoa, if present. If fertilisation occurs, 
meiosis is completed (Rimon-Dahari, Yerushalmi-Heinemann et al. 2016). 
 
Luteal phase 
Following ovulation the walls of the ovarian follicle collapse. Under the influence of LH 
both the theca and the granulosa cells proliferate and the latter develop into luteal cells. 
There is an influx of lipid droplets and lutein, which gives the corpus luteum its 
characteristic yellow appearance.  The E2 and P4 secreted by the luteal cells negatively 
feedback to the anterior pituitary and levels of FSH and LH decrease. The corpus luteum 
is reliant on LH for P4 production and luteolysis occurs in the absence of pregnancy as 
the mature corpus luteum becomes less sensitive to the remaining circulating LH. 
Demise of the corpus luteum begins at around day 24 and the corpus luteum is replaced 
by whitish scar tissue, the corpus albicans. Over subsequent cycles it is replaced by 
connective tissue, then absorbed (Smith and Meidan 2014, Rimon-Dahari, Yerushalmi-
Heinemann et al. 2016). 
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Luteal- Follicular transition 
As the corpus luteum degenerates, circulating concentrations of E2 and P4 rapidly 
decrease.  As a result, FSH and LH plasma concentrations rise and a fresh group of 
follicles are recruited whilst progesterone withdrawal (P-withdrawal) initiates menses 
(Critchley, Kelly et al. 2001, Eppig 2001). 
 
1.2.3 Endometrial response to ovarian stimulus 
The endometrium consists of glandular epithelial cells surrounded by stromal 
fibroblasts, overlaid by a layer of luminal epithelium. There is a small leucocyte 
population and occasional lymphoid follicles may be observed. The endometrium is 
separated into two functionally separate layers overlying the myometrium: the basal 
layer and the functional layer (Mutter and Ferenczy 2001). The basal layer is preserved 
but the functional layer is shed each cycle. The constituent cells may express receptors 
for the sex steroids E2, P4 and androgens, as well as the glucocorticoid hormone, cortisol 
(McDonald, Henderson et al. 2006, Critchley and Saunders 2009). The relative 
expression and localisation of receptors varies with stage of cycle and is described in 
detail in Chapter 3 (3.1.3.1). The endometrium has a complex blood supply 
predominantly arising from the radial branches of the uterine artery with some collateral 
supply from the ovarian vessels. There are both short and straight arteries which supply 
the basal layer and longer, spiral vessels supplying the whole of the endometrium. The 
spiral vessels connect with the venous system though capillary networks and direct 
arterio-venous communications (Girling and Rogers 2009). In addition to the 
vasculature there is a lymphatic system, predominantly limited to the basal layer of the 
endometrium (Girling and Rogers 2012).  
 
The endometrial component of the menstrual cycle is divided into proliferative, 
secretory and menstrual phases, broadly corresponding to the follicular, luteal and 
luteal-follicular transition phases of the ovarian cycle. The classical histological 
description of the cycling endometrium dates from the 1950s (Noyes, Hertig et al. 1950) 
but for research purposes dating may be more robustly determined utilising histological 
features combined with date of reported last menstrual period (LMP) and measurement 




Following menstruation the exposed basal layer of the endometrium proliferates rapidly 
under the influence of rising circulating E2 levels. Glands increase in number and in 
length (Figure 1.3A).  Initially glandular cells are cuboidal and the glands themselves are 
small but become columnar in appearance with pseudo-stratification of nuclei. There are 
numerous mitotic figures and no evidence of mucous secretion or vacuolation (Figure 
1.3E). The stroma is compact, with scanty cytoplasm and frequent mitotic figures. 
Angiogenesis commences with elongation of the spiral arteries. As a result of 
proliferation of both glandular and stromal cells the thickness of the endometrium 
increases from around 2mm in the post-menstrual phase to around 14mm just prior to 
ovulation (Noyes, Hertig et al. 1950, Mutter and Ferenczy 2001).  
 
Secretory phase 
Following ovulation there is an initial interval phase (Day 14-15) as P4 levels start to rise 
and then the characteristic appearances of the progesterone dominated secretory phase 
start to appear. These continue to develop until approximately 48 hours after P-
withdrawal (due to demise of corpus luteum). The hallmarks of the secretory phase are 
glandular secretion and stromal cell differentiation (decidualisation). The secretory 
phase can be broadly subdivided in early-, mid- and late-secretory changes, though these 
phases are continuous and some areas of the endometrium may develop at a different 
rate to other regions.  
 
Early secretory (Day 16-18) 
Following ovulation, secretion of progesterone from the corpus luteum rapidly inhibits 
proliferation. The endometrial glands begin to assume a more tortuous appearance, and 
acquire increased secretion of glycoproteins, evident as sub-nuclear vacuolation (Figure 
1.3B&F). Glandular nuclei move to the centre of cells and mitosis is supressed. 
Subnuclear vacuolation is most obvious in the mid zone of the functional layer initially 
but extends throughout the functional layer, with maximal expression by day 18. In the 
early secretory phase the stroma is indistinguishable from that of the proliferative phase. 
The endometrial spiral arterioles undergo remodelling to become increasingly coiled in 
anticipation of interaction with invading trophoblast if fertilization has occured (Noyes, 





Figure 1.3 Histological changes of the endometrium across the menstrual cycle 
Representative H&E images of full thickness endometrial biopsies (lumen to endometrial/myometrial interface) obtained at the time of hysterectomy from women in 
the proliferative (A&E), early secretory (B&F), mid secretory (C&G) and late secretory (D&H) phase of the menstrual cycle. In proliferative phase glands are cuboidal 
and mitotic figures present (E,↑). In early secretory phase glands appear more tortuous (B) and sub-nuclear vacuolation occurs (F, ↑). By mid secretory phase the 
vacuoles have migrated past the nuclei to the apical surface of the glandular cells (G, ↑) and begin to discharge into the lumen. The glands overall have a more serrated 
appearance (C). By late secretory phase the vacuoles have all discharges and the stroma has a decidualised appearance (H, ↑). 
Scale bars 1000μm low magnification, 50μm high magnification 
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Mid secretory (Day 19-23) 
The glands appear more tortuous, with a serrated appearance when transected along the 
long axis (Figure 1.3C). Basal vacuoles within the glands progressively push past the 
nucleus, and thus the nuclei appeared to be basally located (Figure 1.3G). The vacuoles 
discharge into the lumen of the glands, resulting in dilatation of the glands with 
proteinaceous material. The peak of secretion coincides with anticipated time of 
implantation of a blastocyst. Gland secretion is more marked in the basal layer compared 
to the functional layer of the endometrium. There is stromal oedema as a result of 
increased capillary permeability and predecidual transformation begins around day 22 
of the menstrual cycle. Adjacent to vessels the stromal fibroblasts begin to convert from 
spindle shaped cells into plumper, epithelial-like cells with enlarged nuclei and increased 
cytoplasm (i.e. decidulaisation). Vascular changes include endothelial cell proliferation 
and coiling of the spiral arterioles (Noyes, Hertig et al. 1950, Koji, Chedid et al. 1994, 
Mutter and Ferenczy 2001). 
 
Late secretory (Day 24-28) 
There is reduction in secretory activity of the glands and serration is more pronounced 
(Figure 1.3D&H). The glands become more tightly packed. Decidual change is more 
pronounced and extends from the surface to the deeper stroma (Figure 1.3H). Occasional 
mitotic bodies may appear on day 27. There is an influx of leucocytes beginning on day 
24 and by day 26 a neutrophil populate predominates. Just prior to menstruation 
apoptosis is observed within glands, small fibrin thrombi are present in the arterioles 
and there is extravasation of red blood cells (Noyes, Hertig et al. 1950, Koji, Chedid et al. 
1994, Mutter and Ferenczy 2001). 
 
Menstruation 
In the absence of pregnancy the corpus luteum regresses, resulting in a rapid decrease 
in circulating E2 and P4. It is P-withdrawal that initiates menstruation (Figure 1.4), 
resulting in a local inflammatory response within the endometrium, characterised by 
cytokine release and leucocyte infiltration with consequent oedema, which culminates 
in the shedding of the functional layer with preservation of the basal region. The basal 
layer has an exposed, raw mucosal surface that requires efficient repair (Critchley, Kelly 





Figure 1.4 Progesterone withdrawal activates inflammatory pathways resulting in 
menstruation 
Following demise of the corpus luteum, progesterone withdrawal in the late secretory phase 
increases local prostaglandin production and inhibits breakdown of active prostaglandins, 
resulting in a cascade of inflammation at menses. 
Local increase in prostaglandins results in an influx of leucocytes, vasoconstriction of spiral 
arterioles and resultant hypoxia. The culmination of this process is the shedding of the 
functional layer of endometrium. 
COX-2 cyclo-oxygenase; PLA2 phospholipase A2; PGH2 prostaglandin H2; PGF2 prostaglandin 
F2 alpha; PGFM prostaglandin F2 alpha metabolites; PGE prostaglandin E; PGEM 
prostaglandin E metabolites; VGEF vascular endothelial growth factor; MMP matrix 
metalloproteinases; IL-8 interleukin-8 
 
This is a draft of a figure from the chapter 'The menstrual cycle' that has been accepted for 
publication by Oxford University Press in the forthcoming book Oxford Textbook of 
Obstetrics and Gyanecology (chapter by Lucy Whitaker, Karolina Skorupskaite, Jacqueline A 
Maybin and Hilary O D Critchley), edited by William Ledger due for publication in 2017. 
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Inflammatory mediators generated within the endometrium upon withdrawal of 
progesterone include matrix metalloproteinases (MMPs), prostaglandins, 
cyclooxygenase (COX-2), and interleukin-8 (IL-8) (Figure 1.4). Leukocyte traffic is 
initially neutrophil dominated, which contain high levels of MMPs and may activate 
tissue MMPs, playing a critical role in the induction of endometrial shedding (Marbaix, 
Kokorine et al. 1996). Macrophage numbers also increase, contributing to cytokine 
production, local remodelling of the endometrium and removal of debris. Tight 
regulation of localised “physiological” inflammation is critical to secure satisfactory 
onward endometrial repair and prevent excessive bleeding at menses (Jabbour, Kelly et 
al. 2006, Maybin and Critchley 2015).  
 
An intact endometrial coagulation system is necessary for efficient cessation of 
menstruation.  Endometrial blood vessel injury initiates immediate activation and 
aggregation of platelets with activation of both the intrinsic and extrinsic coagulation 
cascade, ultimately leading to the formation of a stable fibrin clot to seal previously 
bleeding vessels (Maybin and Critchley 2015). In parallel the fibronolytic pathway is 
activated, whereby there is conversion of plasminogen to active plasmin, promoting the 
degradation of fibrin deposits.  Tissue plasminogen activator (t-PA) and urokinase 
plasminogen activator (u-PA) drive the production of plasmin.  In contrast, plasminogen 
activator inhibitor (PAI) inhibits fibrinolytic activity. The human endometrium contains 
t-PA and u-PA, as well as PAI and the u-PA receptor (Gleeson, Devitt et al. 1993, 
Nordengren, Pilka et al. 2004). Tight regulation to balance coagulation and fibrinolysis is 
necessary for normal menstruation. 
 
During menstruation, damaged vasculature at the shed surface leads to bleeding. The 
volume of blood lost is influenced by the viscosity of blood and the radius and length of 
the blood vessels, and of these, vessel radius is the dominant contributory factor 
(Maybin, Critchley et al. 2011). Therefore, the endometrium has evolved specialised 
spiral arterioles that have the ability to undergo intense vasoconstriction during the late 
secretory and menstrual phases to limit blood loss. Experiments in the non-human 
primate, the rhesus macaque, suggest that this vasoconstriction is so forceful that the 
luminal portion of the endometrium becomes hypoxic (Markee 1940). There is 
increasing evidence that this hypoxia may trigger a cellular protective response that 
increases local repair factors and drives blood vessel and tissue regeneration (Maybin, 
Battersby et al. 2011, Maybin, Hirani et al. 2011, Maybin and Critchley 2015). 
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1.3 Abnormal uterine bleeding 
Chronic abnormal uterine bleeding (AUB) is defined as ‘bleeding from the uterine corpus 
that is abnormal in volume, regularity and/or timing that has been present for the 
majority of the last 6 months’ (Fraser, Critchley et al. 2011, Munro, Critchley et al. 2011).  
Abnormality for volume, frequency, regularity and duration were defined as outwith 
accepted 5-95th percentiles by the Menstrual Disorders Group (MDG) of the Fédération 
International de Gynécologie et d’Obstétrique (FIGO) (Fraser, Critchley et al. 2011). In 
addition to these definitions of normality, underlying aetiologies were categorised in a 
structured fashion, covered by the pneumonic PALM-COEIN (Figure 1.5) (Munro, 
Critchley et al. 2011). PALM reflects the structural causes, including polyp, adenomyosis, 
leiomyoma and malignancy. COEIN represents the non-structural causes such as 
coagulopathies, ovulatory dysfunction, endometrial, iatrogenic and not yet classified 
which includes aetiologies such as chronic endometritis and vascular malformations.  
 
1.3.1 AUB and fibroids 
Uterine fibroids (leiomyoma) are benign tumours of the myometrium. They are common, 
whilst overall incidence varies widely (217-3745 cases per 100 000 woman years), and 
by the age of fifty around 70% of Caucasian women and more than 80% of women of 
Afro-Caribbean descent will have a least one fibroid (Baird, Dunson et al. 2003, Stewart, 
Cookson et al. 2017). The relationship between AUB and uterine fibroids still remains 
incompletely understood. Between 50 and 70% of women with fibroids are 
asymptomatic (Stewart, Laughlin-Tommaso et al. 2016) but fibroids are highly prevalent 
in women presenting with AUB. In addition those with fibroids may present with 
pressure symptoms and infertility. 
 
Previous suggested theories for leiomyoma-dependant AUB (AUB-L) include an 
increased endometrial surface area and the presence of engorged and fragile vasculature 
in the peri-fibroid environment (Munro 2012).  The resultant increase in vascular flow 
seen with these enlarged vessels may overwhelm platelet action (Stewart and Nowak 
1996).  However the effect of fibroids on endometrial function is now thought to 
represent a field change,, where endometrial function is altered throughout the entire 
uterine cavity, rather than limited only to the endometrial regions overlying the 
fibroids(s), and knowledge is increasing about the complex cellular and molecular 











Figure 1.5 FIGO classification of causes of abnormal uterine bleeding (AUB); ‘PALM COEIN’ 
A structured approach to the causes of AUB. PALM represents structural causes including 
polyps, adenomyosis, leiomyoma (fibroids) and malignancy. COEIN reflects non-structural 
causes including coagulopathy, ovulatory, endometrial, iatrogenic and not otherwise 
classified causes such as endometritis and vascular malformations. 
Reproduced from Whitaker and Critchley 2016. Abnormal uterine bleeding  
https://doi.org/10.1016/j.bpobgyn.2015.11.012 




Alteration in angiogenesis, vasoactive substrates and growth factors as well as alteration 
in coagulation are now all thought to contribute to AUB in the context of fibroids (Stewart 
and Nowak 1996).   
 
Plasminogen modulators have been demonstrated to be altered in the presence of fibroid 
and this may impact upon haemostasis and repair within the endometrium (Stewart and 
Nowak 1996).  Transforming growth factor-beta (TGF-β3) levels are increased in the 
endometrium in women with fibroids and is associated with reduced levels of 
plasminogen-activator inhibitor-1 (PAI-1), thrombomodulin and antithrombin III, both 
in vivo and in endometrial stromal cells treated in vitro with TGF-β3 (Sinclair, 
Mastroyannis et al. 2011).   
 
As descried in section 1.2 menstruation and endometrial repair is an inflammatory 
event. Alterations in blood plasma levels of circulating interleukin (IL) -13, IL-17 and IL-
10 have been reported in women with fibroids (Wegienka, Baird et al. 2013) but it is 
unknown how this impacts upon immune function and inflammation within the 
endometrium. 
 
1.3.2 Management of AUB and fibroids: the unmet clinical need 
AUB, encompassing heavy menstrual bleeding (HMB) is a common disorder, affecting 
14-25% of women of reproductive age (Shapley, Jordan et al. 2004, Fraser, Langham et 
al. 2009). HMB may have a profound negative impact on multiple aspects of an 
individual’s life (Bitzer, Heikinheimo et al. 2015) and this is reflected in the definition of 
HMB utilised by both the ACOG and RCOG. Rather than the objective measurement of 
>80ml per cycle, they prefer the patient centred definition of heavy menstrual bleeding 
(HMB) as articulated in the National Institute for Health and Care Excellence 2007 
Clinical Guideline: ‘excessive menstrual blood loss which interferes with a woman's 
physical, social, emotional and/or material quality of life’ (NICE 2007).  
 
In addition to the direct impact on the woman and her family, there are significant costs 
both to the economy and the health service.  A study conducted in the USA reported that 
financial losses of >$2000 per patient per annum due to home management costs and 
work absence (Frick, Clark et al. 2009).  In the USA, where the burden of AUB-L is higher, 
the annual economic burden of fibroids is estimated to be between $5.9 billion and $34.4 
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billion (Cardozo, Clark et al. 2012). In the UK each year, over 800 000 women seek help 
for AUB (NICE 2007) and it is the 4th most common reason for referral to UK 
gynaecological services (RCOG 2012). 
 
There remains a paucity of high quality evidence from randomised-controlled trials for 
the treatment of AUB-L (Gliklich, Leavy et al. 2011). Alongside amelioration of bleeding, 
existing treatment options need to address fertility desire, impact of pressure symptoms, 
any other AUB contributors and co-morbidities (Table 1.1). For some, particularly in the 
peri-menopausal phase with amenorrhoea and regression of fibroid size imminent, a 
conservative approach (incorporating oral iron replacement if indicated) may be an 
acceptable treatment approach.  For others either medical or surgical treatment may be 
necessary (Whitaker and Critchley 2016).  
 
In the absence of pressure symptoms, an oversized cavity or leiomyoma related 
infertility the standard treatments of levonorgestrel-releasing intrauterine system (LNG-
IUS), anti-fibrinolytics, non-steroidal anti-inflammatories (e.g. mefenamic acid) or 
systemic progestin’s may be sufficient (NICE 2007). However these may have limited 
utility in the AUB-L phenotype compared with other causes of HMB. Whilst there is 
evidence of efficacy with the LNG-IUS in AUB-L (Maruo, Ohara et al. 2007), the risk of 
expulsion is higher (Sangkomkamhang, Lumbiganon et al. 2013). Dissatisfaction with 
oral treatment has been demonstrated to be higher than LNG-IUS (Gupta, Daniels et al. 
2015) and unscheduled bleeding is common with progestin treatment, irrespective of 
mode of administration, which may limit acceptability (Bitzer, Heikinheimo et al. 2015).  
 
Other medical treatments include selective progesterone receptor modulators (SPRMS) 
and GnRH analogues. SPRMs are discussed in depth in section 1.4. GnRH analogues are 
effective at reducing both menstrual bleeding and the size of fibroids but side effects and 
impact upon bone density limit longer-term utility. Furthermore rebound of symptoms 
is rapid on cessation (Moroni, Martins et al. 2015).  GnRH agonists often have utility as a 
short-term treatment prior to surgery but there is good evidence that the SPRM ulipristal 
acetate (UPA) is better tolerated in those women pre-surgery without loss of efficacy 




Table 1.1 Symptom-based approach for management of abnormal uterine bleeding in the 
context of uterine fibroids 
Symptoms 
 
 AUB only  AUB with pressure 
symptoms; family 
complete and no 
desire to retain 
fertility 














UPA (short course) 





















GnRH analogue  
Tranexamic acid 
Mefenamic acid 
UPA (short course) 










UAE (evidence here needed) 
 
 Medical treatment 
 Surgical treatment 
 
LNG-IUS Levonorgestrel-releasing -intrauterine system 
UPA Ulipristal acetate 
GnRH analogue Gonadotrophin-releasing hormone analogue 
P4 Systemic progestogens 
 Medroxyprogesterone acetate 
 Norethisterone 
 Depo-Medroxyprogesterone acetate 
EA Endometrial ablation 
UAE Uterine artery embolisation 
(MRgFUS) MR-guided focused ultrasound – predominantly experimental 
at present 
TCRF Transcervical resection of fibroid 
 
Reproduced from Whitaker and Critchley 2016. Abnormal uterine bleeding  
https://doi.org/10.1016/j.bpobgyn.2015.11.012 
Open access: https://creativecommons.org/licenses/by/4.0 
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There is no robust evidence for alternative therapies such as herbal remedies or 
acupuncture for the treatment of fibroids (Zhang, Peng et al. 2010, Liu, Yang et al. 2013), 
and trials of selective ER modulators (SERMs) and aromatase inhibitors have remained 
disappointing (Stewart, Laughlin-Tommaso et al. 2016). Other options include uterine 
artery embolization (UAE) (Moss and Christie 2016), MR-guided focused ultrasound 
(MRgFUS) (Quinn, Vedelago et al. 2014), a technique that is not widely available and with 
a small evidence base, and surgical options such as myomectomy, endometrial ablation 
(in the absence of cavity distortion) and hysterectomy. The latter two are fertility ending 
procedures. For those wishing to preserve fertility there is as yet insufficient evidence 
for recommendation of either UAE or myomectomy over the other, though the 
anticipated outputs of the FEMME study (McPherson, Manyonda et al. 2014) will 
hopefully provide robust evidence for impact on symptoms and other qualitative 
measures between these two treatment modalities. Hysterectomy is a definitive 
treatment. Surgery is often challenging, with high potential blood losses and risk of 
ureteric injury due to anatomical distortion in the pelvis, and with increasing obesity the 
complexity of surgery is compounded.   
 
There remains conflict about which treatment strategy results in the highest patient 
satisfaction. The recent RCOG National HMB audit found higher patient satisfaction with 
surgical intervention (RCOG 2014) and hysterectomy remains the most cost-effective 
beyond 5 years (Roberts, Tsourapas et al. 2011). This led to the RCOG postulating that 
those with more severe symptoms may benefit from an earlier recourse to surgery 
(RCOG 2014).  In contrast, a recent Cochrane review, whilst acknowledging that surgical 
intervention was more effective than medical treatment in reducing menstrual bleeding 
at one year, did not find conclusive evidence of a difference in satisfaction between the 
LNG-IUS and surgery.  Furthermore they highlighted the risk of serious complication 
following hysterectomy and thus recommended that women should continue to consider 
less radical treatment options as a first line treatment strategy (Marjoribanks, Lethaby 
et al. 2016). 
 
A recent national audit in England and Wales (RCOG HMB audit) reported that at 1-year 
post referral only a third of women (including those managed with surgery) were 
‘satisfied’ (or better) at the prospect of current menstrual symptoms continuing, as 
currently experienced, for the next 5 years (RCOG 2014).  Despite existing medical 
treatments available, in the USA thousands of UAEs, approximately 30, 000 
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myomectomies, and 200,000 hysterectomies are performed annually for symptomatic 
fibroids (Bulun 2013). Indeed in North America the lifetime risk of hysterectomy is 45%, 
of which only 8% are performed for cancer (Merrill 2008). Of all surgical treatments 
performed specifically for fibroids, nearly three-quarters are hysterectomies (Borah, 
Laughlin-Tommaso et al. 2016), reflecting dissatisfaction with existing alternative 
treatment modalities.   
 
While there may be relief from HMB during pregnancy and lactation, and an end to the 
problem at menopause, women affected will tend to suffer the adverse impacts of AUB 
over what should be the prime years of their lives. Women are increasingly deferring 
child bearing – over half of all UK-born babies are to women in their 4th and 5th decade of 
life (Haines 2016). As the incidence of fibroids rises with age, those affected by AUB-L 
increasingly are likely to wish to preserve their fertility and as such there remains an 
unmet need for effective but fertility sparing treatments. A class of compounds with 
potential utility are the SPRMs. 
 
1.4 The Selective Progesterone Receptor Modulators (SPRMs) 
Progesterone was first isolated in 1934 (Allen and Wintersteiner 1934) and synthetic 
progestins have long been used for both hormonal manipulation and contraception. 
Since the discovery of the progesterone receptor (PR) (Sherman, Corvol et al. 1970), the 
clinical utility of a PR antagonist has long been appreciated but the discovery of the first 
SPRM mifepristone (RU-486) occurred during the search for a potent glucorticoid 
receptor (GR) ligand (Gagne, Pons et al. 1985). Studies in mice and non-human primates 
(NHP) demonstrated potent anti-progestogenic effects and an anti-proliferative effect 
upon the endometrium (Cullingford and Pollard 1988, Chwalisz, Brenner et al. 2000). 
Since the development of mifepristone, multiple other synthetic ligands have been 
derived (Figure 1.6). Early SPRMs were derived from testosterone (Mifepristone, 
asoprisnil, Lonaprisan and onapristone) or progesterone (ulipristal acetate; UPA and 
telapristone) and have a bulky C11 side chain (Petit-Topin, Fay et al. 2014).  
 
Mifepristone was considered to be a relatively pure progesterone anatagonist (P-
antagonist), as determined by the McPhail test.  
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Figure 1.6 Structure of common SPRMs 
Chemical structure of some SPRMs utilised in clinical trials. Only mifepristone and ulipristal 
acetate are currently licensed for clinical use although vilaprisan is currently under 
investigation in an ongoing phase III trial    
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This was the standard test for determining the PR agonist/antagonist activity of 
compound, in which E-primed immature rabbits are administered a compound and the 
effect upon endometrial development assessed (McPhail 1934).  Utilising the McPhail 
test many of these demonstrate potent P-antagonism, in particular lonaprisan, 
onapristone, mifepristone and ZK137316 (Elger, Bartley et al. 2000) and has been 
supported by gene profiling (Afhuppe, Sommer et al. 2009). Ulipristal acetate (UPA) has 
also been demonstrated to be a highly potent P-antagonist (Spitz and Chwalisz 2000, 
Petit-Topin, Fay et al. 2014). Others, such as asoprisnil display more mixed antagonism 
and agonism, and were initially referred to as mesoprogestins (Elger, Bartley et al. 2000). 
Given this, and the subsequent appreciation that all class members may demonstrate 
both cell and tissue mixed antagonism and agonism (Smith and O'Malley 2004), many 
consider all these compounds to be classified as selective progesterone receptor 
modulators (SPRMs).  
 
This change in nomenclature has also had some political origins. Mifepristone and other 
early SPRMs were referred to as progesterone antagonist (PAs). In keeping with an anti-
progesterone effect it was demonstrated that mifepristone and other PAs had the ability 
to interrupt pregnancy (Ulmann and Silvestre 1994). This potential as an abortifacient 
had political ramifications (Ulmann 2000) and in 1989, a year after the licensing of 
mifepristone for termination of pregnancy, it was withdrawn temporarily from the 
market following political pressure (Dorozynski 1997). ‘Political chemistry’ continued 
elsewhere, restricting development of SPRMs, irrespective of intended use (Hodgen 
1991). Indeed it was only in 2000 that it become available in the United States for the 
management of unwanted pregnancy (Gottlieb 2000).  The use of the term SPRM was in 
part adopted to distinguish from compounds that had the ability to interrupt pregnancy 
(Elger, Bartley et al. 2000), though mifepristone is frequently described as an SPRM and 
administration of UPA is both effective as an emergency contraceptive (Glasier 2014) 
and embryotoxic in some animal studies (Tarantal, Hendrickx et al. 1996).  
 
Irrespective of PR-ligand studied, they have all been shown to have similar affinity for 
the PR, and bind both PR isoforms (Chabbert-Buffet, Meduri et al. 2005, Bouchard, 
Chabbert-Buffet et al. 2011). The degree of antagonism/agonism is thought to be 
determined by the relative recruitment of co-regulators (Smith and O'Malley 2004). 
Some SPRMs have affinity for other steroid receptors, most notably mifepristone for GR, 
whilst UPA is highly selective for the PR and has significantly reduced GR binding 
 50 
compared to mifepristone and almost negligible ER, androgen receptor (AR) and 
mineralocorticoid receptor (MR) binding (Wolf, Hsiu et al. 1989, Attardi, Burgenson et 
al. 2004, Petit-Topin, Fay et al. 2014).  This is similar to the receptor binding of asoprisnil 
(Schubert, Elger et al. 2005). 
 
SPRMs have been considered for use in pituitary adenomas, breast disease and several 
cancers (Whitaker, Williams et al. 2014) but the key role that progesterone plays in 
reproductive physiology has resulted in many potential applications of SPRMs within 
gynaecology. At present in the UK only mifepristone and UPA are licensed for use within 
gynaecological practice.  
 
Mifepristone is licensed for the termination of pregnancy. In addition it may have utility 
in the management of miscarriage and in some countries is used for induction of labour 
(Chabbert-Buffet, Meduri et al. 2005). A 30mg dose of UPA is utilised for emergency 
contraception. It acts predominantly by inhibition of ovulation (Brache, Cochon et al. 
2013). It is at least as effective as levonorgestrel and has a longer effective window of 
use. Both mifepristone and UPA have been evaluated as long-term contraceptives and 
have shown promising efficacy and acceptability (Lakha, Ho et al. 2007, Brache, Sitruk-
Ware et al. 2012) but neither have been taken forward at present into clinical use. Phase 
II studies of the use of SPRMs in endometriosis have demonstrated positive results 
(Kettel, Murphy et al. 1998, Chwalisz, Perez et al. 2005). SPRMs have been used 
anecdotally with great effect for adenomyosis but an appropriately designed and 
powered randomised controlled trial (RCT) for this indication has yet to be performed. 
 
The main area of current utility in gynaecology is in the management of symptomatic 
fibroids. The SPRMs mifepristone, asoprisnil and ulipristal acetate (UPA) have all been 
shown to be effective at reducing fibroid size and affording control of bleeding compared 
to placebo but no one agent is more effective than another (Murji, Whitaker et al. 2017). 
Asoprisnil has not been proceeded beyond phase III studies. Multiple clinical trials and a 
meta-analysis have demonstrated efficacy of mifepristone in reducing fibroid size and 
controlling uterine bleeding (Shen, Hua et al. 2013) but long-term use of mifepristone 
has been hampered by concerns regarding endometrial safety, the negative connotations 
of its use as an abortificant and glucorticoid side effects. Further compounds are under 
development, most notably Vilaprisan which is in phase III studies at present and has 
had encouraging phase I results published (Wagenfeld, Bone et al. 2013, Schutt, Kaiser 
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et al. 2016) and phase II results presented at international meetings (Singh, Ren et al. 
2017). 
 
At present UPA is the only licensed SPRM for intermittent management of symptomatic 
fibroids and is now recommended as first line treatment by NICE for those with fibroids 
>3cm and anaemia (NICE 2016). This recommendation is based upon the “PEARL” 
studies, which demonstrated effective and rapid control of bleeding with over 90% of 
women achieving amenorrhoea, and significant reduction in fibroid size. Crucially there 
was also non-inferiority to a GnRH analogue in reduction in fibroid size, and reduced side 
effects (Donnez, Tomaszewski et al. 2012). In addition, repeated cycles demonstrated 
ongoing reduction in fibroid size and added reassurance regarding endometrial safety 
(Donnez, Vazquez et al. 2014, Donnez, Hudecek et al. 2015, Fauser, Donnez et al. 2017). 
Regrowth of fibroids is slower on cessation of UPA compared with a GnRH analogue and 
this may reflect the differing mechanism of volume reduction as UPA significantly 
increases apoptosis in leiomyoma cells (Horak, Mara et al. 2012). Indeed in the first two 
PEARL studies some women chose not to proceed to hysterectomy as previously 
planned, as they had ongoing amelioration of symptoms despite cessation of treatment 
(Donnez, Tatarchuk et al. 2012, Donnez, Tomaszewski et al. 2012). This has also been 
demonstrated by other groups reflecting ‘real world’ use (Fernandez, Schmidt et al. 
2017). Maintenance of circulating E2 at a mid-follicular level is likely responsible for the 
favourable side effect profile compared to GnRH analogues, and provides reassurance 
regarding bone safety, critical for a long-term medical option. Finally there have been 
successful pregnancies in women following UPA treatment, demonstrating that they may 
be an effective fertility preserving treatment (Luyckx, Squifflet et al. 2014) and in some 
women they have been a useful adjunct in reversing subfertility by correcting distortion 
of the uterine cavity (de la Fuente, Borras et al. 2016, Murad 2016).  
 
Whilst a small proportion of women administered UPA do not achieve fibroid shrinkage 
or control of uterine bleeding, for the vast majority it does represent an effective and 
acceptable, and critically, fertility preserving medical option for the management of 
symptomatic fibroids. However despite demonstration of efficacy, reassurance 
regarding safety and the subsequent adoption into standard clinical practice there 
remains many unknowns with regard to effects upon the endometrium and other 













1.5 Hypothesis  
Based upon the information currently available from other studies of SPRMs it is 
hypothesised that:  
 
1. SPRM administration has an endometrial specific effect upon the epithelium of 
the human reproductive tract 
 
2. SPRM administration impacts upon progesterone-regulated genes in the human 
endometrium 
 
3. SPRM administration has an anti-proliferative effect within the epithelium of 




1.6 Aims  
Aim 1 To describe the impact of SPRM administration upon steroid receptor 
expression and localisation in the epithelium of the human female reproductive 
tract 
Research questions: 
- Is there a morphological effect of UPA administration on the endometrium, 
fallopian tube and cervix?  
- Is there alteration in sex-steroid receptor mRNA levels in the endometrium and 
fallopian tube? 
- Is there alteration in sex-steroid receptor protein expression and localisation in 
the endometrium, fallopian tube and cervix?  
- Is the effect endometrial specific? 
 
Aim 2 To study the impact of SPRM administration on progesterone-regulated 
genes in the human endometrium 
Research questions 
- What is the impact upon known endometrial P-regulated gene transcription? 
- Is there alteration in protein localisation of P-regulated genes under 
investigation? 
- Does the presence of co-existing endometriosis alter response of endometrial P-
regulated genes? 
- Does administration of SPRM, UPA alter clearance of PTEN null glands in the 
endometrium? 
 
Aim 3 To study the mechanisms whereby SPRM administration reduces cell 
proliferation in the epithelium of the human female reproductive tract.  
Research Questions 
- Is there reduction in cell proliferation in the fallopian tube and cervix following 
UPA administration? 
- What candidate genes are implicated in the anti-proliferative effect within the 
endometrium?  










































2.1 Reproductive Tract Tissue Resource  
2.1.1 Tissue governance 
Tissue resources are carefully regulated to provide an adequate research resource in 
which participants have their rights and confidentiality carefully protected.  
 
The Critchley Female Reproductive Tract Tissue Resource forms part of the Lothian NRS 
BioResource led by Professor David Harrison (the Designated Individual for tissue). This 
was approved by East of Scotland Research Ethics Service (ESRES; 15/ES/0094; 14th July 
2015). 
 
The Female Reproductive Tract Tissue Resource contains samples from previous studies 
now jointly covered under Research Ethics Committee (REC) approval 16/ES/0007 
(previously 10/S1402/59) and current active studies: 
 07/S1103/20. Mechanisms Involved in Endometrial Repair and Regeneration 
 12/SS/0238 Mechanism of Action of PRMs (Progesterone Receptor Modulators) 
 14/LO/1602 Ulipristal acetate versus conventional management of heavy 
menstrual bleeding (HMB; including uterine fibroids): a randomised controlled 
trial and exploration of mechanism of action: ‘UCON’ 
 
Samples utilised in this doctoral thesis from The Female Reproductive Tract Tissue 
Resource REC approval include samples from superseded REC approvals (Table 2.1).  
 
Table 2.1. Updated REC approved studies for tissue collection 
REC Study Name 
05/S1103/14 Local Cortisol Regulation in the Ovary and Uterus 
05/S1103/32 Regulators of Vascular Function in the Female Reproductive Tract 
2001/6/5 Local mediators in menstruation 
1994/6/17 The Role of Steroid Hormones in Benign Gynaecological Conditions 
 
2.1.2 Reproductive Tract Tissue Resource participation 
Eligible women are aged from 18 years and have benign gynaecological conditions.  
Participants are recruited from NHS Lothian attending gynaecology services including 
outpatient clinics, preadmission services, Day Surgery units and in patient wards  
 58 
 
Figure 2.1 Schematic of potential tissue sample collection points 
GOPD: gynaecology out-patients department, UPA: Ulipristal acetate, UCON: Ulipristal acetate versus 
conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a 
randomised controlled trial and exploration of mechanism of action. Randomised clinical trial. Subjects 
allocated to UPA have 3, 12 weeks courses of treatment each separated by four weeks off treatment. 
 
Table 2.2 Information collected from female reproductive tract “tissue bank” resource 
participants 
Age  
Menstrual Cycle and 
Bleeding pattern 
LMP, Cycle, menses duration, HMB (subjective) 
intermenstrual bleeding 
Pain  
Medication Contraceptives (COCP, POP, parental, LNG-IUS, IUCD & ECP) 
GnRH analogue use 
Sex hormones and their modulators 
SPRMs (and bleeding control when on treatment) 
Corticosteroids and NSAIDs 
Tranexamic acid 
Other regular medications 
Clinical presentation HMB, pain, endometriosis, other clinical presentation 
Fibroids, polyps, ovarian pathology 
Previous gynaecology 
& obstetric history 
Ablation/UAE, other gynaecological surgery 
Infertility, ectopic pregnancy 
Previous or previous pelvic infection/STI 
Parity, mode of delivery 
Pathology Previous pathology reports & report linked to research sample collection 
Imaging USS/MRI/CT 
Clinical comments Findings at the time of surgery 
Obesity status Height, weight & body mass index (BMI) 
Tobacco smoking 
history 
Current, previous, never 
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(Figure 2.1). Other clinical departments involved are Pathology, Clinical laboratory 
services and Operating Theatres. Potential participants are identified by the clinical 
research staff in collaboration with clinical colleagues. They are provided with a 
participant information sheet and given the opportunity to discuss studies with research 
staff. If they wish to take part a consent form is then signed, copies are filed in the clinical 
notes, kept by the clinical research team and given to the participant. 
 
Following consent each participant is allocated a unique participant and laboratory 
number, tissue samples are allocated an additional sample number. Any subsequent 
participation re-uses the participation and laboratory number but receives separate 
sample numbers.  
 
Samples collected include: endometrium, ‘full thickness’ endometrium/myometrial 
biopsy, cervix, fallopian tubes and venous blood. ‘Full thickness’ endometrial biopsies 
are biopsies transecting from the lumen of the uterine cavity, through the full thickness 
of the endometrium (encompassing the functional and basal layer) through to the 
underlying myometrium. Samples are either: fixed in formalin, collected in RNA later and 
frozen, fresh frozen, placed in culture medium, placed in medium for use in animal 
models (eg xenograft studies with appropriate Home Office approval), venous whole 
blood and centrifuged serum/plasma. Further detail about tissue collection, processing 
and storage can be found in section 2.2. 
 
Demographic and clinical data are collected (table 2.2). All identifiable features (Name, 
date of birth, Hospital and Community Health Index (CHI) number) are removed prior to 
releasing information to researchers to ensure anonymity is protected. Data are stored 
on a secure University of Edinburgh computer and with NHS Lothian Caldicott 
Guardianship approval (CG/DF/1437). 
 
2.2 Tissue Collection 
Participants were consented under the appropriate ethics as outlined in 2.1. In addition 




2.2.1.1 Endometrial biopsies, full thickness 
‘Full thickness’ endometrial biopsies were collected at the time of surgery from women 
with uterine fibroids treated with Ulipristal acetate (UPA; 5mg oral once daily) for up to 
15 weeks prior to hysterectomy. ‘Full thickness’ endometrial biopsies are biopsies span 
the lumen of the uterine cavity, through the full thickness of the endometrium 
(encompassing the functional and basal layer) through to the underlying myometrium 
(Figure 2.2). 
 
After surgical removal, the uterus was taken promptly to the local pathology laboratory 
in an unfixed state. The specimen was orientated with the use of a probe inserted through 
the external os of the cervix to fundus of the cavity. The uterus was then opened along 
the plane of the probe utilising a long bladed knife. Tissue blocks for research were 
removed encompassing full thickness endometrium and underlying myometrium. These 
samples were placed in cassette for orientation and immersed in in 4% neutral-buffered 
formalin overnight at 4°C followed by storage in 70% ethanol. They were subsequent 
embedded in paraffin wax for sectioning prior to haematoylin and eosin (H&E) and 
immunohistochemical staining. In addition endometrial samples were removed and 
immersed in RNAlater (Ambion, Texas, USA) at 4°C overnight and then flash frozen at 
−80°C for RNA extraction. The remainder of the uterine specimen was then placed in an 
adequate volume of formalin for overnight fixation and sampled the subsequent day for 
routine diagnostic assessment. 
 
Control proliferative and secretory endometrium from women with HMB/fibroids was 
obtained from endometrial tissue archives (REC approval: 10/S1402/59) and processed 
in the manner described above. All controls were not on hormonal treatment at the time 
of biopsy.  
 
2.2.1.2 Endometrial biopsies 
“Paired” (described below) endometrial biopsies were obtained from women with 
fibroids treated with UPA 5mg daily with ethical approval and written informed consent. 
Samples were obtained using a pipelle biopsy sampler (Pipelle de Cornier Mark II, 
Laboratoire CCD, France). This was inserted into the uterus through the cervical os, 
typically in the outpatient setting. When the fundus was reached the inner tube was 
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pulled back to create a suction. Endometrial tissue was then aspirated from the uterine 
cavity as the sampler was rotated and slowly withdrawn.  
 
Biopsies were divided into equivalent portions and i) immersed in RNAlater, or ii) fixed 
in 4% neutral-buffered formalin and processed as previously described. In addition a 
sample was sent for standard clinical histological assessment.  
 
The index endometrial biopsy was taken prior to treatment with UPA, staged as 
described in section 2.3. A follow-up sample was taken whilst on treatment after the 10th 
week of UPA administration. Additional paired samples were obtained as part of the 
mechanistic arm of the UCON trial. In this multicentre randomised clinical trial (REC 
approval: 14/LO/1602, EudraCT: 2014-003408-65) women with HMB were randomized 
to treatment with either levonorgestrel-releasing intra uterine system or UPA. The UPA 
was prescribed in a different regime to the current UK license. In short women received 
treatment for three twelve-week cycles, each separated by four weeks off treatment. 
Subjects did not require to have a withdrawal bleed between each treatment cycle. The 
lead site, Edinburgh, had an embedded exploratory “mechanistic” arm: 20 of the subjects 
allocated to UPA underwent magnetic resonance imaging (MRI) scan at three time points 
(prior to commencing treatment and in the final week of cycle two and three). In addition 
they underwent endometrial biopsy in the final week of treatment cycle two.  
 
In addition to these “paired” samples, unpaired samples from women with symptomatic 
fibroids in either the proliferative or secretory phase of the menstrual cycle, or following 
UPA administration were also obtained for use as independent controls in certain 
experiments.  
 
2.2.2 Fallopian Tube 
Fallopian tube biopsies were collected with ethical approval and written informed 
consent. They were taken from women who had their fallopian tubes removed at the 
time of hysterectomy (n=6) following treatment with UPA (5mg daily) for up to 15 weeks 
prior to surgery. Samples for RNA extraction were collected from the ampulla (B) and 
following formalin fixation longitudinal samples encompassing fimbrae (A) and ampulla 




Figure 2.2 Endometrial/myometrial junction in full-thickness human endometrial biopsies 
Photomicrograph represents haematoxylin-stained, ‘full-thickness’ human endometrial 
tissue from luminal epithelium (right-most in photomicrograph), through functional and 
basal endometrial layers to endometrial/myometrial junction (left-most in 
photomicrograph).  B: basal layer, F functional layer µm = micrometre, myo = myometrium; 




Figure 2.3 The SEE-FIM protocol for analysis of the fallopian tube in prophylactic salpingo-
oophorectomies.  
This varies from the conventional approaches by longitudinal sectioning of the fimbria (A) to 
maximize exposure of this epithelium (lower left) in addition to the proximal tube (lower 
























for histological assessment is from the widely accepted SEE-FIM protocol (Crum, 
Drapkin et al. 2007) (Figure 2.3). 
 
Control sample fallopian tube biopsies from women in proliferative and secretory phase 
were obtained from fallopian tube tissue archives (n=8 and 8). These consisted of 
biopsies (2–3 cm) from the ampullary region of the fallopian tube collected from 
participants at the time of hysterectomy for benign gynaecological conditions. Cycle 
phase was determined as described in section 2.3. Biopsies were divided into equivalent 
portions and i) immersed in RNAlater, or ii) fixed in 4% neutral-buffered formalin and 
processed as previously described.  
 
2.2.3 Cervical biopsies 
Cervical biopsies were collected with ethical approval and written informed consent. 
Cervical biopsies were taken from women who had had their cervix removed at the time 
of hysterectomy (n=8) following treatment with UPA (5mg daily) for up to 12 weeks 
prior to surgery. The cervix was opened en bloc at the time of opening the uterus. 
Following fixation overnight in formalin full thickness biopsies taken which included the 
endocervical canal, transformation zone and ectocervix. Control proliferative (n=4) and 
secretory (n=5) cervical biopsies from hysterectomy specimens from women with 
HMB/fibroids were obtained from cervical tissue archives. These women had previously 
donated endometrium at the time of their hysterectomy (REC approval: 10/S1402/59) 
facilitating staging as outlined in section 2.3. 
 
2.3 Tissue dating  
2.3.2 Progesterone and oestradiol assay 
For the majority of women a blood serum sample was obtained to determine circulating 
progesterone (P4) and oestradiol (E2) levels at the time of tissue collection. A whole 
blood venous sample was take on the same day as tissue collection, centrifuged and the 
serum frozen prior to quantification.  
 
A notable exception to this were the nine subjects undergoing hysterectomy following 
up to 12 week of UPA under REC approval 12/SS/0238. 
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2.3.2.1 Progesterone assay 
The progesterone ELISA was performed by coating 96-well plates (Greiner Bio-One 
GmbH, Germany) with 100µl of goat anti mouse IgG (Jackson ImmunoResearch Inc, USA) 
per well at a dilution of 1:500 in ELISA coating buffer (100mM Na Bicarbonate, pH 9.6) 
covered and incubated in a fridge at 4oC overnight. Before use the plates were washed 3 
times with wash buffer 0.05M Tris/HCl + 0.05% Tween 20, pH 7.4 (Tween® 20, Sigma-
Aldrich, USA). Standards, samples and controls (20µl per well) were added to each well, 
followed by 80µl of  Progesterone 3 - HRP conjugate (Astra Biotech GmbH, Germany) at 
1:20,000 in assay buffer (PBS pH 7.4 containing 0.1 %BSA and 250 ng/ml Cortisol), 
followed by 50 μl of monoclonal progesterone Ab (Meridian Life Sciences, Memphis, 
USA) 1:100,000 in assay buffer.  Plates were incubated at room temperature for 2 hr on 
a microtitre plate shaker (IKA®, Schuttler MTS4, IKA Labortechnik, Germany), washed 
5 times with assay wash buffer and 120µl of substrate solution (3,3,5,5-
Tetramethylbenzidine, Millipore Corporation, USA) added to each well. Plates were 
incubated at room temperature without shaking in the dark. After 20 min, the reaction 
was stopped by adding 80µl of 2N H2SO4 solution (Sigma-Aldrich Company Ltd., UK). 
Finally, plates were read on a plate reader at 450nm.   
 
Standard curves were prepared with a total of 8 different concentrations (16, 8, 4, 2, 1, 
0.5, 0.25 0 ng/ml). Samples, standards and controls were included in duplicate. Inter- 
and intra-assay CV were calculated from two controls of low and high P4 in duplicate in 
each of eight assays. The inter-assay CV for low and high pools respectively were 11.4 
and 9.1% the intra-assay CV were 8.9 and 5.6%.  The lower limit of detection was 
calculated at 0.1 ng/ml. Cross-reaction with other steroids was: oestrone: 0.17%, 
oestradiol: 0.28%, oestriol: 0.18%, dehydroepiandrosterone: 0.02%, testosterone: 
0.36%, dihydrotestosterone: 0.15%, 17α-hydroxyprogesterone: 2.9%, androstenedione: 
0.14%, 11-deoxycortisol: 0.46%, corticosterone: 0.18%, cortisone: 0.04% and cortisol: 
0.04%. Results were converted into nmol/l by multiplying the ng/ml result by 3.18.  
 
2.3.2.2 Oestradiol assay 
Oestradiol was performed on a Roche Cobas E411 immunoassay analyser (Roche 
Diagnostics, Burgess Hill, UK) using the manufacturer’s kits and controls according to 
their instructions. The lower limit of detection is reported at 18.4 pmol/l. The limit of 
quantitation is 91.8 pmol/L Within assay %CV was found to be <5% across the 
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measurable range and between batch CV 6.5% and 5.7% for the low and high quality 
control material respectively. 
 
2.3.2 Menstrual Cycle staging 
Endometrial biopsies were dated according to the three following criteria: 
1. Histological appearance: as assessed by consultant pathologist (Professor 
Alistair Williams), based on criteria described by Noyes et al (Noyes, Hertig et al. 
1950). 
2. Last menstrual period (LMP): as reported by patient. 
3. Serum progesterone and oestradiol concentrations: measured from serum 
samples collected from patients at the time of their endometrial biopsy.  
The histological assessment of the control samples was undertaken blinded to 
LMP/cycle information and the serum P4 and E2 levels. For samples of UPA treated 
women cycle staging was not undertaken as the majority of treated women are expected 
to be anovulatory. However these women still underwent a histological assessment and 
this information was given to the pathologist in keeping with standard clinical practice. 
 
 
2.4 Sample Characteristics 
Samples were collected under the following REC approvals (as outlined in section 2.1.1) 
and a corresponding code is indicated in the description of sample characteristics (Table 
2.3). 
 
2.4.1 Full thickness endometrial biopsies 
Table 2.4 contains sample details of full thickness endometrial biopsies obtained at the 
time of hysterectomy as described in section 2.2.1.1, from women exposed to UPA for 
up to 15 weeks. Samples for serum P4 and E2 levels were not obtained for many of these 
women. Table 2.5 contains sample details of proliferative and secretory biopsies 
obtained at the time of hysterectomy utilised as controls. 
 
2.4.2 Endometrial biopsies 
Table 2.6 contains sample details of endometrial biopsies obtained in the outpatient 
clinics from women exposed to UPA for up to 15 weeks. Many of the samples were 
‘paired’: a baseline sample was taken prior to commencing UPA. A further biopsy was 
obtained from the same patient after at least 8 weeks of treatment. One sample was taken 
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8 days after completion of treatment. That individual had not had a withdrawal bleed 
from cessation of treatment at the time of biopsy. Samples from the “UCON mechanistic 
study” had their biopsy collected in the final week of their second cycle of UPA treatment 
(see 2.2.1.2). Table 2.7 contains sample details of proliferative and secretory controls 
biopsies obtained in outpatient clinics. 
 
2.4.3 Fallopian Tube biopsies 
Table 2.8 contains sample details of fallopian tubes biopsies obtained at the time of 
hysterectomy from women exposed to UPA for up to 12 weeks, previously described in 
section 2.4.1. Table 2.9 contains samples of details of fallopian tubes from proliferative 
and secretory menstrual cycle phase. Additional participant information was available 
from subjects who had co-consented to the reproductive tract tissue resource; RECs: 
10/S1402/59 (B); 07/S1103/29 (D); 05/S1103/14 (F).  
 
All specimens (UPA exposed and controls) had an H&E stained tissue section reviewed 
by a pathologist. All biopsies had wholly benign features. 
 
2.4.4 Cervical biopsies 
Table 2.10 contains sample details of cervical biopsies obtained at the time of 
hysterectomy from women exposed to UPA for up to 12 weeks, previously described in 
section 2.4.1. Table 2.11 contains samples of details of control cervical biopsies from 
proliferative and secretory menstrual cycle phases.  
 
All specimens (UPA exposed and controls) had an H&E stained tissue section reviewed 









Table 2.3 REC approvals for tissue collection 
REC Study Name Code 
16/ES/0007 Female Reproductive Tissue Resource A 
10/S1402/59 Female Reproductive Tissue Resource B 
12/SS/0238 Mechanism of Action of PRMs (Progesterone Receptor 
Modulators) 
C 
07/S1103/29 Mechanisms Involved in Endometrial Repair D 
14/LO/1602 Ulipristal acetate versus conventional management of heavy 
menstrual bleeding (HMB; including uterine fibroids): a 
randomised controlled trial and exploration of mechanism of 
action: ‘UCON’ 
E 
05/S1103/14 Local Cortisol Regulation in the Ovary and Uterus F 
05/S1103/32 Regulators of Vascular Function in the Female Reproductive Tract G 
2001/6/5 Local mediators in menstruation H 
1994/6/17 The Role of Steroid Hormones in Benign Gynaecological 
Conditions 
I 
04/S1103/20   Expression profiling of trophoblast from women with intra- and 
extra-uterine pregnancies to reveal candidate genes as markers 
for ectopic pregnancy 
J 
10/S1102/40 Improving women's health and pregnancy outcome: 





















Bleeding control E2 P4 Histology RIN 
5746 C 02/05/2013 1600 CP1231E 46 27.5 2+1 Yes Yes No 64 2 Amenorrhoea 
 
 PAEC 8.7 
5747 C 13/05/2013 1609 CP1232E 39 33.1 1+1 Yes Yes No 76 0 Amenorrhoea 
  
PAEC 8.7 
5748 C 17/05/2013 1605 CP1233E 49 26.5 1+1 Yes Yes No 76 2 Amenorrhoea 
  
PAEC 8.7 
5749 C 27/05/2013 1608 CP1234E 45 21.3 0+0 Yes Yes Yes 81 0 HMB unchanged 
  
PAEC 8.8 
5750 C 09/08/2013 1607 CP1235E 48 28.4 3+3 Yes Yes No* 63 1 Amenorrhoea 
  
PAEC 9.1 
5751 C 09/08/2013 1601 CP1236E 43 32.6 1+1 Yes Yes Yes 83 0 Amenorrhoea 
  
PAEC 7.7 
5752 C 19/09/2013 1602 CP1237E 47 31.8 1+0 Yes Yes Yes 75 1 Lighter with IMB 
 
PAEC        9.2 
5753 C 14/10/2013 1603 CP1238E 45 33.7 2+0 Yes Yes Yes* 84 0 Amenorrhoea  
 
PAEC 8.7 
5754 C 09/12/2013 1604 CP1239E 39 29.1 0+0 Yes Yes No 1021 0 Amenorrhoea  PAEC 8.6 
5779 B 13/10/2014 1660 CT1264E 48 26.1 0+0 Yes Yes No 1031 1 Amenorrhoea NS             NS PAEC NA 
8520 B 29/02/2016 1937 CT1916E2 48 27.2 0+0 Yes Yes Yes 72 1 Constant 444 7.1 PAEC NA 
5819 A 18/04/2016 2052 CT1690E 33 29.1 1+4 Yes Yes No 87 5 Lighter 549 0.3 P NA 
5780 B 08/12/2014 1661 CT1265E 48 34.9 3+0 Yes Yes No 67 0 Lighter NS NS P NA 
5793 B 10/09/2015 1675 CT1278E 48 35.4 2+1 Yes Yes Yes 78 2 Lighter with IMB 400 35.7 S NA 
8028 B 12/05/2014 1544 CT1392E 48 36.8 2+0 Yes Yes Yes* 63 0 Amenorrhoea 113 0.3 S NA 
7973 C 20/01/2014 1606 CP1337E 42 24.7 2+0 Yes Yes No 80 1 Lighter NS NS PAEC NA 
8087 A 17/08/2015 1906 CT1450E 46 28.1 0+1 Yes Yes No 94 0 Constant bleeding 473 1 PAEC NA 
 
UPA: Ulipristal acetate, Pt No: participant number, REC: Research ethics committee (approval), S No: sample number, SC No: Study code number, BMI: Body mass index,  
HMB: Heavy menstrual bleeding, Fib: Fibroids, Endo: Endometriosis, Rx: treatment, E2: oestradiol, P: progesterone, RIN: RNA integrity number, IMB: intermenstrual 
bleeding 
PAEC: progesterone receptor modulator endometrial associated changes P: Proliferative S: Secretory 
*: subject had adenomyosis 










REC Date of 
collection 
S No SC No Age BMI Parity HMB Fib Endo LMP Cycle E2 P4 Histology   RIN 
5053 I 24/07/2001 254 118 35 NS 3+0 Yes Yes No 15/07/2001 7/28-31 311 1.4 P NA 
5323 I 03/06/2003 425 154 45 NS 3+0 Yes No No 18/05/2003 5-7/28-32 107 0.94 P NA 
5406 I 12/09/2005 547 268 49 21.0 0+0 No Yes No 30/08/2005 7/26-28 908.69 6.94 P NA 
5412 G 30/11/2005 602 2 48 NS 2+0 Yes Yes No* 17/11/2005 7/26-30 324.83 1.98 P NA 
5492 F 22/05/2006 634 220 43 NS 0+0 Yes Yes No 16/05/2006 10/28-32 67 3.72 P NA 
5575 G 18/02/2008 856 CB242E 44 NS 0+0 Yes Yes No 10/02/2008 7-8/26-28 474 4.04 P NA 
5578 G 17/03/2008 860 CB245E 43 NS 2+2 Yes Yes No 03/03/2008 7/24-26 1410 2.45 P NA  
5582 F 02/06/2008 863 CA248E 44 NS 0+0 Yes Yes No 27/05/2008 8-12/25-30 88 1.24 P NA 
5621 F 17/02/2009 883 CA385E 44 NS 2+1 Yes Yes No 10/02/2009 5-6/28-32 971 4.49 P 8.7 
5670 D 15/11/2010 1133 CH454E 47 34.9 1+0 Yes Yes No* 05/11/2010 5/28-30 5.1 1.4 P 7.9 
5685 D 24/03/2011 1144 CH469E 44 26.6 4+3 Yes Yes No 15/03/2011 7/25-30 497 <3 P 8.4 
7115 I 25/09/2003 461 171 44 NS 2+2 Yes No No 12/09/2003 5/26-30 921 7.89 P NA 
7195 I 07/09/2004 514 187 40 NS 3+0 Yes Yes No 27/08/2004 5/28 667.03 10.86 P 9.4 
7593 G 28/08/2009 1025 CB563E 51 19.4 1+0 Yes Yes Yes* 16/08/2009 8-9/24-28 1682 5.97 P NA 
7750 D 21/03/2011 1271 CH1028E 40 29.1 3+0 Yes Yes No 11/03/2011 10/22-28 762 <3 P 8.9 
7782 B 09/08/2011 1297 CT1060E 47 27.7 3+1 Yes Yes No* 17/07/2011 5-6/21-28 320 3.6 P 9.5 
 
Pt No: Participant number, REC: Research ethics committee (approval), S No: sample number, SC No: Study code number, BMI: Body mass index,  
HMB: Heavy menstrual bleeding, Fib: Fibroids, Endo: Endometriosis, LMP: Last menstrual period, E2: oestradiol, P4: progesterone, RIN: RNA integrity number, NS: 
Not stated  
P: Proliferative  
*: sample had adenomyosis  
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Table 2.5b Sample characteristics of “full thickness” endometrial biopsies from secretory phase of the menstrual cycle 
Pt 
No 
REC Date of 
collection 
S No SC No Age BMI Parity HMB Fib End
o 
LMP Cycle E2 P4 Histology   RIN 
7820 B 17/11/2011 1328 CT1098E 46 24.6 3+0 Yes Yes No 01/11/2011 6-9/28 396 31.4 ES NA 
5005 I 05/04/2001 213 109 33 NS 3+0 Yes Yes Yes 15/03/2001 5-8/28 412 29.3 MS NA 
5212 I 13/05/2002 352 138 44 NS 3+0 Yes Yes No 02/05/2002 6-7/21-28 8.25 12.62 MS NA 
5690 D 07/03/2011 1149 CH474E 39 30.0 3+1 No Yes No* 08/02/2011 2-7/25-30 323 38.6 MS 8.6 
7152 I 19/02/2004 487 179 35 NS 2+0 Yes Yes No 30/01/2004 3-4/28 722 59.94 MS NA 
7187 H 17/08/2004 509 250 43 NS 1+1 No Yes No* 26/07/2004 3-4/24-25 428 50.63 MS NA 
7218 I 22/11/2004 523 194 43 NS 1+0 Yes No No 02/11/2004 3-6/28 853 101 MS NA 
7695 D 27/10/2010 1188 CH973E 39 19.9 1+0 Yes Yes No 27/09/2010 10-14/21-26 78.6 21.4 MS 8.9 
7725 D 07/03/2011 1252 CH1003E 47 28.2 0+0 Yes Yes No 14/02/2011 7/28 228 45.7 MS 8.5 
7759 D 13/05/2011 1277 CH1037E 50 25.8 1+1 Yes Yes No 22/04/2011 7-10/21-24 77.4 21.1 MS 9.2 
7764 D 17/05/2011 1280 CH1042E 43 21.1 3+1 Yes Yes No* 30/04/2011 7-10/21-28 272 27.2 MS 9.4 
7783 B 08/08/2011 1298 CT1061E 45 27.5 2+0 Yes Yes Yes* 21/07/2011 5-7/28 530 28 MS 9.0 
7853 B 16/02/2012 1412 CT1131E 52 27.4 2+1 Yes Yes Yes* 30/01/2012 5-7/21-28 359 22.4 MS 9.3 
7839 B 26/01/2012 1348 CT1117E 42 22.1 1+0 Yes Yes No 03/01/2012 6/22 396 35.9 MS 8.9 
7760 D 16/05/2011 1278 CH1038E 37 25.3 2+1 Yes Yes No* 20/04/2011 11-19/23-30 262 14 LS NA 
5743 B 03/09/2012 1390 CT1227E 47 25.3 1+2 Yes Yes No 04/08/2012 10-12/28 132 6.4 LS 9.4 
8508 B 14/09/2015 1676 CT1905E2 46 28.9 3+1 Yes Yes No* NS 3-7/28-31 259 17.2 LS 9.5 
 
Pt No: Participant number, REC: Research ethics committee (approval), S No: sample number, SC No: Study code number, BMI: Body mass index,  
HMB: Heavy menstrual bleeding, Fib: Fibroids, Endo: Endometriosis, LMP: Last menstrual period, E2: oestradiol, P4: progesterone, RIN: RNA integrity number,  
NS: Not stated  
ES: Early secretory MS: Mid secretory S: Late 
*: sample had adenomyosis  
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 Table 2.6 Sample characteristics of endometrial biopsies from women administered UPA                 
 






S No Study code 
No 






E2 P4 Histology RIN 
5777 A 08/03/2016 1938 CT1262E3+ 52 29.6 1+2 Yes Yes No 81 0 Amenorrhoea 55 5.2 Inactive with no atypia# 7.6 
5785 E 27/04/2016 1958 CU1270E3+ 44 34.6 3+0 Yes No No 781 0 Amenorrhoea 303 15.7 Secretory (some non-physiological) 9.0 
5790 E 22/01/2016 1684 CU1275E+ 40 NS 3+0 Yes No No 791 0 Unchanged NS NS Mildly disordered proliferative 9.6 
5795 A 03/05/2016 1960 CT1280E2+ 47 22.9 2+1 Yes Yes No 77 82 Amenorrhoea 359 0.2 PAEC 8.4 
5805 E 18/10/2016 1812 CU1289E2 48 22.0 2+1 Yes Yes No 811 0 Amenorrhoea 1665 0.5 Inactive with no atypia# 8.8 
5817 A 21/07/2016 1988 CT1691E2+ 48 22.7 2+0 Yes Yes No 80 0 Amenorrhoea 1491 1.7 PAEC 9.1 
7886 A 19/05/2016 1964 CT1162E3+ 46 21.3 0+0 Yes Yes No 60 0 Amenorrhoea 319 0.5 Inactive with no atypia# 9.4 
8002 A 16/03/2016 1942 CT1366E3+ 51 20.9 1+1 Yes Yes Yes 66 0 Amenorrhoea 819 21.8 Disordered proliferative# 7.5 
8045 A 02/06/2016 2062 CT1409E3+ 47 42.7 5+2 Yes Yes No 76 0 Amenorrhoea 72 0.2 PAEC NA 
8097 A 29/03/2016 1951 CT1460E2+ 41 29.0 0+1 Yes Yes No 70 0 Amenorrhoea 149 2.7 Inadequate# 7.5 
8100 A 24/03/2016 1949 CT1463E2+ 49 46.4 2+0 Yes Yes No 82 0 Amenorrhoea 60 3.4 Consistent with UPA# 7.9 
8117 A 18/07/2016 1985 CT1480E2 40 32.3 2+0 Yes Yes No 77 0 Lighter 317 50.3 PAEC 9.2 
8122 A 07/07/2016 1981 CT1485E2+ 41 28.0 1+1 Yes Yes No 69 0 Amenorrhoea 305 0.2 PAEC NA 
8123 A 05/07/2016 1980 CT1486E2+ 41 39.9 3+1 Yes Yes Yes 75 0 Amenorrhoea 162 0.2 PAEC 9.2 
8124 A 18/07/2016 1986 CT1487E2+ 49 30.5 1+1 Yes Yes No 81 0 Amenorrhoea 97 0.2 Consistent with UPA# NA 
8126 E 09/11/2016 1867 CU1489E2+ 45 30.4 0+1 Yes Yes No 811 0 Amenorrhoea 114 <0.2 PAEC 9.2 
8130 A 20/07/2016 1987 CT1493E2+ 44 33.2 0+0 Yes Yes No 70 0 Amenorrhoea 137 4.8 PAEC NA 
8506 E 12/08/2016 1807 CU1903E3+ 41 23.5 3+0 Yes No No 821 0 Lighter 237 1.6 Proliferative 9.1 
8522 A 14/03/2016 1941 CT1929E2+ 46 38.6 0+3 Yes Yes No 80 0 Lighter 302 3.6 PAEC 8 
9046 E 24/08/2016 1993 CU1676E2+ 44 30.1 5+0 Yes No No 801 0 Amenorrhoea 432 <0.2 Inadequate# NA 
9055 A 02/06/2016 2063 CT1685E2+ 47 NS 0+9 Yes Yes Yes 79 0 Lighter 135 0.2 PAEC 7.5 
 
Pt No: participant number REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis Rx: treatment  
LMP: Last menstrual period E2: oestradiol P4: progesterone, RIN: RNA integrity number, NS: Not stated PAEC: progesterone receptor modulator endometrial associated changes  
+: sample has a paired control sample *: sample had adenomyosis  
#: Minimal tissue in biopsy or fragmented sample. Sufficient tissue may be available to exclude malignancy but may be insufficient to assess for features of PAEC or to unequivocally state PAEC 
as diagnosis 
1: sample from UCON subject – pipelles taken in final week of second 12 week cycle of treatment 
2: sample taken 8 days after stopping UPA. Patient remained amenorrhoeic at the time of biopsy 
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Table 2.7 Sample characteristics of endometrial biopsies from proliferative and secretory phase of the menstrual cycle 






Age BMI Parity HMB Fib Endo LMP Cycle E2 P4 Histology RIN 
5706 B 02/06/2011 1354 CT490E 46 24.0 0+0 Yes Yes No 24/05/2011 7/26-28 714 <3 P 7.7 
5777 B 23/11/2015 1678 CT1262E2+ 52 29.6 1+2 Yes Yes No 05/11/2015 7/24-29 145 0.4 P 8.6 
5785 B 28/07/2015 1673 CT1270E2+ 44 34.6 3+0 Yes No No 06/07/2015 5-6/26-27 331 3.6 P 9.6 
5790 B 12/05/2015 1671 CT1275E+ 39 26.8 3+0 Yes Yes No 29/04/2015 5-16/28-31 477 21.7 P 9.1 
5795 B 07/01/2016 1679 CT1280E+ 46 22.9 2+1 Yes Yes No 14/12/2015 8/21-25 522 4.7 P 8.1 
7694 D 26/10/2010 1187 CH972E 51 25.3 0+0 Yes Yes No 14/10/2010 4/28 12.5 3.4 P 9.4 
7718 D 16/12/2010 994 CH996E 42 20.9 2+0 Yes Yes No 09/12/2010 5-6/28-32 672 <3 P 9.0 
7720 D 13/01/2011 996 CH998E 49 19.9 2+0 Yes Yes No 05/01/2011 5/28 142 <3 P 8.3 
7811 B 06/10/2011 1318 CT1089E 38 28.7 2+1 Yes Yes No 20/09/2011 7-10/28 171 5.7 P 8.5 
7835 B 02/02/2012 1343 CT1113E 44 23.2 2+0 Yes Yes No 21/01/2012 5-6/28 1272 <3 P 9.3 
7886 B 25/02/2016 1935 CT1162E2+ 46 21.3 0+0 Yes Yes No 18/02/2016 6-14/28-46 104 5.1 P 8.2 
8097 B 29/10/2015 1916 CT1460E+ 40 28.9 0+1 Yes Yes No 20/10/2015 3-8/21-28 224 2.5 P 7.7 
8100 B 26/11/2015 1920 CT1463E+ 48 46.4 2+0 Yes Yes No NS 10/14-21 229 3.1 P 8.3 
8131 A 23/06/2016 1976 CT1494E 47 25.6 2+0 Yes Yes No 15/06/2016 7/14 1376 0.8 P 9.5 
8506 B 24/11/2015 1917 CT1903E2+ 41 23.8 3+1 Yes No No 13/11/2015 5/28-29 430 1.3 P 10.0 
8522 B 14/12/2015 1724 CT1929E+ 46 38.6 0+3 Yes Yes No 25/11/2015 4-8/35-43 312 8.5 P 8.3 
9046 B 17/09/2015 2027 CT1676E+ 43 31.4 5+0 Yes No No 09/09/2015 7-14/21 213 0 P NA 
9055 B 03/12/2015 2036 CT1685E+ 47 25.9 1+1 Yes Yes Yes 18/11/2015 7-10/21 207 4.5 P 10.0 
8085 A 23/7/2015 1904 CT1448E 46 32.7 1+0 Yes No No 13/07/2015 5-7/26-30 199 1.8 P 9.2 
5817 A 13/04/2016 2053 CT1691E+ 48 22.3 2+0 Yes Yes No NS NS 145 0.4 DP NA 
8002 B 14/12/2015 1723 CT1366E2+ 51 20.9 1+1 Yes Yes Yes 05/11/2015 10/21-28 731 27.2 DP NA 
8122 A 21/04/2016 1953 CT1485E+ 41 28.0 1+1 Yes Yes No 07/04/2016 5/21 444 62.9 ES NA 
7840 B 19/01/2012 1349 CT1118E 49 25.9 2+0 Yes Yes No 28/12/2011 5-7/14-28 418 14.8 MS 9.5 
8045 A 10/03/2016 2050 CT1409E2+ 46 42.7 5+2 Yes Yes No 25/02/2016 5-7/21-28 361 28.8 MS NA 
8124 A 21/04/2016 1955 CT1487E+ 49 30.5 1+1 Yes Yes No 04/04/2016 3-5/28 129 7.4 LS NA 
8130 A 05/05/2016 1963 CT1493E+ 44 33.1 0+0 Yes Yes No NS 8-9/28 170 4.6 LS NA 
8123 A 21/04/2016 1954 CT1486E+ 41 39.1 3+1 Yes Yes Yes 17/04/2016 7/42-29 135 0.2 M NA 
Pt No: Participant number REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis LMP: Last menstrual period 
E2: oestradiol P4: progesterone, RIN: RNA integrity number, NS: Not stated P: Proliferative DP: Disordered proliferative ES: Early secretory MS: Mid secretory LS: Late secretory M 
menstrual+: sample has a paired UPA treated sample *: sample had adenomyosis 
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 Table 2.8 Sample characteristics of fallopian tube biopsies from women administered UPA 
Pt 
No 





code No   
Age BMI HMB Fib Endo Duration 
UPA 
E2 P4 Endometrial 
Histology 
Staging Use 
5746 C 02/05/2013 118 CP1231FR 46 27.5 Yes Yes No 64 NO NO PAEC N/A PCR/IHC 
5747 C 13/05/2013 119 CP1232FR 39 33.1 Yes Yes No 76 NO NO PAEC N/A PCR/IHC 
5748 C 17/05/2013 116 CP1233FL 49 26.5 Yes Yes No 76 NO NO PAEC N/A PCR/IHC 
5750 C 09/08/2013 112 CP1235FR 48 28.4 Yes Yes No* 63 NO NO PAEC N/A PCR/IHC 
5751 C 09/08/2013 113 CP1236FL 43 32.6 Yes Yes Yes 83 NO NO PAEC N/A PCR/IHC 
5754 C 09/12/2013 123 CP1239FL 39 29.1 Yes Yes No 1021 NO NO PAEC N/A PCR/IHC 
UPA: Ulipristal acetate Pt No: participant No REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis  
E2: oestradiol P4: progesterone PAEC: progesterone receptor modulator endometrial associated changes.  
*: subject had adenomyosis 1: Operation deferred, UPA treatment course extended to day of surgery  
All Fallopian tubes had benign appearance under routine H&E clinical pathology review 
 
Table 2.9 Sample characteristics of fallopian tube biopsies from proliferative and secretory phase of the menstrual cycle 





code No   
Age BMI HMB Fib Endo LMP Cycle E2 P4 Endometrial 
Histology 
Use 
7482 J 29/04/2008 68 276 42 NS Yes Yes No 20/4/08 7-10/21-24 503 5 P PCR/IHC 
5621 J, F 17/02/2009 85 385 44 NS Yes Yes No 10/2/09 5-6/2-32 971 4 P IHC 
7568 J, F 29/05/2009 75 538 44 NS Yes Yes No 15/5/09 3/28 513 4 P PCR/IHC 
7680 J, F 31/08/2010 162 748 36 35 Yes No No 24/8/10 7/28 248 <3 P PCR/IHC 
3137  K 03/05/2011 314 875 NS NS NS NS NS 29/4/11 10/14-28 160 <3 P PCR/IHC 
3161 K, B 19/07/2011 325 892 46 37 Yes No No* 13/7/11 5-10/21-28 335 <3 P IHC 
3171 K 22/09/2011 338 2009 NS NS NS NS NS 12/9/11 12/14-21 311 <3 P PCR 
5734 K, B 13/02/2012 345 1218 41 32 Yes No No 2/2/12 5/21 400 <3 P PCR 
3149 K 17/05/2011 317 878 NS NS NS NS NS 29/4/11 7-10/21-28 222 24 E/MS PCR 
7498 J, D 15/07/2008 70 292 41 NS Yes Yes No 23/6/08 5/21-23 532 34 MS IHC 
6316 J 16/01/2009 100 611 43 NS Yes Yes Yes* 24/12/08 7/14-21 357 18 MS IHC 
7567 J, F 27/05/2009 74 537 43 NS Yes Yes No* 4/5/09 10/22-25 494 49 MS PCR/IHC 
7641 J, D 14/04/2010 158 771 38 34 Yes Yes No* 4/4/10 5-7/14-21 691 246 MS PCR/IHC 
7672 J, F 09/08/2010 160 740 47 27 Yes Yes No* 22/7/10 5-6/28 410 70 MS PCR/IHC 
7678 J, F 23/08/2010 161 746 48 29 Yes Yes No 29/6/10 6-10/28-69 598 <3 MS PCR/IHC 
3123 K, B 28/07/2011 327 894 36 25 No No Yes* 7/7/11 4-5/28-31 563 59 MS PCR 
REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis LMP: Last menstrual period E2: oestradiol  
P4: progesterone NS: Not stated P: Proliferative ES: Early secretory MS: Mid secretory *: sample had adenomyosis  
All Fallopian tubes had benign appearance under routine H&E clinical pathology review 
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Table 2.10 Sample characteristics of cervical biopsies from women administered UPA 
Participant 
No 





No   




E2 P4 Endometrial 
Histology 
5746 C 02/05/2013 9 CP1231C 46 27.5 2+1 Yes Yes No Normal 64 No No PAEC 
5747 C 13/05/2013 10 CP1232C 39 33.1 1+1 Yes Yes No Normal 76 No No PAEC 
5748 C 13/05/2013 2 CP1233C 49 26.5 1+1 Yes Yes No Normal 76 No No PAEC 
5749 C 27/05/2013 8 CP1234C 45 21.3 0+0 Yes Yes Yes Normal 81 No No PAEC 
5750 C 09/08/2013 1 CP1235C 48 28.4 3+3 Yes Yes No* Normal 63 No No PAEC 
5751 C 09/08/2013 7 CP1236C 43 32.6 1+1 Yes Yes Yes Normal 83 No No PAEC 
5753 C 07/10/2013 3 CP1238C 45 33.7 2+0 Yes Yes Yes* Normal 84 No No PAEC 
7973 C 20/01/2014 4 CP1337C 42 24.7 2+0 Yes Yes No Negative^ 80 No No PAEC 
UPA: Ulipristal acetate, REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis. E2: oestradiol  
P4: progesterone, PAEC: progesterone receptor modulator endometrial associated changes. 
Negative^: This participant had moderate dyskaryosis on smear in 2005. She underwent LLETZ which revealed CIN2. Subsequent smears were all normal 
All cervixes had benign appearance under routine H&E clinical pathology review 
 
Table 2.11 Sample characteristics of cervical biopsies from proliferative and secretory phase of the menstrual cycle 
Participant 
No 
REC Date of 
collection 
Sample No Study 
code No   
Age BMI Parity HMB Fib Endo Smear 
History 
LMP Cycle E2 P4 Endometrial 
Histology 
5053 I 24/07/2001 UB19964/05 118 35 NS 3+0 Yes No No Normal 15/07/2001 7/28-31 311 1.4 P 
5406 I 12/09/2005 UB11030/03 268 49 21 0+0 No Yes No Normal 30/08/2005 7/26-28 908.69 6.94 P 
5323 I 03/06/2003 UB14651/01 154 45 NS 3+0 Yes No No Normal 18/05/2003 5-7/28-32 107 0.94 P 
7115 I 25/09/2003 UB19713/03 171 44 NS 2+2 Yes No No Normal 12/09/2003 5/26-30 921 7.89 P 
7152 I 19/02/2004 UB25854/04 179 35 NS 2+0 Yes Yes No Normal 30/01/2004 3-4/28 722 59.94 MS 
7187 H 17/08/2004 UB4056/04 250 43 NS 1+1 No Yes No Normal 26/07/2004 3-4/24-25 428 50.63 MS 
7218 I 22/11/2004 UB6748/01 194 43 NS 1+0 Yes No No Normal 02/11/2004 3-6/28 852.79 100.95 MS 
5212 I 13/05/2002 UB18031/04 138 44 NS 3+0 Yes Yes No Normal 02/05/2002 6-7/21-28 8.25 12.62 MS 
5005 I 05/04/2001 UB9523/02 109 33 NS 3+0 Yes Yes Yes Normal 15/03/2001 5-8/28 412 29.3 MS 
REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis LMP: Last menstrual period E2: oestradiol  
P4: progesterone NS: Not stated P: Proliferative MS Mid secretory. All cervixes had benign appearance under routine H&E clinical pathology review 
 75 
2.5 RNA extraction and quantitative reverse transcription polymerase chain 
reaction (RT-qPCR) 
Polymerase chain reaction (PCR) is a molecular biology technique to amplify a single or 
few copies of DNA across several orders of magnitude. Genes of interest in RNA samples 
can be assessed by reverse transcriptase of the mRNA to create complementary DNA 
(cDNA).Through repeat heating and cooling (thermal cycling) in the presence of a heat-
stable DNA polymerase (typically Taq polymerase), selected specific regions of cDNA are 
amplified. A reporter dye emits fluorescence during the amplification of the target 
sequences in real time. This is then detected and quantified. 
 
Amplification of cDNA are determined by specific forward and reverse primers to the 
sequence of interest and a corresponding probe which anneals between the two primers. 
When using the Taqman system, (Taq polymerase) it is the displacement of the probe 
from the cDNA by the primer that results in emission of fluorescence by the reporter dye 
at the 5’ end of the probe.  
 
All RT-qPCR reactions described in this thesis are using the Taqman system.  
 
2.5.1 RNA extraction and cDNA preparation 
Total RNA was isolated from endometrial and fallopian samples using Qiagen RNAeasy 
mini kit as per the manufacturers protocol (Qiagen, Manchester UK) with tissue 
homogenisation with a TissueLyser (Qiagen, Manchester UK). Concentration was 
determined using NanoDrop 1000 spectrophotometer V3.7 (Thermo Fisher Scientific, 
USA) and stored at -80°C. 
 
Endometrial RNA samples for gene microarray had their quality assessed. These was 
performed using the Agilent RNA 6000 nano kit in conjunction with Agilent 2100 
Bioanalyser system with 2100 Expert analysis software (Agilent Technologies, UK). In 
summary samples of mRNA are loaded into gel matrix in a chip containing a set of 
interconnected micro channels. These separate nucleic acid fragments based on their 
size as they are driven through the channels electroporetically. This allows visualisation 
of the 18S and 28S rRNA (ribosomal RNA) fluorescence peaks.  The ratio of 28S to 18S 
fluorescence peaks allows the calculation of an RNA integrity number (RIN), which if 
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below 7.5, is indicative of RNA degradation (Figure 2.4). Some additional samples also 
had RIN previously determined and are indicated in Table 2.4-7. 
 
  
Figure 2.4 Agilent assessment of RNA quality 
Sample 6 has a higher degree of RNA degradation whereas sample 7 has less fragmentation. 




cDNA was prepared according to manufactures protocol using either Superscript Vilo 
cDNA kit (Invitrogen, Paisley UK) or iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
USA). For all cDNA reactions 100ng RNA template was used and 2 control samples 
prepared omitting either reverse transcriptase or RNA to detect contaminating genomic 
DNA or contamination of the cDNA preparation mix respectively.   
 
Following mixing of the samples, an incubation programme was run on a Bioer GenePro 
PCR Cycler (Hangzhou Bioer Ltd., Binjiang, China) for either 20 minutes at 25°C, 60 
minutes at 42°C and 5 minutes at 95°C (Superscript Vilo reaction) or 5 minutes at 25°C, 
30 minutes at 42°C and 5 minutes at 85°C (iscript reaction). cDNA samples were stored 
at -20°C until required.  
 
2.5.2. Primers and probes 
Gene specific primers were designed using the online Universal Probe Assay (Roche 
Diagnostics, USA) and synthesised by Eurofins Genomics (Germany) (Table 2.12).  
 
18s and Indian Hedgehog (IHH) primers were bought as pre-validated sets (Applied 
Biosystems, UK) and used according to the manufacturer’s protocol.  All other primers 
were validated before use. This involved setting up a standard curve using cDNA of 
endometrium at serial dilutions to demonstrate optimal efficiency of the PCR primers 
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used. In summary RT-qPCR of serial 2-fold dilution of cDNA (1/2 to 1/64) produced from 
a pooled set of RNA samples. Log[RNA] was plotted against ΔCq values to determine the 
slope of the line through the x, y coordinates.  All primer/probe sets designed for use in 
this thesis yielded absolute slope values of <0.1.   
 
Validation of primers was performed on secretory endometrium with the exception of 
cell cycle genes (CCNA1, CCNE2, CDC25A, CDK1, CCNB2, CCNA2, CCNB1, E2F2, CDC7, MYC, 
CHEK2 and PCNA) which were validated on proliferative endometrium. Proliferative 
endometrium was chosen for validation of these these cell cycle primers as expression 
of mRNAs was low in secretory phase. This prevented meaningful extended dilution of 
the inputted cDNA and efficacy of the reaction could not be assessed. With the use of 
proliferative endometrium these primers all validated at an acceptable level of efficiency. 
 
Probes were obtained from the Universal Probe Library (Roche Diagnostics, USA). Choice 
of probe was determined by primer design by the Universal Probe assay (Roche 
Diagnostics, USA). 
  
2.5.3 Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
RT-qPCR was performed in triplicate reactions in 384 well plates (STARLAB, Germany). 
10μl reactions containing 5μl Express qPCR Supermix (Thermo Fisher Scientific, USA), 
0.1ul (200nM) each of the reverse and forward primer and 0.1ul (100nM) of probe (UPL, 
Roche, UK), 3.7μl nuclease free water and 1μl of cDNA were placed in each well.  
Secretory endometrium was used as a normalising control. 
Additional controls were provided by 
 Blank (No RNA): The RNA is exchanged for H2O at the time of making cDNA. 
This determines if there is contamination in the mix used to make cDNA. As 
there will be no cDNA made it should give no value in real time PCR.  
 –RT: Reverse transcriptase omitted at time of cDNA preparation. This is to 
detect contaminating genomic DNA. 
 H20: A sample of the water used to formulate the mix for PCR reactions. This is 
to exclude contamination of the water used to prepare the mix for PCR reactions. 
These 3 controls were checked against each gene used. 
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PCR conditions were 95°C for 2 minutes, plus 40 cycles of 95°C for 15 sec and 60°C for 
60 sec using ABI Prism 7900 Fast PCR instrument (Applied Biosystems; Thermo Fisher 
Scientific, USA).  
 
Data from RT-qPCR experiments were analysed by the ΔΔCq (quantification cycle) 
method, as described by Applied Biosystems. Target mRNA-derived cDNA levels are 
normalised to cDNA loading for each sample using the internal controls described prior 
(18S/SHDA and ATP5B, table 2.14), and then related to an internal control. Relevant 
statistical analyses were performed using GraphPad 7.0 and are described in the 
corresponding chapters. 
 
PCR results were not further validated by either gel electrophoresis of the PCR product 
or sequencing of the PCR product. 
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Table 2.12 Primers and Roche probes used for PCR reactions 
Target 
Gene  
Full name Forward primer Reverse primer Roche 
probe 
ATBP5 Human ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
agaggtcccatcaaaaccaa tcctgctcaacactcatttcc 50 
SDHA succinate dehydrogenase  tccactacatgacggagcag ccatcttcagttctgctaaacg 70 
18S 18s Pre validated set  Pre validated set   NA  
PR Human progesterone receptor tttaagagggcaatggaagg cggattttatcaacgatgcag 11 
PRB Human progesterone receptor B aatgggctgtaccgagaggt tctcagtccctcgctgagtt 45 
AR Homo sapiens androgen receptor  gctgatcataggcctctctc tgccctgaaagcagtcctct 14 
ESR1 Human oestrogen receptor 1  aaccagtgcaccattgataaaa tcctcttcggtcttttcgtatc  68 
FKBP51 Homo sapiens FK506 binding protein 5 
(FKBP5) 
ggatatacgccaacatgttcaa ccattgctttattggcctct 15 
FKBP52 Homo sapiens FK506 binding protein 4, 
59kDa (FKBP4) 
cccgggagaagaagctctat aggaagcctctgccttgg 30 
FOXO1 Homo sapiens forkhead box O1 aagggtgacagcaacagctc ttccttcattctgcacacga 11 
HAND2 Homo sapiens heart and neural crest 
derivatives expressed 2 
tcaagaagaccgacgtgaaa gttgctgctcactgtgcttt 35 
BCL6 B-cell CLL/lymphoma 6 tctgcgtcatgcttgtgtta caacgcggtaatgcagttta 76 
KLF-4 Homo sapiens Kruppel-like factor 4 (gut) gggagaagacactgcgtca ggaagcactgggggaagt 52 
KLF-9 Homo sapiens Kruppel-like factor 9 ctccgaaaagaggcacaagt cgggagaactttttaaggcagt 76 
KLF-15 Homo sapiens Kruppel-like factor 15 caaaagcagccacctcaag tcagagcgcgagaacctc 64 
IGFBP-1 Homo sapiens insulin-like growth factor 
binding protein 1 
aatggattttatcacagcagacag ggtagacgcaccagcagagt 58 
IL-15 Homo sapiens interleukin 15 (IL15), 
transcript variant 1 
cagatagccagcccatacaag ggctatggcaaggggttt 46 
IHH Human indian hedgehog Pre validated set     NA 
HOXA10 Homo sapiens homeobox A10 (HOXA10), 
transcript variant 1 
ccttccgagagcagcaaa ttggctgcgttttcacct 61 
COUP-
TFII 
Human nuclear receptor subfamily 2 
group F member 2 
ccatagtcctgttcacctcaga aatctcgtcggctggttg 36 
BMP2 Human bone morphogenetic protein 2 cggactgcggtctcctaa ggaagcagcaacgctagaag 49 
PRL Human prolactin caaaggatcgccatggaa cacaggagcaggtttgacac 18 
GREM2 gremlin 2, DAN family BMP antagonist 
(GREM2) 
cagggaaagcttccagaaca cagggaaagcttccagaaca 8 
MUC1 Human mucin 1, cell surface associated cctgcctgaatctgttctgc catgaccagaacccgtaaca 77 
FOXM1 Homo sapiens forkhead box M1 actttaagcacattgccaagc cgtgcagggaaaggttgt 11 
CCNA1 Cyclin A1 (CCNA1), transcript variant 1 aaatgggcagtacaggagga ccacagtcagggagtgcttt 78 
CCNE2 Homo sapiens cyclin E2 (CCNE2) gccattgattcattagagttcca aaatactgtcccactccaaacc 74 
CDC25A cell division cycle 25A (CDC25A), 
transcript variant 1, 
catggactccaggagggtaa cactgctatctctttcatttgagg 34 
CDK1 Cyclin-dependent kinase 1 (CDK1), 
transcript variant 1, 
tggatctgaagaaatacttggattcta caatcccctgtaggatttgg 79 
CCNB2 Homo sapiens cyclin B2 (CCNB2) tggaaaagttggctccaaag tcagaaaaagcttggcagaga 7 
CCNA2 Cyclin A2 (CCNA2) ggtactgaagtccgggaacc gaagatccttaaggggtgcaa 84 
CCNB1 Homo sapiens cyclin B1 (CCNB1) catggtgcactttcctcctt aggtaatgttgtagagttggtgtcc 18 
E2F2 E2F transcription factor 2 (E2F2), aggggaagtgcatcagagtg gcgaagtgtcataccgagtct 23 
CDC7 cell division cycle 7 (CDC7), transcript 
variant 1, 
tgctatgcaacagataaagtttgtag tcctggtgtacctgcccta 62 
MYC Homo sapiens v-myc myelocytoamtosis 
viral oncogene homolog (avian) (MYC) 
tttttcgggtagtggaaaacc ttcctgttggtgaagctaacg 75 




2.6 Candidate antibody Immunohistochemistry 
Immunohistochemistry (IHC) refers to the process of selectively imaging antigens (e.g. 
proteins) in cells of a tissue section by exploiting the principle of antibodies binding 
specifically to antigens (epitope). Detection can either be direct with a labelled primary 
antibody to the antigen of interest, or an indirect approach with an unlabeled specific 
primary antibody to the antigen. Following binding a secondary, labelled antibody is 
applied. This secondary antibody is typically conjugated either with fluorescent or 
enzyme reporter to permit visualization.  
 
2.6.1 Sectioning and slide rehydration 
Tissue samples were obtained as outlined in section 2.2. The samples were formalin 
fixed for 24 hours then paraffin embedded (FFPE) as tissue blocks. Sections of 5μm 
thickness were cut by microtome (Leica RM2235, Germany), mounted on coated glass 
slides (1mm; Surgipath, Germany) and dried overnight in an oven at 50°C. Slide de-
waxing was performed by immersion in xylene twice for five minutes each time followed 
by rehydration in alcohol of reducing concentrations (x5 immersions). 
 
2.6.2 Antigen retrieval and primary antibody 
Antigen retrieval was performed in a Decloaking Chamber™ Pro (Biocare Medical, USA) 
by boiling at 125°C for 30 seconds then reducing the temperature to 90°C for 10 seconds 
in either 0.01 M citrate buffer (pH 6) or 10 mM Tris, 1 mM EDTA and 0.05% Tween-20 
buffer (pH9) (Table 2.13). The slides were then cooled and rinsed in water for 5 minutes. 
Endogenous peroxidase was inactivated by incubation of the slides in a solution of 3% 
H2O2/methanol (Sigma-Aldrich Ltd, Dorset UK; Thermo Fisher Scientific Ltd.) for 30 
minutes. The slides were then washed in tris-buffered saline with tween (TBST) twice 
for 5 minutes. 
 
1:5 normal horse serum (NHS) with 5% bovine serum albumin (BSA) was applied for 30 
minutes to block non-specific protein binding. 200Ul of primary antibody was then 
applied at the optimised concentration in 1:5 NHS with 5%BSA (Table 2.13) and 
incubated overnight in a humidified chamber at 4°C. Appropriate matched 
weight/concentration IgG was applied as a negative control and incubated overnight in 
the same fashion. Control immunoglobulins were from the same species in which the 
primary monoclonal antibodies were raised or the immunoglobulin fraction of serum 
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from non-immunised animals in which polyclonal antibodies were raised in place of the 
primary antibodies (Table 2.14).  
 
2.6.2 Secondary antibody and 3, 3’-Diaminobenzidine (DAB) 
Immunohistochemistry 
The subsequent day the slides were washed with TBST x2 then incubated with the 
appropriate ImmPRESS Ig reagent (see Table 2.15) for 30 minutes. Following two 
subsequent TBST washes DAB was applied (diluted 1 drop in 1ml of its supplied buffer; 
ImmPACT DAB, Vector laboratories, UK). Oxidisation of DAB by peroxidase enzymes 
yields a brown precipitate, indicating the presence of antibody-antigen complex - 
‘positive immunoreactivity’. The development of brown staining monitored under a 
microscope. The reaction was stopped by immersion in tap water.  
 
2.6.3 Dehydration, counterstain and mounting 
The slides were then counterstained with Harris haematoxylin, briefly rinsed in 1% acid 
alcohol (70% ethanol containing 1% concentrated hydrochloric acid) and immersed in 
Scott’s tap water (distilled water with 20 g/L sodium bicarbonate, 3.5 g/L magnesium 
sulphate) for 25 seconds, followed by dehydration through graded alcohols. Finally they 
were immersed in xylene for 10 minutes and mounted with glass coverslips using Pertex 
(Histolab Products AB, Gothenburg, Sweden). 
 
2.6.4 Exceptions to IHC protocol 
Three IHC experiments were performed in a different fashion to the methods outlined 
above:  
Immuno-localisation of the progesterone receptor (PR) in the cervix, immuno-
localisation of the oestrogen alpha receptor (ERα) in the endometrium and immuno-
localisation of the putative progesterone marker B-cell lymphoma (BCL6) in the 
endometrium. 
 
2.6.4.1 Immuno-localisation of CDC25A in the endometrium and PR in the cervix 
Slides were dewaxed, rehydrated, and antigen retrieval and inactivation of endogenous 
peroxidase performed as above. Prior to protein block an avidin and biotin block (Vector, 
USA) were performed sequentially for 15 minutes each with TBST washes in between. 
The protein block then primary antibody was applied as above then incubated overnight. 
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The following day the slides were washed in TBST and a secondary antibody applied 
(horse anti mouse with biotin conjugate, Vector BA2000) for 30 minutes. Following TBST 
wash, an avidin/biotinylated enzyme complex (ABC, Vector USA) was applied for 30 
minutes. The slides were then washed further in TBST prior to DAB enzyme for antibody 
localisation. Slides were counterstained, dehydrated and mounted as outlined in section 
2.6.3. 
2.6.4.2 Immuno-localisation of ERα in the endometrium 
ERα IHC was performed using an automated IHC staining system (Leica Bond-Max 
immunostainer, Leica Microsystems, UK). In summary slides were dewaxed and 
rehydrated then underwent citrate antigen retrieval as described in section 2.6.1/2. 
They were then inserted into slide chambers, inserted into the bond and underwent the 
following sequence of treatments: 
1. Bond wash (BW; Tris Buffered Saline (Fischer, USA with added Tween 20)); (10 
minutes) 
2. Peroxide block* (5 minutes) → BW (10mins) 
3. Primary antibody (60 minutes) → BW (10mins) 
4. Post primary* (15 minutes) → BW (10mins) 
5. Polymer* (15 minutes) → BW (10mins) 
6. Deionised water* rinse 
7. DAB* (10 minutes) → Deionised water* rinse 
8. Haematoxylin (5 minutes) → Deionised water* rinse 
9. Dehydrated and mounted by hand as described in 2.6.3 
All reagents marked * are from Leica Bond Polymer Refine detection kit. (DS 9800) 
 
2.6.4.3 Immuno-localisation of BCL6 in the endometrium 
BCL6 IHC was performed using an automated IHC staining system (Leica Bond III 
immunostainer, Leica Microsystems, UK). In summary slides were dewaxed and 
rehydrated as described in 2.6.1 then following insertion into slide chambers, inserted 
into the Bond instrument. They then underwent antigen retrieval in ER2 (a Leica Bond 
proprietary antigen retrieval solution pH 9; AR9640, Leica UK) for 20 minutes at 100° C 
then and underwent the following sequence of treatments: 
1. Bond wash (BW; AR9590, Leica UK) (10 minutes) 
2. Peroxide block* (5 minutes) → BW (10mins) 
3. Primary antibody (15 minutes) → BW (10mins) 
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4. Post primary* (8 minutes) → BW (6mins) 
5. Polymer* (8 minutes) → BW (4mins) 
6. Deionised water* rinse 
7. DAB* (10 minutes) → Deionised water* rinse 
8. Haemtoxylin (5 minutes) → Deionised water* rinse 
9. Dehydrated and mounted by hand as described in 2.6.3 
All reagents marked * are from Leica Bond Polymer Refine detection kit. (DS 9800) 
 
2.6.5 Image capture and analysis 
Slides were viewed with a Provis AX70 (Olympus Optical, UK) and photographs taken 
with a fitted Canon DS6031 camera (Cannon Amsterdam). In addition the majority of 
slides were scanned using a slide scanner (Axio scan.Z1; Zeiss, Germany). Scanned 
images were annotated using Zen Blue software. All slides were reviewed by both LHRW 
and ARWW. 
 
2.6.5.1 Histoscoring  
In certain immunohistochemical reactions, tissues staining was either clearly absent or 
present and so was not further quantified. In selected others a semi-quantitative 
histoscoring strategy was employed to determine immunohistochemical staining 
intensity and localisation.  
 
In ‘full thickness’ (section 2.2.1.1) endometrial tissue sections the tissue was divided 
into the following cellular compartments: surface epithelium (if present), glandular 
epithelium and stroma. In endometrial tissue sections derived using a pipelles biopsy 
sampler, tissue was divided in to glandular epithelium and stroma. Fallopian tube and 
cervical biopsies were not semi quantified.  
 
A histoscore of 0 – 300 was determined by multiplying a staining intensity grade of 0 – 3 
(where 0 = no staining, 1 = weak staining, 2 = moderate staining and 3 = strong staining) 
by an estimation of the percentage of tissue staining positive within each cellular 
compartment (to the nearest 10%).  All histoscoring was performed separately by two 
individuals, blinded to stage of cycle or treatment allocation and protein of interest. The 
mean and standard error of mean (SEM) were calculated.  
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Statistical analysis was performed using Graphpad prism software (Graphpad, USA). 
Data were subjected to the D’Agostino-Pearson omnibus normality test. Data with a 
Guassian distribution had a one-way ANOVA applied to determine difference between 
groups. For non-parametric data Kruskal-Wallis test was used to determine differences 
between sample groups.  If statistical significance was found post-hoc tests were applied 
(unpaired t-test or and Mann-Whitney test depending on distribution). p < 0.05 was 
considered to be statistically significant. 
 
This semi-quantitative histoscoring strategy is a standard method, and has been used in 
several previous studies (Aasmundstad, Haugen et al. 1992, Wang, Critchley et al. 1998, 
Critchley, Osei et al. 2006). Scores obtained with this method have been found 
comparable to those obtained by a computerised image analysis system, with a strong 
correlation found between the two methods (Wang et al., 1998).  
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Table 2.13 Antibodies and antigen retrieval used for immunohistochemistry 
Endometrial full thickness biopsy 
Protein Supplier Reference Antibody type Host Retrieval 
buffer 





PR Dako A0098 Polyclonal Rabbit Citrate Rabbit MP-7401 1:200 1 
PRB Cell Signalling 3157S Monoclonal Rabbit Citrate Rabbit MP-7401 1:800 1 
AR Spring Bioscientific M4070 Monoclonal Rabbit Citrate Rabbit MP-7401 1:200 1 
ERα Vector VP-E614 Monoclonal Mouse Citrate N/A: see 2.6.4.2 1:5000 2 
FKBP51 Abcam ab2901 Polyclonal Rabbit TRIS Rabbit MP-7401 1:1000 1 
FKBP52 Proteintech Europe 10655-1-AP Polyclonal Rabbit TRIS Rabbit MP-7401 1:600 1 
FOXO Cell Signalling  2880 Monoclonal Rabbit Citrate Rabbit MP-7401 1:250 1 
HAND-2 Santa Cruz SC9409 Polyclonal Goat Citrate Goat MP-7405 1:200 4 
BCL6 Novacastra NCL-L-Bcl-6-564 Monoclonal Mouse ER2 N/A: see 2.6.4.3 1:100 2 
PTEN Dako M3627 Monoclonal Mouse Citrate Mouse MP-7402 1:750 2 
CDC25A Abcam Ab2357 Monoclonal Mouse Citrate N/A: see 2.6.4.1 1:100 3 
Endometrial biopsy  
PTEN Dako M3627 Monoclonal Mouse Citrate Mouse MP-7402 1:400 2 
Ki67 Novacastra NCL-Ki67-MM1 Monoclonal Mouse Citrate Mouse MP-7402 1:500 2 
Fallopian tube 
PR Dako A0098 Polyclonal Rabbit Citrate Rabbit MP-7401 1:100 1 
PRB Cell Signalling 3157S Monoclonal Rabbit Citrate Rabbit MP-7401 1:800 1 
AR Spring Bioscientific M4070 Monoclonal Rabbit Citrate Rabbit MP-7401 1:500 1 
ERα Vector VP-E614 Monoclonal Mouse Citrate Mouse MP-7402 1:150 2 
Ki67 Novacastra NCL-Ki67-MM1 Monoclonal Mouse Citrate Mouse MP-7402 1:500 2 
Cervix 
PR Novacastra NCL-PCR-312 Monoclonal Mouse Citrate N/A: see 2.6.4.1 1:800 2 
PRB Cell Signalling 3157S Monoclonal Rabbit Citrate Rabbit MP-7401 1:400 1 
AR Abcam ab74272 Polyclonal Rabbit Citrate Rabbit MP-7401 1:200 1 
















Table 2.14 Control Antibodies used for immunohistochemistry 
Protein Supplier Reference Antibody type Concentration Ref No 
(table 2.13) 
Rabbit Ig fraction  Dako X0903 Polyclonal 20g/L 1 
Mouse IgG1 Sigma-Aldrich M7894 Monoclonal 5mg/ml 2 
Mouse IgG2 Sigma-Aldrich M5409 Monoclonal 200ug/ml 3 




















The impact of selective progesterone receptor 
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The composite parts of the female reproductive tract have common embryological 
derivatives yet have highly specialised individual function depending on the region. All 
elements express sex-steroids receptors which regulate their activity.  
3.1.1 Embryological development of the reproductive tract 
In vertebrates the urogenital system, consisting of the kidneys, gonads, urinary and 
reproductive tracts, develop from the mesoderm. The reproductive tracts develop from 
the mesonephric (Wolffian) and paramesonephric (Müllerian) ducts. The female 
phenotype is the default developmental outcome of the reproductive tract. Only in the 
presence of testicular influences (SRY, anti-Müllerian hormone (AMH), testosterone and 
insulin-like 3) does a male phenotype develop with differentiation of the mesonephric 
duct. In the absence of these factors the mesonephric ducts regress to leave vestigial 
structures only, namely the ovarian appendix and Gartner’s duct. The Müllerian ducts 
develop into the female reproductive tract.  This comprises of the urogenital sinus, sexual 
duct (upper vagina, cervix, uterine corpus and fallopian tubes) and the ovaries. External 
genitalia derive from the genital tubercle, fold and swellings (Table 3.1).  
 
The female sexual duct arises from the paramesonephric ducts (Figure 3.1). These 
appear between days 44-48 of gestation and develop as longitudinal invaginations of the 
coelomic mesothelium along the mesonephric ridge lateral to the mesonephric ducts. 
Under the influence on Wnt4 (produced by the mesonephros) these invaginations extend 
towards the mesonephric ducts (Kobayashi, Shawlot et al. 2004) and once associated, 
the tips form a proliferative centre (Figure 3.1A). Under the influence of Wnt9, this 
primitive uterovaginal canal migrates caudally towards the urogenital sinus. On contact 
with the terminal end of the uterovaginal canal it forms Müller’s tubercle. Posterior to 
this the urogenital sinus thickens to form the vaginal epithelial plate. This cannulates 
cranially from the caudal end to produce the lumen of the vagina (Figure 3.1B) (Carlson 
2008). 
 
Once the paramesonephric ducts contact the urogenital sinus they fuse to develop a true 
lumen, which cranially opens into the coelomic cavity. Fusion progresses cranially up to 









Figure 3.1 Embryological development of the female reproductive tract 
A Migration of the mesonephric and Müllerian duct with subsequent fusion in the midline. B 
Caudal protrusion of the fused Müllerian ducts towards the urogenital sinus with 
development of the sinovaginal plate at the distal end of the Müllerian duct. Subsequent 
canulisation of the vaginal plate to form the vagina. C Fusion of the Müllerian duct to form 
the uterus with sparing of the uterine tubes (subsequent fallopian tube).  
 
Adapted from Pansky B (1982). Differentiation of The Female Genital Tracts: Uterus, Vagina, 








Table 3.1. Embryological origins of the female reproductive tract 
Indifferent structure Female derivative 
Genital ridge Ovary 
Primordial germ cells Ova 
Sex cords Follicular (granulosa cells) 
Mesonephric tubules Oöphoron, paroöphoron 
Mesonephric (Wolffian) ducts Appendix of the ovary, Gartner’s duct 
Paramesonephric (Müllerian) ducts Uterine tube 
Uterus 
Upper vagina 
Definitive urogenital sinus (lower part) Lower vagina 
Vaginal vestibule 
Genital tubercle Clitoris 
Genital folds Labia minora 




fallopian tubes. The lower fused caudal element forms the single median uterovaginal 
primordium which gives rise to the epithelium and glands of the uterus. The adjacent 
mesenchyme is the progenitor of the endometrial stroma and myometrium (Figure 
3.1C).  
 
Correct differentiation of the Müllerian duct is dependent on a complex system of Hox 
and Wnt genes. A series of homeobox (Hox) genes are present in the epithelium of the 
human reproductive tract and are critical for the segmental patterning that develops in 
the reproductive tract. Hoxa9 is expressed at high levels in the uterine ducts that 
subsequently develop in the fallopian tubes. Hoxa10 is expressed in the developing 
uterus and Hoxa11 in the primordia of the lower uterine segment and cervix. Hoxa13 is 
expressed in the ecto-cervix and upper vagina (Figure 3.2) (Du and Taylor 2004). Hoxa10 
in particular plays a role in the determination of correct tissue boundaries (Mullen and 
Behringer 2014). The actions of Wnt4 and Wnt9 have been described above, 
differentiation is further modified by Wnt7a which is critical for uterine and fallopian 
tube development and expressed throughout the Müllerian duct. Expression continues 
after birth in the uterus and fallopian tube and appears necessary for the maintenance 
of expression of Hoxa10 and Hoxa11 (Mullen and Behringer 2014).  
 
Figure 3.2 Homeobox (Hoxa) gene expression in the female reproductive tract 
There is differentiation of HOX genes in the reproductive tract. These have a critical role in the regional 
differentiation of the developing reproductive tract and Hoxa10 and Hoxa11 expression persist in 
adult life. 
 
Adapted from and redrawn: Du, H. and H. S. Taylor (2004). Molecular regulation of mullerian 
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3.1.2 Normal histology of the human female reproductive tract 
3.1.2.1 Endometrium 
The endometrium is derived in utero from the median uterovaginal primordium 
(epithelium and glands) and the adjacent mesenchyme (endometrial stroma) as 
described in section 3.1.1. Following maturation of the HPO axis and the onset of 
puberty, the cyclical changes reflective of the menstrual cycle establish. The effects of the 
menstrual cycle upon the morphology of the endometrium have already been described 
in chapter 1 (section 1.2.3) but are briefly summarised below: 
 
Proliferative phase 
Following menstruation the exposed basal layer of the endometrium proliferates rapidly 
under the influence of systemic rising oestradiol (E2) concentrations. Concurrently the 
glandular cells within the endometrium expand: in the early proliferative phase the 
glandular cells are initially cuboidal and the glands themselves are small. By the late 
proliferative phase the glands are tortuous and the individual epithelial cells appear 
columnar. There is brisk proliferation and mitotic figures are observed in both epithelial 
and stroma. The stroma is compact throughout the proliferative phase and angiogenesis 
commences with elongation of the spiral arteries (Noyes, Hertig et al. 1950, Mutter and 
Ferenczy 2001).  
Secretory phase 
The morphological changes associated with progesterone (P4) exposure develop 
between ovulation and approximately 48 hours after P-withdrawal (due to demise of the 
corpus luteum). Following ovulation, proliferation is inhibited by P4 secretion from the 
corpus luteum. Glandular nuclei move to the centre of cells and mitosis is supressed. The 
endometrial glands become more tortuous and acquire increased secretion of 
glycoproteins, evident as sub-nuclear vacuolation (feature of the early secretory phase). 
These vacuoles are then discharged into the lumen of glands in the mid secretory phase. 
The endometrial spiral arterioles undergo remodelling to become increasingly coiled 
(Noyes, Hertig et al. 1950, Mutter and Ferenczy 2001, Girling and Rogers 2009). 
Menstrual phase 
In the absence of pregnancy the corpus luteum regresses, resulting in a rapid decrease 
in circulating P4 and E2. It is P-withdrawal that initiates menstruation. Localised 
inflammation within the endometrium occurs, characterised by infiltration of leucocytes, 
cytokine release with resultant oedema, activation of matrix metalloproteinases (MMPs) 
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and lysis of the extracellular matrix. This culminates in the shedding of the upper two-
thirds of the endometrium (the functional layer). The lower third of the endometrium 
(basal layer) remains in situ but has an exposed, raw mucosal surface that requires 
efficient repair (Maybin and Critchley 2015).  
 
3.1.2.2 Fallopian tube 
The fallopian tubes (FT) develop bilaterally from the uterine tube in utero as described 
in section 3.1.1. Macroscopically the FT connect the posterior superior fundus of the 
uterine cavity with the peritoneal cavity, adjacent to their corresponding ipsilateral 
ovary. The FT are typically 8-12cm long and 0.5-1.2cm in diameter. They have an over-
lying double layer of peritoneum; the mesosalpinx which connects to the broad ligament 
and are also connected to the uterine cornua by the utero-ovarian ligament. They have 4 
distinct segments, the interstitium (lying within the myometrium), the isthmus, the 
ampulla and the infundibulum with protruding fimbriae (Figure 3.3A). 
 
Microscopically the lumen of the tube is lined with a mucosal layer consisting of a single 
layer cells comprising of both ciliated columnar cells and non-ciliated secretory cells, 
with overlying stroma. Ciliated cells are most abundant in the infundibulum and the 
ampulla. The secretory cells produce the tubal fluid essential for the nutrition of the 
fertilised ovum as it proceeds towards the uterine cavity. There is marked folding of the 
mucosa, ‘plica’, which is most evident within the ampulla, which merges into the 
fimbriae. Overlying the stroma is a muscular layer, consisting of 3 layers of smooth 
muscle. The outermost layer is the serosa, formed from the visceral peritoneum (Figure 
3.3B). 
 
Recognition of a distinct oviductal cycle in women was first described in 1928 (Novak 
and Everett 1928). Under the influence of oestrogen in the proliferative phase of the 
menstrual cycle, both the number of ciliated cells and the activity of the cilia are 
increased. Furthermore the secretory cells increase their height and secretory activity, 
peaking at ovulation, with egress of height following discharge of their contents into the 
lumen of the tube (Pauerstein and Eddy 1979). Increased circulating P4 is associated 






Figure 3.3 Anatomy of the human fallopian tube 
A Regions of the fallopian tube  
B Low power representative H&E image of ampullary region of the fallopian tube 
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3.1.3.3 Cervix 
The cervix develops from the caudal end of the fused Müllerian ducts (as described in 
section 3.1.2) and represents the inferior aspect of the uterus. It is continuous at its 
superior margin with the uterine corpus, and at its inferior margins with the vaginal 
epithelium. The cervix itself also protrudes slightly into the vaginal lumen. In adult life it 
measures approximately 2.5cm in diameter and 3cm in length.  It is a fibro-muscular 
organ, lined with a mucous membrane and has 3 distinct regions – the ectocervix, the 
endocervix and the dividing squamo-columnar junction (SCJ) the latter of which has an 
adjacent region of squamous metaplasia, referred to as the transformational zone 
(Figure 3.4A). The epithelial surfaces overlie a predominantly fibrous stroma with some 
smooth muscle fibres. Through the centre of the cervix is a lumen connecting the vagina 
to the uterus: the endocervical canal, the vaginal opening termed the external os and 
opening into the uterine cavity the internal os. Though the cervix comprises of different 
epithelial types, they all arise from the Müllerian ducts (Reich and Fritsch 2014). 
 
The ectocervix is the region protruding into the vagina and covered with non-keratinised 
stratified squamous epithelium (Figure 3.4A & B). Cells are stratified and have 3 layers; 
superficial, intermediate and parabasal/basal (Figure 3.4B). The latter is the most active 
with occasional mitotic activity seen, and all layers have altered levels of glycogen 
depending on the availability of oestrogen.  
 
The endocervix is the tissue adjacent to the endocervical canal and is lined with simple 
glandular epithelium with branching crypts into the underlying stroma (Figure 3.4A & 
C). These cells are mucous producing and are tall and cylindrical. Occasional ciliated cells 
are seen, typically close to the internal os. The nucleus is typically adjacent to the 
basement membrane but can be displaced during active mucous secretion and pushed 
towards the centre of the cell. In the absences of inflammation or pre-
malignancy/malignancy mitosis is rare. The SCJ between the ecto- and endocervix is an 
abrupt transition (Figure 3.4D) but laterally evidence of squamous metaplasia can 
usually be demonstrated with immature squamous epithelium overlying endocervical 
crypts. The location of the SCJ varies during the phase of a woman’s reproductive life and 
can be altered by exogenous hormonal treatment. Squamous metaplasia is maximal 
under high oestrogenic stimulus, such as early pregnancy and when using the COCP. At 
menopause the SCJ recedes into the endocervical canal.
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Figure 3.4 Anatomy and histology of the human cervix 
A Low power microscopic images demonstrating ectocervical squamous epithelium (Sq), endocervical glandular epithelium (Gl) and the underlying 
stroma (St). The transformation zone (Tz) separates the true glandular and squamous epithelium which meet at the squamo-columnar junction.  
B Squamous epithelium C Glandular epithelium D Transformation zone 
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3.1.3 Sex-steroid receptor expression in the human reproductive tract 
Steroid hormones are synthesised from cholesterol, derived from circulating low-
density lipoprotein (LDL) or intracellular cholesterol esters (Figure 3.5). They all have 
the same basic ring structure comprising of 17 carbon atoms with different numbers of 
carbon side-chains. Glucocorticoids, aldosterone and progesterone (P4) all have 21 
carbon atoms, testosterone and other androgens have 19 and oestrogens have 18. They 
circulate either in free form, or protein bound, typically to sex hormone binding globulin 
(SHBG), cortisol binding globulin (CBG) and albumin.  
 
The predominant forms of oestrogen are oestrone (E1), oestradiol (E2) and oestriol (E3). 
The predominant forms of androgens are testosterone, androstenedione and 
dihydroepiandrostenedione (DHEA). In the female human the ovary is the predominant 
source of circulating oestrogen and progesterone, though there is some peripheral 
conversion of oestrogen from circulating androgens in adipose and breast tissue, the 
liver and adrenals. Androgens are synthesised in the adrenals and ovary, and are also 
peripherally converted from the less potent androgens, androstenedione and DHEA. 
 
The sex-steroids receptors act as ligand-activated transcription factors. The sex-steroid 
receptors comprise of the progesterone receptor (PR), the oestrogen receptor (ER) and 
the androgen receptor (AR). PR has two isoforms (PRA and PRB) (Wang, Critchley et al. 
1998) and ER has an alpha and beta sub types (ERα and ERβ) (Kuiper, Enmark et al. 
1996).  
 
These receptors all have a similar structure: a DNA-binding domain that contains 2 zinc 
finger motifs, a hinge domain and a domain responsible for ligand binding (Figure 3.6). 
Ligand selectivity is determined by sequence differences within the ligand-binding 
domains.  Following ligand binding the receptors undergo a conformational change. ER 
is situated in the nucleus but PR and AR are located in the cytoplasm in their unbound 
forms, complexed with a heat shock protein (HSP).  Following ligand binding they 
undergo a conformational change that causes HSP to dissociate, revealing a nuclear 
translocation signal that initiates translocation of the hormone-receptor complex to the 
nucleus. 
 
Once in the nucleus they typically form either homodimers or heterodimers with the 









Figure 3.5 Synthesis of sex-steroids from cholesterol  
Cholesterol is the precursor of all steroid hormones; it is oxidized to pregnenolone and then 
converted into progesterone by oxidation and a keto/enol tautomerization; other steroid 
hormones are derived from progesterone such as mineralocorticoids, cortisol, 












































































Transcriptional activity is further modified by the recruitment of additional co-
regulatory proteins that may either increase (co-activators) or decrease (co-repressors) 
transcription (Critchley and Saunders 2009, Wagenfeld, Saunders et al. 2016). 
 
The activity of the sex-steroids is thus dependent on the availability of the unbound 
ligand, its cognate receptor and co-regulatory proteins. The transcriptional endpoints of 
sex-steroid receptors (SSR) binding are altered by the cell type in which it is located.  
 
3.1.3.1 Endometrium 
The presence of SSR in endometrium and their variation across the menstrual cycle has 
been extensively described. 
Progesterone receptor (PR) 
PR encompasses both the A and B subunit. There is no specific antibody to the A subunit. 
Both expression and localisation of total PR varies across the menstrual cycle. One of the 
most comprehensive descriptions was published by Lessey et al in 1988 following semi-
quantitative immunohistochemical analysis of endometrial biopsies obtained at the time 
of hysterectomy from 33 normally cycling women (Lessey, Killam et al. 1988). Samples 
were dated according to Noyes criteria (Noyes, Hertig et al. 1950)  and split into 5 
categories; menses, early proliferative, late proliferative, early secretory and late 
secretory. Epithelial expression was low at the time of menses and rose throughout the 
proliferative phase. Following ovulation, expression rapidly fell and remained low up to 
and including menstruation. Stromal expression was moderate at the time of menses, 
and rose throughout the cycle, peaking in the early secretory phase. It then fell, with its 
nadir at menstruation (Lessey, Killam et al. 1988). A relatively similar pattern was 
demonstrated by Snijders et al, the exception being that Snijders further categorised the 
secretory women into early-, middle- and late-secretory phase, thus demonstrating the 
maximal epithelial expression to be in the early secretory phase. He also separately 
assessed the functional and basal compartments illustrating relatively similar patterns 
in both layers across the cycle (Snijders, de Goeij et al. 1992). A further assessment of PR 
expression with a separate ovulatory category but summation of both functional and 
basal immunopositivity suggested that ovulation was the point of maximal expression 
prior to decline in levels (Wang, Critchley et al. 1998, Mote, Balleine et al. 1999). 
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Figure 3.6 Structure of sex-steroid receptors 
A Protein structure, number of amino acids and B 3D representation of the sex steroid 
receptor superfamily.  
 
All family members share a common structural arrangement:  
A/B: N-terminal regulatory domain, contains the activation function AF-1 
C: DNA binding domain (DBD) which contains 2 zinc fingers which bind to DNA – hormone 
response elements (HRE) 
D: Hinge region 
E: Ligand binding domain (LBD), contains the activation function AF-2  
F: C-terminal regulatory domain 
 
3.6A Adapted and redrawn from Critchley et al Repro Sci 2009 
3.6B Reproduced form wikipedia. https://en.wikipedia.org/wiki/Nuclear_receptor 





PRB is maximally expressed in the mid-proliferative phase in both epithelium and 
stroma. Whilst levels subsequently fall, there is a brief increase of stromal expression in 
the early-secretory phase, with epithelial expression lowest in the late secretory phase 
and epithelial expression lowest at the time of menstruation (Wang, Critchley et al. 1998, 
Mote, Balleine et al. 1999). Through subtractive inference, it is thought that PRA is the 
dominant subtype in the early secretory phase (Wang, Critchley et al. 1998, Brosens, 
Hayashi et al. 1999), particularly in the basal layer of the endometrium (Snijders, de Goeij 
et al. 1992).   
Oestrogen receptor alpha (ERα)  
Lessey et al have previously described expression of ERα with epithelial expression 
rising through proliferative phase and waning rapidly in secretory with levels lowest at 
the time of menstruation. Stromal expression mirrors that of epithelial, with the 
exception that secretory levels fall less quickly (Lessey, Killam et al. 1988). This was in 
contrast to Snijders (Snijders, de Goeij et al. 1992) who demonstrated that epithelial ER 
expression remained relatively high in early secretory phase prior to very low levels in 
the mid secretory phase. The degree of reduction of expression between early and mid-
secretory phase was higher in the functional layer compared with basal endometrium. 
Snijders furthermore found that stromal expression was lowest in early secretory phase 
with a further small rise in the mid-secretory phase – reflecting circulating E2 levels 
(Snijders, de Goeij et al. 1992).  
 
The α and β subunits have been separately assessed. Both are expressed in the in glands 
and stroma. In the functional layer ERα reduces in both epithelial and stroma cells in the 
secretory phase, whereas ERβ declines only in the epithelial cells. Basal expression of 
both is unchanged by stage of cycle (Critchley, Brenner et al. 2001). ERα up regulates PR 
(Chauchereau, Savouret et al. 1992, Brosens, Tullet et al. 2004) and mediates 
proliferation (Jabbour, Kelly et al. 2006). The role of ERβ in the human endometrium is 
not fully elucidated (Critchley and Saunders 2009) but likely plays a role in attenuating 
ERα mediated response to oestrogen (Hapangama, Kamal et al. 2015). 
Androgen Receptor (AR) 
AR is expressed in the endometrium but expression is predominantly limited to the 
stroma  (Slayden, Nayak et al. 2001, Marshall, Lowrey et al. 2011, Whitaker, Murray et al. 
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2017). Basal expression is relatively constant but expression in the functional layer rises 
from proliferative phase levels to maximal expression in the early secretory stage, with 
minimal expression in late secretory. Glandular expression is minimal (Slayden, Nayak 
et al. 2001), and only occasional positive epithelial cells are observed following P-
withdrawal (Critchley and Saunders 2009).  
 
Cyclical alterations in sex-steroid receptors are summarised in Table 3.2. 
 
Table 3.2 Summary of sex-steroid receptor expression in human endometrium 
Sex-steroid 
receptor 
Phase of cycle 
 Proliferative Secretory 
Glands Stroma Glands Stroma 
PR Present Present Reduced Present 
PRB Present Present Reduced Markedly 
reduced 
ERα Present Present Reduced Reduced 
ERβ Present Present Reduced Present 
AR Absent Present Occasional LS Maximal ES 
ES: early secretory LS: Late secretory 
3.1.3.2 Fallopian tube 
Both PR and ER are present in the fallopian tube (Pollow, Inthraphuvasak et al. 1981). 
Epithelial PR are present throughout the menstrual cycle (Amso, Crow et al. 1994). PR 
and PRB are present in both the fimbriae and the ampulla, the PRB:PR ratio is higher in 
the ampullary region compared to the fimbrial region (Briton-Jones, Lok et al. 2005). 
Both PR and PRB are maximally down regulated in the secretory phase of the menstrual 
cycle (Horne, King et al. 2009). ER are maximal mid cycle with epithelial expression in 
both the ampulla and the fimbriae (Amso, Crow et al. 1994), but another study 
demonstrated that ERα does not alter significantly across the menstrual cycle (Horne, 
King et al. 2009). AR are present in fallopian tubes but are not significantly altered by 
phase of menstrual cycle (Horne, King et al. 2009). 
 
There are both similarities and differences in the effects of progesterone and oestrogen 
within the fallopian tube and the endometrium. In both tissues E2 stimulates cell 
proliferation and up regulates the PR. However within the fallopian tube P4 acts solely 
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as an oestrogen antagonist, and it is E2 that is responsible for epithelial hypertrophy, 
secretion, and ciliogenesis. This is in contrast to endometrium where P4 is responsible 
not only for antagonism of E2 action, but also stimulates cell differentiation, vascular 
proliferation and remodelling and decidualisation (Brenner and Slayden 1994). 
3.1.3.3 Cervix 
PR is expressed within the uterine cervix. Glandular epithelium expresses PR, and levels 
are relatively unchanged by stage of menstrual cycle (Lin 1984, Cano, Serra et al. 1990), 
though a non-significant rise can be detected in late proliferative phase (Snijders, de 
Goeij et al. 1992). There is disagreement as to whether squamous epithelium expresses 
PR with some studies demonstrating presence (Lin 1984, Ackerman, Summerfield et al. 
2016), with no effect of cycle phase (Lin 1984), and others demonstrating either total 
absence (Cano, Serra et al. 1990) or expression limited to the secretory phase (Nikolaou, 
Koumoundourou et al. 2014). PR is present in the cervical stroma but evidence is 
conflicting as to whether there is no cycle change in expression (Cano, Serra et al. 1990) 
or is increased in proliferative phase compared with secretory phase of the menstrual 
cycle (Lin 1984). PRB is also expressed within the stroma of the cervix (Winkler, Kemp 
et al. 2002), but limited evidence is available regarding other localization or change 
throughout the menstrual cycle. ERα is present in both the ecto and endocervix, with 
ectocervical expression down regulated in secretory phase and weak stromal staining 
(Cano, Serra et al. 1990, Nikolaou, Koumoundourou et al. 2014). Endocervical expression 
is either down regulated in secretory phase (Cano, Serra et al. 1990) or unaltered by 
stage of cycle (Snijders, de Goeij et al. 1992). AR is present in both the squamous 
epithelium and stroma of the human cervix (Noel, Bucella et al. 2008). Some small 
studies have indicated presence in the endocervix (van der Kwast, Dommerholt et al. 
1994) but there are no data published regarding effect of cycle stage of protein 
expression. 
 
3.1.4 Known effects of SPRMS on human reproductive tissue 
3.1.4.1 Endometrial morphology; Progesterone receptor modulator-associated 
endometrial changes (PAEC) 
SPRMs have an unusual effect upon the morphology of the endometrium. Initial clinical 
trials of long-term SPRM administration found increases in both endometrial thickness 
and rates of hyperplasia, typically simple in nature (Murphy, Kettel et al. 1995, Eisinger, 
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Meldrum et al. 2003, Levens, Potlog-Nahari et al. 2008, Bagaria, Suneja et al. 2009). This 
finding was felt not to be unexpected due to the likely endometrial impact of unopposed 
oestrogen (Murphy, Kettel et al. 1995). As greater experience of the histological effects 
of SPRMs accumulated, histological findings were increasingly described as non-
physiological secretory changes (Chwalisz, Larsen et al. 2007, Engman, Granberg et al. 
2009).  
 
In 2006 a meeting was called in Bethesda, USA. Stakeholders from industry, the Food and 
Drug Administration (FDA) and researchers were present and recognition of the 
difficulties posed to pathologists acknowledged, particularly given that the findings did 
not appear to easily match established diagnostic entities. Prior to the meeting slides 
from 84 women receiving SPRMs (mifepristone, ulipristal acetate, asoprisnil and JNJ-
17072341) were given to a panel of 7 expert pathologists who were blinded to treatment 
(Mutter, Bergeron et al. 2008).  There was agreement that some of the samples reviewed 
represented normal cycling variations and benign pathologies such as polyps and 
endometritis. Equally the expert pathology group concurred that some represented 
disordered proliferative and there were no overtly pre-malignant malignant cases. 
Finally there was a group that did not fit into any existing standard diagnostic group.  
 
The common theme of these unusual histological features was the co-existence within a 
single sample of individual histological features that are not seen in normal cycling 
endometrium and are usually attributed to either changes associated with hormone 
diminution, or stimulation with exogenous sex-steroids. These included inactive or 
apoptotic glands alongside intact stroma. Ciliated tubal metaplasia (an oestrogen-
associated event) was present in inactive or secretory endometrium. Individual glands 
had unusual combinations of mitotic activity (albeit low) alongside apoptotic 
degeneration or secretory change. Cystic dilatation was present but glands were only 
weakly mitotic and often had associated apoptosis. Within the stroma unusual 
appearances of the vasculature were observed including widely disseminated thick-
walled vessels (the degree of dispersion implying association with an endometrial polyp 
was unlikely) and delicate but prominent anastomosing capillary networks in a ‘chicken-
wire’ pattern.  Furthermore, stromal vessels were occasional ectatic but never 
demonstrated fibrin thrombi (a feature of unopposed oestrogen). These changes were 
summarised into a new histological entity referred to as progesterone receptor 
modulator-associated endometrial changes (PAEC) (Mutter, Bergeron et al. 2008). 
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The features of PAEC have been further refined and a pathologists guide has been 
produced by Gedeon Richter (https://www.hpra.ie/docs/default-source/3rd-party-
documents/educational-materials/esmya_pathologist-guide-sept-2015.pdf?sfvrsn=2 
2015, Gedeon Richter, Hungary) who manufacture the only SPRM licensed for clinical 
use in UK and Europe. They are generally split into four categories of features.  
 
1. Endometrial gland architectural irregularity and cystic dilatation 
a. Scattered cystic ducts intermixed with small tubular or tortuous glands. 
Some show significant cystic dilatation. 
b. Glands are occasionally crowded but this is limited to microscopic foci.  
2. Inactive glandular epithelium 
a. Glands are lined with a single layer of cuboidal or low columnar cells that 
do not have nuclear stratification.  
b. Occasional ciliated metaplasia can be observed. 
c. Infrequent mitoses are present. 
3. Non-physiological secretory appearance 
Glands are tortuous or coiled (thereby resembling secretory phase) but have 
poorly developed secretory activity. 
a. Low levels of mitosis with occasional apoptosis. 
b. Focal cytoplasmic vacuolations. 
c. Surface apocrine-type secretory changes, the lamina of cysts often 
contains a watery secretion. 
4. Glands are irregular distributed in densely cellular stroma without pre-decidual 
change. 
a. Glands are often widely dispersed in columns of dense stroma.  
b. Abnormal vasculature present: ‘chicken wire’ capillaries, thick-walled 





Table 3.3 Features differentiating between PAEC, unopposed oestrogen exposure 
and complex hyperplasia 





Cystic dilatation Usually present Present Absent/focal/widespread 
Disordered architecture Focal Focal Diffuse 
Complex architecture Absent Focal Diffuse 
Budding into stroma Absent May be present Present 
Luminal papillation Absent May be present Present 
Gland crowding Absent Focally present* Present 




Cell type Flat cuboidal Tall columnar Tall columnar 
Stratification of nuclei Absent Present Present 
Mitoses Infrequent Usually frequent Frequent 
Cytoplasmic vacuolation Common Uncommon Uncommon 
Nuclear size Small, ovoid Small or medium Large, rounded 
Nuclear shape Ovoid Ovoid or rounded Rounded 
Nucleoli Usually absent Usually present Present 
Nuclear atypia Absent Absent May be present 
Squamous metaplasia Absent Occasional Frequent 
Stroma 
Stromal density Compact, 
moderately 
cellular 
Abundant, may be 
densely 
cellular/oedematous 
Usually densely cellular 
Foam cells Absent Infrequent Present 
Stromal breakdown Absent Present Present 
Intravascular fibrin Absent Present Present 
*present in disordered proliferative pattern 
Adapted from Esmya® (ulipristal acetate): Pathologist’s guide PRM-Associated 





The key features for distinguishing PAEC from proliferative endometrium or hyperplasia 
are low mitotic activity, abortive sub nuclear vacuoles, apoptosis and absence of stromal 
breakdown and glandular crowding (Williams, Bergeron et al. 2012). Other elements 
help to distinguish from unopposed oestrogen effects and complex endometrial 
hyperplasia (Table 3.3). 
 
Amongst women administered SPRMs, rates of PAEC vary. In the largest clinical trials of 
UPA administration, around 78% of women treated with UPA for 3 months 
demonstrated non-physiological changes after treatment, but these rapidly regress to 
levels comparable to placebo group on cessation of treatment (Donnez, Tatarchuk et al. 
2012, Donnez, Tomaszewski et al. 2012, Williams, Bergeron et al. 2012). Limited 
numbers of randomised clinical trials published subsequent to the guidelines on the 
diagnosis of PAEC have specifically reported on rates of PAEC. One study examining 
mifepristone reported specific PAEC rates of 24.5% (Carbonell, Acosta et al. 2013) and 
other additional studies examining UPA found a rate of 7% (Segal, Zarek et al. 2014), 
10% (Nieman, Blocker et al. 2011) and 48% (Brache, Sitruk-Ware et al. 2012). Studies 
not specifically mentioning PAEC either report non-physiological secretory changes of 
88% [mifepristone; (Engman, Granberg et al. 2009)] and 43-58% [asoprisnil; (Chwalisz, 
Larsen et al. 2007)] or continue to report simple hyperplasia 25-63% [mifepristone; 
(Bagaria, Suneja et al. 2009, Prasad, Varun et al. 2013)]. The reason for such variation is 
unclear but may be influenced by either the duration of treatment, choice of agent, time 
of sampling relative to treatment schedule, familiarity of the reporting pathologist or 
method of sampling.  
 
3.1.4.2 Known effects of SPRMs on sex-steroid receptor expression in the 
endometrium 
As described in chapter 1, SPRMS have high affinity for PR (Attardi, Burgenson et al. 
2004), but do not bind ER (Wolf, Hsiu et al. 1989) or AR (Slayden and Brenner 2004). 
 
Knowledge regarding the effect of SPRMs on the reproductive tract has been derived 
both from clinical trials in humans and from studies in the non-human primate (NHP).  
Old world primates naturally menstruate. The rhesus macaque has a naturally occurring 
28 day cycle and an anatomically similar uterus with structures analogous to the fundus, 
corpus and isthmus (Brenner and Slayden 2012). Arising from the uterus are the 
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oviducts which are equivalent to the fallopian tubes (Brenner and Slayden 2012). The 
isthmus leads into the cervix, the anatomy of which varies between primates; in the 
rhesus macaque there is a colliculum which obstructs the canal (Demers, Macdonald et 
al. 1972). The endometrium is separated into 4 zones, corresponding to those observed 
in women. The upper 2 zones contain the luminal epithelium and straight necked glands. 
These are functional, and undergo secretory transformation and are supplied by spiral 
arteries. Zone III contains branched glands which terminate in zone IV, adjacent to the 
myometrium (Brenner and Slayden 2012). PR and ER are both expressed in the 
endometrium of naturally cycling animals (Brenner, West et al. 1990). 
   
The major contribution of this non-human primate model has been due to the ability to 
exclude hormonal fluctuations that naturally occur in both animals and women. 
Ovariectomy with subsequent sequential administration of oestradiol and progesterone 
as subcutaneous implants simulates the human proliferative and secretory phases, and 
removal of the progesterone implant (analogous to P-withdrawal following demise of 
the corpus luteum) initiates menstruation (Brenner and Slayden 2012). Uniformity of 
hormone exposure allows generation of precise experimental data with a decreased 
number of animals. PR and ER are expressed in an analogous fashion to naturally cycling 
humans (Critchley, Brenner et al. 2001, Slayden, Nayak et al. 2001) and AR expression is 
also observed (Brenner, McClellan et al. 1991, Adesanya-Famuyiwa, Zhou et al. 1999, 
Critchley, Brenner et al. 2001).  
Endometrium  
In the NHP mifepristone resulted in strong epithelial and stromal immunoreactivity of 
PR. This was in contrast to secretory phase where there was slight stromal 
immunolocalisation only. In proliferative phase both stromal and epithelial 
immunopositivity was present (Slayden and Brenner 1994). This was replicated with the 
SPRM ZK 230211 (lonaprisan) (Slayden and Brenner 2004). Treatment with the SPRM 
ZK 137316 also resulted in dense epithelial and stromal immunoreactivity in the 
functional layers, but stromal immunoreactivity was minimal within the basal layer 
(Slayden, Zelinski-Wooten et al. 1998). The previous studies had not differentiated 
between the two regions. There are no NHP studies regarding the impact upon of SPRMS 
on PRB expression and localisation. In human studies where mifepristone was 
administered, epithelial and stromal PR immunopositivity was similar to the 
proliferative phase (Narvekar, Cameron et al. 2004). The SPRM asoprisnil also increased 
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epithelial expression of PR compared with secretory phase, and in contrast to 
mifepristone, abrogated stromal expression (Wilkens, Male et al. 2013). Neither of these 
studies commented on the effects on PRB immunopositivity and localisation but a 
separate study has demonstrated in human endometrium a pattern of glandular 
immunopositivity with relative stromal sparing following administration of 
mifepristone (Sun, Christow et al. 2003). 
 
Endometrial ER expression is altered by administration of SPRMs. In the NHP, treatment 
with mifepristone resulted in moderate epithelial and stromal staining in proliferative 
phase, minimal immunopositivity in both cellular types in secretory phase, with strong 
immunopositivity in both glandular and stromal cells following mifepristone 
administration (Slayden and Brenner 1994). As with PR, the effect on ER expression 
following mifepristone was replicated with the SPRM ZK 230211 (Slayden and Brenner 
2004). The SPRM ZK 137316 also resulted in dense epithelial and stromal 
immunoreactivity, and this was present in both functional and basal layers (Slayden, 
Zelinski-Wooten et al. 1998). In human studies mifepristone administration resulted in 
an immunolocalisation that phenocopied proliferative phase (Narvekar, Cameron et al. 
2004).   
 
AR immunoreactivity in the NHP was limited to the stroma in both functional and basal 
layers in proliferative and secretory phases. Administration of the SPRMs mifepristone, 
ZK 137316 and ZK 2302111 increased stromal immunoreactivity markedly. 
Mifepristone was the most significant up regulator of AR immunopositivity. Strikingly, 
all three SPRMs markedly increased epithelial immunopositivity, most noticeably with 
mifepristone, though this increase was relatively limited to the functional layer. The 
exception to this was ZK 137316, which resulted in significant up regulation of AR 
expression epithelial cells in the basal layer as well (Slayden, Nayak et al. 2001). In 
women treated in vivo with the SPRM mifepristone a similar effect upon stromal and 
epithelial AR expression was noted with significant up regulation at either low dose 
(2mg) treatment for 30 days, or a single dose of 200mg (Slayden, Nayak et al. 2001). 
Samples were collected by suction catheter and so tissue examined was likely to be 
predominantly from the functional layer.  
 
In summary administration of SPRMs other than UPA impacted both upon SSR 
expression and localisation in the endometrium of NHP and humans. The most striking 
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effect upon SSR localisation was upon PR and AR expression, but differs depending on 
SPRM studied. ER expression was increased, without alteration of localisation. The 
effects are summarised in Table 3.4 
Fallopian tube  
Much of the data of the effect of SPRMs on the fallopian tube is limited to reports utilising 
the NHP models. Mifepristone administration is associated with ciliation and secretory 
epithelium morphologically, similar to proliferative phase. Epithelial and stromal PR & 
ER expression were similar to proliferative phase. In the secretory phase 
immunopositivity was limited to the stroma (Slayden and Brenner 1994). This was 
consistent with blockade by mifepristone of progesterone action within the oviduct. Of 
note epithelial PR positivity was not present in all nuclei, both in the proliferative phase 
and in mifepristone treated animals. Compared to secretory phase, ZK 137316 
administration results in a prevention of deciliated and non-secretory appearance in a 
dose dependent fashion, again suggestive of blockade of progesterone, but the impact 
upon SSR were not assessed (Slayden, Zelinski-Wooten et al. 1998).  
 
In human studies one study demonstrated that mifepristone increased PR concentration 
in both epithelial and stromal cells relative to secretory phase. Proliferative phase was 
not assessed. This effect was limited to the ampullary region, with no significant 
alteration in expression noted in the isthmic portion.  Utilising western blot, it was 
demonstrated that both PR and PRB were altered with mifepristone administration and 
that PRB had a greater increase following treatment with mifepristone (Christow, Sun et 
al. 2002). A separate study also demonstrated an increase relative to secretory phase, in 
both epithelial and stromal immunopositivity of PRB following mifepristone, and that 
this was evident both in the ampulla and the isthmus (Sun, Christow et al. 2003). 
Mifepristone increased ER epithelial expression but not in the stroma. In contrast to PR, 
this alteration in expression was more marked at the isthmic region compared with 
ampulla (Christow, Sun et al. 2002).  
 
The proliferative phase was not assessed in the human studies, and so direct comparison 
between immunopositivity of PR in human tissue in proliferative phase and following 
SPRM administration cannot be commented upon, thus conclusions regarding tissue 
specificity effects rely upon the NHP studies described above. These data would suggest 
that it is only relative to secretory phase that tissue morphology and SSR expression are 
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altered, suggesting within the fallopian tube it is a non-competitive anti-oestrogen effect 
that is observed. This is in contrast to the endometrium, and thus suggests an 
endometrial specific effect. 
Cervix 
Much of the existing literature on the cervical effects of SPRMs are in respect to the use 
of mifepristone in the context of management of unintended pregnancy (in conjunction 
with misoprostol), and as a cervical ripening agent for the induction of labour. In the 
setting of pregnancy in animal models, administration of mifepristone results in an influx 
of macrophages (Kirby, Heuerman et al. 2016) and decreased collagen content (Yellon, 
Dobyns et al. 2013).  
 
Oral administration of SPRMs to the non-pregnant cervix does result in altered 
functionality. Cervical dilation is increased following mifepristone treatment (Gupta and 
Johnson 1990, Bokström and Norström 1995). In vitro treatment increases collagen 
synthesis (Bokström and Norström 1995), and abrogates P-agonist-induced PR and PRB 
down-regulation (Ackerman, Summerfield et al. 2016)   
3.1.4.3 Known effects of Ulipristal acetate (UPA) 
Studies of the effect of UPA on the endometrium in NHP models show similar patterns of 
immunolocalisation of PR and ER as in proliferative phase (secretory was not assessed) 
(Brenner, Slayden et al. 2010). Both PR and ER were strongly expressed in epithelial and 
stromal cells in both groups. Studies in NHP demonstrate strong epithelial 
immunopositivity of AR following treatment with UPA, in contrast to proliferative phase 
when immunopositivity was limited to the stroma only (Brenner, Slayden et al. 2010). 
Studies on the effects of UPA on SSR expression in human endometrium have been 
limited to conference abstracts only prior to the publication of data from this thesis 
(Murray, Williams et al. 2014). These demonstrated a similar pattern of 
immunolocalisation of PR as the effect of asoprisnil with no reported data within the 
abstract upon the localisation of ER and AR. The effects on SSR expression and 
localisation following administration both UPA and other SPRMS to date are summarised 





Table 3.4 Summary of known effects of SPRMs on sex steroid receptor expression and 
localisation in the endometrium of the non-human primate (rhesus macaque) and human  
SPRM Model Protein expression and localisation Reference 
  
PR PRB ERα AR 
 
    G S G S G S G S   
Mifepristone NHP ++ ++ NK NK ++ ++ ++* ++ (Slayden and Brenner 
1994, Slayden, Nayak 
et al. 2001)  
Human ++ ++ NK NK ++ ++ ++ ++ (Slayden, Nayak et al. 
2001, Narvekar, 
Cameron et al. 2004)            
ZK137316 NHP ++ ++ NK NK ++ ++ ++# ++ (Slayden, Zelinski-
Wooten et al. 1998, 
Slayden, Nayak et al. 
2001)  
Human NK NK NK NK NK NK NK NK 
 
           
ZK230211 NHP ++ ++ NK NK ++ ++ ++* ++ (Slayden, Nayak et al. 
2001, Slayden and 
Brenner 2004)  
Human ++ ++ NK NK + + ++* ++ (Heikinheimo, Vani et 
al. 2007)            
Asoprisnil NHP NK NK NK NK NK NK NK NK 
 
 
Human ++ - ++ - NK NK NK NK (Sun, Christow et al. 
2003, Wilkens, Male 
et al. 2013)            
           
UPA NHP ++ ++ NK NK ++ ++ ++ ++ (Brenner, Slayden et 
al. 2010) 
  Human NK NK NK NK NK NK NK NK   
 
PR: Progesterone receptor, PRB: Progesterone receptor B, ERα: Oestrogen receptor alpha, 
AR: Androgen receptor, G: Gland, S: Stroma, NHP: Non-human primate, NK: not known 
++ Strong immunopositivity + light immunopositivity +/- infrequent immunopositivity 
*Minimal/absent immunopositivity in basal layer 
++#: ++ in functional layer, + in basal layer 
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Studies of the effects of UPA on the human fallopian tube are limited to in vitro treatment 
with UPA. Ciliary beat frequency was reduced and PR/PRB mRNA levels increased in a 
dose-dependent fashion but effect on protein expression and localisation was not 
assessed (Li, Liao et al. 2014).  
 
A separate group of researchers also using an in vitro treatment system demonstrated 
no alteration in ampullary morphology following treatment with UPA, although baseline 
cycle stage was not stated. They demonstrated increase in ampullary PR and ERα 
epithelial immunolocalisation following UPA treatment. They also observed an increase 
in stromal PR immunopositivity but ERα was unchanged (Yuan, Zhao et al. 2015). 
 
There appear to be no published studies regarding the impact of UPA on cervical 
morphology and SSR expression. 
 
3.2 Hypothesis  
Whilst the effects of UPA on endometrial histological morphology are well recognised, 
incidence varies highly and impact upon the morphology of the human fallopian tube and 
cervix is unknown. There is almost negligible published literature on the effects of UPA 
on SSR expression and localisation in human reproductive tract tissue. The majority of 
the published literature is limited to NHP studies or in vitro studies. Other SPRMs 
demonstrate profound effects upon SSRs within the endometrium but descriptions have 
been limited and are occasionally contradictory. Within the fallopian tube, the effects of 
other class members in NHP models demonstrate alteration relative to secretory phase 
only and within the cervix the very limited data suggests blockade of P-mediated effects 
only. This suggests a possible endometrial specific effect upon localisation and 
expression.  
 
Hypothesis: SPRM administration has an endometrial specific effect upon the 




3.3 Aim  
To describe the impact of SPRM administration upon steroid receptor expression 
and localisation in the epithelium of the human female reproductive tract 
- Is there a morphological effect of UPA administration on the endometrium, 
fallopian tube and cervix?  
- Is there alteration in sex-steroid receptor mRNA levels in the endometrium and 
fallopian tube? 
- Is there alteration in sex-steroid receptor protein expression and localisation in 
the endometrium, fallopian tube and cervix?  
- Is the effect endometrial specific? 
 
3.4 Materials and methods 
Nine women with symptomatic fibroids underwent hysterectomy following treatment 
with Ulipristal acetate (UPA) 5mg orally once daily for up to 15 weeks prior to surgery 
(minimum nine weeks of treatment). They had given informed consent and the study 
had REC approval (12/SS/0238; section 2.1.1). At the time of surgery, biopsies were 
collected from the endometrium and fallopian tube/cervix if removed concurrently. 
Samples were processed as previously described (section 2.2) and tissue taken for RNA 
extraction for RT-qPCR and formalin fixation prior to immunohistochemistry. 
Corresponding control biopsies from women with symptomatic fibroids in proliferative 
and secretory phase of cycle were obtained from tissue archives (section 2.1.1). Subjects 
were well characterised (section 2.4.1 Table 2.3-5, Table 2.10-13). 
 
RNA was extracted, quality checked and cDNA produced prior to performing RT-qPCR 
for PR, PRB, AR and ERα (as previously described; section 2.5) of the endometrium (n=9 
in each group) and fallopian tubes (n=6). Endometrial PCR was performed by AA Murray 
and not repeated by LHRW due to scarcity of RNA from these valuable samples, but ΔΔCT 
transformation of raw data, statistical analysis and figures were all performed by LHRW. 
FFPE sections were cut for H&E staining and immunolocalisation of PR, PRB, AR and ERα 
performed (section 2.6, Table 2.13-2.14). This was performed on the endometrium 
(n=6-9), fallopian tube (n=6) and cervix (n = 8 UPA, 4 proliferative and 5 secretory).  ERβ 
was not assessed in any tissue types. 
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Statistical analysis of RT-qPCR results was performed using Graphpad prism software 
(Graphpad, USA). Data were subjected to the D’Agostino-Pearson omnibus normality 
test. Data with a Guassian distribution had a one-way ANOVA applied to determine 
difference between groups. For non-parametric data Kruskal-Wallis test was used to 
determine differences between sample groups.  Results are presented as ±SEM.  p < 0.05 
was considered to be statistically significant. Following ANOVA/Kruskal-Wallis test 
post-hoc testing was performed if appropriate using Tukey’s or Dunn’s multiple 
comparison.  
3.5 Results 
3.5.1 Effect of UPA administration on endometrial morphology and sex-steroid 
receptor expression 
3.5.1.1 Endometrial morphology is altered by administration of UPA and causes 
characteristic changes 
Administration of UPA impacted upon endometrial morphology (Figure 3.7 & 3.8). All 
subjects demonstrated features of PAEC although the degree of cystic dilatation was 
more marked in some (Figure 3.7D, E F, & I) than others (Figure 3.7A & G). There was 
evidence of focal gland crowding (Figure 3.7A, D, H & 3.8A; 1.), irregular scattering 
(Figure 3.7A, D, F & I) and architectural irregularity:  along with cystic dilatation the 
evidence of tortuosity associated with the gland dilatation (Figure 3.7C & I, 3.8B; 2.).  
 
The glands often appeared relatively inactive: they were lined with a single layer of 
cuboidal cells without nuclear stratification (Figure 3.8C & D; 3.). Occasional ciliated 
metaplasia was seen (Figure 3.8E; 4.). Many glands displayed a non-physiological 
secretory appearance and whilst they were coiled or tortuous (thus resembling 
secretory phase) they had poorly developed secretory activity, i.e. mitoses were 
observed, albeit infrequently (Figure 3.8F; 5.) and apoptosis was occasionally present 
(Figure 3.8G; 6.). Surface apocrine-type secretory changes were often observed with 
characteristic ‘blebbing’ at the luminal surface of the gland (Figure 3.8G; 7.). Some cells 
exhibited cytoplasmic vacuolation but this was infrequent (Figure 3.8C; 8.). The dilated 
glands were filled with fluid (Figure 3.8E & G; 9.). Macroscopically this fluid was watery 
in appearance at the time of endometrial sampling. The stroma was predominantly 
densely packed (Figure 3.7B, C, E-G, 3.8C-G; 10) and there was no evidence of pre-




Figure 3.7 Treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA) results in altered endometrial histology 
Representative H&E images of 9 full thickness endometrial biopsies. All subjects demonstrate 
progesterone receptor associated endometrial changes (PAEC). The degree of cystic 
dilatation is variable with some subjects demonstrating more cystic dilatation (E/F/I) than 
other subjects (A/G).  
A Subject CP1231, B Subject CP1232, C Subject CP1233, D Subject CP1234, E Subject CP1235, 
F Subject CP1236, G Subject CP1237, H Subject CP1238, I Subject CP1239. 







Figure 3.8 Treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA), results in specific features of progesterone receptor modulator associated 
endometrial changes (PAEC) 
Representative H&E images of full thickness (endometrial lumen to endometrial-myometrial 
junction) endometrial biopsies obtained at the time of hysterectomy from women treated 
with UPA for up to 15 weeks. Feature of PAEC are present: 
Endometrial glands demonstrate focal crowding (1; within image A) and extensive cystic 
dilation with a tortuous appearance to glands (2; within image B).  
Glandular epithelium appears inactive with low cuboidal, non-stratified epithelial cells (3; 
within image C & D). There is evidence of ciliated metaplasia (4; within image E). Mitoses are 
present but low in number (5; within image F) and apoptosis is occasionally observed (6; 
within images F & G). There is evidence of non-physiological secretory differentiation with 
surface apocrine-type secretory changes (7; within image G) and occasional cytoplasmic 
vacuolation (8; within image C). Watery secretions may be observed in the lumen of glands 
(9; within image E & G). Glands are irregularly scattered (image A) and stroma is densely 
packed (10; within image C-G) with a non-decidualised appearance. 
Abnormal vasculature may be observed with both thick-walled arterioles (11a; within image 
H) and ectatic thin-walled vessels (11b; within image A). 
Scale bars 500μm low power, 50μm high power  
Key 
1. Focal crowding 
2. Dilated and tortuous glands 
3. Low cuboidal, non-stratified epithelial cells 
4. Ciliated metaplasia 
5. Infrequent mitoses 
6. Apoptosis 
7. Surface apocrine-type secretory changes 
8. Cytoplasmic vacuolation 
9. Watery secretions 
10. Densely cellular stroma  
11. Abnormal vasculature 
a. Thick-walled vessels 
b. Ectatic thin-walled vessels 
 
A Subject CP1231, B/D Subject CP1232, C Subject CP1234, E Subject CP1233, F Subject 






Occasional unusual vasculature could be observed but was not ubiquitous. Some 
arterioles showed a thickened muscularis (Figure 3.8H; 11a.), and observed in only 3 
subjects (CP1235; Figure 3.7E & 3.8H, CP1236; Figure 3.7F and CP1238; Figure 3.7H). 
Others had a thin walled, ectatic appearance (Figure 3.8A, 11b.). Overall the majority of 
the vasculature was normal. 
 
The degree of cystic dilatation did not correspond to duration of treatment or bleeding 
control (table 2.4). The subject who had increased bleeding had occasional significant 
cystic dilatation (CP1234; Figure 3.7D). Of the 2 subjects who had irregular spotting one 
had evidence of dilated cysts (CP1232; Figure 3.7B) and the other had less widespread 
cystic dilatation (CP1237; Figure 3.7G).  
 
All subjects had 2 or more biopsies obtained. One sample was obtained from the fresh 
specimen as described in section 2.2.1.1 and the second following the overnight fixation 
of residual uterine specimen for standard diagnostic assessment. The later were initially 
reported by general pathologists and one was described as normal secretory (CP1231) 
and another as normal proliferative (CP1232). However following expert pathology 
review, (Professor ARW Williams) it was concluded that all biopsies (both research and 
standard diagnostic) demonstrated features of PAEC.  
 
No subjects had evidence of hyperplasia, neoplasia, polyps or infection. 
3.5.1.2 Treatment with UPA increased relative mRNAs levels encoded by sex-
steroid hormone receptors   
UPA increased relative PR and PRB mRNA levels in the endometrium significantly compared 
to secretory phase endometrium but these was not significantly different to proliferative phase 
samples (Figure 3.9A, B).  Relative concentrations of PR and PRB mRNAs were significantly 
lower in secretory endometrium compared to proliferative tissue. Relative AR mRNA levels 
in UPA-treated samples were significantly increased compared to both proliferative and 
secretory phase samples. AR mRNA levels were not significantly different between 
proliferative and secretory phase samples (Figure 3.9C). Relative levels of ESR1 (ERα) 
mRNA were significantly higher in UPA-treated samples and proliferative phase than in 
secretory phase. There was no significant difference in ESR1 concentration between 








































































































































































Figure 3.9 Treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA), increased the concentration of mRNAs encoding sex-steroid receptors in tissue 
extracts from human endometrium as determined by RT-qRT-PCR 
 
Relative mRNA levels of progesterone receptor (PR; A Kruskal-Wallis p <0.0001), PRB 
(B Kruskal-Wallis p = 0.0001), androgen receptor (AR; C Kruskal-Wallis p = 0.0001) and 
oestrogen receptor S1 (ESR1; D Kruskal-Wallis p = 0.0004) from woman with fibroids 
during proliferative and secretory stages after UPA administration. n=9 for each group. 





3.5.1.3 Immunoexpression of endometrial sex steroid receptors is altered by UPA 
administration.   
In agreement with previous studies (Lessey et al., 1988; Wang et al., 1998) intense 
immuno-positive staining for PR (with antibody recognising both isoforms) was 
detected in cell nuclei in both glandular epithelial cells and stromal fibroblasts in 
proliferative endometrium (Figure 3.10A & D).  Intensity was reduced in epithelial cell 
nuclei in the secretory phase with minimal immunopositive staining. Within the stroma 
immunopositive staining appeared strong (Figure 3.10B & E).  UPA-treated 
endometrium showed a pattern of PR immunopositive staining characterised by intense 
staining of nuclei in glandular epithelium and weak/negligible immunoexpression in 
stromal fibroblasts in both functional and basal layers (Figure 3.10C & F).  This pattern 
did not phenocopy either proliferative or secretory endometrium (Figure 3.10D & E).   
 
These results of localisation alteration were mirrored by results obtained using a PRB-
specific antibody (Figure 3.11), although strong immunopositivity appeared less 
frequently in the stromal nuclei of secretory endometrium (Figure 3.11E) and the 
epithelial cells of UPA exposed endometrium (Figure 3.11F) compared with proliferative 
endometrium (3.11D) or PR immunopositivity (Figure 3.10).  
 
Consistent with previous findings in our group (Marshall et al., 2011), immunopositive 
staining for AR was detected in nuclei of stromal fibroblasts in proliferative 
endometrium (Figure 3.12A & D). Occasional AR positive epithelial cells were detected 
in secretory phase (Figure 3.12E), coincident with a reduction in staining intensity in 
stromal cells. Immunostaining of UPA-treated endometrial sections revealed a unique 
pattern characterised by intense immunopositive staining of cell nuclei in both epithelial 
cells and stromal fibroblasts (Figure 3.12C & F).  Immunopositive stromal and epithelial 
nuclei were observed in the full thickness of the endometrium (Figure 3.12C), including 









Figure 3.10 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA), modulates progesterone receptor (PR) localisation 
Representative low- (A-C) and high-power (D-F) immuno-localisation of PR in endometrium 
from woman with fibroids during proliferative (A&D) and secretory stages (B&E) after UPA 
administration (C&F). Samples from UPA-treated women displayed intense immunopositive 
(+ = positive and - = negative) glandular nuclei with only a few immunopositive cells in the 
stroma, a result in contrast with proliferative phase (G+S+) or secretory phase (G-S+). Lower 
power (scale bar = 500µm) and high power magnification (scale bar = 50 µm); G: Glands, S: 











Figure 3.11 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA), modulates PRB receptor localisation 
Representative low- (A-C) and high-power (D-F) immuno-localisation of PRB in endometrium 
from woman with fibroids during proliferative (A&D) and secretory stages (B&E) and after 
UPA administration (C&F). Samples from UPA-treated women displayed intense 
immunopositive (+ = positive and - = negative) glandular nuclei with only a few 
immunopositive cells in the stroma, a result in contrast with proliferative phase (G+S+) or 
secretory phase (G-S+). Lower power (scale bar = 500µm) and high power magnification 
















Figure 3.12 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA), modulates androgen receptor (AR) localisation 
Representative low- (A-C) and high-power (D-F) immuno-localisation of AR in endometrium 
from woman with fibroids during proliferative (A&D) and secretory stages (B&E) and after 
UPA administration (C&F). Samples from UPA-treated women (C & F) displayed intense 
immunopositive (+ = positive and - = negative) glandular and stroma nuclei, a result in 
contrast with proliferative phase (D; G-S+) or secretory phase (E; occasional G+, arrowed, and 
light S+). AR immuno-positive glandular nuclei were present in both the functional and basal 
endometrium (F; basal) and were observed at the myometrial interface (M). Lower power 
(scale bar = 500µm) and high power magnification (scale bar = 50 µm); G: Glands, S: Stroma. 















Figure 3.13 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA), modulates oestrogen receptor alpha (ERα) receptor localisation 
Representative low- (A-C) and high-power (D-F) immuno-localisation of ERα in endometrium 
from woman with fibroids during proliferative (A&D) and secretory stages (B&E) and after 
UPA administration (C&F). Samples from UPA-treated women (C & F) displayed intense 
immunopositive (+ = positive and - = negative) glandular and stroma nuclei, a result in 
contrast with proliferative phase (G+S+) or secretory phase (G+S-). The secretory sample 
shown is from early secretory, hence the maintenance of glandular immunopositivity. 
Lower power (scale bar = 500µm) and high power magnification (scale bar = 50 µm); G: 




The expression profile of ESR1 (ERα) protein differed between proliferative and 
secretory endometrium with reduced immunoexpression detected in secretory phase 
tissue in stromal fibroblasts (Figure 3.13A & C, B & E). In the example shown epithelial 
ERα immunopositivity is maintained (Figure 3.13B &E), this sample is from early 
secretory phase. As expected, in samples from mid- and late-secretory, the epithelial 
immunopositivity was lost (data not shown). ERα immunoexpression in UPA-treated 
endometrium mirrored that of proliferative endometrium and appeared more intense in 
degree of staining (Figure 3.13C & F).  
 
3.5.1.4 Summary of impact of UPA on sex-steroid receptor expression and 
localisation in the endometrium 
The results of the effect of UPA upon sex-steroid receptors in the endometrium are 
summarised in Table 3.5. 
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Table 3.5 Impact of UPA administration on endometrial sex-steroid mRNA levels and 
protein expression and localisation 
SSR Relative mRNA level Protein expression and localisation 
 
 Proliferative Secretory UPA 
G S G S G S 
PR 
 
++ ++ - ++ +++ - 
PRB 
 
++ ++ - ++ ++ - 
AR 
 
- ++ +/- + ++ +++ 
ERα 
 
++ + +/- +/- ++ ++ 
 
SSR: sex steroid receptor, G: glandular epithelium; S: stroma PR progesterone receptor; PRB: 
progesterone receptor B; AR: androgen receptor; ERα: oestrogen receptor alpha.  
* p <0.05, ** p <0.01, *** p <0.001    
+++ Dense immunopositivity, ++ moderate immunopositivity + light immunopositivity +/- 


































































































































































3.5.2 Effect of UPA administration upon fallopian tube morphology and sex-
steroid receptor expression 
 
3.5.2.1 UPA administration did not alter fallopian tube morphology compared to 
proliferative phase 
At low magnification fallopian tubes from women in proliferative phase (Figure 3.14A) 
or secretory phase (Figure 3.14B) of the menstrual cycle or following UPA administration 
(Figure 3.14C) were indistinguishable.  At higher magnification in proliferative phase 
ampullary nuclei in epithelial cells were pseudostratified (Figure 3.14E&I, *) and the 
luminal aspect of cells demonstrated multiple ciliations (arrowed). In contrast nuclei in 
secretory phase were stratified, and more cuboidal in morphology with minimal 
cytoplasm (Figure 3.14F&J). Cilia appeared rarely, though the frequency varied between 
subjects. Epithelium from women administered UPA demonstrated multiple ciliations 
and a pseudostratified appearance (Figure 3.14G&K), resembling proliferative phase 
(Figure 3.14E&I). Fimbria from women administered UPA demonstrated ciliation and 
some pseudostratification (Figure 3.14H&L). 
 
3.5.2.2 Administration of UPA modulated relative mRNA levels of PR and ERα in 
the fallopian tube relative to secretory but not proliferative phase 
UPA increased fallopian tube PR and ERα relative mRNA levels compared with secretory 
phase (p < 0.05; Figure 3.15A & D). There was no statistical difference between UPA and 
secretory phase relative mRNA levels of PRB or AR (Figure 3.15B & C). There was no 
statistical difference between proliferative phase relative mRNA levels of either PR, PRB, 
AR or ERα and UPA exposed fallopian tubes (Figure 3.15). There was a generalised trend 
towards reduced secretory levels of PR, PRB and ERα compared to proliferative phase 
but this did not achieve statistical significance (Figure 3.15A, B &D). 
 
3.5.2.3 Administration of UPA increased expression of PR and ERα but did not 
alter localisation. 
PR nuclear immunopositivity was observed in the ampullary glandular epithelium of 
proliferative phase, secretory and UPA exposed fallopian tubes (Figure 3.16A-C & E-G). 
The intensity of immunopositivity appeared most dense in UPA exposed fallopian tubes 
















Figure 3.14 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA) results in fallopian tube ampullary epithelial histology that resembles that 
from women in proliferative phase 
Representative H&E images from the ampullary region of the fallopian tube from women 
in the proliferative (A, E, I) and secretory (B, F, J) phase of the menstrual cycle, and following 
administration of UPA (C&D, G&H, K&L). 
Nuclei in proliferative phase are pseudostratified (E&I,*) with multiple ciliations (↑). Nuclei 
in secretory phase are stratified, and more cuboidal in morphology with minimal cytoplasm 
(F&J). Cilia are appeared rare though frequency varied between subjects. Epithelium from 
women administered UPA demonstrate multiple ciliations and a pseudostratified 
appearance (G&K), resembling proliferative phase (E&I). Fimbriae from women 











Figure 3.15 Administration of selective progesterone receptor modulator, ulipristal 
acetate (UPA) modulates relative mRNA levels of progesterone receptor (PR) and 
Oestrogen receptor alpha (ERα) in the fallopian tube 
Relative mRNA levels of PR (A Kruskal-Wallis p = 0.0152), PRB (B Kruskal-Wallis p = 0.1881), 
androgen receptor (AR; C Kruskal-Wallis p = 0.7402) and oestrogen receptor S1 (ESR1; D 
Kruskal-Wallis p = 0.0116) from woman with fibroids during proliferative and secretory stages 
and after UPA administration. Samples from UPA-treated women had increased mRNA levels 
of PR and ERα compared to women in the secretory phase. PRB and AR mRNA levels were 




appeared only moderate in secretory phase (Figure 3.16F). This has not been quantified. 
Whilst epithelial staining was intense within the epithelium of ampulla from UPA 
exposed women, a less dense immunopositivity was observed in the epithelium of the 
fimbrial end (Figure 3.16D & H). There was intermittent light stromal immunostaining 
irrespective of stage of cycle or UPA treatment.  
 
In keeping with PR immunopositivity, PRB immunoreactivity was most marked in 
ampullary epithelial nuclei, with occasional moderate stromal staining (Figure 3.17). 
Stromal staining was unaffected by stage of cycle or UPA treatment (Figure 3.17E-H). 
Ampullary epithelial immunopositivity was most dense in proliferative phase (Figure 
3.17A & E), was slightly less ubiquitous following UPA treatment (Figure 3.17C & G) and 
appeared less dense in the secretory phase (Figure 3.17B & F). PRB immunopositivity in 
the fimbrial end phenocopied ampullary staining (Figure 3.17D & H). AR ampullary 
epithelial immunopositivity mirrored that of PRB with the most dense staining evident 
in the proliferative phase (Figure 3.18A & E) and somewhat less extensive in the 
secretory phase (Figure 3.18B and F) and following UPA treatment (Figure 3.18C & G). 
Only occasional stromal immunoreactivity was observed and the pattern of staining in 
the fimbriae of UPA exposed women was similar to that observed at the ampulla (Figure 
3.18D & H). 
 
Ampullary epithelial ERα immunopositivity was widespread in both proliferative 
(Figure 3.19A & E) and secretory (Figure 3.19B & F) phase fallopian tubes as well as 
following UPA treatment (Figure 3.19C & G). Immunopositivity appeared most dense in 
UPA exposed women and appeared slightly reduced in secretory phase compared to 
proliferative phase. Intermittent but moderate stromal immunoreactivity was present 
irrespective of phase of cycle or following treatment with UPA (Figure 3.19E-G).  
Fimbrial epithelial immunopositivity was present but appeared less than when 
compared with the ampulla (Figure 3.19D & H).  
 
3.5.2.4 Summary of impact of UPA on sex-steroid receptor expression and 
localisation in the fallopian tube 
The results of the effect of UPA upon sex-steroid receptors in the fallopian tube are 




Figure 3.16 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), increases ampullary epithelial progesterone 
receptor (PR) expression 
Representative images low- (A-D) and high-power (E-H) immuno-localisation of PR in fallopian tube (FT) biopsies from woman during proliferative and 
secretory stages of the menstrual cycle and after UPA administration. Samples from FT ampulla of UPA-treated women (C&G) displayed intense 
immunopositive epithelial nuclei with only a few immunopositive cells in the stroma, this immunostaining was less marked at fimbriae ends (D&H). In 
contrast to UPA, epithelial staining in the FT ampulla was less intense in proliferative phase epithelium (A & E) and further reduced in secretory (B & F) 
epithelium. There was light intermittent immunopositive nuclear staining of stroma irrespective of phase of cycle or UPA treatment. 
Lower power (scale bar = 200µm) and high power magnification (scale bar = 50 µm); Negative controls shown as inserts on secretory fallopian tube low 







Figure 3.17 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), does not alter ampullary epithelial progesterone 
receptor B (PRB) expression 
Representative images low- (A-D) and high-power (E-H) immuno-localisation of PRB in fallopian tube (FT) biopsies from woman during proliferative and 
secretory stages of the menstrual cycle and after UPA administration. Samples from FT ampulla of UPA-treated women (C&G) displayed intense 
immunoreactive staining in most epithelial nuclei with some immunopositive cells in the stroma, this pattern was replicated at fimbriae ends (D&H). 
The ampullary pattern of epithelial staining was stronger in the proliferative phase (A&E) and appeared slightly less in secretory phase (B&F). Stromal 
immunostaining was unchanged irrespective of cycle phase or treatment with UPA (E-H). Lower power (scale bar = 200µm) and high power magnification 
(scale bar = 50 µm); Negative controls shown as inserts on secretory fallopian tube low power image. 
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Figure 3.18 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), does not alter ampullary epithelial androgen 
receptor (AR) expression 
Representative images low- (A-D) and high-power (E-H) immuno-localisation of AR in fallopian tube  (FT) biopsies from woman during proliferative and 
secretory stages of the menstrual cycle and after UPA administration. Epithelial nuclei in ampullary samples from UPA-treated women (C&G) displayed 
intense immunoreactivity in most epithelial nuclei with some immunopositive cells in the stroma, this pattern was replicated at fimbriae ends (D&H). 
The ampullary pattern of epithelial staining was stronger in proliferative phase (A&E) and appeared slightly reduced in the secretory phase (B&F). 
Stromal immunostaining was unchanged irrespective of cycle phase or treatment with UPA.  






Figure 3.19 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), increases ampullary epithelial oestrogen 
receptor alpha (ERα) expression 
Representative low- (A-D) and high-power (E-H) immuno-localisation of ERα in fallopian tube (FT) biopsies from woman during proliferative and 
secretory stages of the menstrual cycle and after UPA administration. Samples from UPA-treated women (C&G) displayed intense immunopositive 
epithelial nuclei, this immunoreactivity was less marked at fimbriae ends (D&H). In contrast to UPA, epithelial staining was less intense in proliferative 
phase epithelium (A & E) and secretory (B & F) epithelium. There was light positive staining of most stroma nuclei irrespective of phase of cycle or UPA 
treatment. 




Table 3.6 Summary of impact of UPA administration on ampullary fallopian sex-steroid 
mRNA levels and protein expression and localisation 
SSR Relative mRNA level Protein expression and localisation 
 
 Proliferative Secretory UPA 
G S G S G S 
PR 
 
++ +/- ++ +/- +++ +/- 
PRB 
 
+++ +/- + +/- ++ +/- 
AR 
 
+++ +/- + +/- ++ +/- 
ERα 
 
++ + ++ + +++ + 
SSR: sex steroid receptor, G: glandular epithelium; S: stroma PR progesterone receptor; 
PRB: progesterone receptor B; AR: androgen receptor; ERα: oestrogen receptor alpha.  
* p <0.05, ** p <0.01, *** p <0.001    
+++ Dense immunopositivity, ++ moderate immunopositivity + light immunopositivity +/- 


























































































































































3.5.3 Effect of UPA administration upon cervical morphology and sex-steroid 
receptor expression 
3.5.3.1 UPA administration did not alter cervical morphology 
Cervical biopsy gross morphology on H&E staining was unchanged between proliferative 
phase (Figure 3.20A, D & G), secretory phase (Figure 3.20B, E & H) and from women 
receiving treatment with UPA (3.20C, F & I). There no evidence of cervical intraepithelial 
neoplasia (CIN) in any samples. Transformation zone epithelium was absent due to 
sampling artefact in three of the UPA treated women and one from secretory phase. 
There was evidence of squamous metaplasia in two of the UPA treated women – this was 
considered to be acceptable physiological variation.  
 
3.5.3.2 Administration of UPA did not alter sex-steroid receptor expression in the 
cervix 
Strong immunopositivity of PR was observed in the stroma, squamous and glandular 
epithelium of proliferative phase (Figure 3.21A, D & G), secretory phase (Figure 3.21B, E 
&H) and following UPA treatment (Figure 3.21C, F & I). Similarly there was no difference 
in staining intensity or frequency between phase of cycle or UPA for PRB 
immunolocalisation in all cell types (Figure 3.22), although overall positive staining was 
not present in all stromal nuclei (Figure 3.22G-I). The degree of squamous PRB 
immunopositivity (with relative sparing of the basement membrane; Figure 3.22A-C) 
was less compared to PR (Figure 3.21A-C) but unchanged by cycle stage or UPA 
treatment. AR immunolocalisation was unaltered by stage of cycle or UPA treatment with 
dense immunopositivity observed in all glandular epithelium (Figure 3.23D-I), stroma 
(Figure 3.23G-I) and squamous epithelium (including the basement membrane; Figure 
3.23A-C). ERα immunoreactivity was also unaltered between proliferative and secretory 
phase and UPA treatment but appeared less ubiquitous than other sex-steroid receptor 
immunolocalisation (Figure 3.24). Intermittent immunoreactivity was present in the 
squamous epithelium with only occasional positive nuclear staining in basement 
membrane (Figure 3.24A-C). Intermittent but dense staining was present in the stroma 
and glandular epithelium of proliferative (Figure 3.24D & G), squamous (Figure 3.24E & 




Figure 3.20 Representative H&E images of human uterine cervix 
A-C macroscopic images demonstrating ectocervical squamous epithelium (Sq), endocervical 
glandular epithelium (Gl) and the underlying stroma (St). The transformation zone (Tz) 
separates the true glandular and squamous epithelium. Samples from women in proliferative 
phase (A, D & G), secretory phase (B, E & H) and from women receiving treatment with UPA 
(C, F & I). 
Higher power squamous (D-F) and glandular (G-I) demonstrate similar appearance 
irrespective of stage of the menstrual cycle or UPA treatment. 
Scale bars lower power 2000μm high power 50μm 
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Figure 3.21 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), does not alter progesterone receptor (PR) localisation or 
intensity in the endo- or ecto-cervix  
Representative low- (A-F) and high-power (G-I) immuno-localisation of PR in cervical biopsies from woman during proliferative (A/D/G) and secretory (B/E/H) stages 
of the menstrual cycle and after UPA (C/F/I)) administration. Intense immunopositive nuclei were present in the stroma, squamous (D, E F) and glandular (G/H/I) 
epithelium. Localisation and intensity of immunostaining was unchanged irrespective of stage of cycle or treatment with UPA. Medium power (scale bar = 200µm) 
and high power magnification (scale bar = 50 µm); Negative controls shown as inserts on secretory cervix.  
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Figure 3.22 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), does not alter progesterone receptor B (PRB) localisation or 
intensity in the endo- or ecto-cervix  
Representative low- (A-F) and high-power (G-I) immuno-localisation of PR in cervical biopsies from woman during proliferative (A/D/G) and secretory (B/E/H) stages 
of the menstrual cycle and after UPA (C/F/I)) administration. Intense immunopositive nuclei were present in glandular (G/H/I) epithelium. Less intense 
immunopositive nuclei were seen in the stroma (G/H/I).  Lightly stained immunopositive nuclei were seen in the basement membrane of the squamous epithelium 
(D, E F) Localisation and intensity of immunostaining was unchanged irrespective of stage of cycle or treatment with UPA. Medium power (scale bar = 200µm) and 
high power magnification (scale bar = 50 µm); Negative controls shown as inserts on secretory cervix.  
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Figure 3.23 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), does not alter androgen receptor (AR) localisation or intensity 
in the endo- or ecto-cervix  
Representative low- (A-F) and high-power (G-I) immuno-localisation of AR in cervical biopsies from woman during proliferative (A/D/G) and secretory (B/E/H) stages 
of the menstrual cycle and after UPA (C/F/I)) administration. Intense immunopositive nuclei were present in the stroma, squamous (D, E F) and glandular (G/H/I) 
epithelium. Localisation and intensity of immunostaining was unchanged irrespective of stage of cycle or treatment with UPA. Medium power (scale bar = 200µm) 
and high power magnification (scale bar = 50 µm); Negative controls shown as inserts on secretory cervix.  
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Figure 3.24 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA),  replicates secretory phase oestrogen receptor alpha (ERα) 
localisation and intensity in the endo- and ecto-cervix  
Representative low- (A-F) and high-power (G-I) immuno-localisation of AR in cervical biopsies from woman during proliferative (A/D/G) and secretory (B/E/H) stages 
of the menstrual cycle and after UPA (C/F/I) administration. Immunopositive nuclei were present in the squamous epithelium above the basement membrane of 
squamous epithelial cells irrespective of stage of cycle or UPA treatment (A/B/C). Light immuno-positive nuclei of glandular epithelium and some stromal cells were 
visualized in proliferative phase cervical biopsies (A/D/G), in contrast secretory (B/E/H) and UPA-treated (C/F/I) cervix demonstrated more intense immune-positivity 
of glandular epithelial and stromal nuclei though was not present in all nuclei. Medium power (scale bar = 200µm) and high power magnification (scale bar = 50 µm); 
Negative controls shown as inserts on secretory cervix
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3.5.3.2 Summary of impact of UPA on sex-steroid receptor expression and 
localisation in the cervix 
The results of the effect of UPA upon sex-steroid receptors in the cervix are summarised 
in Table 3.7. 
 
Table 3.7 Summary of impact of UPA on sex-steroid receptor expression and localisation 
in the cervix 
SSR Protein expression and localisation 
 Proliferative Secretory UPA 
Squam G S Squam G S Squam G S 
PR ++ +++ ++ ++ +++ ++ ++ +++ ++ 
PRB + +++ + + +++ + + +++ + 
AR +++ +++ ++ +++ +++ ++ +++ +++ ++ 
ERα + ++ + + ++ + + ++ + 
 
SSR: sex steroid receptor, G: glandular epithelium; S: stroma PR progesterone receptor; 
PRB: progesterone receptor B; AR: androgen receptor; ERα: oestrogen receptor alpha.  
+++ Dense immunopositivity, ++ moderate immunopositivity + light immunopositivity +/- 
infrequent immunopositivity – absent immunopositivity 
 
3.6 Discussion  
Ulipristal acetate (UPA) is a SPRM, which, like other members of this class of compound 
has mixed agonist and antagonist effects (Chabbert-Buffet, Meduri et al. 2005, Bouchard 
and Chabbert-Buffet 2016, Wagenfeld, Saunders et al. 2016).  The impact of SPRMs is 
tissue dependent and this may be influenced both by concentrations of different co-
repressor and co-activator proteins and bioavailabilty of different PR isoforms in 
different cell types (Wagenfeld, Saunders et al. 2016).  In this study it was demonstrated 
that UPA administration has profound effects on endometrial morphology and alters the 
pattern of expression of PR, PRB and AR in the endometrium. This is the first 
comprehensive description on the impact of in vivo UPA administration on SSR 
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expression and localisation in human endometrium (Whitaker, Murray et al. 2017). 
Furthermore, administration of UPA appears to increase expression of PR and ERα in the 
fallopian tube relative to secretory but not proliferative phase and has no impact on SSR 
expression in the cervix. 
 
3.6.1 Endometrium 
Whilst all endometrial biopsies demonstrated evidence of PAEC, in keeping with 
established literature (Williams, Bergeron et al. 2012) the degree of histological change 
within the endometrium varied with some biopsies demonstrating a greater degree of 
cystic dilatation. The impact of this histological observation upon symptom control is 
unknown. In our study the degree of cystic dilatation was not correlated with duration 
of treatment or control of bleeding. 
 
Larger studies have demonstrated PAEC rates of around 74% following a 3-month 
course of UPA administration (Williams, Bergeron et al. 2012), and this rapidly regressed 
on cessation of treatment (Donnez, Vazquez et al. 2014, Donnez, Hudecek et al. 2015). It 
should be noted that suction catheters (e.g. pipelle biopsy catheters) obtained the 
biopsies assessed in these studies described above. This sampling technique may disrupt 
the dilated cysts and either render specimens inadequate for assessment or with such 
disrupted tissue that only those with familiarity of the more subtle manifestations of 
PAEC may conclude this as the histopathological opinion (Professor ARW Williams, 
personal communication). In contrast full thickness endometrial biopsies (luminal 
epithelium to endometrial-myometrial junction), obtained at the time of hysterectomy 
(as in this thesis), allow comprehensive assessment of a larger biopsy, which has not 
been unduly distorted by sampling artefact. Familiarity with the features of PAEC 
remains critical for accurate histopathological assessment.  
 
The true incidence of PAEC whilst on SPRM treatment remains uncertain, and it is 
unknown as to whether it results in a field change with the endometrium of the entire 
uterus or results in discrete areas of focal change. Given that two separate biopsies from 
each individual women, obtained from differing areas of the uterine cavity, both 
demonstrated PAEC it would imply the former, but detailed descriptions of the extent of 
histological change within the uterus remains lacking in the literature. The only study to 
comment on rates of PAEC in discrete separate areas of the uterus (fundus, mid corpus 
and isthmus) was one of the studies involving the administration of the SPRM, asoprisnil. 
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That study concluded that rates were similar in each region (Williams, Critchley et al. 
2007).  Whilst PAEC is considered a ‘class effect’ (Mutter, Bergeron et al. 2008), 
variability in reporting classifications (Murji, Whitaker et al. 2017) means that it is 
impossible at present to draw accurate conclusions as to whether different members of 
the SPRM class truly have the same likelihood of development of PAEC. 
 
Administration of UPA increases levels of both PR and PRB mRNA. Both the A and B 
isoforms are expressed in a differential manner within the endometrium in the normally 
cycling woman (Wang, Critchley et al. 1998, Mote, Balleine et al. 1999).  The data herein 
demonstrate marked upregulation within the glandular epithelium of both PR isoforms 
and downregulation within the stroma following UPA administration. This pattern of 
expression neither phenocopied proliferative nor secretory phase endometrium. This is 
inconsistent with a study of PR expression in the NHP following UPA administration 
where in that study expression phenocopied proliferative phase (Brenner, Slayden et al. 
2010). The striking switch in PR protein localisation observed when compared to 
secretory phase demonstrated in this thesis is consistent with previous reports studying 
the effect of another SPRM, asoprisnil, on PR protein localisation in human endometrium 
(Wilkens, Male et al. 2013). In contrast the SPRM mifepristone does not appear to down 
regulate stromal expression in both animal models and human studies (Slayden and 
Brenner 1994, Narvekar, Cameron et al. 2004). The relatively pure P-antagonist ZK 
137316 resulted in stromal down regulation of PR protein localisation that was limited 
to the basal compartment (Slayden, Zelinski-Wooten et al. 1998). In this current study I 
have demonstrated stromal down regulation of PR and PRB in both the functional and 
basal layers. It is not clear whether this differing expression pattern is determined by the 
relative degree of pure PR antagonism associated with mifepristone, ZK 137316 and UPA 
(Elger, Bartley et al. 2000, Chabbert-Buffet, Meduri et al. 2005) or if other factors 
contribute to this such as differing interaction of co-regulators such as the nuclear co-
receptors (NcoR) (Afhuppe, Sommer et al. 2009). 
 
The data presented in this thesis are the first to describe the effects of UPA on PRB 
expression (Whitaker, Murray et al. 2017). The apparent slight reduction in 
immunopositivity of PRB expression compared with PR (A+B isoforms) suggests that 
both isoforms are differentially expressed following UPA administration, but this has not 
been formally quantified. This finding of PRB immunolocalistion mirrors that observed 
with mifepristone in human endometrium (Sun, Christow et al. 2003).  
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One of the most striking findings in this study was the impact on AR expression.  A 
significant increase in concentrations of AR mRNA was demonstrated, which was 
accompanied by a unique pattern of AR protein expression. This was distinct to that 
reported in the endometrium of a woman during a normal menstrual cycle or following 
intra-uterine levonorgestrel exposure (Slayden, Nayak et al. 2001, Burton, Henderson et 
al. 2003, Marshall, Lowrey et al. 2011).  The up-regulation of AR expression in the 
epithelium with preserved stromal immunopositivity in the human described in this 
thesis are consistent with reports of assessment of the endometrium from Rhesus 
macaques following treatment with an intrauterine device containing UPA for three 
artificial menstrual cycles (Brenner, Slayden et al. 2010). These findings are also noted 
in both human and animal studies following administration of mifepristone (both 
following 2mg for 30 days or a single dose of 200mg; (Slayden, Nayak et al. 2001). Studies 
of the effect of SPRM administration on epithelial AR expression in NHP models have 
demonstrated that up regulation is limited to the functional layer of the endometrium. 
The exception to this was ZK 137316 administered to NHP where basal epithelial 
immunopositivity was observed (Slayden, Nayak et al. 2001). This was consistent with 
the observations (data presented in this thesis) of up regulation of AR by UPA in both 
functional and basal layers of the endometrium. This further demonstrates the differing 
impacts of SPRMs with regard to SSR expression and may be either a product or cause of 
the variable degree of progesterone antagonism. The effect upon AR expression in 
women following UPA administration is of particular import as in the NHP AR maybe 
critical to the anti-proliferative effect following SPRM administration (Slayden and 
Brenner 2003). This is discussed in further detail in chapter five of this thesis. 
 
The pattern of expression of ESR1 (ERα) mRNA and protein after treatment with UPA 
was similar to that of the proliferative phase. This suggests that UPA did not induce PR-
dependent down regulation of ERα gene expression.  This is consistent with the 
observation of unaltered ER expression and localisation following the administration of 
UPA to the NHP (Brenner, Slayden et al. 2010). A similar pattern phenocopying 
proliferative phase is also observed in NHP (Slayden and Brenner 1994) and women 
(Narvekar, Cameron et al. 2004) following administration of SPRM, mifepristone.  
 
Whilst the effects on SSR expression have not been quantified in this study, the profound 
effect upon localisation of PR, PRB and AR protein renders this less critical to conclusion 
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regarding the impact of UPA on the endometrium. The non-significant rise in mRNA 
expression of ESR1 compared to proliferative phase and similar pattern of 
immunopositivity may suggest quantification to be of importance, particularly given the 
impact on proliferation and should be considered for future work. 
 
3.6.2 Fallopian tube 
The findings with regard to the effect of UPA administration on the fallopian tube 
complement and extend the existing literature. In keeping with the findings of in vitro 
treatment with UPA on human fallopian tubes, ampullary morphology resembled 
proliferative phase (Yuan, Zhao et al. 2015). This is also consistent with the effect on 
morphology with administration of mifepristone in the NHP (Slayden and Brenner 
1994). SSR mRNA levels were unchanged relative to proliferative phase but PR and ESR1 
were down-regulated relative to secretory phase, consistent with P-antagonism. In 
contrast to SSR protein expression in the endometrium, ampullary SSR expression 
demonstrated no alteration in the localisation of SSR expression. Epithelial 
immunopositivity was increased following UPA administration relative to secretory 
levels of both PR and ERα. The pattern appeared similar to proliferative with an apparent 
slight increase in density of staining following UPA but this has not been formally 
quantified. Given the small number of subjects and lack of quantification in this study 
limited weight can be given to an inference that UPA up regulates PR and ERα relative to 
proliferative phase. The up regulation of PR and ERα relative to secretory phase is 
consistent with the effect of in vitro studies of UPA treatment of human fallopian tubes 
(Yuan, Zhao et al. 2015) and findings in the NHP following in vivo mifepristone 
administration (Slayden and Brenner 1994). In human studies of in vivo mifepristone 
treatment both PR and PRB was markedly up regulated relative to secretory phase 
(Christow, Sun et al. 2002, Sun, Christow et al. 2003). In contrast, this study of UPA the 
effect appeared limited to the PRA isoform only at an mRNA level. It is uncertain if this is 
an effect of a differing SPRM administration, as the NHP study of mifepristone did not 
assess the impact on the PRB isoform. Equally in this study of UPA, it does appear at a 
protein level that PRB expression may be slightly reduced in secretory phase relative to 
UPA but this not been quantified with either stereology or western blot studies. There 
are no published data regarding impact of SPRMs on AR expression in the Fallopian tube 
to compare with the findings of studies in this thesis. Lack of significant alteration in 
mRNA is consistent with no significant alteration in AR in fallopian tube across the cycle 
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(Horne, King et al. 2009). Thus it is perhaps unsurprising that mRNA and protein 
expression of AR do not significantly alter following UPA administration.   
 
It has previously been demonstrated that SSR expression of PR and ER is altered in the 
different regions of the fallopian tube (Amso, Crow et al. 1994). Here in this thesis, it is 
demonstrated that immunopositivity of PRB and AR is unchanged between the ampulla 
and the fimbriae, but expression of PR, and ERα is reduced in the fimbriae relative to the 
ampulla. Limited conclusions can be drawn from this given that untreated fimbriae from 
women in proliferative and secretory phase were not available to assess relative 
alteration at this site. This requires further inspection, not least as the fimbrial ends of 
the fallopian tube are now considered a potential site for the development of future high 
grade serous ovarian cancer (Crum, Herfs et al. 2013) and any compound that impacts 
upon SSR expression in this site may have implications for future tumour genesis. Whilst 
mifepristone has been shown to be ineffective for the treatment of recurrent ovarian 
cancer (Rocereto, Brady et al. 2010) an RCT is currently underway to assess the impact 
of mifepristone on women with BRCA1 & 2 mutations with development of ovarian 
disease investigated as a secondary measure 
(https://clinicaltrials.gov/ct2/show/NCT01898312). 
3.6.3 Cervix 
There was no alteration in morphology and SSR expression in the cervix following 
administration of UPA. The data presented in this thesis are the first description of the 
impact of UPA on the non-pregnant human cervix following in vivo treatment with an 
SPRM, albeit in a small number of samples. mRNA levels were not quantified due to 
difficulties in consistently sampling the same region and availability of control samples. 
Laser capture is a technique for future consideration that may facilitate the accurate 
quantification of transcription in the differing cell compartments. 
 
As previously described, the degree of cyclical change of PR expression in both glandular 
and stromal epithelium is minimal (Lin 1984, Cano, Serra et al. 1990). In vitro studies 
and data from pregnancy models imply that the effect of mifepristone was 
predominantly related to the blockade of progesterone-mediated response that resulted 
in altered functionality. In the former of these high dose P-agonists were administered 
(Ackerman, Summerfield et al. 2016) and in the latter, pregnancy resulted in altered 
circulating P4 (Yellon, Dobyns et al. 2013). Given that both these states are consistent 
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with much higher levels of circulating ligand it is perhaps unsurprising that in the context 
of normally cycling woman, administration of a SPRM results in minimal alteration of 
SSR compared to either proliferative or secretory phase. Studies of mifepristone have 
indicated an alteration in immune-cell (specifically macrophages) populations (Kirby, 
Heuerman et al. 2016). In the endometrium asoprisnil impacted upon CD56 (a marker of 
uterine NK cells) expression (Wilkens, Male et al. 2013). Whilst no apparent alteration in 
SSR expression was observed following UPA administration, the impact on immune-cell 
populations would merit further inspection. 
 
3.6.4 Future work 
The impact of UPA administration on morphology and SSR expression is most dramatic 
in the endometrium. Described in chapter 3 are some of the existing uncertainties with 
regard to the effect of UPA in the reproductive tract including true incidence of PAEC, 
and evidence regarding focality, quantification of SSR expression and localisation in the 
fallopian tube and cervix. In the fallopian tube, UPA administration relatively 
phenocopies proliferative phase and in the cervix there is no demonstrable difference 
following UPA administration. All three structures arise from the paramesonephric duct 
but differentiate into their separate structures. Wnt signalling and Hox genes help 
regulate this process and expression of HOX genes continues through adult life. This 
functional differentiation may explain why, though SSR are expressed in all three 
anatomical regions, the response to UPA is altered. The impact upon HOXA10 is assessed 
in chapter 4, but Hoxa9, -11 and -13 have not been assessed in this study. 
 
The effect of sex-steroid action is regulated by the availability of the ligand (be it 
endogenous or synthetic) and the cognate receptor. The amount of free ligand can be 
modified by steroid metabolising enzymes, in the human these include the 17-
βhydroxysteroid dehydrogenase family (17βHSD) (Lathe and Kotelevtsev 2014). The 
type 2 isoform (17βHSD2) has a major role in regulating the conversion of more potent 
E2 to the less potent oestrone (Thomas and Potter 2013). It also activates progesterone 
and converts androgens to less potent forms (Burton, Henderson et al. 2003). 17βHSD2 
is expressed in the glandular endometrium and is up regulated by progesterone 
(Maentausta, Svalander et al. 1993). However whilst the synthetic progestin 
levonorgestrel initially increases 17βHSD2 mRNA expression, over time this declines 
(Burton, Henderson et al. 2003). There is evidence that the SPRM mifepristone can block 
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the expression of 17βHSD2 (Sivik and Jansson 2012).  There is no published evidence of 
the impact of UPA on 17βHSD2 expression and this merits further investigation given 
the critical role 17βHSD2 plays in the availability of sex-steroid ligands.  
 
This study is limited to the sex-steroids receptors. Only the alpha subunit of ER was 
investigated. ERβ was outwith the scope of this study but merits further study. It is 
postulated to attenuate response of ERα to E2 in the endometrium (Hapangama, Kamal 
et al. 2015) and is differentially expressed in the fallopian tube depending upon stage of 
menstrual cycle (Horne, King et al. 2009).  
 
Other steroid receptors exist within the endometrium including the glucocorticoid 
receptor (GR) and the mineralocorticoid (MR) (Henderson, Saunders et al. 2003, 
McDonald, Henderson et al. 2006). GR is expressed in endometrial stromal cells and MR 
is present in both stromal and glandular compartments (McDonald, Henderson et al. 
2006). Glucocorticoids may play a significant role in endometrial function and repair 
(Critchley and Maybin 2011, Maybin and Critchley 2015).  Inactivation of cortisol is 
associated with HMB (Rae, Mohamad et al. 2009). UPA exhibits GR binding, albeit with a 
much-reduced affinity than mifepristone (Attardi, Burgenson et al. 2004) but data 
regarding impact of SPRMs upon protein expression of GR and MR within the 
endometrium are lacking.  
 
Availability of active cortisol is regulated by the 11β-HSD family (McDonald, Henderson 
et al. 2006) with 11β-HSD1 increasing local tissue availability of cortisol and 11β-HSD2 
decreasing availability by conversion to inactive cortisone (Rae, Mohamad et al. 2009, 
Thiruchelvam, Maybin et al. 2016). This further underscores the need to assess the 
impact of SPRMs on the 11β-HSD family as well as GR and MR.  
 
There is one outstanding epithelial component of the reproductive tract that has not 
been assessed: the squamous epithelium of the vagina. SSR are expressed in the vagina 
and respond to menstrual cycle stage hormonal fluctuations; E2 stimulates vaginal 
epithelial proliferation and P4 promotes epithelial maturation (Ayehunie, Islam et al. 
2015). A previous study of mifepristone administration demonstrated no effect on 
morphology, SSR expression or localisation (Narvekar, Lakha et al. 2007) and thus the 
effect of UPA on vaginal epithelium was not considered a priority for this current series 
 153 
of investigations. The effects upon UPA on fibroids and myometrial SSR are also outwith 
the scope of this thesis.  
 
3.7 Conclusions 
The results presented within this chapter demonstrate that UPA administration has 
profound effects on endometrial morphology, and the data presented herein extend the 
published literature. This is the first description of the impact of in vivo treatment with 
UPA on the morphology of the human fallopian tubes, which resemble proliferative 
phase, in keeping with the effects observed with other SPRMs. UPA does not alter human 
cervical morphology. Sex-steroid receptor mRNA levels of PR, PRB, ERα and AR are 
altered in the endometrium by treatment with UPA. There is alteration in ampullary sex-
steroid receptor mRNA levels in the fallopian tube but this is limited to PR and ERα and 
this is relative only to the secretory phase. This is thus the first extensive description of 
the impact of UPA administration on localisation of sex-steroid receptor in the 
reproductive tract. Within the endometrium PR, PRB and AR all demonstrate profound 
spatial alteration in the localisation of protein expression which does not replicate either 
proliferative or secretory patterns of expression.  In the ampullary fallopian tube 
localisation appeared unaltered, and immunopositivity most closely resembled 
proliferative phase. This suggests the impact of UPA in the fallopian tube is limited to 
blockade of the usual secretory phase progesterone-driven antagonism of the action of 
oestradiol  only. Sex-steroid receptor expression in the cervix was unchanged by UPA. 
Thus in conclusion treatment with ulipristal acetate appears to have an “endometrial 
specific” effect upon the morphology and sex-steroid receptor expression in the 
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Figure 4.1 Activation of the progesterone receptor (PR) by progesterone receptor ligands.  
 
Binding of progesterone to the inactive progesterone receptor complex induces a 
conformational change. This results in dissociation of heat shock proteins, dimerization and 
translocation of PR to the nucleus.  
 
The PR then binds to the progesterone response element (PRE) in promoter regions of target 
genes and subsequent communication with the RNA polymerase RNA POL2 results in 
alteration of gene transcription. This process is modified by co-regulatory proteins, that may 
either increase or decrease gene transcription.  
 
Other ligands (including SPRMs) for the PR results in differing recruitment of co-activators 
and co-repressors, altering transcriptional activity. The same SPRM may have different 











4.1.1 Progesterone regulation of transcription 
Progesterone (P4), as described in Chapter 3, is a 21 carbon sex-steroid hormone 
(Figure 3.5). It has key roles in female reproduction related tissues, regulating 
development, differentiation and normal functioning of target tissues. It may act both by 
ligand binding to its cognate receptor, the progesterone receptor (PR) (Tsai and O'Malley 
1994), a member of the nuclear hormone receptor superfamily (Mangelsdorf, Thummel 
et al. 1995), and via non-genomic signalling following cytoplasmic binding to membrane 
bound receptors (Gellersen, Fernandes et al. 2009). As with others of this family, PR has 
an N-terminal A/B region, a DNA binding domain (DBD, C), a hinge region (D) and a C-
terminal (E) which contains the ligand binding domain (LBD) (Figure 3.6).  PR has two 
protein isoforms: PRA and PRB, both of which are encoded by the same gene. Both PRA 
and PRB act as ligand activated transcription factors (Patel, Elguero et al. 2015).  
 
Unbound PR is located in the cytoplasm, complexed with a heat shock protein (HSP). On 
binding with a ligand, there is a conformational change and the HSP dissociates. This 
process is partly curated by the co-chaperone imunophilin proteins (FKBP), FKBP51 and 
FKBP52 (Jaaskelainen, Makkonen et al. 2011). These are implicated in most sex-steroid 
receptor signalling and with respect to PR, FKBP51 attenuates PR mediated 
transcription, whereas FKBP52 enhances transcription (Sanchez 2012).  
 
Following HSP dissociation from the ligand-receptor complex, the ligand bound PR 
translocates to the nucleus, prior to binding with hormone response elements (PREs) at 
the promoter regions of target genes and subsequent communication with the RNA 
polymerase RNA POL2 (Figure 4.1). This process is further modified by co-regulatory 
proteins, that may either increase or decrease transcription (Critchley and Saunders 
2009). Over 300 co-regulators are reported to interact with the PR (Scarpin, Graham et 
al. 2009). Classical co-activators include members of the steroid receptor co-activator 
family (SRC) and co-repressors include nuclear receptor corepressor (NCoR) and 
silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) (Chabbert-
Buffet, Meduri et al. 2005). The degree of relative recruitment of co-activators and co-
repressors are thus key regulators of subsequent transcriptional activity (Figure 4.1). PR 
can also interact with other transcription factors such as specificity protein 1 (SP1), 
















Figure 4.2 Evidence of PR-mediated paracrine signalling in the endometrium and key 
progesterone regulated pathways derived from murine models 
 
Key signaling pathways at the time of embryo implantation, derived from murine knockout 
models. Indian Hedgehog (Ihh) is a progesterone target activated within the epithelium which 
signals downstream to COUP-TFII (activating Bmp2 and Wnt4) in the stroma establishing the 
Ihh–COUP-TFII axis across the epithelial and stromal compartment.  
 
Both COUP-TFII and PR directly may also play a role in the activation of Hand2 in the stroma 
leading to the inhibition of the FGF pathway, a pathway known to be involved in the 
promotion of epithelial proliferation by oestrogen signaling.  
 




factor-κB (NF-κB) (Gellersen and Brosens 2003, Kim, Kurita et al. 2013) and with proto-
oncogene tyrosine-protein kinase Src (Src kinase) to activate mitogen-activated protein 
kinases (MAPK) signalling (Migliaccio, Piccolo et al. 1998) 
 
As described in Chapter 1, SPRMs are ligands for the PR, and they can result in differing 
degrees of progesterone antagonism depending upon the individual compound. The 
action of ligand binding, HSP dissociation, dimerization and binding to PRE appears to 
be unaffected by SPRMs (Chabbert-Buffet, Meduri et al. 2005), rather it is the relative 
recruitment of co-regulators that results in subsequent progesterone antagonism (Smith 
and O'Malley 2004). Alteration in both SRC-1 and SMRT has been observed following 
administration of the SPRMs mifepristone (RU-486) and asoprisnil (J867) (Madauss, 
Grygielko et al. 2007, Afhuppe, Beekman et al. 2010, Amazit, Roseau et al. 2011). The 
degree of interaction between the co-repressor NCoR appears to alter between the 
differing SPRMs mifepristone, onapristone (ZK 89299) and lonaprisan (ZK 230211) 
(Afhuppe, Sommer et al. 2009). 
 
4.1.2 Progesterone regulated genes 
Within the endometrium P4 regulates gene expression to induce an endometrium that is 
receptive to, and can support a developing pregnancy. During the P4 dominated 
secretory phase, oestrogen driven endometrial proliferation is supressed and the 
endometrium undergoes differentiation and maturation, characterised by secretory 
transformation of glands and influx of inflammatory cells (Strowitzki, Germeyer et al. 
2006).  
 
Mouse models have identified key P-regulated genes and P-regulated functions through 
the use of PR-knockout mice (Wang and Dey 2006). Work by DeMayo and colleagues in 
murine models has identified pivotal P-regulated genes including the indian hedgehog – 
chicken ovalbumin upstream transcription factor II  (IHH – COUP-TFII) pathway (and its 
downstream effect upon wingless related MMTV integration site/bone morphogenetic 
protein (Wnt/Bmp) signalling and Heart and neural crest derivatives expressed 2 
(Hand2) signalling pathway (Figure 4.2) which are critical to endometrial 
decidualisation, proliferation and cell survival (Wetendorf and DeMayo 2012).  
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Key markers of decidualisation are Insulin-like growth factor-binding protein 1 
(IGFBP1), prolactin (PRL) and interleukin-15 (IL-15), all of which are P-regulated (Dunn, 
Critchley et al. 2002, Gellersen and Brosens 2003). Homeobox A10 (HOXA10) regulates 
expression of these markers and is itself P-regulated (Gellersen and Brosens 2003, Eun 
Kwon and Taylor 2004). 
 
Other known P-regulated genes include B-Cell CLL/Lymphoma 6 (BCL6) (Li, Large et al. 
2013), and the kruppel-like factor (KLF) family. Perturbation of the KLFs has been 
observed in reproductive tract pathologies, in particular KLF-4, -9 and -15 have been 
implicated in infertility, endometriosis and endometrial cancer (Ray and Pollard 2012, 
Simmen, Heard et al. 2015).  
 
There is evidence that the gynaecological disorder endometriosis is associated with 
changes in the eutopic endometrium (the uterine endometrium, in a woman with 
endometriosis). These include increased proliferation and decreased apoptosis, altered 
cellular immunity and diminished response to progesterone, termed progesterone 
resistance (Young and Lessey 2010). P-regulated genes found to be altered in the 
presence of co-existing endometriosis include (but are not limited to) PRB (Shen, Yan et 
al. 2015) and the co-chaperone proteins FKBP51 (Yang, Zhou et al. 2012) and FKBP52 
(Joshi, Miyadahira et al. 2017). P-regulated genes for example, FOXO1 (Su, Strug et al. 
2015), HOXA10 (Kim, Taylor et al. 2007), KLF-9 (Heard, Simmons et al. 2014) and BCL6 
(Evans-Hoeker, Lessey et al. 2016) have all been demonstrated to be altered in the 
setting of co-existing endometriosis.  
 
Finally the tumour suppressor gene Phosphatase and tensin homolog (PTEN) is present 
in the endometrium and loss of this is considered a pivotal event in the development of 
endometrial cancer (Mutter, Lin et al. 2000). PTEN null glands may be shed at 
menstruation and exogenous progestins may also play a role in elimination of null glands 
(Orbo, Rise et al. 2006). PTEN is also a negative regulator of phosphoinositide 3-kinase 
(PI3K) signalling, which is a key regulator of cell growth and survival (Carracedo and 
Pandolfi 2008). 
 
In Chapter 3, the significant increase of PR and PRB mRNA levels and striking alteration 
in localisation of both isoforms following administration of the SPRM Ulipristal acetate 
(UPA) was described. Little is known regarding the effect of SPRMs on the P-regulated 
 161 
genes described above. Asoprisnil administration significantly reduced IL-15 and 
reassuringly did not alter levels of PTEN. Microarray and sequencing studies of  
mifepristone, asoprisnil and UPA have identified differentially expressed transcripts 
(Catalano, Critchley et al. 2007, Wilkens, Male et al. 2013, Cuevas, Tapia-Pizarro et al. 
2016, Lira-Albarran, Durand et al. 2017) but have reported conflicting differential gene 
transcripts (Tapia, Vilos et al. 2011), the majority of which are unvalidated, and the 
effects of administration of UPA on the key genes described above is largely unknown.  
 
4.2 Hypothesis 




To study the impact of SPRM administration on progesterone-regulated genes in 
the human endometrium 
Research questions 
- What is the impact upon known endometrial P-regulated gene transcription? 
- Is there alteration in protein localisation of P-regulated genes under 
investigation? 
- Does the presence of co-existing endometriosis alter response of endometrial P-
regulated genes? 
- Does administration of SPRM, UPA alter clearance of PTEN null glands in the 
endometrium? 
 
4.4 Materials and Methods 
Women with symptomatic fibroids underwent hysterectomy following treatment with 
the SPRM, Ulipristal acetate (UPA) 5mg orally once daily for up to 15 weeks prior to 
surgery (minimum nine weeks of SPRM treatment). They had given informed consent 
and the study had Research Ethics Committee (REC) approval (12/SS/0238 and 
16/ES/0007; section 2.1.1). At the time of surgery, biopsies were collected from the 
endometrium. Samples were processed as previously described (section 2.2.1.1) and 
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tissue taken for RNA extraction for RT-qPCR and formalin fixation prior to 
immunohistochemistry. Corresponding control biopsies from women with symptomatic 
fibroids in proliferative and secretory phase of cycle were obtained from tissue archives 
(section 2.1.1). Subjects were well characterised (section 2.4.1, Table 2.4-5). These 
samples were utilised for RT-qPCR and immunohistochemistry. 
Further paired endometrial biopsies were obtained from women prior to, and whilst on 
SPRM (daily) treatment following administration of UPA 5mg once daily for at least ten 
weeks (section 2.2.1.2, Table 2.6-7). The baseline samples were well characterised and 
staged as previously described (section 2.3). These samples were utilised for 
immunohistochemistry of PTEN. 
RNA was extracted, quality checked and cDNA produced prior to performing RT-qPCR 
(as previously described; section 2.5) for the co-chaperones FKBP51, FKBP52, P-
regulated genes IHH, COUP-TFII, BMP2, HAND2, HOXA10, FOXO1, FOXM1, BCL6, KLF-4, -9 
and 15, and the markers of decidualisation IGFBP1 and IL-15 (Table 2.12). For the 
majority of genes an “n” of nine was used for each group (proliferative, secretory and 
following SPRM (UPA) administration) with the exception of KLF-4 and KLF-15 (n=6). 
Comparison of gene expression, as assessed by RT-qPCR, of PR, PRB, FKBP51, FKBP52, 
FOXO1, HOXA10, KLF-9 and BCL6 was also undertaken from women administered SPRM 
(UPA) either with and without endometriosis (n=7 in each group). 
FFPE sections were cut for immunolocalisation of HAND2, FOXO1, BCL6 and PTEN on 
full thickness endometrial biopsies from the women exposed to SPRM (UPA) prior to 
hysterectomy and appropriate archival controls from women in the proliferative and 
secretory phase as described above (n=6-9). PTEN immunolocalisation was also 
performed on paired endometrial biopsies (n=17). These paired endometrial biopsies 
were obtained from 17 women with symptomatic fibroids treated with UPA 5mg daily 
with ethical approval and written informed consent (Table 2.4&2.5). Samples were 
obtained using a pipelle endometrial biopsy sampler (Pipelle de Cornier Mark II, 
Laboratoire CCD, France) as described in section 2.2.1.2. A baseline biopsy was obtained 
prior to commencement of treatment and phase of the menstrual cycle (staged as 
described in section 2.3.2; histological appearance based on Noyes criteria, LMP and 
circulating progesterone and oestradiol). Detailed of IHC protocols and antibodies 
utilised can be found in section 2.6 and Table 2.13-14. 
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Statistical analysis of RT-qPCR results was performed using Graphpad prism software 
(Graphpad, USA). Data were subjected to the D’Agostino-Pearson omnibus normality 
test. Data with a Guassian distribution had an unpaired t-test applied when two 
comparators, and one-way ANOVA when 3 comparators (proliferative, secretory and 
following SPRM (UPA) treatment), to determine difference between groups. For non-
parametric data Kruskal-Wallis test was used to determine differences between sample 
groups when three comparators, and Mann-Whitney test when two. Following 
ANOVA/Kruskal-Wallis test post-hoc testing was performed if appropriate using Tukey’s 
or Dunn’s multiple comparison. Results are presented as ±minimum and maximum.  p < 
0.05 was considered to be statistically significant. To assess impact of endometriosis on 
bleeding control, a 2-by2 table was constructed, Fischer’s exact test was then applied and 
an odds ratio calculated. 
4.5 Results 
4.5.1 Treatment with SPRM, UPA, alters relative mRNA levels of P-regulated 
genes in human endometrium 
Administration of the SPRM UPA significantly decreases mRNA levels of the co-
chaperone FKBP51 relative to secretory levels (Figure 4.3A) but does not alter FKBP52, 
which also demonstrated no significant alteration between proliferative and secretory 
phase mRNA levels (Figure 4.3B). IHH mRNA levels were significantly increased 
following UPA administration and in proliferative phase, compared to secretory phase 
levels (Figure 4.3C). However neither COUP-TFII nor BMP2 demonstrated cyclical 
alteration in mRNA levels and these were not affected by SPRM (UPA) administration 
(Figure 4.3D-E). In contrast HAND2 mRNA levels were markedly increased in secretory 
phase but significantly reduced both in proliferative phase and following UPA 
administration (Figure 4.3F). 
 
In proliferative phase and following SPRM (UPA) administration, mRNA levels of the 
transcription factor HOXA10 were significantly increased relative to secretory phase 
(Figure 4.4A). In keeping with histological absence of decidualisation (Figure 3.7-8), 
both markers of decidualisation IGFBP1 and IL-15 demonstrated low mRNA levels, which 
were significantly reduced compared to secretory levels, and similar to proliferative 























































































































































































































































Figure 4.3 Treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA), increased the concentration of mRNAs encoding genes involved in progesterone 
signalling in tissue extracts from human endometrium as determined by RT-qPCR 
 
Relative mRNA levels of FKBP51 (A Kruskal-Wallis p = 0.0010), FKBP52 (B ANOVA p = 0.6578), 
IHH (C Kruskal-Wallis p = 0.004), COUP-TFII (D Kruskal-Wallis p = 0.01629), BMP2 (E Kruskal-
Wallis p = 0.4373) and HAND2 (F Kruskal-Wallis p = 0.0049) from woman with fibroids during 
proliferative and secretory stages of menstrual cycle and following UPA administration. n=9 
for each group. * P<0.05, ** p<0.01, ***p<0.001.  Box and whisker: box indicates first/third 
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Figure 4.4 Treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA), increased the concentration of mRNAs encoding genes involved in progesterone 
signalling and markers of decidualisation in tissue extracts from human endometrium as 
determined by RT-qPCR 
Relative mRNA levels of HOXA10 (A ANOVA p = 0.0035), IGFBP1 (B Kruskal-Wallis p = 0.0007), 
IL-15 (C Kruskal-Wallis p = 0.0007), FOXO1 (D Kruskal-Wallis p = 0.0003), BCL-6 (E ANOVA p < 
0.0001) FOXM1 (F ANOVA p < 0.0001), KLF-4 (G ANOVA p = 0.0109), KLF-9 (H Kruskal-Wallis p 
= 0.0010) and KLF-15 (I Kruskal-Wallis p = 0.2274) from woman with fibroids during 
proliferative and secretory stages of the menstrual cycle and following UPA administration. 
n=6 or 9 for each group. * P<0.05, ** p<0.01, ***p<0.001, **** p<0.0001. Box and whisker: 





FOXO1 and BCL6 (Figure 4.4D-E). In contrast FOXM1 mRNA levels were significantly 
decreased in both secretory phase and following UPA administration, compared with 
proliferative phase (Figure 4.4F). The kruppel-like factors 4, 9 and 15 mRNA levels were 
all increased in secretory phase compared with proliferative phase although this 
increase did not achieve statistical significance for KLF-15. In contrast UPA 
administration did not significantly alter mRNA levels relative to either secretory or 
proliferative phase levels (Figure 4.4G-I).  
 
4.5.2 SPRM (UPA) administration decreases immunoexpression of HAND2, 
FOXO1 and BCL6 but does not alter location within the endometrium  
HAND2 is expressed predominantly in the endometrial stroma and immunoreactivity is 
increased in secretory phase (Figure 4.5B) relative to proliferative phase (Figure 4.5A). 
Following SPRM (UPA) administration, weakly immunopositive stromal nuclei for 
HAND2, with occasional weak glandular immunoreactivity were observed (Figure 4.5C). 
The level of stromal immunopositivity following UPA administration was consistent with 
that observed in proliferative phase, and markedly less than that observed in the 
secretory phase.  
 
Immunopositivity of FOXO1 was weakly present in both endometrial glands and stroma 
in samples from women in the proliferative phase of the menstrual cycle (Figure 4.5D). 
Samples from women in the secretory phase demonstrated strong immunopositivity in 
glandular cells and moderate immunoreactivity in stromal cells (Figure 4.5E). In contrast 
samples from UPA-treated women displayed almost negligible immunopositivity of 
FOXO1 in both endometrial glands and stroma (Figure 4.5F). 
 
BCL6 is predominantly expressed in the endometrial glandular epithelium, with some 
weak stromal immunopositivity (Figure 4.6). Immunoreactivity was maximal in the 
secretory phase, with intense glandular immunopositivity, and some weak stromal 
immunoreactivity (Figure 4.6B). In contrast following SPRM (UPA) administration 
immunoreactivity was almost complete absent in both glands and stroma (Figure 4.6C), 
a pattern of immunopositivity that phenocopied the proliferative phase (Figure 4.6A). 
Only one subject administered UPA exhibited evidence of BCL6 immunopositivity with 
occasional weak immunoreactivity predominantly in the glands: this subject had active 




Figure 4.5 Administration of selective progesterone receptor modulator, ulipristal acetate 
(UPA), modulates HAND2 and FOXO immunoreactivity 
Representative low-power (inserts) and high-power immuno-localisation of HAND2 (A-C) and 
FOXO1 (D-F) in endometrium from woman with fibroids during proliferative (A&D) and 
secretory stages (B&E) of the menstrual cycle and after UPA administration (C&F).  
 
Samples from UPA-treated women (C) displayed weakly immunopositive stromal cell nuclei 
for HAND2, with occasional weak glandular cell immunoreactivity. The level of stromal cell 
immunopositivity following UPA administration was consistent with that observed in the 
proliferative phase (A). In contrast endometrial samples from women in the secretory phase 
displayed strong immunopositivity in stromal cells (B). 
 
Samples from UPA-treated women (F) displayed negligible immunopositivity of FOXO1 in 
both glands and stroma. This was less than immunopositivity observed in proliferative phase 
(weak staining in both glands and stroma (D). In samples from women in the secretory phase 
strong immunopositivity was observed in endometrial glandular cells and moderate 
immunoreactivity in stromal cells (E) 
 
Lower power (scale bar = 500µm) and high power magnification (scale bar = 50 µm); Negative 


















Figure 4.6 Administration of selective progesterone receptor modulator, ulipristal acetate 
(UPA), modulates BCL6 immunolocalisation in human endometrium 
 
Representative low-power (inserts) and high-power immuno-localisation of BCL6 in 
endometrium from woman with fibroids during proliferative (A) and secretory stages (B) and 
after UPA administration (C&D).  
 
Samples from most UPA-treated women (C) displayed negligible immunopositivity of BCL6 in 
both glands and stroma. This was less than immunopositivity observed in proliferative phase (A) 
where occasional weak immunoreactivity was observed in both glands (↑) and stroma (↑). In 
samples from women in secretory (B) phase strong immunopositivity was observed in glandular 
cells and occasional moderate immunoreactivity in stromal cells (↑).One exception of UPA-
treated subject (with co-exisiting endometriosis) displayed weak glandular immunopositivity 
(↑, D). 
 
Lower power (scale bar = 500µm) and high power magnification (scale bar = 50 µm); Negative 




4.5.3 Co-existing endometriosis is associated with a trend towards lower rates of 
amenorrhoea but does not alter mRNA levels of progesterone receptor and key 
genes associated with progesterone resistance following SPRM (UPA) 
administration. 
In total samples from 38 women who were administered the SPRM, UPA, have been 
utilised in the thesis, and of these 10 women had a diagnosis of co-existing endometriosis 
(Table 2.4 & 2.6). Data were not available regarding stage of disease, or whether the 
diagnosis was historical or of active endometriosis noted at the time of sample collection 
(if the sample was obtained at the time of hysterectomy). Recorded rates of amenorrhoea 
following UPA administration were higher in those without endometriosis (72%) 
compared to those women with a diagnosis of endometriosis, in whom only 50% 
achieved amenorrhoea (Figure 4.7A). The odds of amenorrhoea were not statistically 
different but there did appear to be a trend towards poorer control of bleeding for those 
women with endometriosis, with an odds ratio of achieving amenorrhoea of 0.4 (95% 
confidence interval 0.08-1.837) compared to women without endometriosis. Of note, of 
the three women with histologically proven adenomyosis, all were rendered 
amenorrhoeic by UPA administration. Data regarding impact of UPA administration on 
any pain symptoms (dysmenorrhoea, chronic pelvic pain, dyspareunia, dyschezia or 
dysuria) were not available.  
 
There was no significant difference in mRNA levels of PR or PRB (Figure 4.7B&C), or 
genes associated with progesterone resistance in the setting of endometriosis. These 
included FKBP51 (Figure 4.7D), FKBP52 (Figure 4.7E), FOXO1 (Figure 4.7F), HOXA10 
(Figure 4.7G), KLF-9 (Figure 4.7H) and BCL6 (Figure 4.7I). There was marked variation 
in gene mRNA levels within both groups. For subjects with endometriosis, information 
regarding stage of endometriosis had not been collected. 
 
4.5.4 Impact of SPRM (UPA) administration on presence of PTEN null glands in 
the endometrium 
The majority of subjects undergoing hysterectomy exhibited evidence of strong immuno-
staining of all endometrial glands with PTEN irrespective of stage of cycle or following 
SPRM (UPA) administration (Figure 4.8A-C). However PTEN null glands were observed 
in two women in the proliferative phase of the menstrual cycle (Figure 4.8D&G), two in 
the secretory phase (Figure 4.8E&H), and three who had had administration of UPA prior 
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to surgery (Figure 4.8F&I). In all subjects these PTEN null glands were present in the 
basal layer (Figure 4.8D-F). 
 
Of the 17 “paired” endometrial samples, described in 4.4, 11 women had no evidence of 
PTEN null glands in either the baseline pre-treatment sample or following UPA 
administration (Table 4.1). Three women had PTEN null glands present in their index 
sample (18%), of these only one had convincing evidence of residual PTEN null glands in 
the biopsy obtained when on UPA. Of note one of these ‘normal’ UPA samples was of poor 
quality due to small quantities of highly fragmented tissue (Sample CT1366E3, Table 
4.1). Three women appeared to have developed PTEN null glands whilst administered 
UPA that were not present in their baseline endometrial biopsy. All of these three women 
were amenorrheic and displayed histological signs of UPA administration.  No subjects 













Figure 4.7 Presence of co-existing endometriosis may alter menstrual bleeding control but 
does not alter mRNA levels of progesterone receptor and key genes associated with 
progesterone resistance in women treated with selective progesterone receptor 
modulator, ulipristal acetate (UPA), as determined by RT-qPCR 
 
Menstrual bleeding control following treatment with UPA (A), Relative mRNA levels of PR (B), 
PRB (C), FKBP51 (D), FKBP52 (E), FOXO1 (F), HOXA10 (G), KLF-4 (H) and BCL6 (I) from woman 
with fibroids administered UPA, with and without co-existing endometriosis. n=7 for each 











































































































































































































































































































































Figure 4.8 PTEN null glands are present irrespective of stage of menstrual cycle or following 
administration of selective progesterone receptor modulator, ulipristal acetate (UPA) 
Representative low-power (inserts, A-F) medium-power (A-F) and high-power (G-I) images of 
immuno-localisation of PTEN in endometrium from woman with fibroids during proliferative 
(A&D) and secretory stages (B&E) and after UPA administration (C&F). The majority of 
subjects had immunopositive staining for PTEN in glands following UPA treatment (C), or in 
proliferative (A) or secretory phase (B) of the menstrual cycle. However PTEN null glands 
were observed in two subjects in both proliferative (D&G), in secretory phase (E&H) and also 
following administration of UPA (F&I). None of these subjects with PTEN null glands had 
evidence of endometrial hyperplasia or malignancy. 
 
Low power (scale bar = 500µm), medium-power (scale bar = 100µm) and high power 
magnification (scale bar = 20 µm); Negative controls shown as inserts on proliferative low 
power endometrium (A).  
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Table 4.1 Alteration in rates of PTEN null glands following treatment with selective progesterone receptor modulator, Ulipristal acetate (UPA) 



























5777 CT1262E2 1678 Proliferative x   CT1262E3 1938 81 0 Amenorrhoea Inactive with no atypia# x   
8522 CT1929E 1724 Proliferative   x CT1929E2 1941 80 0 Lighter PAEC   x 
8002 CT1366E2 1723 Disordered 
proliferative 
  x CT1366E3 1942 66 0 Amenorrhoea Disordered proliferative# x   
8100 CT1463E 1920 Proliferative x   CT1463E2 1949 82 0 Amenorrhoea Consistent with UPA#   x 
8097 CT1460E 1916 Proliferative x   CT1460E2 1951 70 0 Amenorrhoea Inadequate# x   
5795 CT1280E 1679 Proliferative x   CT1280E2 1960 77 82 Amenorrhoea PAEC   x 
9055 CT1685E 2036 Proliferative   x CT1685E2 2063 79 0 Lighter PAEC x   
7886 CT1162E2 1935 Proliferative x   CT1162E3 2062 60 0 Amenorrhoea Inactive with no atypia# x   
5817 CT1691E 2053 Disordered 
proliferative 
x   CT1691E2 1988 80 0 Amenorrhoea PAEC x   
8122 CT1485E 1953 Secretory x   CT1485E2 1981 69 0 Amenorrhoea PAEC x   
8124 CT1487E 1955 Secretory x   CT1487E2 1986 81 0 Amenorrhoea Consistent with UPA# x   
8130 CT1493E 1963 Secretory x   CT1493E2 1987 70 0 Amenorrhoea PAEC x   
8045 CT1409E2 2050 Secretory x   CT1409E3 2062 76 0 Amenorrhoea PAEC x   
8123 CT1486E 1954 Menstrual x   CT1486E2 1980 75 0 Amenorrhoea PAEC   x 
5790 CT1275E 1671 Proliferative x   CU1275E1 1684 791 0 Unchanged Mildly disordered 
proliferative 
x   
5785 CT1270E2 1673 Proliferative x   CU1270E31 1958 781 0 Amenorrhoea Secretory (some non-
physiological) 
x   
8506 CT1903E2 1917 Proliferative x   CU1903E31 1903 821 0 Lighter Proliferative x   
PAEC: progesterone receptor modulator associated endometrial changes  
#: Minimal tissue in biopsy or fragmented sample. Sufficient tissue may be available to exclude malignancy but may be insufficient to assess for features of PAEC or to unequivocally state PAEC as 
diagnosis 1: sample from UCON subject – pipelles taken in final week of second 12 week cycle of treatment 2: sample taken 8 days after stopping UPA. Patient remained amenorrhic at the time of 
biopsy 
 
Samples highlighted: Absence of PTEN null glands prior to treatment, but PTEN null glands present in sample obtained following treatment with UPA  
Samples highlighted: PTEN Null glands present prior to treatment but not present in sample obtained following treatment with UPA 
Sample highlighted: PTEN Null glands present both prior to treatment and following treatment with UPA 
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4.6 Discussion 
Ulipristal acetate (UPA) is a SPRM which, like other class members, exhibits both agonist 
and antagonist activities in vitro and may be influenced both by bioavailability of 
different PR isoforms and the concentrations of different co-repressor and co-activator 
proteins (Wagenfeld, Saunders et al. 2016).  The data presented here, demonstrate that 
administration of the SPRM, UPA, to women with symptomatic fibroids, results in 
alteration of many key P-regulated genes, indicating that in the endometrium, UPA acts 
with low P-agonism on many key genes associated with reproductive function.  
 
4.6.1 Co-Chaperones FKBP51 and FKBP52 
FKBP51 mRNA levels were significant reduced compared to secretory phase of the 
menstrual cycle, similar to those seen in proliferative phase, whereas levels of FKBP52 
mRNA were unchanged.  
 
The effect of SPRM (UPA) administration on FKBP51 has not been published but is 
consistent with the effect observed following administration with the SPRM 
mifepristone. In healthy women administered a single dose of mifepristone FKBP51 
mRNA was reduced relative to secretory phase (Cuevas, Tapia-Pizarro et al. 2016). 
FKBP51 has been demonstrated to be increased in decidual cells (Jaaskelainen, 
Makkonen et al. 2011) and following administration of progestin (Hubler, Denny et al. 
2003) and so decrease in FKBP51 mRNA levels relative to secretory phase following UPA 
administration is consistent with UPA acting with low PR-agonist activity. SPRMs have 
previously been described as having unaltered ligand binding, HSP dissociation, 
dimerization and binding to PRE (Chabbert-Buffet, Meduri et al. 2005), and down-stream 
effects related to relative recruitment of co-regulators that results in altered activity 
(Smith and O'Malley 2004). It is unclear what the alteration in FKBP51 mRNA levels 
described here may have on HSP dissociation from PR and subsequent mobilisation from 
the cytoplasm to the nucleus. Co-localisation of PR and FKBP51 by immunofluorescence 
may provide insights into functional effects of UPA administration.  
 
No cyclical alteration in FKBP52 mRNA levels was observed. Other groups have observed 
a rise in secretory phase relative to proliferative (Yang, Zhou et al. 2012). Microarray 
performed by another group observed a 3 fold increase in FKBP52 mRNA levels in the 
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endometrium from women administered a single dose of mifepristone compared to 
women in the secretory phase of the cycle, although this was not validated either by PCR 
or immunohistochemistry (Catalano, Critchley et al. 2007). However there are potential 
explanations for why the data present herein are inconsistent with established literature 
both with respect to alteration in expression between proliferative and secretory phase 
of the cycle, and following administration of an SPRM.  
 
FKP52 is partly regulated by HOXA10 (Yang, Zhou et al. 2012), itself normally increased 
in secretory phase, but HOXA10 expression may be decreased in the presence of fibroids 
(Yang, Zhou et al. 2012, Kulp, Mamillapalli et al. 2016). This was also demonstrated in 
the endometrium of the women presented in this thesis (who had co-existing fibroids), 
in whom HOXA10 mRNA levels were also reduced in the secretory phase. The blunted 
alteration in HOXA10 may explain the apparent absence of cyclical variation of FKBP52 
demonstrated here in this thesis, and makes interpretation of FKBP52 mRNA levels 
following UPA administration more challenging. It is uncertain if the impact of UPA 
directly on FKBP52 mRNA levels occurs by acting with low P-agonism, or if it is alteration 
in HOXA10 due to underlying fibroids that impacts upon FKBP52 mRNA levels. However 
ongoing studies assessing the impact of UPA administration on the endometrium of 
women both with and without fibroids, such as the current UCON trial (Ulipristal acetate 
versus conventional management of heavy menstrual bleeding; EudraCT 2014-003408-
65) described in Chapter 2 (2.2.1.2) may facilitate the assessment FKBP52 mRNA levels 
in women with structurally normal uteri following SPRM administration.  
 
4.6.2 Progesterone regulated genes 
Murine knockout models have identified key P-regulated signalling pathways in the 
development of a receptive endometrium, in particular the IHH – COUP-TFII pathway 
and HAND2 signalling (Wetendorf and DeMayo 2012, Pawar, Hantak et al. 2014). 
 
IHH is signalling protein that acts in a paracrine fashion from epithelial cells to initiate a 
cascade of gene expression in the stromal cell compartment (Takamoto, Zhao et al. 
2002). Loss of IHH in murine models resulted in a total loss of typical uterine P4 
responses, suggesting that IHH is an obligate mediator of uterine P4 function (Lee, Jeong 
et al. 2006). There is some conflict in the literature regarding expression of IHH within 
human endometrium of the normal cycling woman. Some groups have demonstrated 
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that IHH protein expression was increased in secretory phase when compared to 
proliferative phase endometrium (Wei, Levens et al. 2010) though others have observed 
that the secretory rise was abrogated in the presence of co-existing endometriosis 
(Smith, Alnifaidy et al. 2011). This description however was determined from protein 
expression in women without fibroids, and a genome wide molecular phenotyping study 
that was derived from nearly 50% of women with fibroids indicated that IHH was 
downregulated during the progression of the endometrium from proliferative phase 
through the secretory phase (Talbi, Hamilton et al. 2006). The data presented in this 
present thesis are consistent with the latter study, with an observed reduction in IHH 
mRNA levels in the secretory phase relative to the proliferative phase. Of the subjects 
studied in the secretory phase and contributing to RT-qPCR data presented here, all of 
the women had fibroids and two women had a history of endometriosis.  
 
IHH has previously been assessed in women exposed to SPRMs. One group of women 
received a higher dose of UPA (10mg and 20mg), and changes in mRNA level change 
relative to proliferative phase only, studied. They observed that IHH expression was 
significantly increased following UPA administration, and it was unclear if protein 
expression was increased relative to the secretory phase. A study of mifepristone 
administration compared with secretory phase endometrium (no-treatment group) 
revealed an increase in IHH following SPRM administration (Cuevas, Tapia-Pizarro et al. 
2016). Further validation of the findings presented here in this thesis, by protein 
expression studies, and sub grouped by presence of co-existing endometriosis would 
further elucidate whether UPA is acting with low or high P-agonism on IHH expression. 
 
One mechanism of action of IHH is to bind to the transmembrane receptor patched-1 
(PTCH1), resulting in loss of inhibition of smoothened (SMO) (Wetendorf and DeMayo 
2012). This then results in activation of COUP-TFII (Krishnan, Elberg et al. 1997). The 
expression of COUP-TFII is reported to alter across the menstrual cycle, but in a 
contrasting fashion depending on location within the endometrium. Expression 
decreases in the functional layer, but increases in the basal layer following the 
proliferative to secretory transition (Li, Large et al. 2013). No cyclical alteration in mRNA 
levels was observed in data presented in this thesis, but the endometrium used to extract 
RNA was obtained from biopsies obtained at the time of hysterectomy, and so contained 
both basal and functional layer endometrium, and as such may have obscured relative 
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cyclical change. This is also true for assessing the effects of UPA, and assessment of 
effects of UPA administration of protein localisation would be of utility.  
 
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-
beta (TGFβ) superfamily. BMP-2 is P-regulated, a downstream target of COUP-TFII 
(Wetendorf and DeMayo 2012) and is implicated in control of HOXA10 expression 
(Sinclair, Mastroyannis et al. 2011). BMP-2 knockout mice are embryonic lethal but 
conditional knockout results in inability to decidualise and subsequent infertility (Lee, 
Jeong et al. 2007). BMP-2 mRNA levels are increased in decidualised endometrial stromal 
cells compared to undecidualised stromal cells from the proliferative phase (Li, Kannan 
et al. 2007). There was no cyclical alteration in BMP-2 mRNA levels in the data presented 
here in this thesis. It is unclear if this was a result of unaltered COUP-TFII, or due to 
altered response of BMP-2 due to co-existing pathology such as fibroids in the women 
from whom the endometrium utilised in this thesis were obtained. Endometrial 
deficiency of BMP-2 has been demonstrated in the stromal cells of women with fibroids 
(Sinclair, Mastroyannis et al. 2011). UPA administration did not significantly alter BMP-
2 mRNA levels, consistent with an absence of differential expression in previous 
transcriptional arrays following both UPA (Lira-Albarran, Durand et al. 2017) and 
mifepristone administration (Catalano, Critchley et al. 2007, Cuevas, Tapia-Pizarro et al. 
2016). This still requires confirmation by assessment of impact on protein expression, 
both in those women with and without fibroids. It would be of utility to assess impact of 
UPA administration on TGF-β3, which regulates the BMP-2 receptor and has also been 
demonstrated to be altered in stromal cells from women with fibroids (Sinclair, 
Mastroyannis et al. 2011). 
 
Whilst the downstream targets of IHH, COUP-TFII and BMP-2 were unchanged by UPA 
administration, the transcription factor HAND2 was significantly reduced relative to 
secretory phase and similar levels of expression relative to proliferative phase were 
observed, consistent with UPA acting with low P-agonism. This was demonstrated both 
by mRNA levels and protein expression. This is consistent with the effect demonstrated 
by other groups following UPA administration (Lira-Albarran, Durand et al. 2017) and 
following mifepristone administration (Li, Kannan et al. 2011). HAND2 may be regulated 
by COUP-TFII but also directly by PR (Wetendorf and DeMayo 2012). The striking 
reduction in HAND2 following UPA administration in the presence of unaltered COUP-
TFII may mean that the latter mechanism of control is more relevant with regard to 
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HAND2 expression following UPA administration. The abrogation of PR within the 
stroma following UPA administration, described in Chapter 3, may also be implicated in 
the alteration of HAND2 expression following UPA administration. In addition to the role 
of HAND2 in regulating endometrial receptivity, it is also implicated in inhibition of 
fibroblast growth factors (FGF), thereby preventing activation of extracellular-signal-
related kinases (ERK) and epithelial cell proliferation (Li, Kannan et al. 2011).  Loss of 
HAND2 by methylation is a common occurrence in endometrial cancer (Jones, 
Teschendorff et al. 2013). However despite reduction in HAND2, UPA administration is 
not associated with increased proliferation endometrial cell (Whitaker, Murray et al. 
2017), and discussed further in Chapter 5. 
 
As described in Chapter 3 a series of Hox genes are critical for the differentiation of the 
developing reproductive tract. HOXA10 is expressed in the developing uterus and is 
important in determining tissue boundaries (Mullen and Behringer 2014). Expression 
continues into reproductive life and it remains an important transcription factor, both 
for endometrial development and decidualisation.  HOXA10 is expressed in both 
glandular and stromal compartments of the endometrium and expression is regulated 
by both oestradiol and progesterone (Eun Kwon and Taylor 2004). Whilst HOXA10 does 
not regulate PR directly, it is hypothesised to regulate PR co-factors (Daftary and Taylor 
2004), and these have subsequently been demonstrated to include IGFBP1, FOXM1 and 
KLF-9 (Kim, Taylor et al. 2003, Du, Sarno et al. 2010, Gao, Bian et al. 2015). In healthy 
women expression peaks during the mid-secretory phase and its expression is 
considered an important factor in endometrial receptivity (Kulp, Mamillapalli et al. 
2016).  In women with uterine fibroids secretory phase upregulation may be impaired 
(Makker, Goel et al. 2017) and as all the subjects studied in this element of this thesis had 
fibroids this may explain why a reduced mRNA levels of HOXA10 from the secretory 
endometrium compared with proliferative phase was observed. In those subjects 
exposed to the SPRM UPA, HOXA10 mRNA levels were similar to the proliferative phase.  
Impact of UPA administration on HOXA10 has not previously been assessed but 
mifepristone administration in mice are reported to reduce expression. However as 
described above, the presence of fibroids in a human model may explain the contrasting 
data presented herein. Repetition of the experiment with endometrium from women 
without fibroids either in the various phases of the menstrual cycle or following UPA 
administration may yield useful further insights into the impact of SPRM administration 
on HOXA10 expression.  
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As described above, HOXA10 regulates IGBPB1, and as such it is unsurprising that mRNA 
levels of IGFBP1 were reduced relative to secretory phase following UPA administration. 
This was consistent with an observed absence of decidualisation (previously described 
in Chapter 3). Equally HAND2 regulates IGFBP1 (Huyen and Bany 2011) and so the 
absence of decidualisation maybe a product of alteration of multiple aspects of PR 
signaling. Use of genetically manipulated “knockout mice” may further elucidate the 
mechanism, particularly if administration of either HAND2 or HOXA10 might rescue 
decidualisation. Another marker of decidualisation is IL-15 (Gellersen and Brosens 
2014), which, as with IGFBP1,  was significantly reduced following UPA administration. 
This was in keeping with the effect observed following administration a single dose of 
UPA (Lira-Albarran, Durand et al. 2017) and following administration of the SPRM 
asoprisnil (Wilkens, Male et al. 2013). The effect of reduction by UPA administration on 
IL-15 mRNA levels on one of the downstream targets, CD56 positive uterine natural killer 
cells (uNK), has not been investigated. The morphological effects of asoprisnil 
administration on the architecture of the endometrium are slightly different and striking 
thick-walled vessels are widespread, an observation that is far less frequently observed 
following UPA administration. uNK cells may remodel endometrial vessels (Fraser, 
Whitley et al. 2015) and so the effect on uNK cell population may not be consistent 
between SPRMs. Indeed, in vitro treatment with mifepristone of human endometrial 
explants resulted in an increase of CD56 positive cells (Zhu, Zhang et al. 2009). However 
the effect associated with mifepristone potentially may be mediated by glucorticoids 
(Chen, Wang et al. 2012); as mifepristone binds GR with much greater affinity than other 
SPRMs (Attardi, Burgenson et al. 2004). 
 
Consistent with previous reports, mRNA encoded by FOXO1 was significantly increased 
in secretory phase control samples compared with those in proliferative phase (Fan, Li 
et al. 2012). Treatment with UPA resulted in mRNA concentrations similar to the 
proliferative phase and significantly lower than the secretory phase, corroborated by the 
impact upon protein expression, again suggesting UPA results in limited PR-dependent 
agonism in endometrium. This reduction in FOXO1 expression has not previously been 
demonstrated with other SPRMs, nor has been identified as a candidate gene in previous 
arrays or sequencing experiments. FOXO1 is progesterone regulated, with expression of 
FOXO1 in endometrial stromal cells up-regulated by cAMP and progesterone (Labied, 
Kajihara et al. 2006) and previous work using human endometrial stromal cells treated 
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with a decidualisation stimulus has suggested that HAND2 may regulate FOXO1 
expression (Huyen and Bany 2011). Thus the reduction in FOXO1 may be in part due to 
reduction in HAND2 expression. Furthermore, a genomic screen of human endometrial 
stromal cells treated with a decidualisation protocol showed 15% of the genes induced 
were aberrantly expressed if FOXO1 was “knocked down” (Vasquez, Mazur et al. 2015).  
As FOXO1 binding sites are present in the majority of DNA regions associated with PR 
binding (Vasquez, Mazur et al. 2015) the finding of reduced expression of FOXO1 in UPA-
treated women may explain some of the changes in PR-dependent genes.  
 
BCL6 is a nuclear gene repressor associated with cell proliferation (Shaffer, Yu et al. 
2000) and also may decrease the Indian Hedgehog (IHH) pathway involving COUP-TFII 
(Evans-Hoeker, Lessey et al. 2016). Consistent with other groups (Evans-Hoeker, Lessey 
et al. 2016), BCL6 mRNA levels were significantly increased in the secretory phase of the 
menstrual cycle relative to the proliferative phase, and immunopositivity observed both 
in the glandular epithelium and stromal fibroblasts in secretory phase endometrium.  
UPA administration significantly decreased mRNA levels of BCL6 relative to the 
secretory phase, and this was reflected in reduced protein expression, most evident in 
the glandular epithelium. This is consistent with a reduction in BCL6 transcript levels 
noted in a microarray of endometrium from normal healthy women in mid secretory 
phase following a single dose of 30mg UPA (Lira-Albarran, Durand et al. 2017) but was 
not demonstrated to be altered in the two published microarrays of mifepristone 
(Catalano, Critchley et al. 2007, Cuevas, Tapia-Pizarro et al. 2016). It is unclear if this 
discrepancy between the differing SPRMS is due to the compound, dosing schedules or 
associated pathology.  
 
Interestingly one of the subjects administered UPA had some persistent weak glandular 
immunopositivity of BCL6. This subject had active endometriosis at the time of surgery. 
Co-existing endometriosis is associated with significant increased transcription and 
protein expression of BCL6 in the eutopic endometrium (Evans-Hoeker, Lessey et al. 
2016), and it may be that this was implicated in the persistent immunopositivity despite 
UPA administration. However this was not a consistent effect as three other women in 
the current study, who had a history of endometriosis, had no immunopositivity 
following UPA administration and mRNA levels were not significantly altered between 
women with and without endometriosis. Equally these three subjects all achieved 
amenorrhoea or markedly reduced bleeding, whereas the subject with persistent BCL6 
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immunopositivity also had no improvement in bleeding symptoms following UPA 
administration.  
 
FOXM1 is a transcription factor, critical for cell cycle progression at the G1-S and G2-M 
transitions (Kalin, Ustiyan et al. 2011). Consistent with previously reports, FOXM1 was 
highest in the proliferative phase (Jiang, Liao et al. 2015), but in contrast with many of 
the P-regulated genes described above, mRNA levels following UPA administration were 
consistent with the secretory phase rather than proliferative phase levels. The effect of 
SPRM administration on FOXM1 has not previously been examined, and previous 
microarrays of human endometrium have not identified it as differentially expressed 
gene. This is perhaps unsurprising as the published literature with regard to SPRM 
microarray and RNA-Seq have been relative to secretory phase, suggesting that 
transcription of FOXM1 in the secretory phase is similar to that following SPRM 
administration. Of note the microarray of differentially expressed transcripts in human 
endometrium relative to proliferative phase performed for this thesis and described in 
Chapter 5, independently identified FOXM1 as being decreased by UPA administration. 
The mechanism for this is unclear, and is likely separate to that of UPA acting with low 
P-agonism described above. Regulation of FOXM1 by HOXA10 has previously been 
demonstrated (Gao, Bian et al. 2015). In this cohort HOXA10 was reduced in the secretory 
phase compared with the proliferative phase or following UPA administration and so 
does not adequately explain the pattern of transcription of FOXM1 observed and bears 
further investigation. This is particularly pertinent given that FOXM1 inhibition has been 
demonstrated to reduce cyclin B1 expression (Jiang, Liao et al. 2015) and so may be 
critical in the observed anti-proliferative effect of SPRM UPA and impact upon cell cycle 
described in Chapter 5.  
 
Consistent with previous data, in the data presented herein there was increase in the 
secretory phase mRNA levels relative to proliferative phase of KLF-4 (Shimizu, Takeuchi 
et al. 2010) and KLF-9 (Pabona, Simmen et al. 2012). No statistical difference relative to 
either secretory phase or proliferative was noted in mRNA levels of KLF-4, -9 or -15 
following administration of UPA. For both KLF-4 and KLF-15 this may have been due to 
a smaller sample size but the medians were very similar to secretory phase and so 
increasing the number of samples may not result in a statistical difference being 
observed. For KLF-9, a trend towards treatment effect relative to secretory phase was 
observed but the heterogeneity in response prevented this from being statistically 
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significant. The secretory group where not sub-divided into early, mid and late secretory 
and the differing expression of KLF-9 across the luteal phase may have impacted upon 
outcomes (Pabona, Simmen et al. 2012). Some women in the UPA group had 
adenomyosis or endometriosis and this may have impacted on mRNA levels. However 
no kruppel like factors (KLFs) were differentially expressed in other previously reported 
studies of UPA and mifepristone (Catalano, Critchley et al. 2007, Cuevas, Tapia-Pizarro 
et al. 2016, Lira-Albarran, Durand et al. 2017) so the findings in the current thesis may 
represent true effect. However given that KLF-4 and KLF-15 both are known to regulate 
the proliferative response to oestradiol (Ray and Pollard 2012) and KLF-9 has key roles 
in both progesterone and oestrogen function in the endometrium (Simmen, Heard et al. 
2015) a reassessment of the genes in women in all phases of the menstrual cycle 
(including subdivision of the secretory phase) and following UPA administration would 
be of value. The impact on KLF protein expression would also be of import as UPA may 
alter localisation, as HOXA10 impacts upon epithelial but not stromal expression of KLF-
9 (Du, Sarno et al. 2010) and location specific alteration following UPA administration 
may be assessed.  
 
4.6.3 Endometriosis 
The data presented herein suggest that there is a trend towards women who have 
endometriosis being less likely to achieve amenorrhoea when administered UPA, 
although this is not statistically significant. The numbers are small and this is a 
retrospective observation only, and may be affected by selection bias. Whilst this finding 
is consistent with observation data by our clinical team, in that women who reported 
poor control of bleeding whilst undergoing treatment with UPA, were often where found 
to have active endometriosis at the time of surgery, an appropriately powered study with 
potential bias corrected would be necessary to further explore this most interesting 
observation.  
 
The data presented herein suggest that co-existing endometriosis does not result in 
differing mRNA levels of key genes implicated in progesterone resistance following 
treatment with UPA, when compared to women administered UPA who do not have 
endometriosis. However limited conclusions can be drawn from these data. The 
observations have not been confirmed with studies concerning protein expression and 
localisation, the sample size is small and corresponding controls of women in 
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proliferative phase and secretory phase with endometriosis were not available. The 
subjects were poorly characterised with regard to their endometriosis. The anonymised 
database in which clinical information is recorded of subjects recruited to the “in-house” 
Female Reproductive Tract Tissue Resource (REC approval 16/ES/0007) does not 
differentiate between a previous diagnosis of endometriosis (and ensuing treatment) 
and that of active endometriosis prior to commencing UPA or observed at the time of 
sample collection. The stage of endometriosis is not recorded and the eutopic 
endometrium gene profiles has been previously shown, by others, to be altered 
depending upon stage of endometriosis (Wu, Strawn et al. 2006). 
 
It is thus uncertain if an absence of difference in mRNA levels between the two groups is 
due to small sample size and potential heterogeneous samples with regard to disease 
stage and activity, if UPA overcomes relative progesterone resistance associated with 
endometriosis, or low P-agonism reflects merely pre-existing P-resistance. Only three of 
the paired biopsies (biopsy prior to and whilst on UPA treatment) had a diagnosis of 
endometriosis, and all had different histological staging of the baseline sample 
(proliferative, menstrual and disordered proliferative), as such it is not possible with 
study on the samples collected to date to assess the impact of UPA administration on 
genes associated with progesterone resistance in the context of endometriosis. As tissue 
collection in the embedded mechanistic arm of the UCON study continues (Ulipristal 
acetate versus conventional management of heavy menstrual bleeding; EudraCT 2014-
003408-65) described in Chapter 2 (2.2.1.2), information may be obtained regarding 
the impact of endometriosis on alteration in gene expression following UPA 
administration. An alternative would be to explore the effect of in vitro administration of 
UPA on cultured endometrial cells obtained from women with and without 
endometriosis. Given the paracrine effects of P-signalling between the epithelial and 
stromal compartments there would be utility in performing this experiment both in 
isolated stromal cells, isolated epithelial cells and co-culture systems containing both 
epithelial and stromal cells.  
 
Further exploration of the effect of UPA administration in the context of endometriosis 
would be of utility as if one could phenotype patients prior to treatment it might be 
possible to better predict those who would have improved bleeding outcomes, thereby 
facilitating more ‘personalised’ medicine. Furthermore SPRMs are increasingly being 
considered as a treatment for women suffering from the symptoms of endometriosis 
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without co-existing HMB or fibroids. Promising results from animal studies have shown 
positive results with regard to regression of lesions following administration of the 
SPRMs mifepristone (Grow, Williams et al. 1996), onapristone and ZK 136799 
(Stoeckemann, Hegele-Hartung et al. 1995). In clinical trials reduction in endometriosis-
associated pain was observed following administration of both mifepristone (Kettel, 
Murphy et al. 1998), and asoprisnil (Chwalisz, Perez et al. 2005). Preliminary reports of 
a phase II trial of the effects of UPA on endometriosis also reported amelioration of 
symptoms and reduction in lesion size (Simpson, Lonsdale et al. 2017, Simpson, Lonsdale 
et al. 2017).  
 
4.6.4 PTEN 
Whilst women with heavy menstrual bleeding (and thus likely to be offered SPRMs if co-
existing fibroids) overall have a low risk of endometrial cancer (Pennant, Mehta et al. 
2017), there have been historical concerns regarding the safety of the SPRMs given the 
potential risk of normal circulating oestrogen, absence of ovulation, and administration 
of a compound with low P-agonism. Despite this, there is accumulating high volume 
evidence suggesting that SPRM administration is not associated with the development of 
premalignant or malignant disease (Williams, Bergeron et al. 2012). 
  
PTEN is present in the endometrium and acts as a tumour suppressor (Sanderson, 
Critchley et al. 2017). There is cyclical variation in expression (Mutter, Lin et al. 2000) 
but inactivation of PTEN is a common feature of endometrial cancer, particularly 
endometrioid subtypes, and often predates morphological evidence of malignancy and 
pre-malignant precursors (Mutter, Baak et al. 2000). PTEN deletion has been 
demonstrated in benign endometrium of nearly a fifth of healthy women (Yang, Meeker 
et al. 2015). Whilst there was little cyclical variation or impact of UPA on PTEN 
expression, consistent with effect noted after asoprinil (Wilkens, Williams et al. 2009), 
null glands were observed in some cases at both the proliferative and secretory phase of 
the menstrual cycle, and following UPA administration. In no cases was this associated 
with evidence of malignancy or hyperplasia. Reassuringly in paired samples from the 
same women obtained prior to treatment and whilst administered UPA, treatment did 
not appear to affect clearance of PTEN null glands, and was not associated with 
significant rates of new acquisition. This is particularly relevant given that exogenous 
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progestins may play an important role in elimination of PTEN-null glands (Orbo, Rise et 
al. 2006).  
 
It should be noted that interpretation of samples was occasionally compromised by the 
quality of the tissue obtained, which was occasionally highly fragmented following UPA 
administration. There would be utility assessing PTEN deletion in paired samples from 
women prior to commencing UPA, with the subsequent section from the same women 
obtained from a full thickness biopsy (lumen to endometrial-myometrial interface) at 
the time of hysterectomy (thereby obtaining greater architectural preservation to better 
assess the presence of PTEN null glands) in order to add weight to these conclusions.  
 
4.6.5 Future work 
The data presented herein would benefit from additional work. For many of the genes 
discussed, protein validation has yet to be undertaken. Given the alteration in PR and PR 
localisation described in Chapter 3, immunolocalisation in sequential sections and 
compared against PR/PRB expression, or co-localization with PR/PRB may provide 
additional insights.  
 
Furthermore, given the impact of fibroids upon expression of key genes such as IHH, 
BMP-2 and HOXA10, exploration of effect of UPA administration on the endometrium in 
women without fibroids would be of interest. The impact of UPA administration on other 
key genes implicated in P-signalling including WNT4, FGF, FGFR, ERK1/2, HIC-5, SRC-2 
and STAT has yet to be undertaken. In addition the impact upon the co-repressors NcoR 
and SMRT has yet to be ascertained and the former of these has previously been 
demonstrated to have differing alteration depending on SPRM utilised (Afhuppe, 
Sommer et al. 2009).  
 
Further examination of the mechanism of the SPRM UPA action is somewhat hampered 
by the lack of bioidentical model. Well-validated murine models are available of 
menstruation itself, (Cousins, Murray et al. 2014) but are time consuming and expensive 
and there are occasional differences in P-signalling between the mouse and humans. Use 
of culture systems may provide insights, but given the complex interaction and paracrine 
effects between the epithelial and stromal compartments, co-culture systems, which 
have inherent challenges, are likely to be required to more accurately assess mechanism. 
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The limitations of the experimental design to assess the impact of endometriosis on the 
effects of UPA administration have already been comprehensively discussed in section 
4.6.2. The impact of co-existing adenomyosis has not been examined, and as recruitment 
to the “in-house” Female Reproductive Tract Tissue Resource (REC approval 
16/ES/0007) is ongoing, may potentially be assessed alongside the impact of 
endometriosis in the future. The impact of endometriosis and adenomyosis should also 
not be considered on gene expression and localisation in isolation, but also the impact 
upon bleeding control and symptomatology.  
 
4.7 Conclusions 
In conclusion the data presented herein demonstrate that for many key progesterone 
regulated genes, UPA administration alters mRNA levels, consistent with UPA acting with 
low P-agonism. Alteration in HAND2, FOXO1 and BCL2 mRNA levels was reflected in 
altered protein expression but not localisation. In contrast to the majority of genes, 
mRNA levels of FOXM1 reflected UPA acting as a P-agonist and may be implicated in the 
anti-proliferative effect discussed further in Chapter 5. For many of these genes this was 
the first assessment of UPA endometrial effect following in vivo administration, and also 
validates other candidates highlighted by RNA-sequencing and microarray of UPA and 
mifepristone effect described by other groups. Reassuringly, also presented here, despite 
overall low P-agonism, there does not appear to be increased levels of PTEN null gland 
acquisition, adding further mechanistic data to the histological observation of unaltered 
rates of pre-malignancy and malignancy following UPA administration.  
 
Furthermore it is demonstrated that the effect of UPA administration on genes 
implicated in P-resistance appear to be unaltered in the presence of endometriosis but 
further characterisation of this is required. This is of particular importance as in this 
small sample size there appears to be a trend towards co-existing endometriosis 
resulting in poorer bleeding control following UPA administration.   
 
Further work is required to better describe this effect of low P-agonism, including 
protein characterisation, exploration on size of effect relative to the different stages of 
the secretory phase of the menstrual cycle and the relative impact of co-existing fibroids, 
as well further exploration of function in appropriate models, and crucially correlation 
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with bleeding control. However the data presented herein provide novel early insights 
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The endometrium in the human female undergoes repeated cycles of proliferation 
followed by secretory differentiation and subsequent shedding at the time of 
menstruation. As described in chapter one (section 1.2.3, Figure 1.3), under the 
influence of oestradiol (E2), proliferating epithelial and stromal cells arise from the basal 
layer to form the functional layer of the endometrium.  
 
5.1.1 The cell cycle 
Cell proliferation (replication) results from a tightly controlled sequence of events called 
the cell cycle.  
 
The majority of cells exist in a quiescent state (G0) where they are not dividing. Under an 
appropriate stimulus, such as signals from growth factors or from the extracellular 
matrix (ECM) via integrins, they enter the cell cycle to eventually undergo cell division 
(mitosis; M). There are three distinct points in the cell cycle prior to mitosis, Gap 1, (pre-
synthesis; G1), synthesis (DNA synthesis; S) and Gap 2 (pre-mitotic; G2) collectively 
known as interphase (Figure 5.1).   
 
The cell cycle is highly regulated, and as well as tightly controlled entry by growth factor 
and integrin signalling, there are multiple checkpoints and internal controls. Each phase 
of the cycle is dependent on the proper activation and completion of the previous step, 
and the cycle is further limited by appropriate expression of cell cycle proteins.  
 
Entry into G1 is either directly from mitosis (for continually replicating cells) or from G0. 
The transition from quiescent cell to G1 is regulated by transcriptional activation of a 
large number of genes, including proto-oncogenes, and genes required for ribosome 
synthesis and protein translation. The G1/S transition is a restriction point, which is a 
rate-limiting step, and progression beyond this point means that the cell is irreversibly 
committed to DNA replication. Progression through this point is tightly regulated by the 
cyclin group of proteins and their associated enzymes, the cyclin-dependant kinases 
(CDKs). These form complexes with the cyclins, and thus acquire catalytic activity, 













Figure 5.1 The mitotic cell cycle 
Representative images of the eukaryotic cell cycle. Cells transition though the cell cycle to 
eventually undergo cell division (mitosis; M). There are three distinct points in the cell cycle 
prior to M: Gap 1, (pre-synthesis; G1), synthesis (DNA synthesis; S) and Gap 2 (pre-mitotic; 
G2) collectively known as interphase.   
 
Progression is tightly regulated by cyclins which are regulated by cyclin-dependant kinases 
(CDK) and there are other regulatory proteins. In G1 there is restriction point (R), beyond 
which cells are irrevocable committed to DNA replication 
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Further CDK-cyclin complexes have activity in subsequent cell cycle phases. Activity of 
the CDKs is regulated by CDK inhibitors (Figure 5.1). Furthermore there are DNA 
integrity check points at G1/S and G2/M. If damaged DNA is sensed the repair 
mechanisms are activated, or if too severe, the cell either undergoes apoptosis or enters 
senescence, a non-replicative state (primarily through p53 regulated mechanisms).  
 
Within the endometrium, the predominant growth factor driving cells into G1 is E2 
(Groothuis, Dassen et al. 2007). 
 
5.1.2 The proliferative paradox of SPRMs 
In chapter three the profound effects of Ulipristal acetate (UPA) administration on the 
human endometrium have been described. In keeping with other SPRMs extensive cystic 
glandular dilatation is often observed. Prior to the recognition of progesterone receptor 
modulator associated endometrial changes (PAEC) as a distinct histological variant 
(Mutter, Bergeron et al. 2008), this characteristic appearance following treatment with 
an SPRM was often interpreted as simple hyperplasia  (Murphy, Kettel et al. 1995, 
Eisinger, Meldrum et al. 2003, Levens, Potlog-Nahari et al. 2008, Bagaria, Suneja et al. 
2009). The reclassification of the endometrial effects following SPRM administration has 
led to reassurance regarding the histological appearance but the paradox of why women 
administered SPRMs do not develop endometrial cancer at an increased rate remains.  
 
As previously described in section 1.4, using the McPhail test both mifepristone and UPA 
are relatively pure P-antagonists (Elger, Bartley et al. 2000). The majority of women 
receiving mifepristone are anovulatory due to impaired follicular development and 
blockade of the LH surge (Croxatto, Salvatierra et al. 1993, Croxatto, Salvatierra et al. 
1995, Cameron, Critchley et al. 1996) and circulating E2 levels are consistent with mid 
follicular phase levels (Baird, Brown et al. 2003). Similar circulating levels of E2 are 
observed following UPA administration (Donnez, Tatarchuk et al. 2012, Donnez, 
Tomaszewski et al. 2012). Unopposed E2 is one of the main risk factors for developing 
endometrial pre-malignancy and endometrioid endometrial cancer (Trimble, Method et 
al. 2012, Chlebowski, Anderson et al. 2016). Despite this, administration of SPRMs has 
not been associated with cases of endometrial cancer. The largest studies follow UPA 
administration in the PEARL studies: 1049 women were allocated to UPA and increase 
in rates of endometrial malignancy or hyperplasia were not observed (Donnez, 
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Tatarchuk et al. 2012, Donnez, Tomaszewski et al. 2012, Donnez, Vazquez et al. 2014, 
Donnez, Hudecek et al. 2015). 
 
Early insights into why UPA administration does not result in unrestrained endometrial 
proliferation can be derived from the action of SPRMs on other tissue types and previous 
observed findings in the endometrium of other SPRM class members. 
 
5.1.3 SPRM effects upon cell proliferation  
Uterine fibroids 
SPRMs have an anti-proliferative effect upon uterine fibroids. These benign tumours of 
the myometrium express both PR and ER, and with greater abundance than the adjacent 
myometrium (Englund, Blanck et al. 1998). Macroscopically administration of the SPRMs 
mifepristone (Engman, Granberg et al. 2009), asoprisnil (Chwalisz, Larsen et al. 2007) 
and UPA (Donnez, Tatarchuk et al. 2012, Donnez, Tomaszewski et al. 2012) all result in 
in fibroid shrinkage. In vitro work has shown anti-proliferative and pro-apoptotic effects 
on fibroid cells associated with administration of mifepristone (Yin, Lin et al. 2010), 
asoprisnil (Yoshida, Ohara et al. 2010) and UPA (Luo, Yin et al. 2010). Mifepristone 
administration was associated with reduced PCNA and KLF-11 protein expression (Yin, 
Lin et al. 2010). UPA down regulated PCNA and BCL-2 and upregulated cleaved caspase 
3 (Xu, Takekida et al. 2005).  
 
Breast 
Anti-proliferative effects of mifepristone has been described in normal human breast 
tissue with reduction in Ki67 index (Engman, Skoog et al. 2008), an effect replicated in 
non-human primate (NHP) studies both by mifepristone and asoprisnil (Chwalisz, Garg 
et al. 2006, Engman, Skoog et al. 2008). In addition, administration of mifepristone 
prevented development of tumours in Brca1-deficient mice (Poole, Li et al. 2006).  
 
Fallopian tube 
The fallopian tube also expresses sex-steroid receptors (SSR), as described in chapter 3. 
Within the fallopian tube, as demonstrated in in this thesis, UPA alters SSR expression 
relative to secretory phase only, consistent with blockade of P-antagonism. With regard 
to proliferation there is evidence that SPRMs may reduce proliferation slightly. 
Mifepristone administration to a NHP resulted in preservation of ciliation and oviductal 
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wet weight consistent with proliferative phase morphology and unaltered apoptosis. 
However a modest reduction in epithelial Ki67 was observed (Slayden, Hirst et al. 1993, 
Slayden and Brenner 1994). The SPRM ZK 137316 also maintained oviductal wet weight 
but Ki67 was not assessed (Slayden, Zelinski-Wooten et al. 1998). The effect of UPA on 
cell proliferation within the human fallopian tube and cervix has not previously been 
assessed. 
 
5.1.4 Known SPRM effects on endometrial cell proliferation 
Mifepristone, Asoprisnil, ZK 137316 and ZK230211 
In keeping with the impact upon SSR expression described in chapter 3, much of the early 
understanding of the impact of SPRMs upon endometrial proliferation was gained from 
studies utilising mifepristone in both NHP and human studies. In the NHP mifepristone 
administration resulted in endometrial atrophy with both reduction in thickness and wet 
weight, however in this study, despite morphological atrophy, there was no reduction in 
cell proliferation as assessed by Ki67 although increased apoptosis was noted (Slayden, 
Hirst et al. 1993). However subsequent studies did demonstrate a reduction in mitotic 
indices (no of mitoses per 1000 epithelial cells; (Slayden and Brenner 1994)). This 
inconsistent finding in the first study may be due to treatment schedules. Anti-
proliferative effects have been consistently noted with other SPRMS in NHP models. The 
SPRM asoprisnil reduced endometrial thickness and decreased epithelial Ki67 and PH3 
immunopositivity (Chwalisz, Garg et al. 2006). Similarly ZK 137316 inhibited mitosis (as 
assessed by Ki67 immunopositivity) in both epithelial and stromal cells and this was 
observed in both basal and functional layers, in addition to the reduction in thickness 
and wet weight (Slayden, Zelinski-Wooten et al. 1998). A reduction in wet weight and 
thickness, as well as reduction in mitotic indices was also observed after administration 
of the SPRM ZK 230211 (Slayden and Brenner 2003, Slayden and Brenner 2004).  
 
Human studies have been predominantly limited to mifepristone and asoprisnil. 
Mifepristone, whilst increasing endometrial thickness (Baird, Brown et al. 2003) has 
been consistently shown to reduce proliferation, as assessed by number of mitotic 
figures,  as well as Ki67 immunopositivity (Cameron, Critchley et al. 1996, Baird, Brown 
et al. 2003, Engman, Granberg et al. 2009). This reduction in Ki67 expression was 
observed in both glands and stroma. Asoprisnil did not increase endometrial thickness 
in the largest published study (Chwalisz, Larsen et al. 2007). Mitotic figures were 
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reduced (Williams, Critchley et al. 2007) and Ki67 immunoexpression decreased, though 
this was limited to the stroma and compared only to secretory phase endometrium 
(Wilkens, Williams et al. 2009). 
 
In both NHP and human studies this observed anti-proliferative effect has been 
considered a potential factor involved in the reduction of menstrual bleeding resulting 
from administration of an SPRM (Spitz 2003).  
 
Ulipristal acetate 
As with other SPRMS, initial information can be gained from NHP models. Intrauterine 
administration of UPA resulted in endometrial atrophy and histological proliferation 
appeared reduced. This was further confirmed utilising the proliferation marker Ki67 
and PH3 both of which were reduced by UPA administration (Brenner, Slayden et al. 
2010). In human studies, whilst an increase in endometrial thickness is often observed 
(Donnez, Donnez et al. 2016), mitotic activity appears low on histological examination 
(H&E of fixed tissue sections;(Williams, Bergeron et al. 2012)). To date we are the only 
group to quantitatively demonstrate that proliferation is reduced following UPA 
administration compared to the proliferative phase (Whitaker, Murray et al. 2017). We 
demonstrated that there is a reduction in Ki67 immunopositivity both overall in the 
endometrium and specifically in the stromal compartment (Figure 5.2). The reduction in 
the glandular compartment did not quite achieve statistical significance (p = 0.069). 
 
The mechanism by which this reduction in proliferation is brought about is poorly 
understood. Some studies of in vitro models of other disease systems have suggested 
that mifepristone and onapristone results in cell cycle arrest by up regulation of cyclin 
dependant kinase inhibitors p21 in a murine breast cancer model (Peters, Vanzulli et al. 
2001). Mifepristone also increases the CDK inhibitor p27 in a similar mouse model 
(Vanzulli, Soldati et al. 2005) and in metastatic murine cell lines (Vanzulli, Efeyan et al. 
2002). In ovarian cancer cells mifepristone administration is associated with low E2F 
and reduced CDK2 (Goyeneche, Caron et al. 2007) and this and other SPRMs (including 
UPA) upregulate p21 and p27 and reduce cyclin E levels (Goyeneche, Seidel et al. 2012). 














Figure 5.2 Selective progesterone receptor modulator, ulipristal acetate (UPA), 
administration does not increase endometrial cell proliferation 
 
Proliferation assessed by Ki67 immunohistochemistry and stereological quantification. 
Subject A shows endometrium in which PAEC is characterised by extensive cystic glandular 
dilatation; Subject I has PAEC with minimal cystic change. x40 magnification (scale bar = 
50µm); LE: Luminal epithelium, G: Glands, S: Stroma. Negative controls shown as inserts on 
secretory endometrium. Kruskal-Wallis statistical test *p <0.05, **p <0.01    
 
Reproduced with permission (open access) from: 
 
Whitaker LH, Murray AA et al (2017) 
Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on 
the human endometrium  
Human Reproduction 32(3):531-543 
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factors in the endometrium. Ishikawa cancer cells demonstrate reduction in cycle 
progression but the point of arrest appears conflicting (Goyeneche and Telleria 2015). 
In a different endometrial cancer cell line (Hex-1A) p21 was also increased (Schneider, 
Gibb et al. 1998). In a NHP model mifepristone cyclin B was increased but not p21 
(Heikinheimo, Hsiu et al. 1996).  
 
In summary, as a class, SPRMs appear to reduce cell proliferation in some tissues, 
including the endometrium. The effect of UPA administration upon fallopian tube and 
cervix cell proliferation is unknown. Other SPRMs have a limited effect upon fallopian 
tube proliferation, suggesting a relatively endometrial specific effect. The mechanism by 
which endometrial proliferation is reduced by UPA is unknown, and there does not 
appear to be published evidence of the impact of in vivo UPA administration upon cell 




SPRM administration has an anti-proliferative effect within the epithelium of the 




To study the mechanisms whereby SPRM administration reduces cell proliferation 
in the epithelium of the human female reproductive tract.  
Research Questions 
- Is there reduction in cell proliferation in the fallopian tube and cervix following 
UPA administration? 
- What candidate genes are implicated in the anti-proliferative effect within the 
endometrium?  





5.4 Materials and Methods 
5.4.1 Ki67 Immunohistochemistry of human fallopian tube and cervix biopsies 
Nine women with symptomatic fibroids underwent hysterectomy following treatment 
with Ulipristal acetate (UPA) 5mg orally once daily for up to 15 weeks prior to surgery 
(minimum nine weeks of treatment). They had given informed consent and the study 
had REC approval (12/SS/0238; section 2.1.1). At the time of surgery, biopsies were 
collected from the fallopian tube and cervix if removed concurrently. Samples were 
processed as previously described (section 2.2) and tissue taken for formalin fixation 
prior to immunohistochemistry. Corresponding control biopsies from women with 
symptomatic fibroids in proliferative and secretory phases of cycle were obtained from 
tissue archives (section 2.1.1). Subjects were well characterised (section 2.4.1 Table 
2.8-11). FFPE sections were cut for histology (H&E staining) and immunolocalisation of 
Ki67 was performed (section 2.6, Table 2.13-14). This was performed on the fallopian 
tube (n=6 in each group of UPA, proliferative or secretory phase of the menstrual cycle) 
and cervix (n = 8 UPA, 4 proliferative and 5 secretory).   
5.4.2 Gene expression Microarray in human endometrium exposed to SPRM 
5.4.2.1 Sample characteristics  
For gene microarray, paired endometrial biopsies were obtained from six women with 
symptomatic fibroids treated with UPA 5mg daily with ethical approval and written 
informed consent (see below for power calculation). Samples were obtained using a 
pipelle endometrial biopsy sampler (Pipelle de Cornier Mark II, Laboratoire CCD, France) 
as described in section 2.2.1.2. A baseline biopsy was obtained prior to commencement 
of treatment when women were in the proliferative phase of the menstrual cycle (staged 
as described in section 2.3.2; histological appearance based on Noyes criteria, LMP and 
circulating progesterone and oestradiol Table 5.1).  
 
A follow-up sample was taken whilst on treatment after at least eight weeks of UPA 
administration (Table 5.2). One sample (CT1280E2) was form a patient who had 
unexpectedly stopped treatment a week prior to her scheduled biopsy but had no 
bleeding. Consensus was that this sample was acceptable for use in the array as exposure 
had been for 77 days and progesterone and oestradiol levels suggested that ovulation 
had not occurred (Table 5.2). 
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Table 5.1 Sample characteristics of endometrial biopsies from proliferative phase of the menstrual cycle for gene microarray 
Participant 
No 






Age BMI Parity HMB Fib Endo LMP Cycle E2 P4 Histology RIN cRNA 
concentration  
5777 B 23/11/2015 1678 CT1262E2 52 29.6 1+2 Yes Yes No 05/11/2015 7/24-29 145 0.4 P 8.6 624 μg/μl 
5795 B 07/01/2016 1679 CT1280E 46 22.9 2+1 Yes Yes No 14/12/2015 8/21-25 522 4.7 P 8.1 222 μg/μl 
7886 B 25/02/2016 1935 CT1162E2 46 21.3 0+0 Yes Yes No 18/02/2016 6-14/28-46 104 5.1 P 8.2 555 μg/μl 
8097 B 29/10/2015 1916 CT1460E 40 28.9 0+1 Yes Yes No 20/10/2015 3-8/21-28 224 2.5 P 7.7 317 μg/μl 
8522 B 14/12/2015 1724 CT1929E 46 38.6 0+3 Yes Yes No 25/11/2015 4-8/35-43 312 8.5 P 8.3 583 μg/μl 
9055 B 03/12/2015 2036 CT1685E 47 25.9 1+1 Yes Yes Yes 18/11/2015 7-10/21 207 4.5 P 10.0 244 μg/μl 
REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis LMP: Last menstrual period E2: oestradiol P4: 
progesterone  
P: Proliferative phase of menstrual cycle 
 
Table 5.2 Sample characteristics of endometrial biopsies following administration of ulipristal acetate (UPA) for gene microarray 
Participant 
No 







of UPA Rx 
Days 
off Rx 
Control E2 P4 Histology RIN cRNA 
concentration 
5777 A 08/03/2016 1938 CT1262E3 81 0 Amenorrhoea 55 5.2 Inactive with no atypia# 7.6 125 μg/μl 
5795 A 03/05/2016 1960 CT1280E2 77 82 Amenorrhoea 359 0.2 PAEC 8.4 193 μg/μl 
7886 A 19/05/2016 1964 CT1162E3 60 0 Amenorrhoea 319 0.5 Inactive with no atypia# 9.4 230 μg/μl 
8097 A 29/03/2016 1951 CT1460E2 70 0 Amenorrhoea 149 2.7 Inadequate# 7.5 112 μg/μl 
8522 A 14/03/2016 1941 CT1929E2 80 0 Lighter 302 3.6 PAEC 8 565 μg/μl 
9055 A 02/06/2016 2063 CT1685E2 79 0 Lighter 135 0.2 PAEC 7.5 436 μg/μl 
REC: Research ethics committee (approval) E2: oestradiol P4: progesterone PAEC: progesterone receptor modulator associated endometrial changes  
#: Minimal tissue in biopsy or fragmented sample. Sufficient tissue available to exclude malignancy but may be insufficient to assess for features of PAEC or to unequivocally 
state PAEC as diagnosis 





Table 5.3 Sample characteristics of endometrial biopsies from proliferative phase of the menstrual cycle for gene microarray validation 
Participant 
No 






Age BMI Parity HMB Fib Endo LMP Cycle E2 P4 Histology RIN 
5790 B 12/05/2015 1671 CT1275E+ 39 26.8 3+0 Yes Yes No 29/04/2015 5-16/28-31 477 21.7
1 P 9.1 
8100 B 26/11/2015 1920 CT1463E+ 48 46.4 2+0 Yes Yes No NS 10/14-21 229 3.1 P 8.3 
8131 A 23/06/2016 1976 CT1494E 47 25.6 2+0 Yes Yes No 15/06/2016 7/14 1376 0.8 P 9.5 
8085 A 23/07/2015 1904 CT1448E 46 32.7 1+0 Yes No No 13/07/2015 5-7/26-30 199 1.8 P 9.2 
5785 B 28/07/2015 1673 CT1270E2+ 44 34.6 3+0 Yes No No 06/07/2015 5-6/26-27 331 3.6 P 9.6 
8506 B 24/11/2015 1917 CT1903E2+ 41 23.8 3+1 Yes No No 13/11/2015 5/28-29 430 1.3 P 10.0 
REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis LMP: Last menstrual period E2: oestradiol P4: progesterone NS: Not stated P: 
Proliferative phase 
+: sample has a paired UPA treated sample 1: sample had elevated P4 but day of cycle sampling and histology review suggested proliferative phase. Subsequent first day of menstruation also was in keeping with the 
sample having been taken in proliferative phase 
Table 5.4 Sample characteristics of endometrial biopsies from women administered ulipristal acetate (UPA) 






Age BMI Parity HMB Fib Endo Duration 
of UPA Rx 
Days 
off Rx 
Control E2 P4 Histology RIN 
Samples after 3 months of treatment            
8002 A 16/03/2016 1942 CT1366E3 51 20.9 1+1 Yes Yes Yes 66 0 Amenorrhoea 819 21.8 Disordered proliferative# 7.5 
8100 A 24/03/2016 1949 CT1463E2+ 49 46.4 2+0 Yes Yes No 82 0 Amenorrhoea 60 3.4 Consistent with UPA# 7.9 
8123 A 05/07/2016 1980 CT1486E2 41 39.9 3+1 Yes Yes Yes 75 0 Amenorrhoea 162 0.2 PAEC 9.2 
8124 A 18/07/2016 1986 CT1487E2 49 30.5 1+1 Yes Yes No 81 0 Amenorrhoea 97 0.2 Consistent with UPA# NA 
8117 A 18/07/2016 1985 CT1480E2 40 32.3 2+0 Yes Yes No 77 0 Lighter 317 50.3 PAEC 9.2 
5817 A 21/07/2016 1988 CT1691E2 48 22.7 2+0 Yes Yes No 80 0 Amenorrhoea 1491 1.7 PAEC 9.1 
Samples after 6 months of treatment       
5790 E 22/01/2016 1684 CU1275E+ 40 NS 3+0 Yes Yes No 791 (163) 0 Unchanged NS NS Mildly disordered proliferative 9.6 
5805 E 18/10/2016 1812 CU1289E2 48 22.0 2+1 Yes Yes No 811 (165) 0 Amenorrhoea 1665 0.5 Inactive with no atypia# 8.8 
8126 E 09/11/2016 1867 CU1489E2 45 30.4 0+1 Yes Yes No 811 (165) 0 Amenorrhoea 114 <0.2 PAEC 9.2 
5785 E 27/04/2016 1958 CU1270E3+ 44 34.6 3+0 Yes No No 781 (162) 0 Amenorrhoea 303 15.7 Secretory (some non-physiological) 9.0 
8506 E 12/08/2016 1807 CU1903E3+ 41 23.5 3+0 Yes No No 821 (166) 0 Lighter 237 1.6 Proliferative 9.1 
9046 E 24/08/2016 1993 CU1676E2 44 30.1 5+0 Yes No No 801 (164) 0 Amenorrhoea 432 <0.2 Inadequate# NA 
REC: Research ethics committee (approval) BMI: Body mass index HMB: Heavy menstrual bleeding Fib: Fibroids Endo: Endometriosis Rx: treatment LMP: Last menstrual period E2: oestradiol P4: progesterone NS: Not 
stated PAEC: progesterone receptor modulator associated endometrial changes NS: Not stated +: sample has a paired control sample #: Minimal tissue in biopsy or fragmented sample. Sufficient tissue available to 
exclude malignancy but may be insufficient to assess for features of PAEC or to unequivocally state PAEC as diagnosis 1: sample from UCON subject (Ulipristal acetate versus conventional management of heavy 
menstrual bleeding clinical trial): pipelles taken in final week of second 12 week cycle of treatment (total treatment days)
 202 
 
Additional endometrial samples were utilised for validation of the array outputs. For RT-
qPCR endometrial biopsies from six women with HMB in proliferative phase were 
obtained from archival resources (REC approval 16/ES/0007, 14/LO/1602). Three 
women had fibroids and three women did not (Table 5.3). A further six samples were 
obtained from women (all with symptomatic fibroids) after administration of UPA (5mg 
once daily) for at least nine weeks (Table 5.4). A further treatment set was obtained from 
women participating in the mechanistic arm of the UCON trial (described in section 
2.2.1.2) in the final week of the second cycle of treatment (Table 5.4). Three had fibroids 
and three women did not. Three of the UCON UPA samples had had paired biopsies in 
the proliferative phase of the menstrual cycle. All biopsies for RT-qPCR validation of the 
array were obtained by pipelle biopsy sampler (Pipelle de Cornier Mark II, Laboratoire 
CCD, France) as described in section 2.2.1.2. RNA was extracted and quality checked as 
described previously (section 2.5.1). 
 
Full thickness endometrial biopsies (luminal epithelium to endometrial-myometrial 
junction) were obtained from nine women with symptomatic fibroids at the time of 
hysterectomy following treatment with Ulipristal acetate (UPA) 5mg orally once daily for 
up to 15 weeks (section 2.2.1.1 Table 2.4). Control biopsies from nine women in the 
proliferative phase were obtained at the time of hysterectomy and utilised for 
comparison (Table 2.5). FFPE sections were cut for immunolocalisation of cell division 
cycle 25A (CDC25A, Figure 5.1) as previously described (section 2.6, Table 2.13-14). 
 
5.4.2.2 Power calculation 
A power calculation for the number of samples required for micro array was generated 
using data from a prior unrelated study (Talbi, Hamilton et al. 2006). All microarray raw 
data files were downloaded and subject to RMA probe set summation and normalisation. 
After box and whiskers plots used to analyse consistency of data distribution, no samples 
were removed due to an obvious gross differences in data. The raw files were again 
normalised without array outlier and data used as input for Power calculation analysis 
in R statistical software. 
 
A statistical power calculation for a two-sided statistical test determines that n=6 
independent samples per group should provide the ability to detect a 2-fold change in 
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expression with 80% power at p=0.05 (adjusted) for 95% of the gene probes on the 
array. 
 
5.4.2.3 Array RNA processing and biotinylation   
Total RNA was isolated from endometrial samples and quality checked as previously 
described (tissue homogenisation, Qiagen RNAeasy mini kit, nano dropped and Agilent 
RNA 600nano kit; section 2.5.1). Three samples required concentration to yield 
acceptable RNA concentrations (CT1460E2, CT1262E3 and CT1685E2). This was 
performed according the manufacturer’s protocol utilising a Zymo RNA Clean and 
Concentrator™-5 kit (Zymo Research, USA). Despite fragmentation of some samples on 
H&E acceptable RIN were obtained (7.5-10.0; Table 5.1&5.2). Samples were then diluted 
to 150ng/μl.  
 
RNA samples were amplified and labelled with biotin to produce biotinylated anti-sense 
RNA (cRNA). This was performed according to manufacturer’s protocol using an 
Illumina® TotalPrep™ RNA Amplification kit (Life Technologies, USA). In summary 
500ng of total RNA underwent reverse transcription to create first strand cDNA, second 
strand cDNA was then synthesised from this. The cDNA was then purified and incubated 
overnight in a thermal cycler with an in vitro transcription enzyme and biotin-UTP to 
synthesise biotinylated cRNA. The biotinylated cRNA was then purified and eluted into 
100μl of nuclease free water. Concentration was assessed using Agilent RNA 600nano kit 
in conjunction with Agilent 2100 Bioanalyser system as previously described (section 
2.5.1) and stored at -80°C. 
 
5.4.2.4 Illumina platform Gene expression Microarray 
Illumina Whole Genome Gene Expression Profiling was performed by the Genetics Core, 
based in the Wellcome Trust Clinical Research Facility at the Western General Hospital, 
Edinburgh.  
 
Following assessment of adequacy utilising the Agilent results performed above the 12 
samples were placed on an Illumina HumanHT-12 BeadChip and underwent direct 
hybridization assay with readout utilising iScan. The beadchip contains probes from the 
National Center for Biotechnology Information Reference Sequence (NCBI RefSeq 
Release 38, 2009) with additional probe design based upon UniGene release 188. Overall 
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48,804 transcripts (both coding and non-coding) were analysed in each sample. Internal 
quality control was performed and raw data exported for transfer to FIOS Genomics 
(Fios Genomics, UK) for external quality control, statistical analysis and some limited 
bioinformatics interogation. 
 
5.4.2.5 Data Processing 
Quality control (QC) 
Raw data were analysed by Fios genomics using the arrayQualityMetrics package in 
Bioconductor (Kauffmann and Huber 2010). Arrays were scored (outliers identified) on 
the basis of 3 metrics (maplot, boxplot, heatmap).  
MA plots: M and A are defined as 
 M = log2(I1) - log2(I2) 
 A = 1/2 (log2(I1) + log2(I2)) 
where I1 is the intensity of the array studied and I2 is the intensity of a "pseudo"-array, 
which has the median values of all the arrays. Typically, it is expected that the mass of 
the distribution in an MA plot is concentrated along the M = 0 axis, and there should be 
no trend in the mean of M as a function of A. A trend in the lower range of A usually 
indicates that the arrays have different background intensities, this may be addressed by 
background correction. A trend in the upper range of A usually indicates saturation of 
the measurements, in mild cases, this may be addressed by non-linear normalisation (e.g. 
quantile normalisation). 
 
Box plots: Each box corresponds to one array. It gives a simple summary of the 
distribution of feature intensities across all arrays. Typically, one expects the boxes to 
have similar size (IQR) and y position (median). If the distribution of an individual array 
is very different from the others, this may indicate an experimental problem. 
 
Heat map: The heatmap shows the correlation (Pearson) of the raw data (log2 
intensities), prior to QC. Individual arrays are shown along both the X and Y axes, with 
the degree of correlation indicated by the colour (red: higher correlation, blue: lower 
correlation), as shown in the colour key/histogram in the top left of image. Clustering 
(Euclidean distance) is shown by the dendrograms above and to the left of the image 
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Boxplots of the raw, transformed and normalised data were also assessed manually, as 
were outlier and sample relation plots generated for all stages of the processing. 
Exploratory analysis using principle component analysis (orthogonal transformation to 
convert a set of observations of possibly correlated variables into a set of values of 
linearly uncorrelated variables) and hierarchical clustering to determine if there was 
separation of the samples based on the on treatment group.  
 
Non-specific filtering 
Following QC, the data set was filtered to remove features that were not detected at last 
once across all the arrays. Raw data were log2 transformed prior to normalisation across 
all arrays using the robust spline normalisation (RSN) method.  
 
Statistical hypothesis testing 
Normalised data provide the input for statistical hypothesis testing, in order to identify 
features that are statistically significantly different between sample groups. Fold change 
(FC, the degree of difference) was also assessed. In the output, the fold-changes (logFC) 
are given as log2 values, with a positive logFC representing up-regulation, and a negative 
logFC indicating down-regulation.  
 
A single comparison (Post- vs pre- treatment) was undertaken using linear modelling to 
identify differentially expressed genes (DEG).  The null hypothesis was that there was no 
difference between the groups being compared. As pre- and post-treatment samples 
were available from each individual in the study, a paired statistical comparison 
approach was used in order to account for baseline differences between the treated 
individuals. The Bioconductor package limma was used (Smyth 2005). Significance was 
tested using a moderated t-test. The statistical significance of the DEGs was assessed by 
Fios Genomics with a raw (unadjusted) p-value < 0.01 and a fold change >= 1.3. A 
subsequent comparison was performed utilising (FC>2, adjusted p<0.05). The latter has 
a power of 80%. 
Pathway analysis 
An overview of the underlying biological changes occurring within each comparison was 
obtained by functional enrichment analysis. This was performed from two perspectives, 
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namely Kyoto Encyclopedia of genes and Genome (KEGG) pathway membership 
(http://www.kegg.jp) and Gene Ontology (GO) terms (http://www.geneontology.org)  
 
Significant genes with raw p <0.01 and fold change ≥1.3 from each comparison were 
analysed for enrichment of KEGG pathway membership and of enrichment of GO terms 
across all three GO ontologies using a hypergeometric test. Enrichment (p <0.05) was 
assessed for up- and down-regulated genes separately. 
 
5.4.2.6 Validation of gene targets 
5.4.2.6a Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
of gene targets 
Candidates for validation were selected both from the differentially expressed gene list 
and altered genes within the most significantly down regulated KEGG pathway. 
RT-qPCR was performed on RNA submitted for array for internal validation, and then on 
independent sets of women in proliferative phase (n = 6) and whilst receiving treatment 
with UPA. The latter group was further subdivided by women in their first cycle of 
treatment (n = 6) and those at the end of a second cycle of treatment (n = 6) (5.4.2.2). 
 
RT-qPCR performed in triplicate for candidate genes identified by the array as previously 
described (section 2.5.3). Primers and probes can be found in Table 2.12. ATBP5 and 
SHDA were used as housekeeper genes. Data were analysed using the ΔΔCq method as 
described in section 2.5.3.  
 
Statistical analysis of RT-qPCR results was performed using Graphpad prism software 
(Graphpad, USA). Data were subjected to the D’Agostino-Pearson omnibus normality 
test. Data with a Guassian distribution had an unpaired t-test applied when two 
comparators, and one-way ANOVA when 3 comparators (proliferative, secretory and 
following SPRM (UPA) treatment), to determine difference between groups. For non-
parametric data Kruskal-Wallis test was used to determine differences between sample 
groups when three comparators, and Mann-Whitney test when two. p < 0.05 was 
considered to be statistically significant. 
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5.4.2.6b Immunohistochemistry of gene targets 
FFPE sections were cut for histology (H&E staining) and immunolocalisation of Ki67 was 
performed (2.6). This was performed on the baseline and post treatment biopsies 
submitted for the array (n=6 in each group, Table 5.1&5.2). Immunolocalisation was 
semi-quantitated by histoscoring as previously described (section 2.6.5.1). 
Immunolocalisation of CSC25A was performed on full thickness endometrial biopsies 
from women receiving UPA or in proliferative phase (n=9 in each group) (section 2.6). 




5.5.1 Effect of UPA administration upon cell proliferation in the fallopian tube 
and cervix. 
5.5.1.1 UPA administration reduces cell proliferation in the fallopian tube 
relative to proliferative phase of the menstrual cycle 
In all samples cell proliferation, as assessed in the ampulla using an antibody to Ki67, 
was relatively infrequent but appeared lower in women in secretory phase (5.3B & F) 
and following UPA administration (5.3C & G) compared to women in proliferative phase 
of the menstrual cycle (5.3A & E). Women in proliferative phase had between 0 and 58 
positive nuclei per sample (mean 21) compared to secretory (2-30 positive nuclei per 
sample, mean 11.6) and UPA (0-4, mean 12.3). A formal index of cell proliferation was 
not performed. Immunopositivity for Ki67 in the fimbrial ends of the fallopian tubes from 
women treated with UPA (5.3D & H) was consistent with ampullary immunoreactivity 
for Ki67 (5.3C & G). 
 
5.5.1.2 UPA administration does not appear to alter cell proliferation in the 
cervix 
Cell proliferation, as assessed using an antibody to Ki67, appeared low in all groups of 
women and administration of UPA did not appear to alter cell proliferation in the cervix. 
Immunopositive nuclei were infrequently present in the para basal layer of the 
squamous epithelium (5.4A-C). Localisation and intensity of immunostaining in the 
squamous epithelium was unchanged irrespective of stage of cycle or treatment with 




Figure 5.3 Administration of selective progesterone receptor modulator, ulipristal acetate (UPA), appears to decrease cell proliferation marker Ki67 
expression in the ampulla of the fallopian tube relative to proliferative phase. 
Representative images low- (A-D) and high-power (E-H) immuno-localisation of Ki67 in fallopian tube (FT) biopsies from woman during proliferative and secretory stages of 
the menstrual cycle and after UPA administration. Samples from FT ampulla of UPA-treated women (C&G) displayed very rare immunopositive nuclei (indicated by red arrows), 
this immunostaining was consistently observed at the fimbriae ends (D&H). Infrequent Ki67 immunopositivity was also observed in the ampulla from women in secretory (B 
& F) phase of the menstrual cycle.  
In contrast samples from women in proliferative (A & E) phase of the menstrual cycle appeared to have more frequent immunopositive cells  
Red arrows indicate towards immunopositive nuclei. Lower power (scale bar = 100µm) and high power magnification (scale bar = 20 µm); Negative controls shown as inserts 






Figure 5.4 Administration of selective progesterone receptor modulator, ulipristal acetate 
(UPA), does not alter cell proliferation marker Ki67 localisation or intensity in the endo- or 
ecto-cervix  
Representative immuno-localisation of Ki67 in cervical biopsies from woman during 
proliferative (A/D/G) and secretory (B/E/H) stages of the menstrual cycle and after UPA 
(C/F/I)) administration. Immunopositive nuclei (indicated by red arrows) were infrequently 
present in the para basal layer of the squamous epithelium (A-C). There were no 
immunopositive nuclei present in the stroma, glandular (D, E F) and transitional zone (G/H/I) 
epithelium. Localisation and intensity of immunostaining in the squamous epithelium was 
unchanged irrespective of stage of cycle or treatment with UPA.  
Red arrows indicate towards immunopositive nuclei. Scale bar = 100 µm; Negative controls 









glandular (5.4D-F) and transitional zone (5.4G-I) epithelium in women in proliferative 
and secretory phase and following administration of UPA. Immunopositivity has not 
been quantitated either with histoscoring or utilising stereology but given the very low 
frequency of immunopositivity this was not considered to be of use. 
 
These findings in the fallopian tube and cervix suggest that the impact upon cell 
proliferation previously observed within the endometrium is not specific to the 
endometrial region of epithelium of the female human reproductive tract. 
 
5.5.2 Gene Microarray results 
5.5.2.1 Quality control (QC) 
QC of the Illumina microarray raw data was performed as described above by Fios 
Genomics: 
 
MA plots: The mass of distribution is concentrated around the M=0 axis and symmetrical 
which is reassuring (Figure 5.5A). The trend in the lower range of A suggest that the 
arrays have different background intensities. This was corrected for by subsequent 
normalisation. 
Box plots: The box plots have a relatively similar sizes and y positions (Figure 5.5B). 
Overall the pre-treatment samples appeared to have slightly wider IQR, the widest was 
CT1262E2 (5777_Pre).  
Heat map: The data were normalised and the top 25% most variable features within the 
processed dataset were subsetted prior to sample relatedness being assessed by 
Euclidean distance using a complete linkage algorithm (Figure 5.5C). The heatmap shows 
the correlation (Pearson) of the raw data (log2 intensities), prior to QC (Figure 5.5D) and 
following normalisation (Figure 5.5E) 
 
Boxplots of the raw, transformed and normalised data were also assessed manually by 
Fios, as were outlier and sample relation plots generated for all stages of the processing.  
Based on the three metrics (MAplot, Boxplot and Heatmap), one sample (CT1262E2) was 
flagged as a moderate outlier based on automated QC checks. After manual inspection 
however it was decided to include this sample as it did not show any major differences 





Figure 5.5 Quality control (QC) of the Illumina gene microarray  
QC metric MA plots (A), Box plots (B)  were reassuring with clear separation 
between pre-treatment and on treatment samples as assessed by Euclidean 
distance (C). Heatmap shows the correlation (Pearson) of the raw data (log2 
intensities), prior to QC (D) and following normalization (E). Exploratory analysis 
using Principal Component Analysis (PCA) and hierarchial clustering showed a 
clear separation of the samples based on the treatment status of the sample (F)  
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Exploratory analysis using Principle Component Analysis and hierarchial clustering 
showed a clear separation of the samples based on the treatment status of the sample 
(Figure 5.5F). The 3rd principle component was related to patient variation.  
 5.5.2.2 Non-specific filtering  
After QC, the dataset was filtered to remove features that were not detected at least once 
across all arrays. This reduced the number of features from 47,323 to 24,097. 
 
5.5.2.3 Statistical hypothesis testing 
Fios Genomics initially performed statistical hypothesis testing using a raw (unadjusted) 
p-value < 0.01 and a fold change >= 1.3. With these thresholds 1331 genes were 
differentially expressed between the pre and on treatment groups (664 genes up-
regulated and 667 genes down-regulated; Figure 5.6A). These separated into clear pre 
and on treatment groups (Figure 5.6B). A full list of differentially expressed genes at this 
statistical level is to be found in the Appendix (supplementary Tables 1&2).  Of note the 
apoptosis marker caspase 3 was both up and down regulated (FC -1.3 p = 0.03, FC 1.3, p 
= 0.28) and three transcript variants of BCL-2 were upregulated (FC 1.5 p = 0.08, FC 1.6, 
p = 0.10, FC 1.3 p = 0.30). 
 
Utilising a FC>2, adjusted p <0.05 (80% power) 48 genes were differentially expressed 
between the pre-treatment and treatment group. 16 were up-regulated by UPA 
administration (Table 5.5) and 32 were down regulated (Table 5.6). Of those genes 
down-regulated 4 genes were not associated with a named gene and 2 were non-coding 
mRNAs. At this level of statistical robustness, no core cell cycle genes were differentially 
expressed.  
 
5.5.2.4 Pathway analysis 
KEGG 
Functional enrichment of the up- and down-regulated DEG lists obtained from the 
contrast of on-treatment vs. pre-treatment resulted in 19 KEGG pathways enriched for 
up-regulated genes (Figure 5.7A, Table 5.7), and two KEGG pathways enriched for down-





Figure 5.6 Selective progesterone receptor modulator, ulipristal acetate (UPA) administration results in differentially expressed genes within the 
endometrium compared to proliferative phase 
 
1331 genes (p <0.01, fold change >2;  FC>2) were altered following UPA administration in paired endometrial biospies from six women (index sample 
in proliferative phase of the menstrual cycle). A similar number were up-regulated (red) and down-regulated (blue; A). When samples were arranged 
by individual subjects there was clear differentiation between the proliferative phase and subsequent UPA treatment but some differing patterns of 




Table 5.5 Differentially expressed gene candidates in human endometrium up-regulated by administration of ulipristal acetate (UPA) 
Symbol Name Function FC Pvalue adj P value 
SLC13A5 solute carrier family 13 member 5 Sodium-dependant citrate co-transporter 6.874 5.69E-07 6.86E-03 
RNF39  ring finger protein 39 On MHC1 ?early synaptic plasticity 6.441 5.44E-06 1.56E-02 
MUC1 mucin 1, cell surface associated These proteins play a role in intracellular signalling. Overexpression, aberrant intracellular 
localization, and changes in glycosylation of this protein have been associated with carcinomas. 
3.122 5.50E-06 1.56E-02 
MUC1 mucin 1, cell surface associated   3.72 5.81E-06 1.56E-02 
EGLN3  egl-9 family hypoxia-inducible factor 3   5.695 8.03E-06 1.76E-02 
MUC1 mucin 1, cell surface associated 
 
5.807 1.26E-05 1.99E-02 
ABCC3  ATP binding cassette subfamily C member 3   3.632 1.66E-05 2.35E-02 
SOX9  SRY-box 9 Acts with SRY-1 to regulate AMH transcription 8.862 3.46E-05 3.88E-02 
HAMP  hepcidin antimicrobial peptide Iron homeostasis 3.789 5.81E-05 4.63E-02 
TNFSF10  tumor necrosis factor superfamily member 10 This protein preferentially induces apoptosis in transformed and tumour cells, but does not appear to 
kill normal cells 
2.459 7.66E-05 4.63E-02 
LRRN2 leucine rich repeat neuronal 2 Cell-adhesion molecules or as signal transduction receptors 3.492 7.86E-05 4.63E-02 
WDR72  WD repeat domain 72   2.31 8.23E-05 4.63E-02 
SORL1 sortilin-related receptor, L(DLR class) A repeats 
containing 
Epidermal growth factor repeat 5.13 8.51E-05 4.63E-02 
ABTB1  ankyrin repeat and BTB domain containing 1 This gene encodes a protein with an ankyrin repeat region and two BTB/POZ domains, which are 
thought to be involved in protein-protein interactions. Expression of this gene is activated by PTEN 
2.183 8.57E-05 4.63E-02  
SPINT1 serine peptidase inhibitor, Kunitz type 1 Regulation of the proteolytic activation of HGF in injured tissue 2.264 8.84E-05 4.63E-02 
GIMAP5  GTPase, IMAP family member 5 This gene encodes an anti-apoptotic protein that functions in T-cell survival 2.285 9.77E-05 4.90E-02 
 
Genes with Fold change (FC) >2 and adjusted p < 0.05 (80% power) 





Table 5.6 Differentially expressed gene candidates in human endometrium down-regulated by administration of ulipristal acetate (UPA) 
Gene Name                                                                            Description logFC FC adj P 
value 
GREM2 gremlin 2, DAN family BMP antagonist Activation of Wnt/β-catenin signalling -4.468 -22.133 2.05E-03 
GJB2  gap junction protein beta 2 Cell-to-cell channels that facilitate the transfer of ions and small molecules between cells -3.246 -9.485 1.23E-02 
GJA4  gap junction protein alpha 4 Intercellular channels that provide a route for the diffusion of low molecular weight materials from cell to cell -2.178 -4.524 1.23E-02 
GPER1 G protein-coupled estrogen receptor 1 The protein binds oestrogen, play a role in the rapid nongenomic signaling events widely observed following 
stimulation of cells and tissues with oestrogen 
-2.787 -6.903 1.23E-02 
OPN3 opsin 3 Guanine nucleotide-binding protein (G protein)-coupled receptor superfamily -1.976 -3.934 1.99E-02 
LINC00461 long intergenic non-protein coding RNA 
461 
Non-protein coding  -1.762 -3.392 1.99E-02 
DIO3OS DIO3 opposite strand/antisense RNA 
(head to head) 
Non-protein coding  -2.126 -4.366 1.99E-02 
GLA galactosidase alpha Homodimeric glycoprotein ta hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins -2.243 -4.732 2.98E-02 
PAPSS1  3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 
3'-phosphoadenosine-5'-phosphosulfate (PAPS) is the sulfate donor cosubstrate for all sulfotransferase (SULT) 
enzymes 
-1.517 -2.862 3.12E-02 
SGCD sarcoglycan delta One of the four known components of the sarcoglycan complex -2.697 -6.484 3.25E-02 
FXYD4 FXYD domain containing ion transport 
regulator 4 
Modulates the properties of the Na, K-ATPase -2.515 -5.716 3.88E-02 
PAPSS1  3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 
Sulfate donor cosubstrate for all sulfotransferase (SULT) enzymes  -1.329 -2.512 4.31E-02 
PAGE4 PAGE family member 4 Strongly expressed in prostate and prostate cancer. It is also expressed in  female reproductive tissues including 
fallopian tube, uterus, and placenta, as well as in testicular cancer and uterine cancer 
-5.544 -46.651 4.35E-02 
ZCCHC12 zinc finger CCHC-type containing 12 This gene encodes a downstream effector of bone morphogenetic protein (BMP) signalling -1.888 -3.702 4.46E-02 
KAZALD1 Kazal type serine peptidase inhibitor 
domain 1 
Secreted member of the insulin growth factor-binding protein (IGFBP) superfamily -1.584 -2.998 4.56E-02 
GPER1 G protein-coupled estrogen receptor 1 Binds oestrogen, resulting in intracellular calcium mobilisation and synthesis of phosphatidylinositol 3,4,5-
trisphosphate in the nucleus 
-2.713 -6.555 4.56E-02 
TCF19 transcription factor 19 Encoded protein plays a role proliferation -1.488 -2.805 4.63E-02 
CEACAM21 carcinoembryonic antigen related cell adhesion molecule 21 -1.892 -3.711 4.63E-02 
SGK1  serum/glucocorticoid regulated kinase 1 Involvement in the regulation of processes such as cell survival -2.552 -5.866 4.63E-02 
RAB15  RAB15, member RAS oncogene family G-protein -1.565 -2.959 4.63E-02 
TUBA3D tubulin alpha 3d Microtubules maintain cellular structure, function in intracellular transport, and play a role in spindle formation 
during mitosis 
-3.617 -12.265 4.63E-02 
FAM13C family with sequence similarity 13 member C -1.735 -3.329 4.63E-02 
HIST1H2BH histone cluster 1, H2bh Replication-dependent histone that is a member pf the histone H2B family -1.956 -3.879 4.63E-02 
SGK1  serum/glucocorticoid regulated kinase 1 Activates certain K, Na and Cl channels suggesting an involvement in the regulation of processes such as cell survival -2.638 -6.226 4.63E-02 
ARSG arylsulfatase G involved in hormone biosynthesis -1.193 -2.286 4.63E-02 
COL17A1 collagen type XVII alpha 1 Endcodes the alpha chain of type XVII collagen -1.421 -2.678 4.63E-02 
LRRC26  leucine rich repeat containing 26 Expressed in normal salivary and prostate tissue. Increased expression associated with reduced tumourgenesis -3.318 -9.976 4.90E-02 






Figure 5.7 Treatment with selective progesterone receptor modulator, ulipristal acetate (UPA) results in KEGG pathway enrichment for both up and 
down regulation of genes 
 
Functional enrichment of the up- and down-regulated differentially expressed gene lists obtained from the contrast of on-treatment with UPA vs. pre-
treatment proliferative phase resulted in 19 KEGG pathways enriched for up-regulated genes (A), and two KEGG pathways enriched for down-regulated 
genes (B). Adjusted enrichment p-value < 0.05. 
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Table 5.7 KEGG pathways enriched for up-regulated genes 
KEGG Pathway Significant genes (p < 0.01, FC> 1.3) S N N/S (%) OR Adjusted p 
Staphylococcus aureus infection  C1QB, C1QC, C3AR1, CFH, FCGR2A, FCGR2B, FPR3, HLA-DPA1, HLA-DPB1, HLA-DRB4, ITGAM, ITGB2  12 44 27.27 8.11 8.65E-05 
Osteoclast differentiation  BTK, CYBB, FCGR2A, FCGR2B, FOS, FOSL2, GAB2, LILRB4, NCF2, NCF4, PLCG2, PPP3CA, RELB, SPI1, TNF, 
TNFRSF11B, TREM2, TYROBP  
18 110 16.36 4.29 2.28E-04 
Hematopoietic cell lineage  CD14, CD1C, CD1E, CD33, CD37, CD3D, CD4, CD9, HLA-DRB4, ITGAM, KIT, TNF  12 66 18.18 4.78 2.72E-03 
Leishmaniasis  FCGR2A, FOS, HLA-DPA1, HLA-DPB1, HLA-DRB4, ITGAM, ITGB2, NCF2, NCF4, PRKCB, TNF 11 59 18.64 4.91 2.80E-03 
Cytokine-cytokine receptor interaction ACVR2A, CCL14, CCL15, CCL2, CCL3L3, CTF1, CX3CL1, CX3CR1, CXCL10, CXCL9, CXCR3, IL25, KIT, PDGFB, 
TNF, TNFRSF10C, TNFRSF11B, TNFRSF6B, TNFSF10, TNFSF13B  
20 166 12.05 3 2.80E-03 
Fc epsilon RI signaling pathway  BTK, FCER1G, GAB2, INPP5D, MAP2K3, PLA2G4C, PLCG2, PRKCB, TNF, VAV3 10 57 17.54 4.54 8.28E-03 
Tuberculosis  CD14, CD74, CORO1A, CTSD, FCER1G, FCGR2A, FCGR2B, HLA-DPA1, HLA-DPB1, HLA-DRB4, ITGAM, 
ITGB2, LAMP2, PPP3CA, SPHK1, TNF  
16 134 11.94 2.93 9.81E-03 
Rheumatoid arthritis  ATP6V1B1, CCL2, CCL3L3, CD86, FOS, HLA-DPA1, HLA-DPB1, HLA-DRB4, ITGB2, TNF, TNFSF13B 11 72 15.28 3.86 9.81E-03 
Leukocyte transendothelial migration CYBB, GNAI1, ITGAM, ITGB2, MMP9, NCF2, NCF4, PLCG2, PRKCB, PXN, RASSF5, VASP, VAV3 13 96 13.54 3.36 9.81E-03 
Chemokine signaling pathway  CCL14, CCL15, CCL2, CCL3L3, CX3CL1, CX3CR1, CXCL10, CXCL9, CXCR3, DOCK2, ELMO1, GNAI1, HCK, 
PRKCB, PXN, STAT3, VAV3  
17 152 11.18 2.73 1.22E-02 
Transcriptional misregulation in cancer  ARNT2, CD14, CD86, CDKN2C, CEBPA, HPGD, ITGAM, MAX, MMP9, MYCN, PROM1, SLC45A3, SPI1, 
SPINT1, SUPT3H, TSPAN7 
16 142 11.27 2.74 1.48E-02 
Phagosome ATP6V1B1, CD14, CORO1A, CYBB, FCGR2A, FCGR2B, HLA-DPA1, HLA-DPB1, HLA-DRB4, ITGAM, ITGB2, 
LAMP2, MARCO, NCF2, NCF4 
15 131 11.45 2.78 1.67E-02 
Fc gamma R-mediated phagocytosis  DOCK2, FCGR2A, FCGR2B, GAB2, HCK, INPP5D, PLCG2, PRKCB, SPHK1, VASP, VAV3 11 83 13.25 3.26 2.10E-02 
Asthma  FCER1G, HLA-DPA1, HLA-DPB1, HLA-DRB4, TNF 5 19 26.32 7.51 2.10E-02 
Antigen processing and presentation CD4, CD74, HLA-DPA1, HLA-DPB1, HLA-DRB4, IFI30, LGMN, TAPBP, TNF 9 61 14.75 3.67 2.36E-02 
Steroid biosynthesis  CYP51A1, DHCR7, FAXDC2, SC5D, TM7SF2 5 20 25 7.01 2.36E-02 
Pertussis  C1QB, C1QC, CASP7, CD14, FOS, GNAI1, ITGAM, ITGB2, TNF 9 65 13.85 3.41 3.44E-02 
Natural killer cell mediated cytotoxicity CD48, FCER1G, ITGB2, PLCG2, PPP3CA, PRKCB, TNF, TNFRSF10C, TNFSF10, TYROBP, VAV3 11 92 11.96 2.89 3.76E-02 
Systemic lupus erythematosus  C1QB, C1QC, CD86, FCGR2A, H2AFJ, HIST2H2BE, HLA-DPA1, HLA-DPB1, HLA-DRB4, TNF 10 82 12.2 2.95 4.71E-02 
S: No of significant genes N: No of genes in pathway OR: Odds ratio  
Table 5.8 KEGG pathways enriched for down-regulated genes 
KEGG Pathway Significant genes (p < 0.01, FC> 1.3) S N N/S (%) OR Adjusted p 
Cell cycle  ANAPC4, CCNA1, CCNA2, CCNB1, CCNB2, CCNE2, CDC20, CDC25A, CDC7, CDK1, CDKN2A, CHEK2, E2F2, 
ESPL1, MAD2L1, MYC, PCNA, PTTG1 
18 114 15.79 6.07 4.21E-06 
Oocyte meiosis ADCY7, ANAPC4, AURKA, CCNB1, CCNB2, CCNE2, CDC20, CDK1, ESPL1, ITPR2, MAD2L1, PTTG1, SGOL1 13 94 13.83 5.04 9.81E-04 
S: No of significant genes N: No of genes in pathway OR: Odds ratio  
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The top three KEGG pathways enriched for up-regulated genes were: 
 Staphylococcus aureus infection 
 Osteoclast differentiation 
 Hematopoietic cell lineage 
There was additionally enrichment in a relatively large set of pathways involved in 
infection and inflammatory responses in the upregulated genes. 
The two KEGG pathways enriched for down regulated genes were: 
 Cell cycle 
 Oocyte meiosis 
GO 
The enrichment analysis in GO terms resulted in a large number of terms reaching 
statistical significance at an adjusted p-value <0.05 (416 up- and 103 down-regulated 
terms). The top 50 for up regulation and down regulation are displayed in Figure 5.8. 
Up-regulated GO terms largely relate to membrane processes and immune response. 
Down-regulated GO terms largely relate to cell-cycle processes and DNA replication.  
5.5.3 Validation of array outputs 
5.5.3.1 Differentially expressed genes: GREM2 and MUC1 
The most significantly down regulated gene following treatment with UPA was GREM2 
(adjusted p = 0.002). The most significantly up-regulated gene was the sodium 
dependant citrate co-transporter SLC13A5 (adjusted p = 0.0086). However MUC1 
transcripts accounted for half of the six most up regulated genes and MUC1 is known to 
be P-regulated and as result this gene was selected for validation along with GREM2 
(adjusted p = 0.0156 – 0.0199). 
 
Both genes validated on the original gene microarray samples (p <0.0001 and p <0.01; 
Figure 5.9A & D), despite considerable patient variation in MUC1 following UPA 
administration (Figure 5.9G). This variability in response was also observed in the three 
and six month treatment independent sample sets (Figure 5.9E&F H&I). After 3 months 
of treatment with UPA two patients had no alteration in MUC1 mRNA levels compared to 
samples from women in proliferative phase; the same was observed in the group of 
women who received six months of treatment with UPA (Figure 5.9H&I). This attenuated 
response was observed in subjects both with and without fibroids and no subject had 
endometriosis. In both these independent sets the maximal level of MUC1 increase 
















































































































































































































































































































A r r a y  s a m p le  v a lid a t io n In d e p e n d a n t  s a m p le s  fo r  e x te r n a l v a lid a t io n  o f  a r r a y  o u tp u t s
 
Figure 5.9 Validation by RT-qPCR of differentially expressed genes in the endometrium 
following treatment with selective progesterone receptor modulator, ulipristal acetate 
(UPA)  
Relative mRNA levels of GREM2 and MUC1 in the endometrium of women in proliferative 
phase and after UPA administration. Endometrial biopsy after UPA administration was either 
paired to a proliferative phase endometrial sample (A D & G) or were independent samples 
of endometrium, not submitted to the microarray after 3 months of UPA treatment (B, E & 
H); or after six months of treatment with a 4 week mid-point break (C, F & I). G-I indicate 
heterogeneity of alteration of MUC1 alteration following UPA administration 
n=6 for each group. * p <0.05, ** p <0.01, **** p <0.0001. NS not significant.  
A-F Box and whisker, whiskers: median, minimum and maximum  
G Scatter plot 




and there was no statistical difference between proliferative phase and following UPA 
treatment in the 3 month group, though an alteration was observed in the 6 month group 
(Figure 5.9E&F).  
 
GREM2 validated in both the three and six month independent sample sets (p <0.01 and 
p <0.05; (Figure 5.9B & C). 
 
5.5.3.2 Genes within the cell-cycle KEGG pathway are altered following 
administration of UPA 
The most significantly down-regulated enriched pathway was the cell cycle (Figure 
5.7B). This was supported by the GO analysis where the majority of down-regulated GO 
terms largely relate to cell-cycle processes and DNA replication.  
 
Reduction of cell proliferation was confirmed using Ki67 immunolocalisation of the 
paired endometrial samples from women prior to and whilst receiving treatment with 
UPA (Figure 5.10). Whilst some samples had less reduction in immunopositivity 
following UPA administration (Figure 5.10E-F, reduction in Ki67 immunopositivity 
limited to the stroma only) than others (Figure 5.10A-D), overall there was significant 
reduction in immunopositivity (p <0.001; Figure 5.10G) which was more marked in the 
glands (p <0.001 Figure 5.10H) than the stroma (p <0.05 Figure 5.10I). Circulating E2 
levels were not statistically different between the pre-treatment proliferative phase 
samples and following UPA administration (Figure 5.10J & K).  
 
The KEGG cell cycle pathway contains 18 significantly down regulated genes (Table 
5.8&5.9, Figure 5.11). In addition to those genes down regulated in cell cycle, three were 
up-regulated:  cyclin-dependant kinase inhibitor 2C (CDKN2C, also known as p18 and 
INK4C; FC 1.86 p = 4.42e-4), cyclin-dependant kinase inhibitor 2B (CDKN2B, also known 
as p15 INK4B; FC 1.99 p = 8.26e-3) and growth arrest and DNA damage inducible alpha 
(GADD45A; FC 1.72 p = 6.62e-3).  
 
For onward validation it was decided to limit to down-regulated genes involved in G1, S 
and G2 phase of the cell cycle (Figure 5.1 & 5.11). CDKN2A and CHEK2 were subsequently 












Serum Oestradiol levels (pmol/L) at the time of endometrial biopsy 
 
J  
Subject Proliferative UPA Control 
CT1162 104 319 Amenorrhoea 
CT1262 145 55 Amenorrhoea 
CT1929 312 302 Lighter 
CT1280 522 359 Amenorrhoea 
CT1460 224 149 Amenorrhoea 






























Figure 5.10 Selective progesterone receptor modulator, ulipristal acetate (UPA) 
administration reduces endometrial cell proliferation 
 
Representative immunolocalisation of Ki67 in endometrium from 3 women in the 
proliferative phase of the menstrual cycle (A, C & E) and following UPA administration (B, D 
& F). There is down regulation of Ki67 in both glands and stromal cells in the majority of 
subjects (B&D) though the reduction was not consistent in all (F).  Immunopositivity overall 
was significantly reduced following UPA treatment (G), though this was more marked in 
glandular than stromal cell nuclei (H-I).  
 
Circulating oestradiol levels were not significantly altered by UPA treatment J and K (data 
presented as mean +/- SEM) and did not impact upon control of menstrual bleeding (J). 
 
Scale bars 100μm low power, 50μm high power, negative control shown as insert on 
proliferative phase low power endometrium image (A). N= 6 in each group * p < 0.05 **** 







Table 5.9 Down-regulated genes differentially expressed in enriched KEGG Cell cycle 
Gene Code in 
diagram 
Description logFC FC P.value adj.P.value 
CDC25A Cdc25A cell division cycle 25A -1.569 -2.967 0.0001577 0.05897 
ANAPC4 APC/C anaphase promoting complex subunit 4 also known as APC4 -1.603 -3.037 0.0004937 0.07621 
CCNA1 CycA cyclin A1 -2.423 -5.364 0.0005527 0.07834 
ESPL1 Esp1 extra spindle pole bodies like 1, separase -1.549 -2.926 0.001385 0.113 
MYC c-Myc v-myc avian myelocytomatosis viral oncogene homolog -0.905 -1.872 0.001556 0.1136 
CHEK2 Chk 2 checkpoint kinase 2 -0.716 -1.642 0.001744 0.1174 
CDKN2A ARF cyclin-dependent kinase inhibitor 2A (also known as p16, INK4A) -0.834 -1.783 0.003143 0.1298 
E2F2 E2F 2 E2F transcription factor 2 -1.085 -2.121 0.003276 0.1315 
CCNE2 CycE cyclin E2 -1.803 -3.489 0.00471 0.1478 
CCNA2 CycA cyclin A2 -1.222 -2.333 0.006487 0.1654 
PCNA PCNA proliferating cell nuclear antigen -0.645 -1.564 0.006523 0.1655 
CDC20 Cdc20 cell division cycle 20 -1.493 -2.814 0.006807 0.1673 
CCNB2 CycB cyclin B2 -1.349 -2.547 0.006999 0.1683 
CDK1 CDCK1 cyclin-dependent kinase 1 -1.474 -2.777 0.00762 0.1707 
PTTG1 PTTG pituitary tumor-transforming 1 -1.258 -2.391 0.007952 0.1727 
MAD2L1 Mad2 MAD2 mitotic arrest deficient-like 1 (yeast) -1.188 -2.278 0.008578 0.1759 
CDC7 Cdc7 cell division cycle 7 -1.036 -2.051 0.009082 0.1782 
CCNB1 CycB cyclin B1 -1.211 -2.314 0.009377 0.1784 
 




Figure 5.11 KEGG Cell cycle 
Genes implicated in the cell cycle as identified by KEGG 
(http://www.genome.jp/kegg-bin/show_pathway?map=hsa04110&show_description=show) Diffentially expressed genes following UPA 
(downregulated) in red. Upregulated genes idenitfied by blue boxes. Downregulated genes within G1, S and G2 (enclosed within purple box) 
were selected for onward validation  
G1	 G2	 M	S	
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Some but not all genes validated from the original array samples (Figure 5.12). A 
statistical outlier was identified (Grubbs alpha = 0.5) for CDC25A, with an unusual 
pattern of response for many other genes (Figure 5.13). This was sample CT1280E2, the 
subject who had inadvertently stopped treatment eight days prior to sampling. Given the 
potential for biological difference due to clearance of the drug this sample was excluded 
from all validation analysis. 
 
Further validation of candidate genes identified by the microarray was undertaken 
utilising independent sets of endometrial biopsies from women in proliferative phase or 
from women who had received 3 or 6 months of treatment with UPA.  
 
In addition to the eight genes that validated on the original array samples (CDC25A, 
CCNA1, MYC, CCNA2, CCNB2, CDK1, E2F2 and CCNB1) CCNE2, PCNA and CDC7 all validated 
in the independent 3 months of UPA administration samples (Figure 5.14). After 6 
months of treatment only MYC failed to validate (Figure 5.15). Three of the six subjects 
in the proliferative phase of cycle and three of the subjects biopsied after 6 months of 
UPA treatment did not have fibroids. However presence or absence of fibroids did not 
correlate with degree of alteration of mRNA levels and did not contribute to the non-
significance of MYC levels. 
 
A summary of statistically altered genes in the three different subject groups (array UPA, 
3 months of UPA administration and 6 month (x2 3-months) administration of UPA) is 
presented in Table 5.10. 
 
5.5.3.3 CDC25A immunolocalisation in the endometrium is altered by UPA 
administration 
CDC25A was the most significantly altered cell-cycle gene identified by the gene 
microarray and validated both internally and in the independent biopsies collected from 
women administered UPA for 3 and 6 month (Table 5.10). CDC25A regulates elements 
of G1, S and G2 phase of the cell cycle and for these reasons was selected for assessment 
of impact of UPA on protein expression (Figure 5.16).  
 
Samples from women in the proliferative phase displayed intense immunopositive 














































































































































































































































































































































































Figure 5.12 Internal validation by RT-qPCR of differentially expressed down regulated cell 
cycle genes in the endometrium following treatment for 3 months with selective 
progesterone receptor modulator, ulipristal acetate (UPA)  
Relative mRNA levels of selected cell cycle genes in paired samples from the endometrium 
of women in proliferative phase and then following subsequent UPA administration for up to 
twelve weeks.   
n=6 for each group. * p <0.05, ** p <0.01. NS not significant. Box and whisker, whiskers: 
median, minimum and maximum  
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Figure 5.13 Premature cessation of selective progesterone receptor modulator, ulipristal 
acetate (UPA) appears to affect mRNA levels of differentially expressed cell cycle genes as 
assessed by RT-qPCR 
Individual relative mRNA levels of cell cycles genes in the endometrium from six women in 
the proliferative phase of the menstrual cycle and then following subsequent UPA 
administration for up to 12 weeks. One sample (CT1280E2, red dot) was from a subject who 
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Figure 5.14 Validation by RT-qPCR of differentially expressed down regulated cell cycle 
genes in the endometrium following treatment for three months with selective 
progesterone receptor modulator, ulipristal acetate (UPA) 
Relative mRNA levels of selected cell cycle genes in samples from the endometrium of 
women either in proliferative phase or following UPA administration for up to twelve weeks.   
n=6 for each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001. NS not significant. 






















































































































































































































































































































































































Figure 5.15 Validation by RT-qPCR of differentially expressed down regulated cell cycle 
genes in the endometrium following treatment for six months with selective progesterone 
receptor modulator, ulipristal acetate (UPA)  
Relative mRNA levels of selected cell cycle genes in samples from the endometrium of 
women either in proliferative phase or following UPA administration for up to six months 
with a 4-week midpoint treatment break.   
n=6 for each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001. NS not significant. 









Table 5.10 Summary of PCR validation of genes of interest identified by gene microarray 








             
GREM2 -22.133 0.0000001 ↓ **** ** * 
MUC1 3.122 0.0000055 ↑ ** NS **** 
   
 
   
CDC25A -2.967 0.0001577 ↓ ** *** ** 
CCNA1 -5.364 0.0005527 ↓ ** * ** 
MYC -1.872 0.0015560 ↓ * * NS 
E2F2 -2.121 0.0032760 ↓ * ** ** 
CCNE2 -3.489 0.0047100 ↓ NS ** **** 
CCNA2 -2.333 0.0064870 ↓ ** *** ** 
PCNA -1.564 0.0065230 ↓ NS ** *** 
CCNB2 -2.547 0.0069990 ↓ * ** **** 
CDK1 -2.777 0.0076200 ↓ * **** **** 
CDC7 -2.051 0.0090820 ↓ NS *** *** 
CCNB1 -2.314 0.0093770 ↓ ** ** ** 
 





















Figure 5.16 Administration of selective progesterone receptor modulator, ulipristal acetate 
(UPA) appears to reduce endometrial CDC25A expression 
 
Representative low- (A-E) and high-power (F-O) immuno-localisation of CDC25A in 
endometrium from woman with fibroids during proliferative (A, F, K, P) and after UPA 
administration (B-E, G-J, L-O, Q).  
 
Samples from women in proliferative phase displayed intense immunopositivity in the 
luminal epithelium (LE) glands (G) and stroma (S) (LE+G+S+). Intensity of epithelial 
immunopositivity appeared less in the basal layer (K) compared with the functional layer (F). 
UPA-treated women displayed variable alteration in immunopositivity. The majority had 
positive luminal epithelium (G, H, J) though in some subject the immunoreactivity was less 
dense (I). Epithelial immunopositivity reduced (R), most evident in the basal layer in most 
subjects (L-N, Q) when compared to proliferative phase (K, P). In one woman there was also 
reduced epithelial immunopositivity in the functional layer (I). There was one exception 
where the patient has similar epithelial expression as proliferative phase (J&O).  
 
All women administered UPA had persistent stromal immunopositivity (G-J & L-O) but the 
intensity was reduced (S). In one subject stromal staining was markedly reduced in the basal 
layer (O).  
 
Lower power (scale bar = 500µm), high power magnification (scale bar = 50 µm), glands (scale 
bar = 20 µm); Negative controls shown as inserts on proliferative endometrium (A). * p <0.05 




epithelial immunopositivity appeared less in the basal layer (Figure 5.16K) compared 
with the functional layer (Figure 5.16F).  
 
The localisation of CDC25A within the endometrium of women treated with UPA was 
variable. The majority had positive luminal epithelium (Figure 5.16G, H & J) though in 
some this was less dense (Figure 5.16I). Epithelial immunopositivity was reduced 
(Figure 5.16P-R) and this was most marked in the basal layer in most subjects (Figure 
5.16L-N) when compared to proliferative phase (Figure 5.16K). In one sample there was 
clear reduction in epithelial immunopositivity in the functional layer (Figure 5.16I) and 
overall this was significantly reduced (Figure 5.16R). All women administered UPA 
appeared to have persistent stromal immunopositivity (Figure 5.16G-J & L-O), though 
this was reduced in intensity (Figure 5.15S). In one subject (Figure 5.16O) stromal 
immunopositivity was almost entirely absent.  
 
There was one of the nine women administered UPA, CP1239, who had an entirely 
different pattern of immunolocalisation with similar epithelial expression observed as 
proliferative phase and reduction in stromal immunopositivity as described above 




This is the first description of the effect of in vivo administration of UPA upon cell 
proliferation in the human fallopian tube (FT) and uterine cervix. Cell proliferation 
appeared reduced in the fallopian tube from women administered UPA relative to those 
from women in the proliferative phase, and in the cervix was low irrespective of cycle 
stage or following UPA administration.  
 
This is also the first unbiased description of the impact of UPA administration upon gene 
expression in the endometrium compared with proliferative phase endometrium. 
Furthermore, in keeping with the anti-proliferative effect observed in the endometrium, 
administration of UPA alters gene expression of multiple elements of the cell cycle, many 
of which are novel compared to those identified following administration of other SPRMs 
by previous groups.  
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5.6.1 Fallopian Tube 
When ampullary cell proliferation was assessed it appeared that whilst proliferation (as 
assessed by Ki67 immunopositivity) overall was low, proliferation was further reduced 
by UPA administration relative to the proliferative phase. Other studies have 
demonstrated that whilst numbers of Ki67 positive cells are low, there is alteration in 
immunopositivity between fallopian tubes from women in proliferative and secretory 
phase of the menstrual cycle (George, Milea et al. 2012) with progesterone (exogenous 
or endogenous) reducing cell proliferation (Donnez, Casanas-Roux et al. 1985). This 
reduction in cell proliferation between proliferative and secretory phase of the 
menstrual cycle was consistent with that observed in this small sample of fallopian tube 
biopsies. 
 
In chapter 3 it was demonstrated that UPA alters cell morphology and steroid receptor 
expression in the fallopian tube relative to secretory phase only, suggesting that UPA 
administration was resulting in blockage of the antagonistic effect of progesterone on E2 
action. As such one would expect proliferation to also be consistent between fallopian 
tubes from women in proliferative phase and following UPA administration. Whilst these 
findings have not been formally quantified it does appear that in contrast to this 
expectation, UPA reduces cell proliferation in the ampulla of the fallopian tube. This 
observation is consistent with the effect of other SPRMs (mifepristone) on Ki67 
expression in NHP oviducts (Slayden, Hirst et al. 1993, Slayden and Brenner 1994). The 
mechanism by which cell morphology and SSR expression is preserved relative to 
proliferative phase, but cell proliferation is reduced is unclear, and suggests that whilst 
UPA results in loss of P-antagonism within the fallopian tube, there are also other 
indirect effects on the fallopian tube. This impact upon cell proliferation requires further 
interrogation, particularly given the fimbrial ends of the fallopian tube are now 
considered a potential site for the development of future high grade serous ovarian 
cancer (Crum, Herfs et al. 2013). As cell proliferation is reduced this may indicate that 
despite preservation of PR and ERα in the fallopian tube, SPRMs may hold the potential 
to have a protective role against the future development of epithelial ovarian cancer. As 
previously discussed in Chapter 3, the rate of ovarian malignancy is currently under 
investigation as a secondary outcome in high risk women with BRCA mutations 




In the cervix Ki67 immunopositivity was limited to the squamous epithelium and was 
unaltered by UPA administration. The uterine cervix is ordinarily relative quiescent but 
Ki67 immunopositivity reflecting proliferating cells may be observed in the squamous 
cells and glandular cells of the normal cervix (Calil, Edelweiss et al. 2014, Stewart and 
Crook 2015). As with SSRs, there is a relative dearth of evidence regarding both cyclical 
variation of protein expression of Ki67 in the squamous and endoglandular 
compartments of the normal cervix and the effects of SPRM administration upon this. 
The data presented in this thesis suggest that cell turnover in the cervix is very low and 
is not increased by administration of an SPRM. This is perhaps unsurprising given the 
lack of impact upon SPRM administration upon SSR expression in the cervix as 
demonstrated in Chapter 3 of this thesis. Further, in other cell types SPRM 
administration appears to reduce rather than increase cell proliferation.  
 
The age of the control specimens may have contributed slightly to the degree of cell 
proliferation observed. Ki67 expression is altered by the age of the specimen with 10% 
loss of protein expression by 5 years from collection (Combs, Han et al. 2016). The 
control cervical samples from women in the proliferative and secretory phases had been 
collected between eight and twelve years prior to the timing of collection of the UPA 
specimens (which themselves were three years old at the time of sectioning and 
staining). This may have impacted upon immunopositivity slightly but whilst the sample 
size is small, antigen degeneration is unlikely to cause complete abrogation of 
immunopositivity seen in the glandular cells of all samples and is thus unlikely to have 
impacted significantly on current conclusions.  
 
5.6.3 Endometrium 
In Chapter 4 it was demonstrated that UPA administration typically either alters P-
regulated genes relative to secretory phase only (e.g. FOXO1, HOXA10 and HAND2), or 
has no effect (e.g. COUP-T11). FOXM1 was the only exception where altered levels of gene 
expression relative to proliferative phase rather than secretory was identified by this 
candidate approach. Techniques such as sequencing and gene microarray interrogation 
allow an unbiased approach and may identify novel transcript targets.  However an 
unbiased approach needs to be cognisant of the difference between a statistically 
significant and biologically significant effect.  
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Alteration of the transcriptome by SPRMs has been assessed previously. However many 
of these either assess alteration in cell lines (Tamm-Rosenstein, Simm et al. 2013), other 
tissues such as fibroids (Engman, Varghese et al. 2013) or in murine and NHP models 
(Bagchi, Li et al. 2005, Ghosh, Sharkey et al. 2009). In studies assessing the effect of in 
vivo administration of a SPRM on human endometrium, the majority of the literature 
concerns administration of mifepristone (Catalano, Critchley et al. 2007, Cuevas, Tapia-
Pizarro et al. 2016) and to date only one study has investigated UPA (Lira-Albarran, 
Durand et al. 2017). However, in contrast to the data presented in this thesis, all these 
studies assess the alteration in mRNA levels between secretory phase and SPRM 
administration. It is thus unsurprising that very different transcripts are identified when 
compared to the data presented in this thesis as the comparator groups reflect a very 
different functional and hormonal status. 
 
5.6.3.1 Differentially expressed genes: GREM2 and MUC1 
Neither GREM2 nor MUC1 have previously been identified as differentially expressed in 
gene microarray studies of the endometrium of women exposed to SPRMs.  
 
GREM2 
GREM2 was the most significantly altered gene following administration of UPA and 
was markedly down-regulated compared to the proliferative phase (FC -22.1, p = 8.5 
x10-8). GREM2 is a cytokine and acts as an antagonist of bone morphogenetic proteins 
(BMP), particularly BMP-2 and BMP-4 (Zuniga, Rippen et al. 2011). In addition Grem2 
also promotes nuclear translocation of β-catenin (Wu, Tang et al. 2015). It is expressed 
in multiple tissues in the human including all tissues of the female reproductive tract 
with the exception of the vagina (http://www.proteinatlas.org/ENSG00000180875-
GREM2/tissue Accessed 27/3/17).  
 
The function of GREM2 in normal endometrium has not been assessed. However one of 
its targets, BMP-2 has a role in the endometrium. It increases the progesterone co-
chaperone FKBP52 and Wnt4 (Lee, Jeong et al. 2007), and knockout murine models are 
unable to decidualise (Lee, Jeong et al. 2007). In humans it is critical for decidualisation 
(Wetendorf and DeMayo 2012) and an endometrial deficiency has been demonstrated in 
the stromal cells of women with fibroids (Sinclair, Mastroyannis et al. 2011). 
Furthermore in this study treatment with UPA slightly increased BMP-2 levels but not 
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significantly (FC 1.3, p = 0.18), despite the significant down-regulation of its antagonist. 
This finding of a non-significant rise of BMP-2 levels following UPA administration is in 
keeping with PCR data presented in Chapter 4 (Figure 4.3E). Furthermore BMP-2 is also 
regulated by TGF-β3, also known to be increased in the presence of fibroids and may 
down-regulate the expression of the receptor for BMP-2 (Sinclair, Mastroyannis et al. 
2011). However the impact of GREM2 mRNA down-regulation upon GREM2, BMP-2 and 
TGF-β3 protein expression and function is unknown.  
 
GREM2 is also expressed in the ovary and has roles in late follicular development (Sudo, 
Avsian-Kretchmer et al. 2004). There is also some evidence it may regulate the transition 
of primordial follicles to primary follicles within the ovary and can directly bind to AMH 
and inhibit its effects (Nilsson, Larsen et al. 2014). Women receiving treatment with 
SPRMs are typically anovulatory, with E2 levels in the mid-follicular range and normal 
circulating levels of LH and FSH (Baird, Thong et al. 1995, Chabbert-Buffet, Pintiaux-
Kairis et al. 2007). If the reduction of GREM2 RNA levels is reflected in reduced protein 
expression, loss of AMH inhibition may contribute to the anovulatory effect. 
 
As previously described GREM2 promotes β-catenin translocation. β-catenin is an 
integral Wnt signaling component and implicated in cell proliferation and survival 
(Moradi, Ghasemi et al. 2017). Mutation is associated with endometrial cancer and a 
poorer disease free survival (Kurnit, Kim et al. 2017). Furthermore a single study 
assessing differentially expressed genes in endometrial cancers observed a reduction in 
GREM2, and that in vitro treatment with GREM2 inhibited tumour cell growth 
(Tsubamoto, Sakata et al. 2016). The array performed in this thesis demonstrated that 
despite significant down-regulation of GREM2, β-catenin was not differentially altered by 
UPA treatment. The finding by Tsubamoto is of note, but has not been substantiated by 
other sequencing studies of endometrial cancers (Chang, Huang et al. 2017, Garcia-Sanz, 
Trivino et al. 2017, Jones, Xiu et al. 2017) and the significance of down-regulation of 
GREM2 in healthy endometrium is unknown. 
 
MUC1 
The most significantly up regulated gene was SLC13A5 but, as previously described, 
three of the six most up regulated genes were MUC1 transcripts and as such it was thus 
decided that this should be the candidate gene taken forward for validation. MUC1 is a 
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glycoprotein which belongs to a family of very large and heavily glycosylated proteins 
that are present upon the apical surfaces of almost all simple epithelial tissues and 
function to maintain cell surface lubrication as well as environmental control and 
protection from pathogens (Hattrup and Gendler 2008). They protect from apoptosis, 
and dysregulation is associated with cancer (Hollingsworth and Swanson 2004, Ren, 
Agata et al. 2004). Within the endometrium expression is progesterone regulated 
(Meseguer, Aplin et al. 2001). Mucins play a key role in embryo implantation (Dharmaraj, 
Gendler et al. 2009) and altered expression within the uterus is associated with infertility 
(Horne, Lalani et al. 2005). Whilst MUC1 expression is progesterone mediated, it is the 
PRB isoform that is predominantly responsible for up-regulation whereas PRA 
antagonizes PRB-mediated stimulation (Brayman, Julian et al. 2006). 
 
The data presented in the thesis demonstrated that MUC1 levels were differentially 
expressed in paired samples from the same women prior to and following administration 
of UPA with significant up-regulation observed. This is somewhat surprising given that 
MUC1 expression is typically increased by progesterone (Meseguer, Aplin et al. 2001) 
but may reflect alteration of relative PR isoform expression. The finding of up-regulation 
of MUC1 following UPA treatment is also in contrast to that observed by one group 
following administration of the SPRM mifepristone, where MUC1 was reported to be 
down regulated (Meng, Andersson et al. 2009). However this was following in vitro 
administration of mifepristone to an endometrial co-culture of primary endometrial 
stromal and epithelial cells. As a result it is difficult to ascertain if their contrasting 
observations are a result of a differing SPRM effect on PR isoform or a reflection of in 
vitro treatment of a co-culture model. 
 
The finding of increased expression of MUC1 demonstrated in this thesis requires further 
investigation to determine the relevance of this observation. Firstly increased mRNA 
levels have not yet been subsequently validated by alteration in protein expression. 
Furthermore, a differential expression was not confirmed in independent cohorts. In all 
groups there was a very heterogeneous response of MUC1 to administration of UPA. The 
samples utilized in the array validated by PCR, but three samples had a very marked 
increase in mRNA levels whereas in the other three this increase was very much 
attenuated.  In the independent groups again some subjects had an attenuated or absent 
change in MUC1 and this was not explained by presence or absence of fibroids. 
Quantification of protein expression may provide valuable insights into this variability 
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and confirm the up-regulation observed in paired samples. MUC1 is an epithelial 
expressed protein and a significant variation in the degree of cystic dilatation (and thus 
relative glandular to stromal ratios) may impact upon relative expression levels of 
mRNA. Previous studies in endometriosis have demonstrated that normalizing 
expression against epithelial cell markers has a significant impact upon perceived 
cyclical alteration of mRNA levels (Dharmaraj, Chapela et al. 2014). It is impossible to 
correlate MUC1 levels in this study against the degree of cystic dilatation: endometrial 
biopsies obtained by suction catheter often have significant distortion and fragmentation 
of the sample by this sampling method, as was the case in the samples utilized here. 
Correlation between mRNA levels and protein expression in endometrium obtained at 
the time of hysterectomy, where the fixation of a full thickness biopsy may allow for more 
accurate assessment of the degree of dilatation will allow further interrogation of 
possible explanations for the variability in MUC1 alteration.  
 
Other biological relevance of this alteration in MUC1 is unclear. Given the association of 
increased MUC1 expression with infertility, up-regulation may be increased with an 
alteration in receptivity of the endometrium, contributing to its potential for prevention 
of unplanned pregnancy. If a correlation between MUC1 and the degree of cystic 
dilatation is demonstrated it raises the intriguing possibility of the role that MUC1 might 
play in the development of the striking cystic dilatation often observed in many, but not 
all, subjects following administration of an SPRM. Increased glycosylation of the apical 
surface may alter the osmotic potential of the lumen of an endometrial gland. However 
there would be significant challenges in demonstrating causality given the lack to date of 
an effective co-culture system that can demonstrate the histological features of PAEC. 
 
5.6.3.2 Cell Cycle 
Consistent with data previously presented by our group (Whitaker, Murray et al. 2017), 
down-regulation of proliferation in human endometrium following administration of 
UPA is described herein. This is in keeping with an anti-proliferative effect observed 
following in vivo administration of mifepristone and asoprisnil (Engman, Granberg et al. 
2009, Wilkens, Williams et al. 2009). One of the most striking observations presented in 
this thesis is the alteration in endometrial mRNA levels of multiple elements of the cell 
cycle following administration of UPA. Down-regulation was identified both by KEGG 
pathway enrichment and by GO interrogation and selected candidates were confirmed 
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by RT-qPCR and IHC. This effect also persisted in subjects who had had repeated courses 
of UPA and in those with and without fibroids.  
 
The data presented in this thesis provide fresh insights into the potential mechanisms by 
which the anti-proliferative effect might be caused, and identify different candidates 
implicated within the cell cycle compared to other SPRMs. Whilst the degree of fold 
change of these candidates may have been less dramatic than many of the differentially 
expressed genes observed with greater statistical stringency, the biological relevance is 
of great import, particular given the confirmation of reduced cell proliferation as 
assessed by Ki67 immunopositivity.  
 
Cell cyclins 
Critical to progression through the cell cycle are the cyclins. The novel data presented in 
this thesis suggest that whilst A, B and E cyclins mRNA are all down regulated in the 
endometrium by in vivo treatment with UPA, D cyclins were unaltered. CDK1 but not 
CDK2 was also downregulated. B Cyclins are regulated by CDK1, E by CDK2 and D by 
CDK4. A cyclins are regulated by both CDK1 and CDK2. The down-regulation of CDK1 
may in part explain the subsequent down-regulation of A and B cyclins, but the down-
regulation of E cyclins suggests a mechanism independent of CDK2. To date there have 
been no published studies of the effect of UPA of endometrial expression of cyclins. In 
ovarian cancer cell lines UPA reduced cyclin E, but this was less marked that other SPRMs 
and was associated with a reduction in CDK2 (Goyeneche, Seidel et al. 2012).  
 
CDK2 
In the data presented in this thesis there was no significant alteration in CDK2 observed 
following UPA treatment. Studies on the effect of mifepristone on cell cycle have 
demonstrated that cell cycle arrest occurs predominantly in the G1 phase and involves 
up-regulation of the CDK inhibitors p21cip1 and p27kip1 and these result in inhibition of 
CDK2 (Goyeneche and Telleria 2015).  
 
This effect was observed in murine breast cancer models (Vanzulli, Soldati et al. 2005). 
This finding has also been replicated following in vitro treatment of breast cancer cell 
lines (Vanzulli, Efeyan et al. 2002) and endometrial cancer cell lines (Schneider, Gibb et 
al. 1998). Multiple SPRMs, including UPA increase p21cip1 and p27kip1 (Goyeneche and 
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Telleria 2015) expression with consequent reduction in CDK2 in ovarian cancer cell 
lines, however UPA was the least potent with regard to this effect (Goyeneche, Seidel et 
al. 2012).  
 
In contrast to these studies in other cell types, the data presented in this thesis revealed 
that in the endometrium of women with fibroids, p21cip1 and p27kip1 are not increased, 
and that CDK2 was not reduced. It is uncertain whether this is result of differing cell 
types, or due to pharmacological differences between mifepristone and UPA.  
Interestingly FOXM1 affects G1/S by diminishing p21cip1 and p27kip1 (Costa 2005) 
however in Chapter 4 data are presented that demonstrate a reduction in FOXM1 relative 
to proliferative phase followed administration of UPA. As such the mechanism by which 
p21cip1 and p27kip1 are maintained remains unclear.  
 
CDC25A 
CDK-cyclin complexes are the only known substrates for CDC25 phosphatases. The 
CDC25 proteins dephosphorylate and thereby activate the CDK-complex. There are 3 
isoforms: A, B & C. All three act as key regulators of the G1-S and G2-M transitions. CDC25A 
mainly activates CDK2 complexes with cyclin E and A in the G1-S transition and CDK1-
cyclin B at the G2-M (Boutros, Lobjois et al. 2007). CDC25B and C are primarily required 
for entry into mitosis (Millar, Blevitt et al. 1991, Lammer, Wagerer et al. 1998) but also 
contribute to S-phase progression (Boutros, Dozier et al. 2006). 
 
Only CDC25A of the CDC25 phosphatases was significantly altered in the data presented 
from this array, and this down-regulation was confirmed by protein expression. This is 
the first evidence of alteration by UPA of CDC25A expression. Down-regulation was most 
evident in epithelial cells, but a reduction of intensity of staining in individual nuclei was 
also noted in stroma cells when semi-quantified. This has not been further quantified 
either by stereology or immunofluorescence.  
This has also not previously been observed with administration of other SPRMs. This 
may contribute to the down-regulation of CDK1-cyclin B activity and may also contribute 
to the down-regulation of cyclin A/E despite preserved CDK2.  
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Other cell cycle targets 
Other cell cycle candidates validated by this array include MYC, E2F2 and CDC7. MYC is a 
proto-oncogene that encodes a transcription factor that is essential for cell proliferation 
(Dominguez-Sola, Ying et al. 2007). E2F2 is one of the E2F family of transcription factors 
that bind to retinoblastoma (Rb) tumour suppressor protein (Liban, Thwaites et al. 
2016). E2F2 is a transcription activator and so down-regulation may thus contribute to 
reduction in cell cycle progression at the G1/S transition. CDC7 regulates DNA replication 
(Yamada, Masai et al. 2014) and this down-regulation may alter S-phase transition. 
 
5.6.4 Limitations of the gene microarray 
One of the significant strengths of this array was that the endometrial biopsies compared 
were “paired” samples: both the comparator and the on treatment groups were derived 
from the same women. There is often significant heterogeneity between individual 
women regarding underlying pathology (such as fibroid size and location), co-
morbidities and clinical response. This is evident in the principal component analysis, 
which identified individual variation as the third highest principal component 
discriminator. Subjects had variable circulating progesterone and oestradiol levels 
following UPA administration, and it is uncertain what impact this has on cell 
proliferation irrespective of UPA treatment. Equally it should be noted that the subjects 
with the least and greatest reduction in proliferation (as assessed by Ki67 
immunopositivity), had almost identical circulating E2 levels (302 and 319pmol/L 
respectively). All biopsies were obtained by the same technique and by the same 
operator and this may reduce variation between relative proportions of functional 
versus basal sampling. All samples were immediately fixed and so alteration in 
phosphorylation due to prolonged ischaemia was avoided. This has previously been 
noted in samples obtained at the time of hysterectomy, when ligation of the blood supply 
to the uterus may precede by some time the final removal of the specimen and 
subsequent fixation (Sivalingam, Kitson et al. 2016). 
 
One sample in the array (CT1280E2) was from a subject who had stopped her UPA 
administration eight days prior to endometrial sampling. She had not had a withdrawal 
bleed, her circulating progesterone and oestradiol levels suggested she had not ovulated 
and her endometrial histology demonstrated that she had PAEC. As such it was jointly 
agreed that she was suitable for inclusion in the UPA treatment group for the gene 
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microarray study. This was a pragmatic approach given the difficulty of obtaining paired 
samples from women who had had their index sample in the proliferative phase and 
were willing to have a repeated sample for the purposes of research. Whilst in the array 
QC this sample did not appear to be an outlier, at the stage of validation this sample was 
a statistical outlier for several genes, most notably CDC25A. The half-life of UPA is around 
38 hours (Esmya Summary of product characteristics http://esmya.co.uk/wp-
content/uploads/2016/06/Apr-2016-SPC-UK-clean.pdf Accessed 27th May 2017). As 
such by 8 days, assuming standard pharmacokinetics less than 4% of UPA would have 
been circulating. Whilst morphology would be unlikely to change until ovulation then 
subsequent shedding of the functional layer, the impact of the significant reduction in 
circulating UPA concentration on cell cycle activity is unknown. Given a robust biological 
reason for outlier status it was decided to exclude this sample from the RT-qPCR 
validation. Whilst this may have introduced bias, the cell cycle genes still validated in the 
independent sets (with the exception of MYC in the group who had received treatment 
for 2 cycles of UPA). As such the interpretation of these genes being significantly down 
regulated by UPA appears valid.  
 
The level of statistical significance for functional analysis (KEGG pathway enrichment 
and GO interrogation) would normally be chosen to be the most stringent level at which 
1% of the features were, on average, significant (which would have been adjusted p-
value <0.01). In this instance, as the number of significant features across the 
comparisons was quite skewed, the significance threshold was manually chosen to be 
raw p-value < 0.01. Given that targets identified by this method validated by RT-qPCR, 
this decision appears justified for the cell cycle targets but may not necessarily hold true 
for other pathways identified as altered, and as ever, candidates identified from a 
microarray require external validation prior to robust conclusions being drawn. 
 
The use of gene microarrays for assessing the transcriptome has been well established 
(Zhao, Fung-Leung et al. 2014) but this technology is increasing being superseded by 
newer techniques such as RNA-sequencing (RNA-seq). RNA-Seq has the benefits of not 
being limited by a fixed number of known probes, (and is thus less biased), and in 
contrast to microarrays may more readily identify alteration in splice junctions, allele-
specific expression and detection of novel transcripts (Mutz, Heilkenbrinker et al. 2013). 
However at present, data analysis of RNA-Seq is a more costly option and and data 
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analysis is complex, particularly when combined with proteomics (Kumar, Bansal et al. 
2016).  
 
In the validation set not all biopsies were from women with fibroids. Whilst there was 
no evidence of clustering between fibroid/non fibroid groups and this does not appear 
to have affected the validation of candidates, it is a potential source of error, particularly 
given the small numbers in the validation sets. As previously discussed in both chapter 
4 and in this chapter presence of fibroids may alter endometrial mRNA levels and protein 
expression (Sinclair, Mastroyannis et al. 2011, Makker, Goel et al. 2017). It is uncertain if 
SPRMs have a differing effect on the transcriptome of the endometrium in the presence 
or absence of fibroids. Tissue collection of samples following repeated cycles of UPA is 
ongoing and this will allow an increase in n numbers in validation sets of subject both 
with and without fibroids to facilitate further enquiry.  
 
5.6.5 Future work 
A pragmatic approach was taken with regard to selection of candidates for onward 
validation. Clearly the outstanding targets from the cell cycle (both up and down-
regulated) need to be completed initially. These include CDKN2A, Chek2, ANAPC4, ESPL1, 
CDC20, PTTG1 and MAD2L1 (down-regulated) and CDKN2C, CDKN2B and GADD45A. All 
differentially expressed genes then need to undergo assessment of alteration in protein 
expression. Given the apparent contrast between effect of mifepristone and UPA upon 
cell cycle genes, further assessment of the effect of UPA administration on alteration of 
mRNA levels and protein expression of CDK2, p21 and p27 would also be of utility.  
 
Functional studies then need to be undertaken. One strategy would be in vitro treatment 
of cultured endometrial cells with UPA. An assessment of cell proliferation could then be 
assessed by a functional assay such as a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MMT) assay or a DNA synthesis assay. Alteration in 
protein expression (if sufficient quantity) may be assessed by western blot. One 
limitation of endometrial cell culture systems is that in vivo there is a complex interplay 
between endometrial epithelial and stromal cells (Wetendorf and DeMayo 2012). Co-
culture models have historically been challenging but methods have now been 
established (Eritja, Llobet et al. 2010) and may allow a more precise interrogation of the 
in vitro effects of UPA administration.  
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Consideration of assessment of micro-RNA (miRNA) involved in cell cycle would be of 
potential utility, particularly if there is discordance between mRNA levels and protein 
expression. P-regulated miRNA have previously been implicated in the control of 
endometrial proliferation (Pan, Yuan et al. 2017) and so some alteration of miRNA levels 
may be evident. It is also unclear that whilst cell cycle genes appear affected at many 
points of the cell cycle, whether the majority of cells actually arrest in G1/S.  
 
Cell proliferation can be assessed in a number of ways and commonly used antigens 
include Ki67, PCNA and Phospho Histone 3 (PH3). Ki-67 is a nuclear protein expressed 
during all stages of the cell cycle except G0 and is a standard index of overall cellular 
proliferation (Yerushalmi, Woods et al. 2010), and is frequently used specifically in 
endometrial studies (Kitson, Sivalingam et al. 2017). Because histone 3 is 
phosphorylated only during mitosis and is expressed only in mitotic chromosomes, PH3 
staining provides a direct indication of mitotic activity (Brenner, Slayden et al. 2003). As 
such specific assessment of alteration of PH3 may give further insight into anti-
proliferative effect. 
 
The data presented in this thesis offers insights into targets potentially implicated in the 
endometrial anti-proliferative effect but does not explain the mechanism by which this 
is brought about. One possible factor that should be further explored is the role of the 
androgen receptor (AR). In Chapter three it was demonstrated that UPA administration 
has a striking effect on AR expression with an increase in mRNA levels and protein 
expression which was evident in both the endometrial stroma and the glands. This is 
similar to the effect observed in NHP models following administration of the SPRM ZK 
230211 (Slayden, Nayak et al. 2001). In the NHP SPRM administration was also 
associated with a reduction in endometrial wet weight, thickness and mitotic indices. 
However this anti-proliferative effect was abrogated by administration of the anti-
androgen flutamide (Slayden and Brenner 2003). Androgens are known to suppress E2 
action in the endometrium and thus the authors postulated that local up-regulation of 
AR may suppress stromally derived, E2-dependent growth factors (Brenner, Slayden et 
al. 2003). Given the class effect of reduced proliferation by the SPRMs this may well be 
implicated in the anti-proliferative effect observed in the endometrium following UPA 
administration. Without access to NHP models one option would be to treat primary 
endometrial cells in vitro with UPA and then assess the effect of co-administration of 
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flutamide on functional proliferation assays, cell cycle mRNA levels and protein 
expression. Ideally this would be done in a co-culture system but some information may 
be derived from culture of endometrial stromal cells only. Further exploration of this 
effect may be undertaken by in silico studies – particularly analysis of common genes to 
both androgen pathways and those differentially expressed following UPA treatment. 
This includes both those identified by the array and from the candidate-based approach 
with known roles in proliferation such as HAND2, FOXM1 and KLF-4, -9 & -15.  
 
Finally this chapter has predominantly focused upon the impact of UPA on the cell cycle. 
This may in part explain why increased levels of malignancy and pre-malignancy are not 
observed following administration of a progesterone antagonist. However the 
complement to proliferation is apoptosis. This process was not identified by this array 
as a significantly altered KEGG pathway but both apoptosis markers Caspase-3 and BCL-
2 were altered, albeit not at the most stringent statistical level. These merit further 
investigation and validation, not least as both in vivo and in vitro treatment of fibroids 
with UPA up regulates caspase-3 with an associated increase in apoptosis and in vitro 
Bcl-2 was down regulated (Xu, Takekida et al. 2005, Yun, Seong et al. 2015). In addition, 
gene microarray studies assessing the impact on the endometrium following exposure 
to mifepristone have demonstrated down-regulation of anti-apoptosis transcripts 
(Cuevas, Tapia-Pizarro et al. 2016) although these analyses were in comparison to 




This chapter demonstrates that administration of UPA reduces proliferation in the 
endometrium and fallopian tube but not the cervix.  This is the first demonstration of 
effect of UPA on Ki67 expression in the human fallopian tube and cervix. Administration 
of UPA has a highly significant impact upon GREM2 mRNA levels, but up-regulation of 
MUC1 is highly variable between subjects. Furthermore that the data presented herein 
demonstrate for the first time that administration of UPA impacts upon mRNA levels of 
critical cell cycle genes in the endometrium. This was reflected in reduced expression of 
the cyclin-dependant kinase regulator CDC25A what was particularly striking in the 
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glandular epithelium. The effect on protein expression of other cell cycle candidates has 











































6.1 Summary of findings 
Progesterone receptors (PR) are present throughout the human female reproductive 
tract. The synthetic ligand for the PR, ulipristal acetate (UPA), a member of the family of 
selective progesterone receptor modulators (SPRMs), hold promise for the amelioration 
of numerous gynaecological conditions. Whilst the effect upon endometrial morphology 
is well recognised, to date data have been lacking of the effect of administration upon key 
aspects of the epithelial layers of the reproductive tract. The data presented herein 
provide novel descriptions of the effect of UPA administration upon sex steroid receptor 
(SSR) expression, and proliferation within the endometrium, fallopian tubes and cervix 
of women with symptomatic fibroids. Furthermore the effect of UPA administration 
upon key progesterone regulated genes is described. Candidates implicated in the anti-
proliferative effect within the endometrium are also identified. 
 
In keeping with established literature, profound effects upon endometrial morphology 
were observed, but with greater prevalence than previously described. This is the first 
description of the impact of in vivo treatment with UPA on the morphology of the 
fallopian tubes, which resemble proliferative phase, in keeping with the effects observed 
with other SPRMs. However UPA administration does not alter cervical morphology. The 
morphological effects of UPA in the fallopian tube are consistent with UPA acting with 
low P-agonism within this region however the morphological changes within the 
endometrium do not phenocopy either proliferative or secretory phase, suggesting UPA 
has an “endometrial specific” effect within the human uterus.  
 
Within the endometrium UPA administration increases both PR and PRB mRNA levels 
and localisation with a particular pattern of protein expression that is not observed 
either in proliferative or secretory phase endometrium. UPA binds the PR but has 
minimal affinity for other SSR such as the oestrogen receptor (ER) and androgen 
receptor (AR). Despite this, UPA administration results in alteration of ER and AR mRNA 
levels. Protein expression is also increased both in the stromal fibroblasts and glandular 
epithelium, for AR this reflects a spatial alteration in the localisation of protein 
expression which does not replicate either proliferative or secretory patterns of 
expression. There is alteration in ampullary sex-steroid receptor mRNA levels in the 
fallopian tube but this is limited to PR and ERα and this is relative only to the secretory 
phase. SSR protein localisation appeared unaltered, and immunopositivity most closely 
resembled the proliferative phase. This suggests the impact of UPA in the fallopian tube 
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is limited to blockade of P-antagonism only. Sex-steroid receptor expression in the cervix 
was unchanged by UPA. Thus it appears, despite PR being present in all three locations, 
consistent with the effect upon morphology, UPA appears to have an “endometrial 
specific” effect upon the SSR expression in the epithelium of the human reproductive 
tract. 
 
To assess the endometrial impact of altered SSR expression, the effect of UPA 
administration on key P-regulated genes was examined. An alteration relative to 
secretory levels was frequently observed, consistent with UPA acting with low P-
agonism. However despite alteration in SSR localisation between glands and stroma, 
localisation of protein expression of selected P-regulated genes was similar to the 
proliferative phase. Furthermore other P-regulated genes were unaltered. Further 
characterisation is required to assess the impact of UPA on the complex paracrine 
signalling environment within the endometrium.   
 
Genes implicated in P-resistance associated with endometriosis were demonstrated to 
have similar mRNA levels as women without endometriosis but it remains unclear 
whether UPA is acting to overcome the putative P-resistance associated with 
endometriosis, or merely reflects pre-existing altered levels. Further investigation would 
be of value as there appears to be a trend towards poorer bleeding control following UPA 
administration in those women with co-existing endometriosis. Alteration in the eutopic 
endometrium of these women may render them less able to achieve the bleeding control 
obtained by those women without endometriosis.   
 
Reassuringly, also presented here, despite overall low P-agonism, and normal circulating 
oestradiol levels there was no increased rates of hyperplasia or malignancy. 
Furthermore, despite absence of endometrial shedding and the altered hormonal milieu 
described above, UPA administration was not associated with accumulation of PTEN null 
glands. 
 
Despite P-regulated genes reflecting low P-agonism UPA has previously been 
demonstrated to have an anti-proliferative effect within the endometrium. It was 
determined here that UPA administration may also reduce proliferation within the 
fallopian tube.  
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Unbiased microarray studies of the endometrium identified the cell cycle as the most 
down regulated pathway following UPA administration relative to proliferative phase. 
Multiple aspects from all phases of the cell cycle were identified as being down-regulated 
and were confirmed by PCR in independent samples from women both and without 
fibroids. Many of these candidates were novel compared to those identified by 
interrogation of other SPRMs. The mechanism for this anti-proliferative effect is unclear.  
Demonstrated here was alteration of the transcription factor FOXM1 relative to 
proliferative phase within the endometrium, both this and the up-regulation of AR may 
potentially be implicated in the endometrial anti-proliferative effect but require further 
investigation in functional studies.  
 
6.2 Further work and future directions 
In each chapter suggestion for further work to address deficiencies in current knowledge 




 Steroid receptors: Impact of UPA administration upon expression and 
localisation of ERβ, MR and GR 
 Availability of ligands: modulation of steroid metabolising enzymes, 11β- and 
17β-hydroxysteroid dehydrogenases  
 Assessment on UPA administration on co-repressors NCoR and SMRT 
 P-regulated genes: 
o Protein expression of (+/-co-localisation with PR) of co-chaperones, IHH 
pathway, TGFβ3 signalling and HOXA10 
o Impact of UPA on Wnt4, FGF, FGFR, CRK, His-5, SRC 
o uNK cell population (given impact on IL-15) 
 Endometriosis:  
o well phenotyped patients ideally with paired biopsies (pre and on 
treatment) to assess impact of UPA on P-regulated genes previously 
demonstrated to be aberrantly expressed in the context of endometriosis 
o In vitro treatment with UPA of stromal cells/co-culture models from 
women with and without endometriosis 
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o Exploration of differences between those with and without control of 
bleeding 
  Array outputs:  
o GREM2 protein localisation, impact upon β-catenin 
o MUC1 immunolocalisation 
 Reduction in proliferation: 
o Assessment of mRNA levels of remaining candidates identified in cell 
cycle, along with p21 and p27 and CDK2, with subsequent 
immunolocalisation 
o In vitro treatment with UPA and other SPRMs of cell culture models: 
functional proliferation assay, impact upon cell cycle, and impact of co-
administration of flutamide (anti-androgen) to determine role of AR in 
the anti-proliferative effect 
o Further exploration of role of FOXM1 in the anti-proliferative effect 
Fallopian tube: 
 Assessment of impact upon sex steroid receptors and proliferation  in the 
fimbriae 
 Quantification of Ki67 immunopositivity in the fallopian tube and impact upon 
cell-cycle genes 
Cervix: 
 Impact of UPA administration upon the immune cell populations 
6.3 Overall conclusions 
UPA has previously been demonstrated to be an effective and acceptable medical agent 
for establishing bleeding control in those women with symptomatic fibroids. UPA also 
has potential for utility in those with HMB in the context of structurally normal uteri, and 
in the management of endometriosis. These conditions are often incapacitating and have 
significant socioeconomic costs. The novel data presented in this thesis considerably 
extend the data available to date concerning the actions of the SPRM, UPA, on the female 
reproductive tract, and increases knowledge regarding a compound with promising 
utility for the management of debilitating gynaecological conditions.  
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Supplementary Table 1. Up-regulated transcripts following UPA Administration (FC >1.3, 
p <0.01) 
Symbol Description logFC FC P.Value adj.P.Val 
SLC13A5 solute carrier family 13 member 5 2.781 6.874 5.69E-07 0.006861 
RNF39 ring finger protein 39 2.687 6.441 5.44E-06 0.01555 
MUC1 mucin 1, cell surface associated 1.643 3.122 5.50E-06 0.01555 
MUC1 mucin 1, cell surface associated 1.895 3.72 5.81E-06 0.01555 
EGLN3 egl-9 family hypoxia-inducible factor 3 2.51 5.695 8.03E-06 0.01759 
MUC1 mucin 1, cell surface associated 2.538 5.807 1.26E-05 0.01992 
ABCC3 ATP binding cassette subfamily C member 3 1.861 3.632 1.66E-05 0.02351 
SOX9 SRY-box 9 3.148 8.862 3.46E-05 0.03879 
HAMP hepcidin antimicrobial peptide 1.922 3.789 5.81E-05 0.04632 
TNFSF10 tumor necrosis factor superfamily member 
10 
1.298 2.459 7.66E-05 0.04632 
LRRN2 leucine rich repeat neuronal 2 1.804 3.492 7.86E-05 0.04632 
WDR72 WD repeat domain 72 1.208 2.31 8.23E-05 0.04632 
SORL1 sortilin-related receptor, L(DLR class) A 
repeats containing 
2.359 5.13 8.51E-05 0.04632 
ABTB1 ankyrin repeat and BTB domain containing 1 1.127 2.183 8.57E-05 0.04632 
SPINT1 serine peptidase inhibitor, Kunitz type 1 1.179 2.264 8.84E-05 0.04632 
GIMAP5 GTPase, IMAP family member 5 1.192 2.285 9.77E-05 0.04902 
CD86 CD86 molecule 1.218 2.326 0.0001082 0.05014 
STMN2 stathmin 2 3.225 9.351 0.0001137 0.05167 
ABLIM1 actin binding LIM protein 1 1.113 2.163 0.0001187 0.05202 
METRNL meteorin, glial cell differentiation regulator-
like 
1.056 2.08 0.0001242 0.05345 
NA NA 1.394 2.628 0.0001333 0.05432 
DHRS3 dehydrogenase/reductase (SDR family) 
member 3 
1.251 2.38 0.0001375 0.05432 
ALPPL2 alkaline phosphatase, placental like 2 4.778 27.43 0.0001444 0.05614 
BCL11A B-cell CLL/lymphoma 11A 1.198 2.295 0.0001617 0.05905 
NA NA 3.973 15.7 0.0001687 0.06068 
LMCD1 LIM and cysteine rich domains 1 1.499 2.826 0.0001787 0.06081 
PCDH9 protocadherin 9 1.639 3.115 0.0001815 0.06081 
PDGFB platelet derived growth factor subunit B 1.016 2.022 0.0001845 0.06081 
MYCN v-myc avian myelocytomatosis viral 
oncogene neuroblastoma derived homolog 
3.003 8.014 0.0001962 0.06195 
ZSCAN31 zinc finger and SCAN domain containing 31 0.922 1.895 0.0002016 0.06224 
SCNN1G sodium channel epithelial 1 gamma subunit 1.353 2.555 0.0002092 0.06224 
HPGD hydroxyprostaglandin dehydrogenase 15-
(NAD) 
2.636 6.217 0.0002144 0.06224 
CD68 CD68 molecule 1.815 3.519 0.0002151 0.06224 
TNFRSF6B tumor necrosis factor receptor superfamily 
member 6b 
2.304 4.939 0.0002172 0.06224 
RGS10 regulator of G-protein signaling 10 1.392 2.625 0.000228 0.06224 
BCL2L15 BCL2 like 15 1.462 2.755 0.0002349 0.06224 
LTC4S leukotriene C4 synthase 1.509 2.846 0.0002353 0.06224 
CFH complement factor H 1.278 2.425 0.0002363 0.06224 
TNIP1 TNFAIP3 interacting protein 1 0.9893 1.985 0.000248 0.06224 
TNFRSF6B tumor necrosis factor receptor superfamily 
member 6b 
2.098 4.281 0.000251 0.06224 
STMN2 stathmin 2 2.031 4.087 0.0002517 0.06224 
TMEM108 transmembrane protein 108 1.886 3.696 0.0002552 0.06224 
ELMO1 engulfment and cell motility 1 1.498 2.824 0.0002625 0.06262 
DPP4 dipeptidyl peptidase 4 2.664 6.337 0.0002712 0.06307 
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BCL11A B-cell CLL/lymphoma 11A 1.198 2.294 0.0002795 0.06307 
VAV3 vav guanine nucleotide exchange factor 3 1.92 3.784 0.0002908 0.06309 
FMOD fibromodulin 0.8828 1.844 0.0002964 0.06309 
SORL1 sortilin-related receptor, L(DLR class) A 
repeats containing 
2.358 5.126 0.0003111 0.06464 
FCGBP Fc fragment of IgG binding protein 2.213 4.636 0.0003232 0.06656 
CISH cytokine inducible SH2-containing protein 1.139 2.202 0.0003506 0.07159 
SCNN1G sodium channel epithelial 1 gamma subunit 1.31 2.479 0.000371 0.07328 
PLS1 plastin 1 1.049 2.069 0.0003833 0.07394 
TMEM139 transmembrane protein 139 1.122 2.177 0.0003959 0.07394 
NA NA 3.112 8.645 0.0004019 0.07394 
ZSCAN31 zinc finger and SCAN domain containing 31 0.9546 1.938 0.0004045 0.07394 
NA NA 1.339 2.531 0.0004056 0.07394 
BHLHE41 basic helix-loop-helix family member e41 1.656 3.152 0.0004113 0.07394 
C22orf24 chromosome 22 open reading frame 24 1.24 2.363 0.000417 0.07394 
EVA1A eva-1 homolog A, regulator of programmed 
cell death 
0.8855 1.847 0.0004265 0.07394 
CDKN2C cyclin-dependent kinase inhibitor 2C 0.8917 1.855 0.000442 0.07525 
ENTPD3 ectonucleoside triphosphate 
diphosphohydrolase 3 
1.215 2.321 0.0004466 0.07525 
MB21D2 Mab-21 domain containing 2 1.209 2.311 0.0004521 0.07565 
SLC7A7 solute carrier family 7 member 7 1.159 2.234 0.0004601 0.07575 
LPL lipoprotein lipase 1.305 2.471 0.0004604 0.07575 
CFH complement factor H 1.323 2.503 0.0004668 0.07575 
ABLIM1 actin binding LIM protein 1 1.24 2.363 0.0004721 0.07575 
ADGRG5 adhesion G protein-coupled receptor G5 1.139 2.203 0.0004747 0.07575 
C1QB complement component 1, q 
subcomponent, B chain 
0.8236 1.77 0.0004843 0.07621 
TGFA transforming growth factor alpha 1.451 2.734 0.0004878 0.07621 
ARHGAP31 Rho GTPase activating protein 31 1.126 2.183 0.0005031 0.07621 
GREM1 gremlin 1, DAN family BMP antagonist 2.516 5.721 0.000504 0.07621 
EPHA1 EPH receptor A1 0.7881 1.727 0.0005154 0.07621 
NA NA 1.326 2.508 0.0005187 0.07621 
UPK1B uroplakin 1B 1.971 3.919 0.0005237 0.07648 
PROSER2 proline and serine rich 2 1.303 2.468 0.0005401 0.07766 
IER3 immediate early response 3 1.331 2.516 0.0005766 0.07961 
KIAA0040 KIAA0040 1.003 2.005 0.0005798 0.07961 
NA NA 1.097 2.14 0.0005871 0.07961 
APBB1IP amyloid beta precursor protein binding 
family B member 1 interacting protein 
0.9872 1.982 0.000611 0.07961 
AHNAK AHNAK nucleoprotein 0.7176 1.644 0.0006144 0.07961 
KRT18 keratin 18 1.009 2.013 0.0006237 0.07961 
CFH complement factor H 1.314 2.487 0.0006265 0.07961 
VAV3 vav guanine nucleotide exchange factor 3 2.137 4.398 0.000628 0.07961 
MAP3K3 mitogen-activated protein kinase kinase 
kinase 3 
1.061 2.086 0.0006282 0.07961 
ALAS2 5'-aminolevulinate synthase 2 1.337 2.527 0.0006426 0.07961 
NA NA 1.184 2.273 0.0006447 0.07961 
FCER1G Fc fragment of IgE receptor Ig 1.124 2.18 0.000647 0.07961 
SLC34A2 solute carrier family 34 member 2 1.688 3.222 0.0006475 0.07961 
NA NA 1.178 2.262 0.0006526 0.07961 
CX3CR1 chemokine (C-X3-C motif) receptor 1 1.972 3.923 0.0006528 0.07961 
NA NA 0.785 1.723 0.0006574 0.07961 
NA NA 1.189 2.279 0.0007015 0.08274 
SPINT1 serine peptidase inhibitor, Kunitz type 1 1.802 3.488 0.0007039 0.08274 
ACY3 aminoacylase 3 2.018 4.05 0.0007126 0.08336 
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KBTBD11 kelch repeat and BTB domain containing 11 0.896 1.861 0.0007685 0.08694 
SGK223 homolog of rat pragma of Rnd2 1.211 2.315 0.0007817 0.08773 
NA NA 1.296 2.456 0.0007905 0.08818 
SLC9A1 solute carrier family 9 member A1 0.905 1.873 0.0008037 0.08891 
CEBPA CCAAT/enhancer binding protein alpha 1.567 2.963 0.0008043 0.08891 
SPECC1 sperm antigen with calponin homology and 
coiled-coil domains 1 
1.382 2.606 0.000831 0.09091 
FOXC1 forkhead box C1 1.228 2.342 0.0008402 0.09091 
MGAT3 mannosyl (beta-1,4-)-glycoprotein beta-1,4-
N-acetylglucosaminyltransferase 
1.299 2.461 0.0008413 0.09091 
ERBB3 erb-b2 receptor tyrosine kinase 3 0.8359 1.785 0.0008649 0.09263 
TLR7 toll like receptor 7 1.69 3.227 0.0008743 0.09264 
SGF29 SAGA complex associated factor 29 0.8769 1.836 0.0008766 0.09264 
TMPRSS3 transmembrane protease, serine 3 1.331 2.516 0.0008811 0.09272 
NPRL3 NPR3-like, GATOR1 complex subunit 1.029 2.041 0.0008867 0.0929 
STOX2 storkhead box 2 1.113 2.163 0.0009121 0.09379 
VWA1 von Willebrand factor A domain containing 1 0.9984 1.998 0.0009146 0.09379 
NA NA 0.9545 1.938 0.0009186 0.0938 
RUNX3 runt related transcription factor 3 1.358 2.564 0.0009324 0.0948 
DHRS9 dehydrogenase/reductase (SDR family) 
member 9 
1.087 2.124 0.000955 0.09511 
C3AR1 complement component 3a receptor 1 1.148 2.216 0.0009898 0.09788 
APOL3 apolipoprotein L3 0.7362 1.666 0.001026 0.1001 
TOX3 TOX high mobility group box family member 
3 
2.316 4.98 0.001031 0.1002 
MS4A7 membrane spanning 4-domains A7 0.9763 1.967 0.001037 0.1004 
RNF150 ring finger protein 150 0.945 1.925 0.001046 0.1007 
ABI3 ABI family member 3 1.191 2.282 0.001048 0.1007 
GPR37 G protein-coupled receptor 37 (endothelin 
receptor type B-like) 
1.486 2.801 0.001053 0.1007 
SLC39A4 solute carrier family 39 member 4 0.6904 1.614 0.001064 0.1013 
TBXAS1 thromboxane A synthase 1 1.025 2.036 0.001076 0.1021 
NCF4 neutrophil cytosolic factor 4 1.173 2.255 0.001118 0.1048 
PROSER2 proline and serine rich 2 1.758 3.381 0.001136 0.1055 
UBD ubiquitin D 2.336 5.048 0.001142 0.1055 
SLC7A5 solute carrier family 7 member 5 1.432 2.699 0.001153 0.1061 
NA NA 1.04 2.056 0.001175 0.1063 
NA NA 0.9909 1.987 0.001178 0.1063 
ANXA8L1 annexin A8-like 1 1.003 2.004 0.001194 0.1063 
NA NA 1.412 2.661 0.001197 0.1063 
BTK Bruton tyrosine kinase 1.564 2.958 0.001203 0.1063 
CYBB cytochrome b-245, beta polypeptide 1.276 2.422 0.001206 0.1063 
NA NA 1.488 2.806 0.001207 0.1063 
ATP8B1 ATPase phospholipid transporting 8B1 1.616 3.066 0.001209 0.1063 
SPI1 Spi-1 proto-oncogene 1.66 3.161 0.001212 0.1063 
ABCG1 ATP binding cassette subfamily G member 1 1.508 2.844 0.001212 0.1063 
RGS10 regulator of G-protein signaling 10 0.9213 1.894 0.001213 0.1063 
NA NA 1.085 2.121 0.001251 0.1073 
NA NA 1.221 2.33 0.001253 0.1073 
LINC00452 long intergenic non-protein coding RNA 452 0.7319 1.661 0.001254 0.1073 
THRA thyroid hormone receptor, alpha 0.9966 1.995 0.001256 0.1073 
USP25 ubiquitin specific peptidase 25 1.271 2.413 0.001265 0.1077 
NA NA 3.277 9.692 0.001273 0.108 
NA NA 1.654 3.147 0.001322 0.1111 
SLC19A2 solute carrier family 19 member 2 0.8329 1.781 0.001329 0.1112 
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MARCO macrophage receptor with collagenous 
structure 
1.373 2.59 0.001333 0.1112 
PROM1 prominin 1 1.38 2.602 0.00134 0.1114 
SHOX2 short stature homeobox 2 1.566 2.962 0.001374 0.113 
TNFRSF6B tumor necrosis factor receptor superfamily 
member 6b 
2.529 5.771 0.001401 0.113 
NA NA 1.005 2.007 0.001408 0.113 
TNFRSF11B tumor necrosis factor receptor superfamily 
member 11b 
1.719 3.293 0.00141 0.113 
DGCR11 DiGeorge syndrome critical region gene 11 
(non-protein coding) 
0.6954 1.619 0.001418 0.113 
NA NA 1.019 2.026 0.00142 0.113 
GREM1 gremlin 1, DAN family BMP antagonist 2.65 6.278 0.001433 0.113 
GPR183 G protein-coupled receptor 183 1.424 2.683 0.001451 0.113 
MVP major vault protein 0.8102 1.753 0.001456 0.113 
LYPD6B LY6/PLAUR domain containing 6B 1.758 3.383 0.001464 0.113 
EVA1A eva-1 homolog A, regulator of programmed 
cell death 
0.8713 1.829 0.001465 0.113 
ENTPD3 ectonucleoside triphosphate 
diphosphohydrolase 3 
0.9926 1.99 0.001476 0.113 
ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 0.9172 1.888 0.001495 0.1136 
LAMA3 laminin subunit alpha 3 1.182 2.268 0.001501 0.1136 
KCNQ1 potassium voltage-gated channel subfamily 
Q member 1 
1.015 2.021 0.001502 0.1136 
CD160 CD160 molecule 1.285 2.436 0.001517 0.1136 
LILRB4 leukocyte immunoglobulin like receptor B4 0.8568 1.811 0.001524 0.1136 
KIZ kizuna centrosomal protein 1.71 3.271 0.001535 0.1136 
NA NA 1.208 2.31 0.001536 0.1136 
SPI1 Spi-1 proto-oncogene 1.441 2.714 0.001541 0.1136 
ATP6V1B1 ATPase H+ transporting V1 subunit B1 1.582 2.994 0.001553 0.1136 
CFH complement factor H 1.55 2.928 0.00156 0.1136 
ACVR2A activin A receptor type 2A 0.7089 1.635 0.001593 0.1153 
NA NA 0.7671 1.702 0.001626 0.1163 
NA NA 0.6245 1.542 0.001627 0.1163 
IFI30 interferon, gamma-inducible protein 30 0.9888 1.984 0.001631 0.1163 
STARD10 StAR related lipid transfer domain 
containing 10 
0.9202 1.892 0.001689 0.1174 
TM7SF2 transmembrane 7 superfamily member 2 0.7031 1.628 0.001728 0.1174 
SLAMF8 SLAM family member 8 1.207 2.308 0.001733 0.1174 
NA NA 1.315 2.488 0.001738 0.1174 
KIT KIT proto-oncogene receptor tyrosine kinase 0.743 1.674 0.001742 0.1174 
METTL7B methyltransferase like 7B 1.56 2.949 0.001749 0.1174 
NA NA 0.632 1.55 0.001762 0.1174 
ARNT2 aryl hydrocarbon receptor nuclear 
translocator 2 
0.7639 1.698 0.001783 0.1174 
RBMS3 RNA binding motif, single stranded 
interacting protein 3 
1.5 2.828 0.001784 0.1174 
SIK2 salt inducible kinase 2 1.093 2.133 0.001805 0.1176 
CD37 CD37 molecule 1.939 3.834 0.001812 0.1176 
ABHD12 abhydrolase domain containing 12 0.7744 1.71 0.001816 0.1176 
NA NA 1.575 2.979 0.001867 0.1176 
ABTB1 ankyrin repeat and BTB domain containing 1 0.734 1.663 0.001869 0.1176 
RNASE4 ribonuclease A family member 4 0.6636 1.584 0.001876 0.1176 
CD48 CD48 molecule 1.295 2.454 0.001893 0.1176 
RHOF ras homolog family member F (in filopodia) 1.07 2.1 0.001893 0.1176 
SLC15A3 solute carrier family 15 member 3 0.7039 1.629 0.00191 0.1176 
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ALDH2 aldehyde dehydrogenase 2 family 
(mitochondrial) 
0.796 1.736 0.001911 0.1176 
AIF1 allograft inflammatory factor 1 0.9575 1.942 0.001916 0.1176 
ARRDC1 arrestin domain containing 1 0.7442 1.675 0.001923 0.1176 
SORCS2 sortilin related VPS10 domain containing 
receptor 2 
1.993 3.982 0.001953 0.1182 
JPH2 junctophilin 2 0.9371 1.915 0.001973 0.1182 
FHIT fragile histidine triad 1.17 2.25 0.001979 0.1182 
SNX22 sorting nexin 22 0.6791 1.601 0.001985 0.1182 
SFTA2 surfactant associated 2 1.297 2.457 0.002006 0.1182 
HIPK2 homeodomain interacting protein kinase 2 0.9156 1.886 0.002022 0.1182 
TYMP thymidine phosphorylase 1.097 2.139 0.00203 0.1182 
PLS1 plastin 1 0.8281 1.775 0.002034 0.1182 
NRTN neurturin 1.136 2.197 0.00205 0.1182 
PRKD2 protein kinase D2 1.038 2.053 0.002055 0.1182 
HAVCR2 hepatitis A virus cellular receptor 2 0.7539 1.686 0.002057 0.1182 
NUAK2 NUAK family kinase 2 1.21 2.313 0.002058 0.1182 
ANXA3 annexin A3 0.9444 1.924 0.002076 0.1182 
NA NA 0.6243 1.542 0.00208 0.1182 
PPP1R13B protein phosphatase 1 regulatory subunit 
13B 
0.584 1.499 0.002093 0.1182 
IGF2BP2 insulin like growth factor 2 mRNA binding 
protein 2 
0.7524 1.685 0.002095 0.1182 
ABCG1 ATP binding cassette subfamily G member 1 1.032 2.045 0.002099 0.1182 
CXCR3 chemokine (C-X-C motif) receptor 3 0.7691 1.704 0.002099 0.1182 
NA NA 1.013 2.018 0.00211 0.1185 
GPRC5C G protein-coupled receptor class C group 5 
member C 
1.102 2.147 0.002142 0.1189 
CD68 CD68 molecule 0.7095 1.635 0.002147 0.1189 
C1QC complement component 1, q 
subcomponent, C chain 
0.6496 1.569 0.002163 0.1189 
TLR10 toll like receptor 10 0.7984 1.739 0.002167 0.1189 
BEND5 BEN domain containing 5 0.8845 1.846 0.00217 0.1189 
NA NA 0.9816 1.975 0.002181 0.1189 
NA NA 0.6945 1.618 0.002191 0.1189 
RNF39 ring finger protein 39 1.553 2.934 0.0022 0.1189 
NA NA 0.774 1.71 0.002224 0.119 
C1orf162 chromosome 1 open reading frame 162 0.7064 1.632 0.002225 0.119 
KLRF1 killer cell lectin like receptor F1 0.8163 1.761 0.002229 0.119 
VASP vasodilator-stimulated phosphoprotein 0.6774 1.599 0.002267 0.1195 
KIT KIT proto-oncogene receptor tyrosine kinase 0.702 1.627 0.002285 0.1198 
RELN reelin 2.299 4.921 0.002289 0.1198 
MPPED2 metallophosphoesterase domain containing 
2 
1.129 2.186 0.002299 0.1198 
NA NA 0.9932 1.991 0.002302 0.1198 
SLC2A12 solute carrier family 2 member 12 1.592 3.015 0.002303 0.1198 
TRH thyrotropin releasing hormone 2.919 7.561 0.002327 0.1204 
CEBPD CCAAT/enhancer binding protein delta 0.7986 1.739 0.002336 0.1204 
CLUL1 clusterin like 1 1.348 2.545 0.002355 0.1205 
PPP3CA protein phosphatase 3 catalytic subunit 
alpha 
1.06 2.085 0.002377 0.1208 
ARG2 arginase 2 0.8437 1.795 0.002387 0.1208 
SETD3 SET domain containing 3 0.8872 1.85 0.002433 0.1227 
CCDC184 coiled-coil domain containing 184 1.131 2.19 0.00245 0.1232 
AIF1 allograft inflammatory factor 1 0.9197 1.892 0.002464 0.1237 
APOC1 apolipoprotein C-I 1.058 2.082 0.002482 0.1243 
GPC4 glypican 4 1.018 2.026 0.002492 0.1243 
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CD33 CD33 molecule 1.145 2.211 0.002539 0.1248 
FOS FBJ murine osteosarcoma viral oncogene 
homolog 
0.9808 1.974 0.002541 0.1248 
TMPRSS3 transmembrane protease, serine 3 1.415 2.666 0.002547 0.1248 
CD9 CD9 molecule 0.981 1.974 0.002561 0.1248 
NA NA 0.8763 1.836 0.002563 0.1248 
HOXB5 homeobox B5 0.7398 1.67 0.002588 0.125 
NA NA 0.7799 1.717 0.002589 0.125 
LAMP2 lysosomal associated membrane protein 2 1.096 2.138 0.002622 0.1254 
SCRN1 secernin 1 0.6246 1.542 0.002627 0.1254 
ROBO2 roundabout guidance receptor 2 2.014 4.038 0.002642 0.1254 
SLC1A3 solute carrier family 1 member 3 1.584 2.998 0.002644 0.1254 
FBLN1 fibulin 1 1.17 2.25 0.002713 0.1268 
ZNF543 zinc finger protein 543 0.6165 1.533 0.002721 0.1268 
PILRA paired immunoglobin-like type 2 receptor 
alpha 
1.685 3.215 0.002773 0.1277 
CD1C CD1c molecule 0.9087 1.877 0.002773 0.1277 
RNF10 ring finger protein 10 0.742 1.673 0.002792 0.1277 
ZNF540 zinc finger protein 540 1.511 2.851 0.002799 0.1277 
CELSR2 cadherin EGF LAG seven-pass G-type 
receptor 2 
0.9197 1.892 0.002801 0.1277 
APOC2 apolipoprotein C-II 1.387 2.616 0.002839 0.1277 
TTLL3 tubulin tyrosine ligase like 3 0.8753 1.834 0.002839 0.1277 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 4.07 16.8 0.00284 0.1277 
FAM109A family with sequence similarity 109 member 
A 
0.6014 1.517 0.002855 0.1277 
CD82 CD82 molecule 0.876 1.835 0.002859 0.1277 
RBM47 RNA binding motif protein 47 0.7843 1.722 0.002875 0.1277 
LAMTOR3 late endosomal/lysosomal adaptor, MAPK 
and MTOR activator 3 
0.8845 1.846 0.002879 0.1277 
MYCN v-myc avian myelocytomatosis viral 
oncogene neuroblastoma derived homolog 
2.178 4.525 0.002883 0.1277 
RNASE2 ribonuclease A family member 2 1.556 2.94 0.002883 0.1277 
OGDHL oxoglutarate dehydrogenase-like 1.498 2.824 0.002901 0.128 
NA NA 1.312 2.482 0.002927 0.1287 
FAM83F family with sequence similarity 83 member 
F 
0.7871 1.726 0.002928 0.1287 
NA NA 1.262 2.399 0.002966 0.1298 
NA NA 0.6561 1.576 0.002991 0.1298 
FAM21A family with sequence similarity 21 member 
A 
1.119 2.172 0.002996 0.1298 
GIMAP1 GTPase, IMAP family member 1 1.3 2.462 0.003012 0.1298 
CD74 CD74 molecule 1.403 2.644 0.003013 0.1298 
TMPRSS3 transmembrane protease, serine 3 1.22 2.33 0.00303 0.1298 
HLA-DRB6 major histocompatibility complex, class II, 
DR beta 6 (pseudogene) 
0.9642 1.951 0.003033 0.1298 
RNLS renalase, FAD-dependent amine oxidase 0.8675 1.824 0.003063 0.1298 
MTUS1 microtubule associated tumor suppressor 1 0.7746 1.711 0.003078 0.1298 
C1orf64 chromosome 1 open reading frame 64 2.447 5.453 0.003084 0.1298 
LAIR2 leukocyte associated immunoglobulin like 
receptor 2 
1.032 2.045 0.003088 0.1298 
COL9A1 collagen type IX alpha 1 3.023 8.131 0.003095 0.1298 
LY86 lymphocyte antigen 86 1.066 2.094 0.003103 0.1298 
RASSF5 Ras association domain family member 5 0.6709 1.592 0.003138 0.1298 
KRT7 keratin 7 1.607 3.047 0.003143 0.1298 
RELB v-rel avian reticuloendotheliosis viral 
oncogene homolog B 
1.077 2.11 0.003143 0.1298 
 292 
ACSF2 acyl-CoA synthetase family member 2 0.6423 1.561 0.003146 0.1298 
SPHK1 sphingosine kinase 1 1.408 2.654 0.003151 0.1298 
CDH3 cadherin 3 1.585 2.999 0.003175 0.1302 
NA NA 1.374 2.591 0.003182 0.1302 
COL9A1 collagen type IX alpha 1 2.031 4.087 0.003187 0.1302 
MMP9 matrix metallopeptidase 9 1.992 3.978 0.003188 0.1302 
DPP7 dipeptidyl peptidase 7 0.7785 1.715 0.003195 0.1303 
NA NA 0.9924 1.989 0.003262 0.1315 
SH3TC1 SH3 domain and tetratricopeptide repeats 1 0.956 1.94 0.00328 0.1315 
CD163 CD163 molecule 0.7405 1.671 0.003295 0.1315 
SUPT3H SPT3 homolog, SAGA and STAGA complex 
component 
0.7974 1.738 0.003309 0.1315 
FGFRL1 fibroblast growth factor receptor-like 1 0.9466 1.927 0.003315 0.1315 
SMPDL3A sphingomyelin phosphodiesterase acid like 
3A 
1.34 2.531 0.003316 0.1315 
LYZ lysozyme 1.246 2.372 0.003349 0.1316 
SP110 SP110 nuclear body protein 1.268 2.409 0.003368 0.1322 
NA NA 1.459 2.75 0.003384 0.1322 
PRKCB protein kinase C beta 1.32 2.497 0.003391 0.1322 
LGALS8 lectin, galactoside-binding, soluble, 8 0.7031 1.628 0.003411 0.1323 
FAM26F family with sequence similarity 26 member 
F 
1.136 2.197 0.003416 0.1323 
LAMA3 laminin subunit alpha 3 1.129 2.186 0.00342 0.1323 
WTIP Wilms tumor 1 interacting protein 0.7678 1.703 0.003442 0.1327 
NA NA 0.8859 1.848 0.003497 0.1343 
NA NA 0.7454 1.676 0.003509 0.1343 
NA NA 0.8637 1.82 0.003515 0.1343 
INPP5D inositol polyphosphate-5-phosphatase D 0.9707 1.96 0.003517 0.1343 
NA NA 1.265 2.404 0.003518 0.1343 
NOTCH2 notch 2 0.945 1.925 0.00357 0.1354 
SEMA3F semaphorin 3F 0.7713 1.707 0.003607 0.1354 
NA NA 1.013 2.018 0.003608 0.1354 
HLA-DPB1 major histocompatibility complex, class II, 
DP beta 1 
1.095 2.136 0.003609 0.1354 
NXNL2 nucleoredoxin-like 2 1.383 2.608 0.003613 0.1354 
NCF1C neutrophil cytosolic factor 1C pseudogene 1.358 2.564 0.003614 0.1354 
SLC28A2 solute carrier family 28 member 2 0.968 1.956 0.003616 0.1354 
SLC45A3 solute carrier family 45 member 3 1.343 2.537 0.003617 0.1354 
DHX8 DEAH-box helicase 8 0.555 1.469 0.003618 0.1354 
ERBB3 erb-b2 receptor tyrosine kinase 3 0.7574 1.69 0.003636 0.1355 
NA NA 1.175 2.258 0.00364 0.1355 
PLCG2 phospholipase C gamma 2 0.9817 1.975 0.003661 0.1359 
RASSF9 Ras association domain family member 9 1.276 2.422 0.003666 0.1359 
RCAN2 regulator of calcineurin 2 1.954 3.874 0.003694 0.1365 
NUAK2 NUAK family kinase 2 1.228 2.342 0.003712 0.1368 
TYMP thymidine phosphorylase 1.171 2.251 0.003728 0.1371 
SUSD6 sushi domain containing 6 0.663 1.583 0.003734 0.1372 
PKP4 plakophilin 4 0.6689 1.59 0.003788 0.1379 
PTP4A1 protein tyrosine phosphatase type IVA, 
member 1 
0.8728 1.831 0.003792 0.1379 
GBP1P1 guanylate binding protein 1 pseudogene 1 1.188 2.279 0.003814 0.1382 
TNFRSF10C tumor necrosis factor receptor superfamily 
member 10c 
0.9577 1.942 0.003829 0.1384 
CD14 CD14 molecule 1.048 2.068 0.0039 0.1399 
GIMAP8 GTPase, IMAP family member 8 0.9323 1.908 0.003901 0.1399 
TMEM176A transmembrane protein 176A 0.9104 1.88 0.003906 0.1399 
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CX3CL1 C-X3-C motif chemokine ligand 1 1.297 2.457 0.003936 0.1401 
DACH1 dachshund family transcription factor 1 0.8528 1.806 0.003936 0.1401 
LGMN legumain 0.6629 1.583 0.00396 0.1401 
SOX11 SRY-box 11 1.158 2.232 0.003992 0.1407 
FAM129B family with sequence similarity 129 member 
B 
0.8493 1.802 0.003996 0.1407 
PPL periplakin 1.498 2.825 0.004074 0.1425 
SCNN1A sodium channel epithelial 1 alpha subunit 0.7246 1.652 0.004096 0.1429 
CXCL10 C-X-C motif chemokine ligand 10 1.504 2.836 0.00411 0.1431 
ABLIM1 actin binding LIM protein 1 1.434 2.702 0.004122 0.1433 
HLA-DRB4 major histocompatibility complex, class II, 
DR beta 4 
1.303 2.468 0.004131 0.1433 
ANKRD40 ankyrin repeat domain 40 0.5403 1.454 0.004138 0.1433 
PLP1 proteolipid protein 1 0.9681 1.956 0.004153 0.1435 
SLC40A1 solute carrier family 40 member 1 0.8954 1.86 0.00418 0.1435 
PHC2 polyhomeotic homolog 2 0.6496 1.569 0.004192 0.1435 
PRR5-
ARHGAP8 
PRR5-ARHGAP8 readthrough 1.002 2.002 0.004204 0.1435 
CXCL9 C-X-C motif chemokine ligand 9 1.92 3.783 0.004249 0.1435 
SLC27A6 solute carrier family 27 member 6 1.177 2.261 0.004261 0.1435 
NA NA 1.184 2.272 0.004263 0.1435 
ARHGAP25 Rho GTPase activating protein 25 0.9182 1.89 0.004278 0.1435 
HIST2H2BE histone cluster 2, H2be 0.7469 1.678 0.004278 0.1435 
FRZB frizzled-related protein 1.164 2.24 0.004279 0.1435 
WWC3 WWC family member 3 0.6425 1.561 0.004282 0.1435 
KCTD6 potassium channel tetramerization domain 
containing 6 
0.5015 1.416 0.004318 0.1441 
BIK BCL2-interacting killer 1.999 3.997 0.00433 0.1443 
OPTN optineurin 0.7782 1.715 0.004335 0.1443 
MAPK8IP2 mitogen-activated protein kinase 8 
interacting protein 2 
0.8934 1.858 0.004361 0.1445 
PTP4A1 protein tyrosine phosphatase type IVA, 
member 1 
0.7483 1.68 0.004384 0.1446 
FBLN1 fibulin 1 1.667 3.176 0.004387 0.1446 
ADORA3 adenosine A3 receptor 1.412 2.662 0.004406 0.145 
SKAP1 src kinase associated phosphoprotein 1 0.9839 1.978 0.004417 0.1452 
NA NA 1.075 2.107 0.004441 0.1458 
B3GALT4 Beta-1,3-galactosyltransferase 4 0.9531 1.936 0.004457 0.1459 
NA NA 0.9771 1.968 0.00446 0.1459 
HCK HCK proto-oncogene, Src family tyrosine 
kinase 
1.128 2.185 0.004468 0.1459 
BAHD1 bromo adjacent homology domain 
containing 1 
1.504 2.836 0.004477 0.146 
P2RY8 purinergic receptor P2Y8 0.9666 1.954 0.004519 0.1465 
NA NA 1.364 2.574 0.004522 0.1465 
LPAR5 lysophosphatidic acid receptor 5 1.593 3.016 0.004537 0.1468 
TREM2 triggering receptor expressed on myeloid 
cells 2 
1.097 2.139 0.004563 0.147 
HERC5 HECT and RLD domain containing E3 
ubiquitin protein ligase 5 
0.8158 1.76 0.004589 0.1473 
AVPR2 arginine vasopressin receptor 2 0.5359 1.45 0.004663 0.1474 
NCKAP1L NCK associated protein 1 like 1.215 2.322 0.004665 0.1474 
SOD3 superoxide dismutase 3, extracellular 1.952 3.869 0.004668 0.1474 
NA NA 0.9588 1.944 0.004688 0.1477 
SASH3 SAM and SH3 domain containing 3 0.7889 1.728 0.004699 0.1478 
SLC40A1 solute carrier family 40 member 1 1.141 2.205 0.004713 0.1478 
TAPBP TAP binding protein (tapasin) 0.7925 1.732 0.004732 0.1478 
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BMP4 bone morphogenetic protein 4 0.64 1.558 0.004732 0.1478 
EPN3 epsin 3 1.403 2.644 0.004742 0.1478 
STK26 serine/threonine protein kinase 26 0.5967 1.512 0.004745 0.1478 
NA NA 0.6573 1.577 0.004765 0.1478 
KAZN kazrin, periplakin interacting protein 1.063 2.089 0.004789 0.1478 
NECTIN2 nectin cell adhesion molecule 2 0.5588 1.473 0.004813 0.1479 
MEGF8 multiple EGF like domains 8 0.7623 1.696 0.004828 0.1481 
OSGIN1 oxidative stress induced growth inhibitor 1 1.037 2.052 0.004859 0.1481 
TYROBP TYRO protein tyrosine kinase binding 
protein 
0.9236 1.897 0.004876 0.1481 
PPID peptidylprolyl isomerase D 1.258 2.392 0.004879 0.1481 
PTPRO protein tyrosine phosphatase, receptor type 
O 
0.9793 1.972 0.004934 0.1488 
GAPT GRB2-binding adaptor protein, 
transmembrane 
1.243 2.367 0.004941 0.1488 
FOSL2 FOS like antigen 2 0.7217 1.649 0.004972 0.1495 
NA NA 0.6325 1.55 0.004977 0.1495 
ABHD12 abhydrolase domain containing 12 0.6351 1.553 0.005028 0.1507 
NA NA 0.7831 1.721 0.005036 0.1507 
SERTM1 serine rich and transmembrane domain 
containing 1 
1.155 2.227 0.005074 0.1513 
MATN3 matrilin 3 1.025 2.035 0.005074 0.1513 
NA NA 0.669 1.59 0.005117 0.1518 
TPP1 tripeptidyl peptidase I 0.577 1.492 0.005125 0.1518 
EVA1A eva-1 homolog A, regulator of programmed 
cell death 
0.87 1.828 0.005129 0.1518 
NA NA 0.7428 1.673 0.005161 0.1521 
BEX2 brain expressed X-linked 2 0.7707 1.706 0.005176 0.1521 
NA NA 0.9313 1.907 0.005187 0.1521 
FCN1 ficolin 1 1.432 2.697 0.005188 0.1521 
IL25 interleukin 25 0.6597 1.58 0.005193 0.1521 
CX3CR1 chemokine (C-X3-C motif) receptor 1 1.254 2.386 0.00521 0.1522 
LEMD1 LEM domain containing 1 1.743 3.347 0.005224 0.1523 
PSTPIP2 proline-serine-threonine phosphatase 
interacting protein 2 
0.8123 1.756 0.005228 0.1523 
PLEK pleckstrin 0.9363 1.914 0.005237 0.1524 
CASP7 caspase 7 1.102 2.146 0.005253 0.1526 
LAPTM5 lysosomal protein transmembrane 5 0.9563 1.94 0.005303 0.1536 
CITED4 Cbp/p300 interacting transactivator with 
Glu/Asp rich carboxy-terminal domain 4 
0.9804 1.973 0.005345 0.1544 
ZSWIM3 zinc finger SWIM-type containing 3 0.6035 1.519 0.005388 0.1555 
NA NA 1.079 2.113 0.005396 0.1555 
CD37 CD37 molecule 1.682 3.209 0.005438 0.1561 
PURA purine-rich element binding protein A 0.6099 1.526 0.005442 0.1561 
NINJ2 ninjurin 2 0.8424 1.793 0.005462 0.1565 
SNTB1 syntrophin beta 1 0.7259 1.654 0.005472 0.1566 
Sep-01 septin 1 0.6558 1.576 0.005497 0.1571 
FCHO2 FCH domain only 2 0.7156 1.642 0.005523 0.1574 
SYNGR1 synaptogyrin 1 1 2 0.005549 0.1577 
NA NA 0.7158 1.642 0.00556 0.1578 
RTP4 receptor (chemosensory) transporter 
protein 4 
0.6798 1.602 0.005573 0.1579 
FCGR2B Fc fragment of IgG receptor IIb 0.8681 1.825 0.0056 0.158 
CD1E CD1e molecule 0.9902 1.986 0.00561 0.158 
TPBG trophoblast glycoprotein 0.7555 1.688 0.005615 0.158 
CALY calcyon neuron specific vesicular protein 1.067 2.096 0.005623 0.158 
INSIG1 insulin induced gene 1 0.6844 1.607 0.005626 0.158 
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ARHGAP30 Rho GTPase activating protein 30 0.6094 1.526 0.005632 0.158 
TESC tescalcin 1.046 2.065 0.005646 0.1581 
BBC3 BCL2 binding component 3 0.6759 1.598 0.005649 0.1581 
CD86 CD86 molecule 0.6192 1.536 0.005659 0.1582 
KIAA0922 KIAA0922 0.525 1.439 0.005666 0.1582 
MS4A6A membrane spanning 4-domains A6A 0.638 1.556 0.005671 0.1582 
HLA-DPA1 major histocompatibility complex, class II, 
DP alpha 1 
1.057 2.081 0.005682 0.1583 
NLRC3 NLR family, CARD domain containing 3 0.6622 1.582 0.005691 0.1583 
DHCR7 7-dehydrocholesterol reductase 0.6111 1.527 0.005701 0.1583 
ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 0.9113 1.881 0.00571 0.1583 
GNAI1 G protein subunit alpha i1 1.076 2.108 0.005715 0.1583 
NA NA 0.8065 1.749 0.005725 0.1584 
RPS6KA3 ribosomal protein S6 kinase A3 0.7042 1.629 0.005744 0.1586 
IL32 interleukin 32 0.9596 1.945 0.005747 0.1586 
Mar-02 membrane associated ring-CH-type finger 2 0.5516 1.466 0.005757 0.1586 
DUSP16 dual specificity phosphatase 16 0.5973 1.513 0.005783 0.1589 
FOLR1 folate receptor 1 (adult) 2.066 4.188 0.00579 0.1589 
PRR5 proline rich 5 0.6321 1.55 0.005791 0.1589 
RAMP3 receptor (G protein-coupled) activity 
modifying protein 3 
1.429 2.693 0.005836 0.1598 
NA NA 0.6705 1.592 0.005846 0.1598 
ETNK2 ethanolamine kinase 2 0.8736 1.832 0.005853 0.1598 
CYP51A1 cytochrome P450 family 51 subfamily A 
member 1 
0.8016 1.743 0.005862 0.1598 
OSBPL3 oxysterol binding protein like 3 0.7595 1.693 0.005883 0.16 
NA NA 0.6282 1.546 0.005899 0.1601 
CRCP CGRP receptor component 0.7279 1.656 0.005919 0.1603 
GPR183 G protein-coupled receptor 183 1.259 2.394 0.005951 0.1603 
TNF tumor necrosis factor 1.094 2.135 0.005952 0.1603 
NR3C2 nuclear receptor subfamily 3 group C 
member 2 
1.103 2.149 0.005963 0.1603 
RNF19B ring finger protein 19B 0.8014 1.743 0.005992 0.1603 
NA NA 1.002 2.002 0.006 0.1603 
NA NA 2.184 4.546 0.006001 0.1603 
RYR1 ryanodine receptor 1 0.8836 1.845 0.006015 0.1603 
NA NA 0.8506 1.803 0.006056 0.1607 
NA NA 1.002 2.003 0.006072 0.1607 
SMOX spermine oxidase 0.5011 1.415 0.006072 0.1607 
TACSTD2 tumor-associated calcium signal transducer 
2 
0.8627 1.818 0.00613 0.1615 
GPRC5C G protein-coupled receptor class C group 5 
member C 
1.136 2.197 0.006145 0.1615 
ERLIN2 ER lipid raft associated 2 0.6246 1.542 0.006174 0.1619 
CD276 CD276 molecule 0.963 1.949 0.006194 0.162 
TOP1P1 topoisomerase (DNA) I pseudogene 1 1.043 2.061 0.006198 0.162 
PANX2 pannexin 2 0.8306 1.778 0.006244 0.1627 
NELL1 neural EGFL like 1 4.057 16.65 0.0063 0.1638 
ANXA11 annexin A11 0.7059 1.631 0.006326 0.1643 
NA NA 0.7838 1.722 0.006373 0.1651 
EVI2A ecotropic viral integration site 2A 0.9154 1.886 0.006378 0.1651 
NA NA 0.6043 1.52 0.006393 0.1651 
ST8SIA4 ST8 alpha-N-acetylneuraminate alpha-2,8-
sialyltransferase 4 
1.367 2.579 0.006394 0.1651 
KCTD1 potassium channel tetramerization domain 
containing 1 
1.109 2.157 0.006437 0.1654 
ARFGEF3 ARFGEF family member 3 1.323 2.501 0.006469 0.1654 
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RHPN2 rhophilin, Rho GTPase binding protein 2 0.719 1.646 0.006474 0.1654 
NA NA 1.287 2.44 0.006509 0.1655 
ITGAM integrin subunit alpha M 1.437 2.707 0.006536 0.1655 
NA NA 1.132 2.192 0.006536 0.1655 
ELOVL7 ELOVL fatty acid elongase 7 0.8629 1.819 0.00657 0.1657 
GAPT GRB2-binding adaptor protein, 
transmembrane 
0.8588 1.814 0.006581 0.1657 
STK38L serine/threonine kinase 38 like 0.6749 1.596 0.006604 0.1657 
OR9A4 olfactory receptor family 9 subfamily A 
member 4 
0.6581 1.578 0.006615 0.1657 
EGR1 early growth response 1 0.8533 1.807 0.006616 0.1657 
GADD45A growth arrest and DNA damage inducible 
alpha 
0.7826 1.72 0.006624 0.1657 
GIMAP6 GTPase, IMAP family member 6 0.6881 1.611 0.006643 0.1657 
KDM7A lysine demethylase 7A 0.8711 1.829 0.006653 0.1657 
NA NA 0.8383 1.788 0.00667 0.1657 
RBM47 RNA binding motif protein 47 0.8003 1.741 0.006678 0.1657 
NA NA 0.8947 1.859 0.006687 0.1657 
NA NA 0.7084 1.634 0.00669 0.1657 
TMPRSS4 transmembrane protease, serine 4 0.8114 1.755 0.006707 0.1658 
GABARAPL2 GABA(A) receptor-associated protein like 2 0.6088 1.525 0.006718 0.1659 
SLC3A2 solute carrier family 3 member 2 0.5659 1.48 0.006731 0.1659 
NA NA 1.93 3.811 0.006732 0.1659 
HYDIN HYDIN, axonemal central pair apparatus 
protein 
0.7732 1.709 0.006841 0.1675 
BAIAP2 BAI1 associated protein 2 0.7542 1.687 0.006854 0.1675 
PXN paxillin 0.61 1.526 0.006861 0.1675 
ADGRL2 adhesion G protein-coupled receptor L2 0.6675 1.588 0.006895 0.1676 
LRP5 LDL receptor related protein 5 1.094 2.134 0.006908 0.1676 
KIAA1522 KIAA1522 0.6426 1.561 0.00696 0.1683 
CCL14 C-C motif chemokine ligand 14 1.523 2.873 0.006987 0.1683 
LST1 leukocyte specific transcript 1 1.29 2.446 0.006994 0.1683 
NA NA 0.8064 1.749 0.007006 0.1683 
ZBTB7A zinc finger and BTB domain containing 7A 0.7212 1.649 0.007021 0.1685 
SLCO2B1 solute carrier organic anion transporter 
family member 2B1 
0.8762 1.836 0.007038 0.1686 
B4GALT4 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 4 
0.6306 1.548 0.007073 0.1688 
NA NA 1.267 2.407 0.007076 0.1688 
FAXDC2 fatty acid hydroxylase domain containing 2 0.9597 1.945 0.007108 0.1688 
RAI2 retinoic acid induced 2 0.987 1.982 0.007143 0.1688 
CCL2 C-C motif chemokine ligand 2 1.2 2.298 0.007154 0.1688 
RARB retinoic acid receptor beta 1.242 2.365 0.00718 0.1688 
FAM134A family with sequence similarity 134 member 
A 
0.6986 1.623 0.007187 0.1688 
MAN2B1 mannosidase alpha class 2B member 1 0.6676 1.588 0.007191 0.1688 
CD3D CD3d molecule 1.121 2.175 0.007208 0.1688 
NA NA 0.9685 1.957 0.007208 0.1688 
PCIF1 PDX1 C-terminal inhibiting factor 1 0.6655 1.586 0.007227 0.1688 
RPL23AP32 ribosomal protein L23a pseudogene 32 0.5495 1.464 0.007242 0.1688 
TSC22D4 TSC22 domain family member 4 1.138 2.201 0.007275 0.1688 
FPR3 formyl peptide receptor 3 0.9664 1.954 0.007279 0.1688 
NA NA 0.557 1.471 0.007285 0.1688 
DMRTA1 DMRT like family A1 0.5433 1.457 0.007294 0.1688 
BCAM basal cell adhesion molecule (Lutheran 
blood group) 
1.039 2.055 0.007296 0.1688 
TBC1D17 TBC1 domain family member 17 0.9786 1.971 0.007309 0.1688 
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NA NA 0.8761 1.835 0.007329 0.1688 
NA NA 0.8082 1.751 0.007345 0.1688 
KLRB1 killer cell lectin like receptor B1 0.7827 1.72 0.007346 0.1688 
PATZ1 POZ/BTB and AT hook containing zinc finger 
1 
1.129 2.188 0.007347 0.1688 
NA NA 1.045 2.064 0.007351 0.1688 
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 
1.151 2.22 0.007353 0.1688 
NA NA 0.679 1.601 0.007358 0.1688 
KLK10 kallikrein related peptidase 10 1.434 2.702 0.007388 0.1691 
TNFSF13B tumor necrosis factor superfamily member 
13b 
1.3 2.462 0.007394 0.1691 
NA NA 0.8583 1.813 0.007421 0.1692 
CPAMD8 C3 and PZP like, alpha-2-macroglobulin 
domain containing 8 
1.304 2.468 0.007422 0.1692 
FUOM fucose mutarotase 0.7906 1.73 0.007438 0.1692 
LRBA LPS responsive beige-like anchor protein 0.5477 1.462 0.007465 0.1694 
NA NA 0.9464 1.927 0.007492 0.1696 
DPP10 dipeptidyl peptidase like 10 0.9001 1.866 0.007507 0.1696 
CLIC6 chloride intracellular channel 6 1.885 3.693 0.007509 0.1696 
NA NA 1.144 2.21 0.007611 0.1707 
LOC401052 uncharacterized LOC401052 0.6352 1.553 0.007614 0.1707 
IGSF11 immunoglobulin superfamily member 11 0.9277 1.902 0.007618 0.1707 
H1F0 H1 histone family member 0 0.5188 1.433 0.00767 0.1713 
CCL3L3 C-C motif chemokine ligand 3 like 3 1.179 2.265 0.007695 0.1714 
MICALL1 MICAL like 1 0.6245 1.542 0.007703 0.1714 
ZNF33B zinc finger protein 33B 1.061 2.086 0.007706 0.1714 
LAMC2 laminin subunit gamma 2 1.233 2.351 0.007733 0.1717 
SEMA3B semaphorin 3B 0.6669 1.588 0.007745 0.1717 
NA NA 2.983 7.905 0.007754 0.1717 
MIR657 microRNA 657 0.8715 1.83 0.007786 0.1718 
CPTP ceramide-1-phosphate transfer protein 0.6274 1.545 0.007838 0.1725 
STAT3 signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
0.5022 1.416 0.007839 0.1725 
L3MBTL4 l(3)mbt-like 4 (Drosophila) 0.4496 1.366 0.007845 0.1725 
BCAR3 breast cancer anti-estrogen resistance 3 0.8226 1.769 0.007862 0.1727 
FAM46A family with sequence similarity 46 member 
A 
1.097 2.14 0.007878 0.1727 
GAB2 GRB2 associated binding protein 2 0.5015 1.416 0.007882 0.1727 
SHB Src homology 2 domain containing adaptor 
protein B 
0.6111 1.527 0.007939 0.1727 
CCL15 C-C motif chemokine ligand 15 1.219 2.328 0.00795 0.1727 
FCGR2A Fc fragment of IgG receptor IIa 1.061 2.087 0.007951 0.1727 
CPEB3 cytoplasmic polyadenylation element 
binding protein 3 
0.8233 1.769 0.007953 0.1727 
DIS3L2 DIS3 like 3'-5' exoribonuclease 2 1.122 2.177 0.008008 0.1731 
SEMA3E semaphorin 3E 1.57 2.969 0.008033 0.1731 
NA NA 0.8587 1.813 0.008033 0.1731 
NA NA 1.823 3.537 0.008034 0.1731 
S1PR4 sphingosine-1-phosphate receptor 4 0.9547 1.938 0.008067 0.1731 
MAFF v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog F 
1.131 2.191 0.008087 0.1732 
CD53 CD53 molecule 0.9508 1.933 0.008097 0.1732 
MBNL3 muscleblind like splicing regulator 3 0.7191 1.646 0.008125 0.1732 
RCAN1 regulator of calcineurin 1 0.6945 1.618 0.008128 0.1732 
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CMTM7 CKLF like MARVEL transmembrane domain 
containing 7 
0.8919 1.856 0.008175 0.1737 
COL26A1 collagen type XXVI alpha 1 1.08 2.114 0.008198 0.1737 
GPR65 G protein-coupled receptor 65 0.9245 1.898 0.008214 0.1737 
NA NA 0.746 1.677 0.008233 0.1737 
ARAP1 ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 1 
1.054 2.076 0.00824 0.1737 
GBE1 glucan (1,4-alpha-), branching enzyme 1 1.053 2.075 0.008241 0.1737 
NA NA 0.658 1.578 0.008256 0.1738 
CDKN2B cyclin-dependent kinase inhibitor 2B 0.99 1.986 0.008263 0.1738 
DUSP5 dual specificity phosphatase 5 0.6656 1.586 0.008264 0.1738 
NA NA 0.7359 1.665 0.008325 0.1744 
CTF1 cardiotrophin 1 1.204 2.304 0.008329 0.1744 
PLAUR plasminogen activator, urokinase receptor 0.9034 1.87 0.008435 0.175 
FURIN furin, paired basic amino acid cleaving 
enzyme 
0.9635 1.95 0.008444 0.175 
CPVL carboxypeptidase, vitellogenic like 0.8386 1.788 0.008454 0.175 
ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 0.6887 1.612 0.008511 0.1759 
MAP2K3 mitogen-activated protein kinase kinase 3 0.8401 1.79 0.008549 0.1759 
CALN1 calneuron 1 0.5786 1.493 0.008583 0.1759 
LRP10 LDL receptor related protein 10 0.5315 1.445 0.00859 0.1759 
MAGED4B melanoma antigen family D4B 0.4584 1.374 0.00865 0.1764 
CKMT1A creatine kinase, mitochondrial 1A 0.8286 1.776 0.008667 0.1765 
FCGR2A Fc fragment of IgG receptor IIa 1.211 2.316 0.008702 0.1765 
CORO1B coronin 1B 0.7197 1.647 0.008704 0.1765 
NA NA 0.6231 1.54 0.008708 0.1765 
NA NA 0.4917 1.406 0.008716 0.1765 
DOCK2 dedicator of cytokinesis 2 0.7797 1.717 0.008729 0.1766 
NA NA 0.5671 1.482 0.008742 0.1766 
BST2 bone marrow stromal cell antigen 2 0.5737 1.488 0.008764 0.1766 
P2RY6 pyrimidinergic receptor P2Y6 0.9395 1.918 0.008778 0.1766 
ACSF2 acyl-CoA synthetase family member 2 0.9026 1.869 0.008779 0.1766 
NA NA 0.8846 1.846 0.008781 0.1766 
SLC1A5 solute carrier family 1 member 5 1.024 2.034 0.00879 0.1766 
MGLL monoglyceride lipase 0.8846 1.846 0.00879 0.1766 
ATG3 autophagy related 3 0.6636 1.584 0.008819 0.1766 
DOCK8 dedicator of cytokinesis 8 1.053 2.075 0.008835 0.1767 
NA NA 1.219 2.327 0.008838 0.1767 
CMKLR1 chemerin chemokine-like receptor 1 0.4598 1.375 0.008858 0.177 
WWC1 WW and C2 domain containing 1 0.5631 1.477 0.0089 0.1774 
Mar-01 membrane associated ring-CH-type finger 1 1.142 2.207 0.008908 0.1774 
GBP2 guanylate binding protein 2 0.8141 1.758 0.008984 0.1782 
MAX MYC associated factor X 0.9206 1.893 0.009002 0.1782 
NA NA 1.348 2.546 0.00904 0.1782 
RTF1 RTF1 homolog, Paf1/RNA polymerase II 
complex component 
0.7127 1.639 0.009043 0.1782 
DOCK3 dedicator of cytokinesis 3 0.9776 1.969 0.009064 0.1782 
TNFSF13B tumor necrosis factor superfamily member 
13b 
0.9206 1.893 0.009083 0.1782 
METTL9 methyltransferase like 9 1.139 2.203 0.009096 0.1782 
SEMA4A semaphorin 4A 0.7294 1.658 0.009124 0.1782 
NA NA 0.5809 1.496 0.009129 0.1782 
TSPAN7 tetraspanin 7 0.585 1.5 0.009146 0.1782 
KRT23 keratin 23 0.821 1.767 0.009161 0.1782 
MS4A6A membrane spanning 4-domains A6A 0.6117 1.528 0.009205 0.1782 
TRIB1 tribbles pseudokinase 1 0.7748 1.711 0.009208 0.1782 
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ITGB2 integrin subunit beta 2 0.8281 1.775 0.009219 0.1782 
SPRY1 sprouty RTK signaling antagonist 1 0.5412 1.455 0.009251 0.1782 
PRR5 proline rich 5 0.5066 1.421 0.00926 0.1782 
NA NA 0.8035 1.745 0.009263 0.1782 
FAM49B family with sequence similarity 49 member 
B 
0.4379 1.355 0.009265 0.1782 
LOC100288208 uncharacterized LOC100288208 1.028 2.04 0.009298 0.1782 
ZNF764 zinc finger protein 764 0.768 1.703 0.009311 0.1782 
FAM189B family with sequence similarity 189 member 
B 
1.448 2.729 0.009312 0.1782 
RNLS renalase, FAD-dependent amine oxidase 0.5861 1.501 0.009319 0.1782 
PLA2G4C phospholipase A2 group IVC 0.5534 1.468 0.009348 0.1783 
NTNG1 netrin G1 1.433 2.699 0.009381 0.1784 
PACS1 phosphofurin acidic cluster sorting protein 1 1.204 2.304 0.009416 0.1784 
MMEL1 membrane metallo-endopeptidase-like 1 1.333 2.519 0.009419 0.1784 
PBXIP1 pre-B-cell leukemia homeobox interacting 
protein 1 
0.7975 1.738 0.009457 0.1784 
GPX3 glutathione peroxidase 3 1.655 3.15 0.009486 0.1787 
FKBP8 FK506 binding protein 8 1.066 2.093 0.009505 0.1787 
NCF2 neutrophil cytosolic factor 2 1.107 2.153 0.009509 0.1787 
CDK18 cyclin-dependent kinase 18 1.493 2.815 0.009524 0.1787 
H2AFJ H2A histone family member J 0.7098 1.636 0.009547 0.1788 
SLC23A2 solute carrier family 23 member 2 0.6255 1.543 0.009568 0.179 
GIMAP4 GTPase, IMAP family member 4 0.7587 1.692 0.009595 0.179 
HDAC7 histone deacetylase 7 0.6505 1.57 0.009608 0.179 
LDLR low density lipoprotein receptor 0.8021 1.744 0.00967 0.1795 
CTSD cathepsin D 0.5263 1.44 0.009724 0.1801 
CORO1A coronin 1A 1.092 2.132 0.00976 0.1803 
DIRAS2 DIRAS family GTP binding RAS like 2 0.8663 1.823 0.009787 0.1803 
JDP2 Jun dimerization protein 2 0.8329 1.781 0.009812 0.1803 
ERO1A endoplasmic reticulum oxidoreductase 
alpha 
0.6607 1.581 0.009881 0.1807 
SC5D sterol-C5-desaturase 0.6223 1.539 0.00989 0.1807 
CD4 CD4 molecule 1.167 2.245 0.009891 0.1807 
QSOX1 quiescin sulfhydryl oxidase 1 1.109 2.157 0.009901 0.1807 
HCLS1 hematopoietic cell-specific Lyn substrate 1 0.8 1.741 0.009939 0.1807 
NA NA 0.9288 1.904 0.00994 0.1807 
TRIM47 tripartite motif containing 47 0.748 1.679 0.00994 0.1807 
CA12 carbonic anhydrase XII 1.107 2.154 0.00995 0.1807 
IRX3 iroquois homeobox 3 0.893 1.857 0.009971 0.1807 
EZR-AS1 EZR antisense RNA 1 0.8426 1.793 0.009978 0.1807 
CMTM7 CKLF like MARVEL transmembrane domain 
containing 7 




Supplementary Table 2. Down-regulated transcripts following UPA Administration (FC 
>1.3, p <0.01) 
GREM2 gremlin 2, DAN family BMP antagonist -4.468 -22.13 8.51E-08 0.00205 
GJB2 gap junction protein beta 2 -3.246 -9.485 1.65E-06 0.01225 
GJA4 gap junction protein alpha 4 -2.178 -4.524 2.68E-06 0.01225 
NA NA -3.077 -8.44 2.98E-06 0.01225 
GPER1 G protein-coupled estrogen receptor 1 -2.787 -6.903 3.05E-06 0.01225 
NA NA -2.178 -4.525 7.32E-06 0.01759 
OPN3 opsin 3 -1.976 -3.934 1.13E-05 0.01992 
LINC00461 long intergenic non-protein coding RNA 461 -1.762 -3.392 1.20E-05 0.01992 
NA NA -2.195 -4.58 1.24E-05 0.01992 
DIO3OS DIO3 opposite strand/antisense RNA (head to 
head) 
-2.126 -4.366 1.32E-05 0.01992 
GLA galactosidase alpha -2.243 -4.732 2.23E-05 0.02982 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 
-1.517 -2.862 2.46E-05 0.03118 
SGCD sarcoglycan delta -2.697 -6.484 2.70E-05 0.03252 
FXYD4 FXYD domain containing ion transport 
regulator 4 
-2.515 -5.716 3.54E-05 0.03879 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 
-1.329 -2.512 4.12E-05 0.04313 
PAGE4 PAGE family member 4 -5.544 -46.65 4.33E-05 0.04352 
ZCCHC12 zinc finger CCHC-type containing 12 -1.888 -3.702 4.63E-05 0.04462 
KAZALD1 Kazal type serine peptidase inhibitor domain 1 -1.584 -2.998 5.02E-05 0.04563 
GPER1 G protein-coupled estrogen receptor 1 -2.713 -6.555 5.11E-05 0.04563 
TCF19 transcription factor 19 -1.488 -2.805 5.50E-05 0.04632 
CEACAM21 carcinoembryonic antigen related cell 
adhesion molecule 21 
-1.892 -3.711 6.16E-05 0.04632 
SGK1 serum/glucocorticoid regulated kinase 1 -2.552 -5.866 6.55E-05 0.04632 
HES6 hes family bHLH transcription factor 6 -0.9837 -1.977 7.03E-05 0.04632 
RAB15 RAB15, member RAS oncogene family -1.565 -2.959 7.29E-05 0.04632 
TUBA3D tubulin alpha 3d -3.617 -12.27 7.89E-05 0.04632 
FAM13C family with sequence similarity 13 member C -1.735 -3.329 7.93E-05 0.04632 
NA NA -2.473 -5.552 8.01E-05 0.04632 
HIST1H2BH histone cluster 1, H2bh -1.956 -3.879 8.19E-05 0.04632 
SGK1 serum/glucocorticoid regulated kinase 1 -2.638 -6.226 8.25E-05 0.04632 
ARSG arylsulfatase G -1.193 -2.286 8.46E-05 0.04632 
COL17A1 collagen type XVII alpha 1 -1.421 -2.678 8.76E-05 0.04632 
LRRC26 leucine rich repeat containing 26 -3.318 -9.976 9.60E-05 0.04902 
EDN3 endothelin 3 -1.371 -2.586 1.00E-04 0.04918 
SCGB1D4 secretoglobin family 1D member 4 -7.571 -190.1 0.000107 0.05014 
EDN3 endothelin 3 -1.446 -2.725 0.000107 0.05014 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 5 
-3.223 -9.336 0.000116 0.05167 
SLC39A14 solute carrier family 39 member 14 -0.9807 -1.973 0.00013 0.05432 
NA NA -1.392 -2.624 0.000137 0.05432 
SGOL2 shugoshin-like 2 (S. pombe) -1.733 -3.324 0.000137 0.05432 
MSX2 msh homeobox 2 -3.03 -8.168 0.000149 0.05697 
CDC25A cell division cycle 25A -1.569 -2.967 0.000158 0.05897 
NA NA -2.069 -4.197 0.000159 0.05897 
TUBGCP6 tubulin gamma complex associated protein 6 -1.377 -2.597 0.000173 0.06081 
LRRC26 leucine rich repeat containing 26 -3.51 -11.39 0.00018 0.06081 
SGK1 serum/glucocorticoid regulated kinase 1 -2.647 -6.262 0.000186 0.06081 
FAM122B family with sequence similarity 122B -0.9426 -1.922 0.000187 0.06081 
SPC25 SPC25, NDC80 kinetochore complex 
component 
-1.305 -2.471 0.000195 0.06195 
MKI67 marker of proliferation Ki-67 -1.231 -2.347 0.000198 0.06195 
CST1 cystatin SN -3.441 -10.86 0.000209 0.06224 
AMD1 adenosylmethionine decarboxylase 1 -1.095 -2.136 0.000217 0.06224 
GGT1 gamma-glutamyltransferase 1 -1.562 -2.954 0.000222 0.06224 
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SLC39A6 solute carrier family 39 member 6 -1.192 -2.284 0.000228 0.06224 
PENK proenkephalin -3.4 -10.56 0.000232 0.06224 
SGOL1 shugoshin-like 1 (S. pombe) -1.638 -3.112 0.00024 0.06224 
SOX7 SRY-box 7 -1.472 -2.774 0.000248 0.06224 
SCGB1D2 secretoglobin, family 1D member 2 -4.226 -18.71 0.000253 0.06224 
NA NA -1.065 -2.092 0.000256 0.06224 
ATP8B3 ATPase phospholipid transporting 8B3 -1.819 -3.527 0.000259 0.06231 
MOGAT1 monoacylglycerol O-acyltransferase 1 -2.365 -5.152 0.000272 0.06307 
ERRFI1 ERBB receptor feedback inhibitor 1 -1.073 -2.103 0.000278 0.06307 
GJB6 gap junction protein beta 6 -3.291 -9.789 0.000279 0.06307 
EDNRA endothelin receptor type A -1.115 -2.165 0.00028 0.06307 
ANXA9 annexin A9 -1.881 -3.682 0.000283 0.06309 
GJB6 gap junction protein beta 6 -3.939 -15.33 0.000286 0.06309 
NA NA -3.612 -12.23 0.000297 0.06309 
SNORD14C small nucleolar RNA, C/D box 14C -1.445 -2.722 0.000298 0.06309 
MT3 metallothionein 3 -2.846 -7.189 0.000299 0.06309 
PCDH10 protocadherin 10 -2.086 -4.244 0.000302 0.06317 
ACSL5 acyl-CoA synthetase long-chain family member 
5 
-1.39 -2.621 0.000357 0.07221 
SRRM4 serine/arginine repetitive matrix 4 -2.37 -5.171 0.00036 0.07221 
NA NA -1.443 -2.72 0.000364 0.07254 
SGCD sarcoglycan delta -1.138 -2.2 0.000384 0.07394 
E2F7 E2F transcription factor 7 -1.653 -3.145 0.000386 0.07394 
ALDH1A2 aldehyde dehydrogenase 1 family member A2 -1.224 -2.336 0.00039 0.07394 
ST3GAL5 ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 
-1.197 -2.292 0.000394 0.07394 
NA NA -1.404 -2.647 0.000402 0.07394 
SYNDIG1 synapse differentiation inducing 1 -1.335 -2.523 0.000417 0.07394 
ANGPTL2 angiopoietin like 2 -1.308 -2.476 0.000419 0.07394 
TMEM132D transmembrane protein 132D -1.118 -2.17 0.000423 0.07394 
NA NA -1.119 -2.172 0.000426 0.07394 
NA NA -1.604 -3.04 0.000442 0.07525 
UCHL1 ubiquitin C-terminal hydrolase L1 -2.212 -4.633 0.000446 0.07525 
RNU11 RNA, U11 small nuclear -1.755 -3.376 0.00047 0.07575 
FAM124B family with sequence similarity 124 member B -2.48 -5.579 0.000474 0.07575 
IGSF10 immunoglobulin superfamily member 10 -1.381 -2.604 0.00048 0.07604 
ANAPC4 anaphase promoting complex subunit 4 -1.603 -3.037 0.000494 0.07621 
DUSP2 dual specificity phosphatase 2 -1.321 -2.499 0.000495 0.07621 
CCDC74A coiled-coil domain containing 74A -1.262 -2.399 0.000509 0.07621 
SPINK8 serine peptidase inhibitor, Kazal type 8 
(putative) 
-2.406 -5.3 0.00051 0.07621 
POU5F1B POU class 5 homeobox 1B -2.63 -6.189 0.000513 0.07621 
PLCXD3 phosphatidylinositol specific phospholipase C 
X domain containing 3 
-2.458 -5.493 0.000518 0.07621 
MCOLN2 mucolipin 2 -0.7876 -1.726 0.000537 0.07766 
ANKRD23 ankyrin repeat domain 23 -0.9233 -1.896 0.000541 0.07766 
NA NA -1.295 -2.453 0.000545 0.07775 
CCNA1 cyclin A1 -2.423 -5.364 0.000553 0.07834 
POLQ polymerase (DNA) theta -1.252 -2.382 0.000581 0.07961 
SYTL4 synaptotagmin like 4 -1.028 -2.039 0.000582 0.07961 
GGA1 golgi-associated, gamma adaptin ear 
containing, ARF binding protein 1 
-1.348 -2.545 0.000586 0.07961 
SAPCD2 suppressor APC domain containing 2 -1.611 -3.056 0.000589 0.07961 
LIMS1 LIM zinc finger domain containing 1 -1.16 -2.234 0.00059 0.07961 
SERHL serine hydrolase-like (pseudogene) -1.387 -2.615 0.000608 0.07961 
AMFR autocrine motility factor receptor, E3 ubiquitin 
protein ligase 
-1.282 -2.431 0.000622 0.07961 
NAPSA napsin A aspartic peptidase -2.175 -4.517 0.000629 0.07961 
OPN3 opsin 3 -0.9263 -1.9 0.000629 0.07961 
C1orf186 chromosome 1 open reading frame 186 -2.244 -4.738 0.00064 0.07961 
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KMO kynurenine 3-monooxygenase (kynurenine 3-
hydroxylase) 
-3.273 -9.668 0.000647 0.07961 
MOGAT2 monoacylglycerol O-acyltransferase 2 -0.9805 -1.973 0.00065 0.07961 
KIAA1210 KIAA1210 -0.9168 -1.888 0.000658 0.07961 
SNORD14A small nucleolar RNA, C/D box 14A -1.903 -3.74 0.000669 0.08062 
MCC mutated in colorectal cancers -1.2 -2.298 0.000675 0.08087 
ALDH3B2 aldehyde dehydrogenase 3 family member B2 -2.312 -4.964 0.000678 0.08087 
NDP Norrie disease (pseudoglioma) -2.235 -4.707 0.000697 0.08273 
MYL10 myosin light chain 10 -1.41 -2.657 0.000722 0.08407 
PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 -2.028 -4.078 0.000731 0.08472 
NA NA -0.7654 -1.7 0.000738 0.08511 
PRKAR2A protein kinase cAMP-dependent type II 
regulatory subunit alpha 
-0.8314 -1.779 0.000747 0.08572 
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 -1.637 -3.109 0.000764 0.08694 
MMP26 matrix metallopeptidase 26 -3.157 -8.92 0.000765 0.08694 
ABCC5 ATP binding cassette subfamily C member 5 -1.504 -2.836 0.000783 0.08773 
AMFR autocrine motility factor receptor, E3 ubiquitin 
protein ligase 
-0.7788 -1.716 0.00082 0.09021 
CRYGS crystallin gamma S -1.831 -3.558 0.000841 0.09091 
IGDCC3 immunoglobulin superfamily, DCC subclass, 
member 3 
-1.535 -2.898 0.000855 0.09192 
SCGB2A2 secretoglobin family 2A member 2 -2.737 -6.666 0.000869 0.09263 
NA NA -1.258 -2.392 0.000894 0.0933 
ZMIZ2 zinc finger MIZ-type containing 2 -0.9524 -1.935 0.000899 0.09335 
CERKL ceramide kinase like -1.344 -2.538 0.000914 0.09379 
DAPL1 death associated protein like 1 -1.651 -3.14 0.000945 0.09511 
NA NA -1.264 -2.402 0.000946 0.09511 
ORM2 orosomucoid 2 -2.506 -5.682 0.000951 0.09511 
TMEM101 transmembrane protein 101 -1.4 -2.638 0.000955 0.09511 
EFEMP1 EGF containing fibulin-like extracellular matrix 
protein 1 
-0.8847 -1.846 0.000991 0.09788 
NAPSB napsin B aspartic peptidase, pseudogene -1.429 -2.692 0.00101 0.09935 
NA NA -0.7386 -1.669 0.001026 0.1001 
BASP1 brain abundant membrane attached signal 
protein 1 
-0.7256 -1.654 0.001105 0.1045 
PDZD8 PDZ domain containing 8 -0.8621 -1.818 0.001114 0.1048 
SULF2 sulfatase 2 -0.8939 -1.858 0.001128 0.1054 
HACD1 3-hydroxyacyl-CoA dehydratase 1 -0.856 -1.81 0.001142 0.1055 
DDIAS DNA damage induced apoptosis suppressor -1.186 -2.276 0.001161 0.1063 
ALDH1A2 aldehyde dehydrogenase 1 family member A2 -1.154 -2.225 0.001191 0.1063 
NA NA -0.9147 -1.885 0.001226 0.1069 
NA NA -0.903 -1.87 0.001229 0.1069 
CKAP2L cytoskeleton associated protein 2 like -1.621 -3.075 0.001239 0.1073 
ALG3 ALG3, alpha-1,3- mannosyltransferase -1.192 -2.285 0.001321 0.1111 
KYNU kynureninase -1.496 -2.821 0.001323 0.1111 
BCAN brevican -1.595 -3.022 0.001376 0.113 
ENPP3 ectonucleotide 
pyrophosphatase/phosphodiesterase 3 
-4.088 -17 0.001384 0.113 
ESPL1 extra spindle pole bodies like 1, separase -1.549 -2.926 0.001385 0.113 
NAV2 neuron navigator 2 -1.398 -2.636 0.00139 0.113 
RHBDL1 rhomboid, veinlet-like 1 (Drosophila) -1.094 -2.135 0.001391 0.113 
CCDC74B coiled-coil domain containing 74B -1.173 -2.254 0.001403 0.113 
SLC39A6 solute carrier family 39 member 6 -1.086 -2.123 0.001441 0.113 
SAPCD2 suppressor APC domain containing 2 -1.263 -2.4 0.001442 0.113 
FAM234B family with sequence similarity 234 member B -1.753 -3.371 0.001458 0.113 
ADAMTS8 ADAM metallopeptidase with thrombospondin 
type 1 motif 8 
-2.373 -5.179 0.001463 0.113 
PPP1R12C protein phosphatase 1 regulatory subunit 12C -1.09 -2.129 0.001468 0.113 
DKK1 dickkopf WNT signaling pathway inhibitor 1 -1.826 -3.545 0.001476 0.113 
DNAJC22 DnaJ heat shock protein family (Hsp40) 
member C22 
-0.8233 -1.769 0.001477 0.113 
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GAL galanin/GMAP prepropeptide -1.748 -3.359 0.001518 0.1136 
SULF2 sulfatase 2 -0.6941 -1.618 0.001523 0.1136 
SPAG8 sperm associated antigen 8 -2.039 -4.111 0.001523 0.1136 
CTAGE5 CTAGE family member 5 -1.192 -2.284 0.001541 0.1136 
OLFM1 olfactomedin 1 -1.695 -3.237 0.001551 0.1136 
MYC v-myc avian myelocytomatosis viral oncogene 
homolog 
-0.9049 -1.872 0.001556 0.1136 
NA NA -0.7184 -1.645 0.001579 0.1146 
CACYBP calcyclin binding protein -0.9221 -1.895 0.001604 0.1157 
C6orf141 chromosome 6 open reading frame 141 -2.703 -6.51 0.001613 0.116 
SMOC2 SPARC related modular calcium binding 2 -1.526 -2.88 0.001648 0.1171 
NA NA -1.187 -2.276 0.001658 0.1174 
FEN1 flap structure-specific endonuclease 1 -0.8501 -1.803 0.001662 0.1174 
TCF12 transcription factor 12 -0.6735 -1.595 0.001668 0.1174 
TUBA3E tubulin alpha 3e -2.856 -7.242 0.00168 0.1174 
PSMC3IP PSMC3 interacting protein -1.064 -2.09 0.001685 0.1174 
CCNO cyclin O -1.352 -2.553 0.001685 0.1174 
SPEF2 sperm flagellar 2 -1.015 -2.021 0.001704 0.1174 
BCAP29 B-cell receptor-associated protein 29 -0.7246 -1.652 0.001713 0.1174 
RADIL Ras association and DIL domains -0.946 -1.927 0.001731 0.1174 
TTF2 transcription termination factor, RNA 
polymerase II 
-0.8072 -1.75 0.001738 0.1174 
CHEK2 checkpoint kinase 2 -0.7159 -1.642 0.001744 0.1174 
AUNIP aurora kinase A and ninein interacting protein -1.109 -2.157 0.001749 0.1174 
ARMCX4 armadillo repeat containing, X-linked 4 -2.227 -4.682 0.001749 0.1174 
SLC26A6 solute carrier family 26 member 6 -1.06 -2.086 0.001755 0.1174 
NA NA -1.33 -2.514 0.001767 0.1174 
SNORA26 small nucleolar RNA, H/ACA box 26 -1.618 -3.069 0.001781 0.1174 
ALPL alkaline phosphatase, liver/bone/kidney -1.485 -2.8 0.001783 0.1174 
NA NA -0.8658 -1.822 0.001787 0.1174 
AMD1 adenosylmethionine decarboxylase 1 -0.8899 -1.853 0.001788 0.1174 
GPM6B glycoprotein M6B -0.9018 -1.868 0.001796 0.1176 
EEF1E1 eukaryotic translation elongation factor 1 
epsilon 1 
-0.6784 -1.6 0.001803 0.1176 
NA NA -2.098 -4.281 0.001828 0.1176 
SCN2B sodium voltage-gated channel beta subunit 2 -1.291 -2.447 0.001837 0.1176 
TEKT4 tektin 4 -1.22 -2.329 0.001847 0.1176 
SMAD9 SMAD family member 9 -2.234 -4.704 0.001851 0.1176 
SMAD9 SMAD family member 9 -1.711 -3.274 0.001882 0.1176 
GREB1 growth regulation by estrogen in breast cancer 
1 
-0.6939 -1.618 0.001883 0.1176 
ZNF589 zinc finger protein 589 -1.068 -2.096 0.001893 0.1176 
FGF12 fibroblast growth factor 12 -1.183 -2.27 0.001897 0.1176 
IL17RB interleukin 17 receptor B -1.069 -2.098 0.001902 0.1176 
TUBA3D tubulin alpha 3d -0.6871 -1.61 0.001904 0.1176 
CTNNA2 catenin alpha 2 -2.978 -7.877 0.001908 0.1176 
IL17D interleukin 17D -1.253 -2.384 0.001916 0.1176 
PLK4 polo like kinase 4 -1.259 -2.394 0.001923 0.1176 
GLIS2 GLIS family zinc finger 2 -0.9945 -1.992 0.001961 0.1182 
OIP5 Opa interacting protein 5 -1.328 -2.511 0.001969 0.1182 
SULF2 sulfatase 2 -0.7477 -1.679 0.001972 0.1182 
DLEC1 deleted in lung and esophageal cancer 1 -1.557 -2.942 0.00198 0.1182 
NA NA -1.17 -2.251 0.001993 0.1182 
RTN4 reticulon 4 -1.205 -2.306 0.002009 0.1182 
NA NA -1.785 -3.447 0.002027 0.1182 
ETNPPL ethanolamine-phosphate phospho-lyase -1.825 -3.543 0.002031 0.1182 
PSMC3IP PSMC3 interacting protein -1.15 -2.22 0.00204 0.1182 
NA NA -1.174 -2.256 0.002062 0.1182 
FAM63A family with sequence similarity 63 member A -1.385 -2.611 0.002064 0.1182 
RASSF2 Ras association domain family member 2 -0.988 -1.983 0.002068 0.1182 
LRRC6 leucine rich repeat containing 6 -0.9267 -1.901 0.002087 0.1182 
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HOMER2 homer scaffolding protein 2 -1.562 -2.953 0.002088 0.1182 
NA NA -1.439 -2.712 0.002092 0.1182 
NGEF neuronal guanine nucleotide exchange factor -0.8481 -1.8 0.0021 0.1182 
NA NA -0.6832 -1.606 0.002126 0.1189 
TCAIM T-cell activation inhibitor, mitochondrial -0.8712 -1.829 0.002131 0.1189 
RGS7BP regulator of G-protein signaling 7 binding 
protein 
-1.522 -2.871 0.002182 0.1189 
TMEM132B transmembrane protein 132B -1.335 -2.522 0.002183 0.1189 
TCF12 transcription factor 12 -0.6957 -1.62 0.002187 0.1189 
NA NA -0.8489 -1.801 0.002188 0.1189 
MRPS12 mitochondrial ribosomal protein S12 -0.6968 -1.621 0.002191 0.1189 
COL9A2 collagen type IX alpha 2 -1.865 -3.643 0.002198 0.1189 
BAIAP2L2 BAI1 associated protein 2 like 2 -1.002 -2.003 0.002199 0.1189 
DYNC1I1 dynein cytoplasmic 1 intermediate chain 1 -1.444 -2.721 0.00222 0.119 
PBK PDZ binding kinase -2.106 -4.306 0.00222 0.119 
CNTNAP2 contactin associated protein-like 2 -1.921 -3.786 0.002236 0.119 
BARD1 BRCA1 associated RING domain 1 -0.5967 -1.512 0.002238 0.119 
KIF4A kinesin family member 4A -1.87 -3.655 0.002251 0.1195 
EPB41L2 erythrocyte membrane protein band 4.1-like 2 -0.7377 -1.668 0.002265 0.1195 
SLC46A2 solute carrier family 46 member 2 -2.99 -7.943 0.002267 0.1195 
SGOL1 shugoshin-like 1 (S. pombe) -1.619 -3.072 0.002271 0.1195 
MMP16 matrix metallopeptidase 16 -1.125 -2.181 0.002308 0.1198 
PIR pirin -1.129 -2.188 0.002335 0.1204 
CCDC34 coiled-coil domain containing 34 -0.9194 -1.891 0.002338 0.1204 
MIR503 microRNA 503 -2.016 -4.045 0.002343 0.1204 
FANCL Fanconi anemia complementation group L -0.9485 -1.93 0.002348 0.1204 
MFSD2A major facilitator superfamily domain 
containing 2A 
-1.644 -3.126 0.002375 0.1208 
ANTXR1 anthrax toxin receptor 1 -0.953 -1.936 0.002382 0.1208 
GTPBP3 GTP binding protein 3 (mitochondrial) -0.8371 -1.786 0.002383 0.1208 
SLC7A4 solute carrier family 7 member 4 -1.047 -2.067 0.002426 0.1226 
NA NA -0.7917 -1.731 0.002487 0.1243 
LRRC73 leucine rich repeat containing 73 -0.6712 -1.592 0.002508 0.1248 
NA NA -1.022 -2.031 0.002516 0.1248 
BHMT betaine--homocysteine S-methyltransferase -1.053 -2.075 0.002518 0.1248 
P2RY14 purinergic receptor P2Y14 -1.675 -3.193 0.002551 0.1248 
RECQL4 RecQ like helicase 4 -0.7944 -1.734 0.002552 0.1248 
FAM65C family with sequence similarity 65 member C -1.5 -2.829 0.002559 0.1248 
MYC v-myc avian myelocytomatosis viral oncogene 
homolog 
-0.9114 -1.881 0.00256 0.1248 
RXFP1 relaxin/insulin-like family peptide receptor 1 -1.723 -3.301 0.002577 0.125 
HELLS helicase, lymphoid-specific -1.522 -2.872 0.00258 0.125 
MTPN myotrophin -0.7009 -1.626 0.002614 0.1254 
LRRC75B leucine rich repeat containing 75B -1.22 -2.329 0.002626 0.1254 
CDC20B cell division cycle 20B -1.821 -3.534 0.002626 0.1254 
NA NA -1.049 -2.068 0.002637 0.1254 
CCDC173 coiled-coil domain containing 173 -1.382 -2.605 0.002644 0.1254 
ECI1 enoyl-CoA delta isomerase 1 -0.6746 -1.596 0.002676 0.1265 
NA NA -1.079 -2.113 0.002676 0.1265 
TYMSOS TYMS opposite strand -0.9022 -1.869 0.0027 0.1268 
C17orf58 chromosome 17 open reading frame 58 -1.088 -2.125 0.0027 0.1268 
BRICD5 BRICHOS domain containing 5 -2.237 -4.713 0.002712 0.1268 
NA NA -0.6039 -1.52 0.002717 0.1268 
MKS1 Meckel syndrome, type 1 -0.7035 -1.628 0.00272 0.1268 
PAQR4 progestin and adipoQ receptor family member 
IV 
-1.075 -2.107 0.002749 0.1277 
PCDH20 protocadherin 20 -0.9733 -1.963 0.002767 0.1277 
ACADL acyl-CoA dehydrogenase, long chain -1.057 -2.08 0.002777 0.1277 
NA NA -1.426 -2.686 0.002779 0.1277 
MMS22L MMS22 like, DNA repair protein -0.5925 -1.508 0.002781 0.1277 
RAB7B RAB7B, member RAS oncogene family -1.604 -3.04 0.002813 0.1277 
 305 
NA NA -1.762 -3.392 0.002818 0.1277 
NUF2 NUF2, NDC80 kinetochore complex 
component 
-1.699 -3.247 0.00282 0.1277 
FANK1 fibronectin type III and ankyrin repeat domains 
1 
-1.382 -2.606 0.002832 0.1277 
GPM6B glycoprotein M6B -0.8129 -1.757 0.002839 0.1277 
NTN5 netrin 5 -0.8793 -1.839 0.00284 0.1277 
MID1 midline 1 -0.7674 -1.702 0.002872 0.1277 
CCDC74B coiled-coil domain containing 74B -1.458 -2.747 0.002882 0.1277 
PDZK1 PDZ domain containing 1 -2.932 -7.629 0.002891 0.1278 
ECI2 enoyl-CoA delta isomerase 2 -0.7238 -1.652 0.00298 0.1298 
CEP152 centrosomal protein 152kDa -1.484 -2.798 0.002994 0.1298 
GNB4 G protein subunit beta 4 -0.7639 -1.698 0.002995 0.1298 
ODF2L outer dense fiber of sperm tails 2 like -0.8544 -1.808 0.002996 0.1298 
PKHD1L1 polycystic kidney and hepatic disease 1 
(autosomal recessive)-like 1 
-2.342 -5.072 0.003001 0.1298 
CCDC146 coiled-coil domain containing 146 -2.081 -4.231 0.003028 0.1298 
POU5F1B POU class 5 homeobox 1B -1.69 -3.227 0.003034 0.1298 
HAGHL hydroxyacylglutathione hydrolase-like -0.9996 -1.999 0.003036 0.1298 
ZNF432 zinc finger protein 432 -0.5796 -1.494 0.00304 0.1298 
SLC46A1 solute carrier family 46 member 1 -0.8348 -1.784 0.003068 0.1298 
ZDHHC23 zinc finger DHHC-type containing 23 -1.023 -2.032 0.003078 0.1298 
SRL sarcalumenin -1.153 -2.223 0.003083 0.1298 
PYCRL pyrroline-5-carboxylate reductase-like -0.725 -1.653 0.003121 0.1298 
IGSF9 immunoglobulin superfamily member 9 -1.593 -3.018 0.003129 0.1298 
CCDC189 coiled-coil domain containing 189 -0.9936 -1.991 0.00313 0.1298 
ABCC8 ATP binding cassette subfamily C member 8 -1.569 -2.966 0.003142 0.1298 
CDKN2A cyclin-dependent kinase inhibitor 2A -0.8345 -1.783 0.003143 0.1298 
NA NA -1.354 -2.556 0.003147 0.1298 
KIR2DL4 killer cell immunoglobulin like receptor, two Ig 
domains and long cytoplasmic tail 4 
-0.8404 -1.791 0.003148 0.1298 
OPN3 opsin 3 -0.6681 -1.589 0.003177 0.1302 
ADAM28 ADAM metallopeptidase domain 28 -1.195 -2.289 0.003211 0.1304 
TBRG1 transforming growth factor beta regulator 1 -1.419 -2.674 0.003215 0.1304 
DONSON downstream neighbor of SON -1.467 -2.764 0.003215 0.1304 
NA NA -0.9703 -1.959 0.003242 0.1313 
TDP1 tyrosyl-DNA phosphodiesterase 1 -1.032 -2.045 0.003268 0.1315 
E2F2 E2F transcription factor 2 -1.085 -2.121 0.003276 0.1315 
KCTD8 potassium channel tetramerization domain 
containing 8 
-1.837 -3.574 0.003278 0.1315 
APOA1 apolipoprotein A-I -1.421 -2.678 0.003287 0.1315 
ARMCX6 armadillo repeat containing, X-linked 6 -0.7313 -1.66 0.003311 0.1315 
ITPKA inositol-trisphosphate 3-kinase A -1.636 -3.108 0.003311 0.1315 
KIF11 kinesin family member 11 -1.318 -2.493 0.003319 0.1315 
ART3 ADP-ribosyltransferase 3 -1.578 -2.986 0.003326 0.1316 
BHMT2 betaine--homocysteine S-methyltransferase 2 -1.348 -2.546 0.003331 0.1316 
ARHGAP20 Rho GTPase activating protein 20 -1.687 -3.219 0.003337 0.1316 
XPR1 xenotropic and polytropic retrovirus receptor 
1 
-0.5547 -1.469 0.003346 0.1316 
ZNF692 zinc finger protein 692 -1.043 -2.06 0.003384 0.1322 
NA NA -1.331 -2.515 0.003394 0.1322 
MICB MHC class I polypeptide-related sequence B -1.147 -2.215 0.003398 0.1322 
DOK6 docking protein 6 -0.7838 -1.722 0.003402 0.1322 
STX2 syntaxin 2 -0.8474 -1.799 0.00344 0.1327 
NA NA -1.017 -2.024 0.003517 0.1343 
NEK2 NIMA related kinase 2 -1.568 -2.964 0.003592 0.1354 
NA NA -1.364 -2.573 0.003608 0.1354 
PDE8A phosphodiesterase 8A -1.037 -2.051 0.003609 0.1354 
TMEM107 transmembrane protein 107 -1.108 -2.156 0.003619 0.1354 
RAB36 RAB36, member RAS oncogene family -0.723 -1.651 0.003641 0.1355 
CEP120 centrosomal protein 120kDa -1.097 -2.14 0.003643 0.1355 
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CEP57L1 centrosomal protein 57kDa-like 1 -0.7313 -1.66 0.003679 0.1362 
SFI1 SFI1 centrin binding protein -1.336 -2.524 0.003701 0.1366 
SLC51B solute carrier family 51 beta subunit -2.244 -4.736 0.003765 0.1379 
CEP55 centrosomal protein 55kDa -1.399 -2.637 0.003775 0.1379 
PCBP4 poly(rC) binding protein 4 -0.7471 -1.678 0.003783 0.1379 
PTN pleiotrophin -1.505 -2.838 0.003783 0.1379 
HIST1H2BC histone cluster 1, H2bc -1.321 -2.499 0.003793 0.1379 
FGFR3 fibroblast growth factor receptor 3 -0.8195 -1.765 0.003813 0.1382 
C7orf57 chromosome 7 open reading frame 57 -2.214 -4.639 0.003832 0.1384 
NDC80 NDC80 kinetochore complex component -1.192 -2.285 0.003861 0.1393 
CHST3 carbohydrate (chondroitin 6) sulfotransferase 
3 
-0.6199 -1.537 0.003895 0.1399 
NA NA -1.512 -2.851 0.003906 0.1399 
ARL4D ADP ribosylation factor like GTPase 4D -1.655 -3.149 0.003941 0.1401 
RCN2 reticulocalbin 2 -0.9515 -1.934 0.003944 0.1401 
ST3GAL5 ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 
-1.838 -3.575 0.003951 0.1401 
OXCT1 3-oxoacid CoA-transferase 1 -1.243 -2.367 0.003961 0.1401 
APOBEC4 apolipoprotein B mRNA editing enzyme 
catalytic polypeptide like 4 
-0.8922 -1.856 0.003962 0.1401 
OGFOD1 2-oxoglutarate and iron dependent oxygenase 
domain containing 1 
-0.6969 -1.621 0.003965 0.1401 
RDM1 RAD52 motif containing 1 -1.223 -2.334 0.003999 0.1407 
ARHGEF19 Rho guanine nucleotide exchange factor 19 -0.8389 -1.789 0.004006 0.1407 
CAPRIN2 caprin family member 2 -1.798 -3.478 0.004038 0.1416 
ALDH3B2 aldehyde dehydrogenase 3 family member B2 -1.821 -3.533 0.004073 0.1425 
IGHMBP2 immunoglobulin mu binding protein 2 -0.7298 -1.658 0.004096 0.1429 
POC1B POC1 centriolar protein B -0.5508 -1.465 0.004136 0.1433 
WIPI1 WD repeat domain, phosphoinositide 
interacting 1 
-0.8721 -1.83 0.004181 0.1435 
TSKU tsukushi, small leucine rich proteoglycan -0.9125 -1.882 0.004198 0.1435 
SLC25A15 solute carrier family 25 member 15 -1.018 -2.025 0.004213 0.1435 
KIF15 kinesin family member 15 -1.466 -2.763 0.004219 0.1435 
NA NA -0.6884 -1.611 0.004221 0.1435 
NA NA -0.7697 -1.705 0.004227 0.1435 
ZNF93 zinc finger protein 93 -0.9974 -1.996 0.00423 0.1435 
PSRC1 proline/serine-rich coiled-coil 1 -1.427 -2.689 0.004234 0.1435 
SNORD96A small nucleolar RNA, C/D box 96A -1.025 -2.034 0.004244 0.1435 
IKBIP IKBKB interacting protein -0.7914 -1.731 0.004264 0.1435 
NA NA -0.7465 -1.678 0.00427 0.1435 
ANKRD35 ankyrin repeat domain 35 -0.8591 -1.814 0.004274 0.1435 
SLC45A1 solute carrier family 45 member 1 -1.621 -3.076 0.004309 0.1441 
CHORDC1 cysteine and histidine rich domain containing 
1 
-0.6257 -1.543 0.004312 0.1441 
CCDC24 coiled-coil domain containing 24 -0.8458 -1.797 0.004348 0.1445 
C19orf48 chromosome 19 open reading frame 48 -0.6379 -1.556 0.004356 0.1445 
KLRA1P killer cell lectin like receptor A1, pseudogene -0.7278 -1.656 0.004374 0.1446 
RNU11 RNA, U11 small nuclear -1.439 -2.711 0.00438 0.1446 
UCN2 urocortin 2 -1.688 -3.223 0.004466 0.1459 
PCDH10 protocadherin 10 -1.277 -2.423 0.004482 0.146 
CLASRP CLK4-associating serine/arginine rich protein -0.9667 -1.954 0.004502 0.1463 
CEP131 centrosomal protein 131kDa -0.6626 -1.583 0.004504 0.1463 
GDAP1 ganglioside induced differentiation associated 
protein 1 
-0.773 -1.709 0.00455 0.147 
COX15 COX15 cytochrome c oxidase assembly 
homolog 
-0.8658 -1.822 0.00456 0.147 
NA NA -1.058 -2.083 0.004583 0.1473 
MEN1 menin 1 -0.9787 -1.971 0.00459 0.1473 
NAA40 N(alpha)-acetyltransferase 40, NatD catalytic 
subunit 
-1.131 -2.189 0.004603 0.1473 
SNAP91 synaptosome associated protein 91kDa -0.7163 -1.643 0.004605 0.1473 
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KIAA1524 KIAA1524 -1.369 -2.582 0.004615 0.1473 
NA NA -1.283 -2.433 0.004616 0.1473 
ITPR2 inositol 1,4,5-trisphosphate receptor type 2 -0.7363 -1.666 0.004639 0.1474 
RGS22 regulator of G-protein signaling 22 -1.338 -2.528 0.004645 0.1474 
CELF1 CUGBP, Elav-like family member 1 -0.7809 -1.718 0.004667 0.1474 
USP35 ubiquitin specific peptidase 35 -0.8707 -1.829 0.004667 0.1474 
SNHG15 small nucleolar RNA host gene 15 -0.5249 -1.439 0.004668 0.1474 
ZNF662 zinc finger protein 662 -0.8987 -1.864 0.004688 0.1477 
CCNE2 cyclin E2 -1.803 -3.489 0.00471 0.1478 
SMC4 structural maintenance of chromosomes 4 -0.7561 -1.689 0.004735 0.1478 
TMEM106C transmembrane protein 106C -0.6716 -1.593 0.004753 0.1478 
OLFM1 olfactomedin 1 -1.528 -2.884 0.004757 0.1478 
GGCT gamma-glutamylcyclotransferase -0.6011 -1.517 0.004761 0.1478 
TRIP13 thyroid hormone receptor interactor 13 -0.8317 -1.78 0.004781 0.1478 
FERMT1 fermitin family member 1 -0.9183 -1.89 0.004781 0.1478 
TBC1D31 TBC1 domain family member 31 -1.178 -2.262 0.004787 0.1478 
REV3L REV3 like, DNA directed polymerase zeta 
catalytic subunit 
-1.217 -2.324 0.00481 0.1479 
AURKA aurora kinase A -1.284 -2.435 0.004811 0.1479 
SAMD11 sterile alpha motif domain containing 11 -0.7804 -1.718 0.004833 0.1481 
THBS3 thrombospondin 3 -0.7304 -1.659 0.004855 0.1481 
KLK4 kallikrein related peptidase 4 -1.84 -3.58 0.004857 0.1481 
BCAP29 B-cell receptor-associated protein 29 -0.6343 -1.552 0.004865 0.1481 
TSPYL2 TSPY-like 2 -0.6123 -1.529 0.00487 0.1481 
CCDC191 coiled-coil domain containing 191 -0.947 -1.928 0.004871 0.1481 
MME membrane metallo-endopeptidase -1.247 -2.374 0.004903 0.1486 
PIR pirin -1.306 -2.472 0.004917 0.1488 
CNIH2 cornichon family AMPA receptor auxiliary 
protein 2 
-1.681 -3.206 0.004924 0.1488 
TRIOBP TRIO and F-actin binding protein -1.306 -2.473 0.004927 0.1488 
ASPHD1 aspartate beta-hydroxylase domain containing 
1 
-1.01 -2.013 0.005015 0.1505 
GAS2L3 growth arrest specific 2 like 3 -0.9647 -1.952 0.005072 0.1513 
SMC4 structural maintenance of chromosomes 4 -1.117 -2.169 0.005083 0.1514 
C2orf88 chromosome 2 open reading frame 88 -1.401 -2.641 0.005105 0.1518 
NA NA -0.9333 -1.91 0.005107 0.1518 
PIAS3 protein inhibitor of activated STAT 3 -0.7938 -1.734 0.005148 0.1521 
ERI2 ERI1 exoribonuclease family member 2 -1.33 -2.514 0.005167 0.1521 
HOMER2 homer scaffolding protein 2 -1.666 -3.173 0.005167 0.1521 
CMAHP cytidine monophospho-N-acetylneuraminic 
acid hydroxylase, pseudogene 
-0.6514 -1.571 0.005185 0.1521 
NA NA -1.024 -2.034 0.005211 0.1522 
HPRT1 hypoxanthine phosphoribosyltransferase 1 -0.5219 -1.436 0.005255 0.1526 
WDR73 WD repeat domain 73 -0.7533 -1.686 0.005284 0.1532 
SEMA3C semaphorin 3C -0.9447 -1.925 0.005313 0.1537 
RFC4 replication factor C subunit 4 -0.8234 -1.77 0.005414 0.1559 
MAP9 microtubule associated protein 9 -1.172 -2.254 0.005423 0.156 
AURKA aurora kinase A -1.053 -2.075 0.005512 0.1574 
F3 coagulation factor III, tissue factor -1.17 -2.25 0.005526 0.1574 
SNORA67 small nucleolar RNA, H/ACA box 67 -1.689 -3.225 0.005532 0.1574 
MND1 meiotic nuclear divisions 1 -1.157 -2.23 0.005577 0.1579 
MAP6D1 MAP6 domain containing 1 -0.8417 -1.792 0.005617 0.158 
OFD1 oral-facial-digital syndrome 1 -0.8271 -1.774 0.005632 0.158 
LOC441268 uncharacterized LOC441268 -1.695 -3.237 0.005697 0.1583 
KIF24 kinesin family member 24 -1.491 -2.811 0.00576 0.1586 
GGT1 gamma-glutamyltransferase 1 -0.9276 -1.902 0.00583 0.1598 
KNSTRN kinetochore-localized astrin/SPAG5 binding 
protein 
-0.8135 -1.757 0.005855 0.1598 
NA NA -0.9639 -1.951 0.005888 0.16 
FAM179A family with sequence similarity 179 member A -1.117 -2.169 0.005889 0.16 
CORO2B coronin 2B -0.8396 -1.79 0.005925 0.1603 
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NA NA -2.489 -5.613 0.005949 0.1603 
ARMCX6 armadillo repeat containing, X-linked 6 -0.5331 -1.447 0.005953 0.1603 
ZSCAN29 zinc finger and SCAN domain containing 29 -0.9685 -1.957 0.005968 0.1603 
NA NA -0.8604 -1.816 0.005971 0.1603 
RNF144A ring finger protein 144A -0.5865 -1.502 0.005983 0.1603 
KLRC1 killer cell lectin like receptor C1 -1.153 -2.224 0.005985 0.1603 
ARHGEF39 Rho guanine nucleotide exchange factor 39 -1.307 -2.474 0.006005 0.1603 
CNOT11 CCR4-NOT transcription complex subunit 11 -0.4775 -1.392 0.00606 0.1607 
SIMC1 SUMO interacting motifs containing 1 -0.896 -1.861 0.006062 0.1607 
NA NA -0.9149 -1.885 0.006069 0.1607 
NA NA -0.8495 -1.802 0.006074 0.1607 
CENPK centromere protein K -1.56 -2.948 0.006102 0.1612 
ECM1 extracellular matrix protein 1 -0.5612 -1.476 0.006114 0.1614 
GPR83 G protein-coupled receptor 83 -1.343 -2.536 0.006142 0.1615 
DPY19L1 dpy-19 like 1 (C. elegans) -0.8525 -1.806 0.006143 0.1615 
FEN1 flap structure-specific endonuclease 1 -0.8893 -1.852 0.006176 0.1619 
NPHP1 nephronophthisis 1 (juvenile) -1.152 -2.222 0.006198 0.162 
DLGAP5 discs large homolog associated protein 5 -1.589 -3.008 0.00621 0.1621 
UBE2C ubiquitin conjugating enzyme E2C -1.302 -2.466 0.006239 0.1627 
NA NA -1.246 -2.371 0.006254 0.1627 
AEN apoptosis enhancing nuclease -0.6696 -1.591 0.006355 0.1648 
PMP22 peripheral myelin protein 22 -0.8619 -1.817 0.006407 0.1652 
ANKRD26 ankyrin repeat domain 26 -1.023 -2.031 0.006412 0.1652 
SNORA33 small nucleolar RNA, H/ACA box 33 -1.089 -2.128 0.006437 0.1654 
NA NA -1.606 -3.044 0.006441 0.1654 
MITF microphthalmia-associated transcription 
factor 
-1.12 -2.173 0.006458 0.1654 
TXN thioredoxin -0.5166 -1.431 0.006461 0.1654 
FOXM1 forkhead box M1 -1.395 -2.629 0.006478 0.1654 
LINC00926 long intergenic non-protein coding RNA 926 -1.224 -2.336 0.006482 0.1654 
CCNA2 cyclin A2 -1.222 -2.333 0.006487 0.1654 
NA NA -0.8333 -1.782 0.006509 0.1655 
PCNA proliferating cell nuclear antigen -0.6453 -1.564 0.006523 0.1655 
NSUN5P1 NOP2/Sun RNA methyltransferase family 
member 5 pseudogene 1 
-1.365 -2.576 0.006526 0.1655 
RTTN rotatin -0.7653 -1.7 0.006537 0.1655 
ADCK5 aarF domain containing kinase 5 -0.7908 -1.73 0.006594 0.1657 
GDF11 growth differentiation factor 11 -0.8359 -1.785 0.006599 0.1657 
RAD54L RAD54-like (S. cerevisiae) -1.723 -3.301 0.006618 0.1657 
GNLY granulysin -1.418 -2.671 0.00663 0.1657 
NPEPPS aminopeptidase puromycin sensitive -0.7039 -1.629 0.006648 0.1657 
CENPL centromere protein L -1.248 -2.376 0.006656 0.1657 
FIGNL1 fidgetin like 1 -1.147 -2.215 0.006664 0.1657 
ZNF280C zinc finger protein 280C -0.6937 -1.617 0.006683 0.1657 
POLR1A polymerase (RNA) I subunit A -0.6053 -1.521 0.006685 0.1657 
NA NA -0.7178 -1.645 0.006702 0.1658 
C20orf27 chromosome 20 open reading frame 27 -0.6521 -1.571 0.006739 0.1659 
CDC20 cell division cycle 20 -1.493 -2.814 0.006807 0.1673 
NA NA -0.8066 -1.749 0.006813 0.1673 
NA NA -0.9215 -1.894 0.006844 0.1675 
MXD3 MAX dimerization protein 3 -2.004 -4.011 0.006846 0.1675 
MNS1 meiosis specific nuclear structural 1 -0.919 -1.891 0.006852 0.1675 
DEFB124 defensin beta 124 -2.586 -6.005 0.006875 0.1675 
NA NA -0.8588 -1.814 0.006878 0.1675 
GINS4 GINS complex subunit 4 (Sld5 homolog) -1.225 -2.338 0.006883 0.1675 
INPP5J inositol polyphosphate-5-phosphatase J -1.583 -2.996 0.006904 0.1676 
NA NA -1.382 -2.605 0.006947 0.1683 
NA NA -0.9065 -1.874 0.006955 0.1683 
SLC17A9 solute carrier family 17 member 9 -1.305 -2.471 0.006969 0.1683 
ZNF385B zinc finger protein 385B -2.252 -4.763 0.006988 0.1683 
CCNB2 cyclin B2 -1.349 -2.547 0.006999 0.1683 
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KIF2C kinesin family member 2C -1.381 -2.604 0.007003 0.1683 
ARVCF armadillo repeat gene deleted in 
velocardiofacial syndrome 
-1.057 -2.081 0.007039 0.1686 
GMNN geminin, DNA replication inhibitor -0.6746 -1.596 0.007056 0.1688 
BORA bora, aurora kinase A activator -0.8164 -1.761 0.007108 0.1688 
SIRT5 sirtuin 5 -0.7995 -1.74 0.00711 0.1688 
PHLDB1 pleckstrin homology like domain family B 
member 1 
-0.6389 -1.557 0.007129 0.1688 
GABBR1 gamma-aminobutyric acid type B receptor 
subunit 1 
-1.239 -2.36 0.007142 0.1688 
GJD3 gap junction protein delta 3 -1.066 -2.093 0.007154 0.1688 
SNORD22 small nucleolar RNA, C/D box 22 -1.094 -2.135 0.007206 0.1688 
TUBA3C tubulin alpha 3c -1.237 -2.356 0.007224 0.1688 
NA NA -0.7169 -1.644 0.00725 0.1688 
NA NA -1.147 -2.215 0.007267 0.1688 
FAM13C family with sequence similarity 13 member C -1.406 -2.65 0.007284 0.1688 
CKS2 CDC28 protein kinase regulatory subunit 2 -0.8584 -1.813 0.007304 0.1688 
NA NA -1.135 -2.197 0.007306 0.1688 
BRSK2 BR serine/threonine kinase 2 -1.047 -2.067 0.007317 0.1688 
CENPA centromere protein A -1.451 -2.733 0.00732 0.1688 
PTRH2 peptidyl-tRNA hydrolase 2 -1.159 -2.233 0.007323 0.1688 
CFAP69 cilia and flagella associated protein 69 -1.068 -2.096 0.007327 0.1688 
COL4A5 collagen type IV alpha 5 -0.6189 -1.536 0.007332 0.1688 
CUX2 cut like homeobox 2 -1.485 -2.8 0.007358 0.1688 
EZH2 enhancer of zeste 2 polycomb repressive 
complex 2 subunit 
-1.792 -3.463 0.007363 0.1688 
PXYLP1 2-phosphoxylose phosphatase 1 -0.815 -1.759 0.007396 0.1691 
PLCL1 phospholipase C like 1 -0.9403 -1.919 0.007412 0.1692 
NA NA -0.8936 -1.858 0.007432 0.1692 
AKAP7 A-kinase anchoring protein 7 -0.7548 -1.687 0.007444 0.1692 
ID2 inhibitor of DNA binding 2, HLH protein -0.7414 -1.672 0.007462 0.1694 
ATP6V0E2 ATPase H+ transporting V0 subunit e2 -0.5798 -1.495 0.007471 0.1694 
TRIM6 tripartite motif containing 6 -0.9693 -1.958 0.007496 0.1696 
CFAP157 cilia and flagella associated protein 157 -2.216 -4.647 0.007549 0.1703 
CDK20 cyclin-dependent kinase 20 -0.6488 -1.568 0.007565 0.1704 
HUS1 HUS1 checkpoint clamp component -1.271 -2.413 0.007565 0.1704 
QPRT quinolinate phosphoribosyltransferase -0.5329 -1.447 0.007602 0.1707 
CDK1 cyclin-dependent kinase 1 -1.474 -2.777 0.00762 0.1707 
NA NA -1.44 -2.714 0.007623 0.1707 
CNNM1 cyclin and CBS domain divalent metal cation 
transport mediator 1 
-1.119 -2.171 0.007647 0.1711 
FAM159A family with sequence similarity 159 member A -1.218 -2.325 0.007653 0.1711 
MOXD1 monooxygenase, DBH-like 1 -1.07 -2.099 0.007702 0.1714 
CRABP2 cellular retinoic acid binding protein 2 -0.9861 -1.981 0.007734 0.1717 
NA NA -0.513 -1.427 0.007752 0.1717 
SNORD49A small nucleolar RNA, C/D box 49A -1.891 -3.71 0.007766 0.1718 
ATRIP ATR interacting protein -0.7752 -1.711 0.00777 0.1718 
SNORD52 small nucleolar RNA, C/D box 52 -1.674 -3.191 0.007779 0.1718 
TACC3 transforming acidic coiled-coil containing 
protein 3 
-0.7532 -1.686 0.007821 0.1724 
DEPDC1 DEP domain containing 1 -0.9623 -1.948 0.007872 0.1727 
HJURP Holliday junction recognition protein -2.053 -4.151 0.007895 0.1727 
EMILIN3 elastin microfibril interfacer 3 -1.111 -2.159 0.0079 0.1727 
CKS1B CDC28 protein kinase regulatory subunit 1B -0.641 -1.559 0.007908 0.1727 
C5 complement component 5 -0.6039 -1.52 0.007931 0.1727 
CCDC34 coiled-coil domain containing 34 -0.8109 -1.754 0.007933 0.1727 
PTTG1 pituitary tumor-transforming 1 -1.258 -2.391 0.007952 0.1727 
RACGAP1 Rac GTPase activating protein 1 -1.35 -2.548 0.007963 0.1727 
NA NA -0.5737 -1.488 0.007975 0.1727 
CCDC171 coiled-coil domain containing 171 -0.9955 -1.994 0.007979 0.1727 
AKAP8 A-kinase anchoring protein 8 -0.5782 -1.493 0.008006 0.1731 
 310 
NA NA -1.327 -2.508 0.008048 0.1731 
CENPU centromere protein U -1.653 -3.145 0.008052 0.1731 
PKD1L2 polycystin 1 like 2 (gene/pseudogene) -1.692 -3.23 0.008067 0.1731 
RUVBL1 RuvB like AAA ATPase 1 -0.4649 -1.38 0.008071 0.1731 
PHF19 PHD finger protein 19 -0.6882 -1.611 0.008073 0.1731 
CABP4 calcium binding protein 4 -1.14 -2.203 0.00813 0.1732 
KLKP1 kallikrein pseudogene 1 -1.599 -3.029 0.008131 0.1732 
NA NA -1.142 -2.207 0.008135 0.1732 
PIDD1 p53-induced death domain protein 1 -1.444 -2.72 0.008138 0.1732 
ZNF799 zinc finger protein 799 -0.7419 -1.672 0.008188 0.1737 
SPC24 SPC24, NDC80 kinetochore complex 
component 
-0.9091 -1.878 0.008209 0.1737 
OGFOD1 2-oxoglutarate and iron dependent oxygenase 
domain containing 1 
-0.6318 -1.55 0.008216 0.1737 
NA NA -0.9195 -1.891 0.008217 0.1737 
FBLN2 fibulin 2 -1.285 -2.437 0.008229 0.1737 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta -1.351 -2.55 0.0083 0.1742 
RNF144A ring finger protein 144A -0.5621 -1.476 0.008301 0.1742 
NA NA -1.562 -2.952 0.00831 0.1743 
IL6R interleukin 6 receptor -1.071 -2.101 0.008347 0.1745 
CCHCR1 coiled-coil alpha-helical rod protein 1 -1.114 -2.165 0.008352 0.1745 
GPR180 G protein-coupled receptor 180 -0.5256 -1.439 0.008367 0.1745 
STEAP1 six transmembrane epithelial antigen of the 
prostate 1 
-0.973 -1.963 0.008369 0.1745 
FANCC Fanconi anemia complementation group C -0.9718 -1.961 0.008372 0.1745 
ADCY7 adenylate cyclase 7 -0.935 -1.912 0.008382 0.1746 
EML1 echinoderm microtubule associated protein 
like 1 
-0.7171 -1.644 0.008395 0.1747 
NA NA -0.9786 -1.971 0.008428 0.175 
ARFGAP1 ADP ribosylation factor GTPase activating 
protein 1 
-0.5397 -1.454 0.008446 0.175 
ARFGAP1 ADP ribosylation factor GTPase activating 
protein 1 
-1.231 -2.347 0.008452 0.175 
STX2 syntaxin 2 -0.8562 -1.81 0.008506 0.1759 
NA NA -0.6299 -1.547 0.008519 0.1759 
NLGN3 neuroligin 3 -1.124 -2.179 0.008526 0.1759 
EBAG9 estrogen receptor binding site associated, 
antigen, 9 
-1.422 -2.679 0.008535 0.1759 
APOBEC3F apolipoprotein B mRNA editing enzyme 
catalytic subunit 3F 
-0.6056 -1.522 0.008551 0.1759 
LONRF2 LON peptidase N-terminal domain and ring 
finger 2 
-0.7587 -1.692 0.008565 0.1759 
TMEM145 transmembrane protein 145 -0.8079 -1.751 0.008572 0.1759 
BRINP1 BMP/retinoic acid inducible neural specific 1 -0.9691 -1.958 0.008576 0.1759 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) -1.188 -2.278 0.008578 0.1759 
NA NA -1.611 -3.055 0.008604 0.176 
IGFBP5 insulin like growth factor binding protein 5 -1.384 -2.61 0.008637 0.1764 
ZWINT ZW10 interacting kinetochore protein -1.533 -2.895 0.008644 0.1764 
RLN2 relaxin 2 -0.7598 -1.693 0.008652 0.1764 
XRRA1 X-ray radiation resistance associated 1 -0.9527 -1.935 0.008681 0.1765 
UBE2C ubiquitin conjugating enzyme E2C -1.425 -2.685 0.008693 0.1765 
NA NA -0.7301 -1.659 0.008694 0.1765 
FAM72D family with sequence similarity 72 member D -1.659 -3.158 0.008787 0.1766 
ASF1B anti-silencing function 1B histone chaperone -1.178 -2.263 0.008798 0.1766 
ID1 inhibitor of DNA binding 1, HLH protein -1.588 -3.006 0.008807 0.1766 
SKA1 spindle and kinetochore associated complex 
subunit 1 
-1.443 -2.719 0.008811 0.1766 
NA NA -0.8566 -1.811 0.008871 0.1771 
NA NA -0.8072 -1.75 0.008882 0.1772 
KIFC1 kinesin family member C1 -1.274 -2.418 0.008931 0.1777 
DDX17 DEAD-box helicase 17 -0.5734 -1.488 0.008987 0.1782 
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SNORA10 small nucleolar RNA, H/ACA box 10 -1.148 -2.216 0.009005 0.1782 
PHF19 PHD finger protein 19 -0.8484 -1.8 0.009006 0.1782 
XPR1 xenotropic and polytropic retrovirus receptor 
1 
-0.5045 -1.419 0.009033 0.1782 
ATP6AP1L ATPase H+ transporting accessory protein 1 
like 
-1.261 -2.397 0.009036 0.1782 
ZIM3 zinc finger imprinted 3 -1.321 -2.498 0.009055 0.1782 
CDCA8 cell division cycle associated 8 -1.409 -2.656 0.009069 0.1782 
PPIEL peptidylprolyl isomerase E like pseudogene -1.279 -2.427 0.009072 0.1782 
CEACAM1 carcinoembryonic antigen related cell 
adhesion molecule 1 
-0.88 -1.84 0.009076 0.1782 
CDC7 cell division cycle 7 -1.036 -2.051 0.009082 0.1782 
N6AMT1 N-6 adenine-specific DNA methyltransferase 1 
(putative) 
-0.5185 -1.432 0.009086 0.1782 
SUGP2 SURP and G-patch domain containing 2 -0.6241 -1.541 0.009095 0.1782 
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase 
-0.8012 -1.743 0.009107 0.1782 
RAD9A RAD9 checkpoint clamp component A -0.7601 -1.694 0.009129 0.1782 
E4F1 E4F transcription factor 1 -0.5793 -1.494 0.009145 0.1782 
FOXN4 forkhead box N4 -1.627 -3.088 0.009178 0.1782 
NA NA -1.249 -2.377 0.009181 0.1782 
NA NA -0.8875 -1.85 0.009183 0.1782 
CCDC18 coiled-coil domain containing 18 -1.333 -2.52 0.009246 0.1782 
MRI1 methylthioribose-1-phosphate isomerase 1 -0.7748 -1.711 0.00926 0.1782 
NAAA N-acylethanolamine acid amidase -1.062 -2.087 0.009261 0.1782 
POC1A POC1 centriolar protein A -0.8614 -1.817 0.009271 0.1782 
CDCA5 cell division cycle associated 5 -1.328 -2.511 0.009274 0.1782 
MID1 midline 1 -0.4811 -1.396 0.009281 0.1782 
CEP85L centrosomal protein 85kDa-like -0.7564 -1.689 0.009283 0.1782 
NA NA -0.9163 -1.887 0.00929 0.1782 
KIAA0895L KIAA0895-like -1.994 -3.982 0.009292 0.1782 
ARL17A ADP ribosylation factor like GTPase 17A -0.719 -1.646 0.009347 0.1783 
ID2 inhibitor of DNA binding 2, HLH protein -0.7549 -1.687 0.009348 0.1783 
NA NA -1.652 -3.142 0.009376 0.1784 
CCNB1 cyclin B1 -1.211 -2.314 0.009377 0.1784 
CDKL2 cyclin dependent kinase like 2 -0.7326 -1.662 0.009391 0.1784 
SSX2IP synovial sarcoma, X breakpoint 2 interacting 
protein 
-1.131 -2.19 0.009396 0.1784 
USP4 ubiquitin specific peptidase 4 (proto-
oncogene) 
-0.8234 -1.77 0.009403 0.1784 
NA NA -0.7034 -1.628 0.009411 0.1784 
NA NA -0.906 -1.874 0.009434 0.1784 
NXF3 nuclear RNA export factor 3 -0.9553 -1.939 0.009437 0.1784 
PTTG3P pituitary tumor-transforming 3, pseudogene -1.334 -2.522 0.009442 0.1784 
SCNN1D sodium channel epithelial 1 delta subunit -1.314 -2.486 0.009446 0.1784 
PRC1 protein regulator of cytokinesis 1 -1.221 -2.331 0.009478 0.1787 
HMGB2 high mobility group box 2 -0.7584 -1.692 0.009491 0.1787 
F12 coagulation factor XII -0.6995 -1.624 0.009516 0.1787 
FANCI Fanconi anemia complementation group I -1.321 -2.499 0.009531 0.1787 
ZEB1 zinc finger E-box binding homeobox 1 -1.176 -2.26 0.009551 0.1788 
MOCOS molybdenum cofactor sulfurase -1.061 -2.086 0.009587 0.179 
IDH1 isocitrate dehydrogenase 1 (NADP+) -0.608 -1.524 0.009592 0.179 
CCP110 centriolar coiled-coil protein 110kDa -0.5664 -1.481 0.009598 0.179 
TYMS thymidylate synthetase -1.331 -2.517 0.00961 0.179 
TK1 thymidine kinase 1, soluble -0.9221 -1.895 0.00962 0.179 
FILIP1 filamin A interacting protein 1 -1.141 -2.206 0.009625 0.179 
NA NA -0.6905 -1.614 0.009645 0.1792 
ACOT7 acyl-CoA thioesterase 7 -0.6774 -1.599 0.00969 0.1798 
GPR156 G protein-coupled receptor 156 -0.9671 -1.955 0.009725 0.1801 
NT5DC3 5'-nucleotidase domain containing 3 -0.5341 -1.448 0.009742 0.1803 
PGP phosphoglycolate phosphatase -0.4644 -1.38 0.009753 0.1803 
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DNAH12 dynein axonemal heavy chain 12 -0.9119 -1.882 0.00977 0.1803 
C11orf70 chromosome 11 open reading frame 70 -1.424 -2.684 0.00978 0.1803 
NAALAD2 N-acetylated alpha-linked acidic dipeptidase 2 -0.9759 -1.967 0.009804 0.1803 
NA NA -0.8332 -1.782 0.00981 0.1803 
NA NA -1.147 -2.214 0.009814 0.1803 
FGFR3 fibroblast growth factor receptor 3 -1.072 -2.103 0.009821 0.1803 
NA NA -0.6129 -1.529 0.009823 0.1803 
PSRC1 proline/serine-rich coiled-coil 1 -1.254 -2.386 0.009849 0.1806 
DLGAP5 discs large homolog associated protein 5 -1.908 -3.753 0.009853 0.1806 
MPHOSPH6 M-phase phosphoprotein 6 -0.5895 -1.505 0.009941 0.1807 
CENPM centromere protein M -1.013 -2.017 0.009943 0.1807 
NA NA -0.8954 -1.86 0.00995 0.1807 
GPR162 G protein-coupled receptor 162 -0.9158 -1.887 0.009967 0.1807 
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